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ABSTRACT 
INTRODUCTION: Lung resection surgery (LRS) remains the treatment of choice for early 
stages of lung cancer but significant morbidity is associated, especially among patients with 
poor preoperative status. Preoperative exercise training (PET) has been proposed as an 
effective way of optimizing patients’ condition before surgery and enhancing postoperative 
recovery. However, it remains unknown whether or not similar results can be achieved after 
video-assisted thoracic surgery (VATS). Therefore, the aim of this thesis is to determine the 
feasibility, safety and efficacy of a preoperative pulmonary rehabilitation program (PPRP) on 
the functional and postoperative outcomes on patients undergoing VATS. 
MATERIALS AND METHODS: This thesis was structured in three studies: 1) a systematic 
review and meta-analysis of the effects PET on the functional and postoperative outcomes 
after LRS; 2) a small pilot investigation to assess the feasibility, safety and preliminary 
effects of a PPRP in patients awaiting VATS; and 3) a randomized controlled trial examining 
the effects of the PPRP after VATS for lung cancer on selected postoperative and functional 
outcomes in comparison to the standard care. 
RESULTS: Results from the study #1 show that PET improves pulmonary function before 
surgery and hastens postoperative recovery by reducing postoperative complications and 
hospital length of stay. In study #2, we concluded that a PPRP is safe and feasible and can 
potentially improve functional fitness. Finally, study #3, confirmed that a PPRP significantly 
improves exercise capacity, muscle strength and health-related quality of life while 
minimizing the impact of LRS during the first 3 months after VATS. 
CONCLUSIONS: We conclude that preoperative exercise-based interventions in patients 
with lung cancer awaiting VATS are feasible, safe and can significantly improve exercise and 
functional performance and enhance postoperative recovery.    
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RESUMEN 
INTRODUCCION: La cirugía de resección pulmonar (CRP) continúa siendo el tratamiento 
de elección en estadios iniciales del cáncer de pulmón pero la morbilidad asociada continúa 
siendo elevada, especialmente en pacientes con peor condición física. La Rehabilitación 
Pulmonar Preoperatoria (RPP) podría constituir una herramienta útil a la hora de disminuir el 
riesgo perioperatorio y optimizar la recuperación postoperatoria. Sin embargo, dichos 
programas no han sido probados en pacientes operados por videocirugía. Así pues, el objetivo 
de esta tesis es investigar la viabilidad, seguridad y eficacia de un programa de RPP en 
pacientes sometidos a resección pulmonar por videocirugía.  
MATERIAL Y METODOS: Esta tesis está estructurada en tres estudios: 1) revisión 
sistemática y meta-análisis sobre la eficacia del ejercicio preoperatorio en pacientes 
sometidos a CRP en cuanto a mejorar el estado funcional de los pacientes y acelerar la 
recuperación postoperatoria; 2) estudio piloto centrado en la viabilidad, seguridad y eficacia 
preliminar de la RPP en pacientes sometidos a videocirugia;  y 3) un ensayo controlado 
aleatorizado sobre la eficacia de la RPP en los outcomes funcionales y postoperatorios en 
pacientes sometidos a videocirugia en comparación con el tratamiento estándar.   
RESULTADOS: Los resultados obtenidos en el estudio #1 muestran que el ejercicio 
preoperatorio mejora la función pulmonar y acelera la recuperación postoperatoria al reducir 
la estancia hospitalaria y el número de complicaciones; con el estudio #2 se comprobó que la 
RPP es viable, segura y potencialmente eficaz a la hora de incrementar la capacidad 
funcional, mientras que el estudio #3 corroboró los resultados anteriores demostrando que la 
RPP incrementa la tolerancia al esfuerzo, la fuerza muscular y la calidad de vida al tiempo 
que optimiza la recuperación postoperatoria los tres primeros meses tras videocirugia.  
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CONCLUSION: La RPP en pacientes con cáncer de pulmón sometidos a videocirugia es 
viable, segura y eficaz a la hora de incrementar el estado funcional preoperatorio de los 
pacientes así como optimizar la recuperación postoperatoria.  
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     RESUMO 
INTRODUCCION: A cirurxía de resección pulmonar (CRP) constitue o tratamiento de 
elección en pacientes con cancro de pulmón en estadios iniciáis pero a morbilidade asociada 
continua a ser elevada especialmente en pacientes con peor condición física de base. Neste 
contexto, a Rehabilitación Pulmonar Preoperatoria (PRP) podería considerarse como unha 
ferramenta útil para disminuir o risco quirúrxico e optimizar o estado funcional dos pacientes. 
Non obstante, desconecese o rol destos programas nos pacientes operados por videocirurxía. 
Así pois, o obxectivo desta tese de doutoramento e estudar a viabilidade, seguridade e 
eficacia da Rehabilitación Pulmonar Preoperatoria (RPP) en pacientes con cancro de pulmón 
sometidos a resección pulmonar por videocirurxía. 
MATERIAL E METODOS: Esta tese está estructurada en tres estudos: 1) revisión 
sistemática e meta-analice da efectividade da RPP en pacientes con cancro de pulmón 
sometidos a CRP para mellorar o estado funcional e acelerar a recuperación postoperatoria; 
2) estudo piloto sobre a viabilidade, seguridade e eficacia preliminar da RPP en pacientes 
operados por videocirurxía e 3) ensaio clínico aleatorizado sobre o impacto da RPP sobre a 
tolerancia o esforzo, a capacidade funcional e a tolerancia o esforzo no postoperatorio de 
CRP en comparación co tratamento estándar.  
RESULTADOS: Os resultados obtidos no estudo #1 mostraron que o exercicio preoperatorio 
en pacientes sometidos a CRP mellora a función pulmonar e acelera a recuperación 
postoperatoria ao reducir o número de complicacións postoperatorias e a estadía hospitalaria; 
no estudo #2 quedo comprobada a viabilidade da intervención así como a ausencia de eventos 
adversos así como o potential da intervención para mellorar a funcionalidade dos pacientes; 
finalmente, o estudo #3 corroborou a efectividade da RPP para optimizar o estado funcional 
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dos pacientes previo a cirurxía e disminuir o impacto ocasionado pola CRP durante os tres 
primeiros meses tras videocirurxía. 
CONCLUSIÓNS: A RPP en pacientes con cancro de pulmón sometidos a videocirurxía e 
viable, segura e eficaz para incrementar a tolerancia o estado funcional previo a cirurxía e 
optimizar a recuperación postoperatoria.  
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INTRODUCTION 
Lung cancer is the most common diagnosed malignancy in the world (American Cancer 
Society, 2015). An estimated 1.8 million new cases occurred in 2012 accounting for 13% of all 
cancer diagnoses. Lung cancer is a pandemic disease, with a high burden and elevated economic 
cost. Individuals with lung cancer often experience significant levels of symptom distress, anxiety, 
depression and low quality of life. Furthermore, the overall five-year survival rates are among the 
lowest of all cancer types (ranging between 10 and 18 %) (Siegel et al., 2015, De Angelis et al., 
2014). Unsurprisingly, survival is higher for those diagnosed with early stages, increasing to 55% 
for localized disease (stages I and II), thereby highlighting the importance of an early diagnosis 
and adequate therapeutic management (Amer et al., 2011).  
Approximately 85% of lung cancers correspond to non-small-cell type (NSCLC). 
Surgery remains the gold treatment for stages I and II of lung cancer (Molina et al., 2008). 
Unfortunately, patients diagnosed with resectable disease represent only 20 to 25 % of all cases 
(Howington et al., 2013, Brunelli et al., 2013a). In addition, lung cancer patients frequently exhibit 
low cardiopulmonary fitness, impaired pulmonary function, associated chronic co-morbidities and 
advanced age, which are known to negatively impact on surgical tolerability and increase the risk 
of post-operative mortality and morbidity (Brunelli et al., 2013a, Beckles et al., 2003, Mazzone, 
2012). In addition, all forms of cancer therapy are associated with some degree of physical and 
psychological impairment (Jones et al., 2009a). In particular, after surgical resection, patients 
experience a significant decrease in exercise capacity, pulmonary function, health-related quality 
of life (HRQoL) and self-care (Win et al., 2007, Granger et al., 2014, Kenny et al., 2008). As a 
result, several perioperative strategies have been proposed in recent years to reduce post-operative 
complications, enhance post-operative recovery and minimize the impact of local and systemic 
therapies. One of the most important advances in thoracic surgery has been the introduction and 
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further optimization of a minimally invasive approach. Video-assisted thoracic surgery (VATS) 
was first introduced for the management of lung cancer in the early 90s and its use has been steadily 
increasing ever since. Among the numerous benefits associated with this approach are a reduction 
in post-operative pain (Handy et al., 2009, Cheng et al., 2007), fewer post-operative complications, 
shortened hospital length of stay (Cao, 2012, Cheng et al., 2007, Whitson et al., 2008) and enhanced 
post-operative recovery (Che et al., 2013, Demmy and Nwogu, 2008). Furthermore, VATS has 
allowed patients of an advanced age or poor cardiopulmonary fitness, who would previously have 
been denied surgery, to undergo lung resection, thereby improving their prognosis and survival. 
Although both cardiopulmonary fitness and pulmonary function are strong independent predictors 
of post-operative pulmonary complications (PPCs) after thoracic surgery, adequate preoperative 
evaluation and management of these patients should be undertaken to minimize post-operative 
morbidity and prevent further deterioration.       
A recent review conducted by a panel of experts recommended pulmonary rehabilitation 
as part of the preoperative measures to optimize functional status before thoracic surgery (Jones et 
al., 2013). Pulmonary rehabilitation (PR) is a non-pharmacological, cost-effective intervention 
aimed at improving the physical and psychological status of people with chronic respiratory disease 
(Spruit et al., 2013, Rochester et al., 2015). Exercise training (especially endurance training) is 
regarded as the cornerstone of the whole intervention and it can be argued that it is the most 
effective therapy for improving dyspnoea, exercise tolerance and HRQoL in chronic obstructive 
pulmonary disease (COPD) (Casaburi, 2008). Recent research conducted in the context of lung 
cancer suggests that exercise training delivered both pre- and postoperatively is safe and can also 
improve exercise capacity, pulmonary function, HRQoL and global functioning (Granger et al., 
2011, Nagarajan et al., 2011). However, the majority of the research has been conducted in patients 
undergoing conventional thoracotomy. With the widespread use of videothoracoscopic resection 
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in the management of lung cancer, it is unknown whether patients undergoing VATS for lung 
lesions can benefit from a PR intervention in a similar way to those operated on by thoracotomy. 
Additionally, there is still some controversy regarding the impact of the surgical approach on the 
short- and long-term outcomes, particularly those related to functional and psychological well-
being. Finally, very few randomized controlled trials have been undertaken to assess the 
effectiveness of a preoperative intervention on functional outcomes in comparison to the standard 
care. Therefore, it’s the purpose of this thesis to fill those gaps in the literature and to provide a 
solid foundation for further research. 
SIGNIFICANCE OF RESEARCH 
Lung cancer is the second most common malignant diagnosis among Spanish men and 
the fourth among women (GLOBOCAN, 2012). According to the latest report of the Spanish 
Bureau of Statistics, 21,664 people died of lung cancer in 2013, which translates into a 0.8% 
increase in comparison to previous data. Despite this increment in raw mortality, the five-year 
overall survival rates have been slowly increasing in recent decades, especially among patients 
with localized disease (De Angelis, 2014). About 50 to 68 % of those patients diagnosed with stage 
I and II NSCLC would become lung cancer survivors each year (living five or more years after 
diagnosis). However, a high percentage of them still experience some degree of dyspnoea and 
fatigue for a long time after treatment cessation, which could lead to low physical activity levels 
and poor HRQoL (Ostroff et al., 2011, Coups et al., 2009, Feinstein et al., 2010). Although post-
operative rehabilitation has been successfully undertaken in this population to restore functional 
capacity (Crandall et al., 2014, Cavalheri et al., 2014), the appropriate timing for exercise has not 
been established yet. Furthermore, it is common for patients after lung resection to undergo 
adjuvant chemo- or radiotherapy, which may limit the subject’s capacity and willingness to engage 
in an exercise-based programme. In this scenario, prehabilitation of patients awaiting surgery may 
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be a better way to reduce post-operative morbidity and accelerate recovery than post-operative 
interventions, especially in elderly patients and individuals with poor preoperative status (Gillis et 
al., 2014, Debes et al., 2014).  
OBJECTIVES 
The aims of this thesis were: 
a) To identify, synthesize and analyse the current body of evidence regarding the effectiveness 
of a preoperative exercise-based intervention for improving functional capacity, exercise 
tolerance, HRQoL and post-operative outcomes in lung cancer patients. 
b) To assess the feasibility, safety and tolerability of a supervised pulmonary rehabilitation 
programme in individuals awaiting lung resection surgery by VATS. 
c) To examine the efficacy of the preoperative intervention for enhancing exercise capacity, 
functional capacity, muscle strength and HRQoL and hastening post-operative recovery. 
d) To provide a solid foundation for further research involving patients in the preoperative 
period of diverse cancer types to reduce post-operative morbidity and accelerate functional 
and psychological recovery. 
THESIS STRUCTURE 
I. Chapter one provides an overview of lung cancer including the latest trends and advances 
in epidemiology, aetiology, diagnosis, treatment and prognosis, with a special focus on 
NSCLC. This chapter plays an important role in stating the magnitude of the problem 
and the need for further research in this field.   
II. Chapter two looks more deeply into the clinical and socio-economic impact of lung 
cancer in our society, providing a detailed description of the lung cancer patient 
including major signs and symptoms, associated co-morbidities and other findings 
related to the disease and its background.  
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III. Chapter three presents a description of the perioperative management of the patient 
being considered for lung resection surgery, including the potential risks associated 
with surgery and the impact of the treatment on the short- and long-term outcomes.  
IV. Chapter four contains the results of a systematic review and meta-analysis of the 
effects of a preoperative exercise-based intervention on post-operative and 
functional outcomes in patients with lung cancer. This piece of research is 
fundamental to set the current body of knowledge in the topic as well as the 
limitations and research gaps. 
V. Chapter five reports on the results of a pilot investigation conducted in a small 
sample of individuals with lung malignancies awaiting VATS to assess the viability 
of the research project in terms of feasibility, tolerability and safety.   
VI. Chapter six details the results of the main study of this thesis, a randomized single-
blinded controlled trial undertaken in patients with suspected or confirmed lung 
cancer undergoing VATS. Post-operative morbidity, functional exercise capacity, 
muscle strength and health-related quality of life were analysed pre- and post-
intervention and in comparison to the standard care to determine the effectiveness 
of the intervention for enhancing physical functioning and accelerating recovery. 
VII. Finally, chapter seven summarizes the main findings yielded by this thesis as well 
as recommendations for future research.
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CHAPTER ONE:  LUNG CANCER – AN OVERVIEW 
1.1 Brief history of lung cancer 
 Lung cancer was once a rare disease. In the early 1900s, only about 140 cases had been 
published in the medical literature (Proctor, 2012). One of those was the case of Mary Benbow, a 
woman who was admitted to Guy’s Hospital in London complaining of shortness of breath, 
haemoptysis and a dry cough. She had been presenting symptoms for at least two years and she 
died only a couple of months after being admitted to the hospital with her doctors not knowing 
what to do to save her life. It was not until the autopsy was carried out that the doctors saw a 
proliferation of cells in her lung similar to that seen in other malignant diseases (Timmermann, 
2014). In 1840 there were only 2,786 cases of cancer reported in England and Wales. By 1905, the 
number of diagnosed cases had increased tenfold (Adler, 1980). This led physicians to 
acknowledge that the disease was becoming more common and they started to look for a cause. 
The American doctor Isaac Adler was the first to strongly suggest that smoking and alcohol abuse 
were the main causes of lung cancer. By the end of World War II, the link between smoking and 
lung cancer incidence was evident, with the first epidemiological studies showing the likelihood of 
tobacco smoking leading to the development of lung cancer. These first impressions were later 
confirmed with animal experimentation and with the discovery of cancer-causing agents present in 
cigarette smoke (Proctor, 2012).  
 If there is any hope for a cure for lung cancer, Adler wrote in 1912, he expected it to come 
from surgeons (Timmermann, 2014). That same year, Dr. Morriston Davies, a surgeon from the 
London Chest Hospital, was the first to perform what is today considered the first successful 
dissection lobectomy. However, the patient barely made it through the surgery and died on the 8th 
post-operative day of an empyema (Timmermann, 2014). The first lung cancer lobectomy was 
performed in 1933 by Evarts Graham and was later recognized as the most dramatic contribution 
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to pulmonary resection (Meade, 1961). Only a few months later, Dr. Edward Archibald at the Royal 
Victoria Hospital in Montreal performed the first successful hilar dissection pneumonectomy for a 
sarcoma of the left upper lobe (Deslauriers et al., 2011). Thanks to further advances in anaesthesia, 
the development of modern mechanical ventilators and most importantly the widespread use of 
penicillin, lung cancer became successfully treated. By 1990, surgery was universally 
acknowledged as the gold treatment for lung cancer and it has remained so ever since.  
 In 1992, Landreneau and colleagues described the first lobectomy using a minimally 
invasive technique (Landreneau et al., 1992). Two decades later, video-assisted thoracic surgery 
(VATS) has become the treatment of choice for stage I NSCLC, and as the technique evolves 
further, the percentage of thoracic surgeries performed by VATS continues to rise. Thanks to this 
minimally invasive approach, patients with poor pulmonary function, high body mass index (BMI), 
poor performance status and/or severe cardiovascular and respiratory co-morbidities have been 
surgically treated improving their prognosis and survival. 
 Despite the advantages in local and systemic therapies, lung cancer continues to be the 
leading cause of cancer-related death worldwide and is expected to surpass cardiovascular diseases 
as the top cause of overall death. In this chapter, an overview of lung cancer epidemiology, 
aetiology, diagnosis and current treatment modalities is provided to establish the magnitude of the 
problem and the need for further research. 
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1.2 Epidemiology of lung cancer: incidence, mortality and five-year survival rates 
1.2.1 Incidence of lung cancer 
 With an estimated 1.8 million new cases around the world, lung cancer is the most 
frequently diagnosed cancer accounting for 13% of all diagnoses (Torre et al., 2015, American 
Cancer Society, 2015). In males, lung cancer is both the most frequent malignancy and the most 
fatal, resulting in more than 1 million deaths in 2012. In more developed countries, lung cancer is 
also the leading cause of cancer death in females, being responsible for 209,900 deaths in 2012 
(Figure 1.1). In the US, lung cancer accounts for more deaths than breast, prostate and colorectal 
cancers combined (approximately 27% of all cancer deaths) (Siegel et al., 2015).  
 
 The highest incidence of lung cancer is currently found in more developed countries, and is 
particularly frequent in Australia and New Zealand, where it is the most common type of cancer 
diagnosed in both sexes, and in southern Europe (Torre et al., 2015) (Figure 1.2). The incidence of 
lung cancer in women is generally lower than in men, and appears to be markedly influenced by 
geographical location. For instance, in eastern Asia, lung cancer is relatively common among 
women despite the lower prevalence of smoking (International Agency for Research Cancer, 2012). 
Figure 1.1: Incidence and mortality in developed countries; GLOBOCAN, 2012. 
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  Figure 1.2: Lung Cancer Incidence Rates by sex and World Area; GLOBOCAN, 2012. 
In Spain, numbers are consistent with the other Western developed countries. Data derived 
from the GLOBOCAN study show that lung cancer is the second most common malignancy among 
men and the fourth among women, accounting for 12.4% of all diagnoses (Table 1.1) (Sociedad 
Española de Oncologia Medica, 2014). The raw incidence rates varied between regions ranging 
from 51.5 to 102 in men (with the maximum incidence reported in 1997–1999) and from 2.4 to 20 
in women (Sánchez De Cos Escuín, 2009).  
Table 1.1: Most common cancer types diagnosed in Spain; GLOBOCAN, 2012. 
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 International variations in lung cancer rates and trends are a reflection of the geographical 
and sex differences in the tobacco epidemic (Torre et al., 2015). In developed countries, lung cancer 
incidence has started to plateau as a result of the anti-tobacco politics and consequent reduction in 
smoking prevalence, while in less developed countries, the incidence continues to grow. In the US, 
for instance, where tobacco consumption peaked in the mid-1960s, lung cancer incidence has been 
steadily declining since 1980 in males and more recently in females (Figure 1.3) (Houston et al., 
2014). In contrast, in Spain, lung cancer incidence has started to decline in men but continues to 
rise in females (Figures 1.4) (Sánchez et al., 2010, Linares et al., 2015). The male-to-female ratio 
has also experienced a significant change in recent years due to the increase in smoking prevalence 
among women; in the US, the ratio is approaching the unity (1.5:1) (Houston et al., 2014), while 
in Spain, although the difference is still significant, the gap is slowly closing (from 7:1 in 2006 to 
4:1 in 2012) (Sánchez et al., 2010). 
 
  
Figure 1.3: Cancer Incidence trends in US in males and females; Torre et al., 2015. 
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1.2.2 Prevalence of lung cancer 
Prevalence refers to the number of people diagnosed with lung cancer who are alive 
regardless of the time from diagnosis. Prevalence is determined by two factors: incidence and 
survival. In 2008, the estimated five-year prevalence of lung cancer in Spain was 4.8%, which 
means that 28,148 people were alive after a lung cancer diagnosis (Bray et al., 2013). The five-year 
most prevalent cancers in our country are breast (17.9%) and prostate (31.4%) in females and 
males, respectively.   
1.2.3 Mortality and five-year survival rates 
Lung cancer is the leading cause of cancer-related death worldwide (Torre et al., 2015). 
According to the latest report of the National Bureau of Statistics, in Spain, 21,664 people died of 
lung cancer in 2013 accounting for 20.6% of all cancer deaths (Sociedad Española de Oncologia 
Medica, 2014). By gender, lung cancer was the leading cause of cancer-related deaths in males and 
Figure 1.4: Cancer Incidence trends in males (A) and females (B) in some European Countries; SEOM, 2014. 
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the second in women. This represents a small reduction of -0.7% for men but a significant increase 
of 7.3% for females (Instituto Nacional de Estadistica, 2015).  
Globally, mortality from lung cancer has been declining over the past two decades in males 
but has increased in women (Cayuela et al., 2008) (Figure 1.5). This variation is caused by historical 
differences in tobacco consumption between males and females, with women achieving peak 
tobacco consumption about a decade later than men. In Spain, even though tobacco consumption 
has been steadily reducing in recent years, it is expected that we must wait around 10 to 15 years 
to actually see a reduction in lung cancer incidence and mortality (Hernández et al., 2006). 
   
Figure 1.5: Mortality trends in Spain for males and females (1985–2005); Hernández et al., 2006.            
The elevated mortality registered for lung cancer is mostly due to the tardiness in the 
detection of the disease. At the time of diagnosis, approximately 70% of patients will present with 
advanced disease (Hernández et al., 2006), which accounts for the lowest survival rate. The overall 
five-year survival rates for lung cancer are 18% in the US (Siegel et al., 2015), around 13% across 
European countries and 10.7% in our environment (De Angelis et al., 2014). Likewise for many 
cancer types, the five-year survival rates for lung cancer are stage-dependent: 78.6% for stages IA 
and IB, 54% for stages I and II combined, 39.8% for stage IIIB and only 4% for advanced, distance 
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disease (Hernández et al., 2006, Jones et al., 2009a, Alberg et al., 2013). In light of these figures, 
patients at high risk of developing lung cancer (heavy smokers, patients with COPD) should be 
monitored closely to enable an early diagnosis and optimize treatment. 
1.3 Aetiology of lung cancer 
1.3.1 Tobacco exposure 
The most dramatic aspect of lung cancer is that 90% of related deaths are entirely 
preventable (Proctor, 2012). Tobacco smoking is, by far, the leading cause of lung cancer in 
developed countries. The World Health Organization (WHO) estimates that 70% of the lung cancer 
diagnoses worldwide are caused by cigarette smoking. In developed countries, smoking is 
responsible for up to 90% of lung cancer cases (Alberg et al., 2013, León-Atance et al., 2011). The 
relationship between smoking and lung cancer was first suggested by Isaac Adler in the first decade 
of the twentieth century and it became more obvious in the mid-1900s, when two large 
observational studies conducted in the US found that 96.5% of lung cancer diagnoses occurred in 
those who had been moderate to heavy smokers for many years (Wynder and Graham, 1950). In 
fact, compared with those who have never smoked, current smokers have a tenfold increased risk 
of developing lung cancer (Sánchez De Cos Escuín, 2009, Alberg et al., 2013). Although the risk 
decreases gradually after quitting, even for those who gave up smoking 40 years ago, the risk of 
lung cancer remains higher than for lifetime non-smokers (Alberg et al., 2013).  
The risk of lung cancer in smokers is strongly correlated with the number of cigarettes 
smoked per day as well as the number of years smoking (De la Cruz et al., 2011). Heavy smokers 
have a 20- to 30-fold increased risk of developing lung cancer than lifetime non-smokers. Other 
factors such as age of onset and depth of inhalation also influence the risk of developing the disease 
(De la Cruz et al., 2011). In addition, changes in cigarette composition, including less nicotine and 
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the use of filters, have affected smoking patterns and now smokers tend to smoke more vividly 
with deeper inhalations to satisfy their nicotine needs (De la Cruz et al., 2011). Despite the strong 
link between smoking and lung cancer, only one out of nine smokers will develop the disease in 
the course of their lifetimes (De la Cruz et al., 2011), suggesting that there are also other powerful 
factors involved.  
Pipe and cigar smoking have also been associated with an increased risk of lung cancer but 
the relationship seems weaker than with cigarette smoking, possibly due to the differences in 
smoking frequency and/or depth of inhalation (De la Cruz et al., 2011, Alberg et al., 2013). 
Although an association between smoking marijuana or other opioids and lung cancer is likely to 
exist, there is currently no evidence to back up this assumption (Alberg et al., 2013).  
Smoking is also the main risk factor for lung cancer in our country (Hernández et al., 2006). 
The prevalence of smoking among individuals recently diagnosed with lung cancer has been 
reported to be as high as 95% in several national series (León-Atance et al., 2011, Montero et al., 
2003, Gullón et al., 2012). All lung cancer types are associated with smoking; however, there are 
some differences across the histological types. For example, it has been demonstrated that small-
cell lung cancer (SCLC) has the strongest association with tobacco consumption while some 
histological types of NSCLC are more common among non-smokers. Furthermore, lung cancer 
among non-smokers is almost considered a different entity since it exhibits a completely different 
behaviour affecting primarily women and is strongly associated with geographic location (De la 
Cruz et al., 2011).  
1.3.2 Second-hand smoke exposure 
Tobacco can also cause lung cancer indirectly in lifetime non-smokers. Second-hand smoke 
exposure is responsible for 1.6% of all cases of lung cancer and 21,400 deaths annually (Molina et 
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al., 2008, Alberg et al., 2013). Living together with a smoker is highly associated with lung cancer 
in non-smokers as it is has been shown to increase the risk of developing lung cancer in 30% 
(Alberg et al., 2013). More importantly, researchers believe that second-hand smoke exposure 
during childhood and early adolescence is responsible for approximately 17% of the lung cancer 
cases in non-smokers (De la Cruz et al., 2011). The studies also suggest that the longer the 
exposure, the higher the risk.  
1.3.3 Environmental and occupational carcinogens 
Environmental and/or occupational exposure to certain carcinogens is the other major cause 
of lung cancer and is estimated to be responsible for 10% of all diagnoses in developed countries 
(Alberg et al., 2013). Many work settings involve being exposed to several well-known carcinogens 
(Table 1.2). Asbestos is derived from silicate minerals and is the most common occupational agent 
associated with lung cancer (De la Cruz et al., 2011). It is not clear, however, whether it is the 
exposure itself or the consequent asbestosis after being repeatedly exposed to asbestos that actually 
causes lung cancer (De la Cruz et al., 2011). Radon contamination is another common occupational 
carcinogen and is estimated to be responsible for at least 15% of all lung cancer diagnoses in the 
US and 11% of deaths (Alberg et al., 2013, De la Cruz et al., 2011). In lifetime non-smokers, the 
effects of radon contamination are especially noticeable (accounting for 70% and 30% of incidence 
and deaths, respectively).  
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Table 1.2: Common carcinogens found in the workplace; Alberg et al., 2013. 
Outdoor and indoor pollution derived from the combustion of fossil and natural fuels has 
also been linked to an increase in lung cancer risk, especially in heavily industrialized countries 
such as the US, Japan and China. In Europe, the proportion of lung cancer diagnoses attributable 
to outdoor pollution is estimated to be around 11% (Molina et al., 2008). In less developed areas 
such as southern Asia, outdoor and especially indoor pollution are the most common causes of lung 
cancer in women, causing approximately 80% of all diagnoses (De la Cruz et al., 2011). The 
precarious working conditions reported in those countries, including overcrowding and the absence 
of ventilation systems, could mainly explain the high percentage of lung cancer found in this 
population. Nonetheless, a large fraction of cases of lung cancer in non-smokers don’t respond to 
any of the aforementioned causes, which means that in this population, there might be intrinsic, 
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lifestyle and environmental factors determining the likelihood of developing lung cancer, which 
will be covered in the next subsections.  
1.3.4 Genetic factors 
Genetic factors are deemed to play an important role in the risk of developing lung cancer. 
In a meta-analysis of 41 cohort and case-control studies, the authors concluded that having a family 
history of lung cancer (two or more relatives) was associated with a 1.7-fold increase in lung cancer 
risk (95% CI: 1.6–1.9) (Lissowska et al.). Given the potential association between genetics and 
lung cancer, several studies have focused on candidate susceptibility to developing lung cancer 
targeting the genes involved in the absorption, metabolism and accumulation of tobacco and other 
known carcinogens (De la Cruz et al., 2011). Mutations in the epidermal growth factor receptor 
(EGFR) have been associated with an increased risk of several cancer types, including lung cancer. 
Gene polymorphism factor has been reported as being an important factor that increases the 
susceptibility of lung cancer (Feng et al., 2014). In 40% to 80% of NSCLC patients, EGFR is 
overexpressed, which is associated with a poor prognosis. This finding has led researchers to 
investigate new targeted therapies, with several EGFR inhibitors being currently tested (Molina et 
al., 2008).    
1.3.5 Age, gender and other non-modifiable factors 
Aging is the single biggest risk factor for cancer. For many years, cancer was a disease 
associated with the elderly and nowadays, with our lifespan being constantly extended, the number 
of patients over 80 years old who are diagnosed with lung cancer has noticeably increased. In fact, 
currently, more than 50% of individuals diagnosed with lung cancer are over 70 years old (De la 
Cruz et al., 2011). Aging is a natural process that occurs as a result of cell senescence. The precise 
pathways involved in the relationship between aging and carcinogenesis are not entirely known 
and are beyond the scope of this thesis. In brief, aging is associated with multiple events occurring 
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at a molecular, cellular and physiologic level that influence carcinogenesis and ease cancer growth. 
Three major hypotheses have been proposed to explain the association between age and cancer. 
The first holds that the link between the two processes is a mere consequence of the duration of the 
exposure to carcinogens. The second maintains that the natural changes occurring at a cellular and 
physiologic level during aging provide a more favourable environment for already existent but 
otherwise latent malignant cells to grow. Finally, the last theory is fundamentally a combination of 
both the previous hypotheses (Anisimov, 2007).  
Lung cancer has been traditionally associated with male gender. However, lung cancer 
among women has exponentially increased over the past two decades and has now surpassed breast 
cancer as the leading cause of cancer death in more developed countries (Torre et al., 2015). The 
increase in lung cancer incidence and mortality among women has been attributed to the historical 
differences in smoking patterns between the sexes (women started smoking later than men and 
peak consumption was reached one decade later) but also to the premise that women are more 
susceptible to the adverse effects of smoking than men. A study using National Health Foundation 
data in the US found that the relative risk of lung cancer was consistently higher in women than in 
men even after adjusting for cigarette consumption (Zang and Wynder, 1996). This presumption 
has also been used to explain the increase in COPD incidence among women in recent years. 
However, there is still much controversy around the topic and no definitive conclusions can be 
drawn.  
Significant variations in the incidence and mortality of lung cancer have been reported 
among different races and ethnicities. Black race has been associated with high incidence of lung 
cancer and poor prognosis in several epidemiological studies even though white Americans smoke 
in larger quantities than black Americans (De la Cruz et al., 2011). The five-year survival rates 
have also been reported to be substantially lower for black Americans than their white counterparts 
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(Siegel et al., 2015). Conversely, the risk of lung cancer seems to be lower among other non-
Caucasian races such as Hispanic and Asian at equal smoking dosage.  
1.3.6 Lifestyle and other modifiable factors 
The presence of an underlying respiratory disease can increase the risk of developing lung 
cancer. Chronic obstructive pulmonary disease (COPD) is strongly associated with lung cancer, 
especially in men, though it is not clear whether the co-occurrence is in fact a cause-effect 
relationship, since both of them are closely linked to tobacco consumption. In a study comparing 
smokers with and without COPD, authors found that individuals with COPD had a six-fold 
increased risk of developing lung cancer than those without COPD, which indicates that there might 
be some pathophysiological factors in COPD beyond smoking implicated in the risk of developing 
lung cancer (Young et al., 2009). This finding is consistent with other investigations that have 
shown that there is a strong association between chronic airflow obstruction and lung cancer after 
controlling for smoking habits, with a 2.8-fold increase in the lung cancer risk in those individuals 
with moderate or severe pulmonary obstruction (95% CI: 1.8–4.4) (Mannino et al., 2003). In this 
line of research, asthma has been identified as an independent risk factor associated with lung 
cancer particularly for non-adenocarcinomas (Santillan et al., 2003). Other common respiratory 
diseases that have been associated with lung cancer are tuberculosis and idiopathic pulmonary 
fibrosis (Alberg et al., 2013). 
Diet and physical activity have also been extensively studied regarding their protective 
effect in several cancer types. So far, the intake of fruits and vegetables is the only dietary factor 
associated with a low risk of lung cancer (De la Cruz et al., 2011, Alberg et al., 2013). It is believed 
that the antioxidants contained in them could play an important role in preventing several cancers. 
In particular, vitamin A and beta-carotenes were associated with a decrease in lung cancer risk (De 
la Cruz et al., 2011). Cruciferous vegetables such as broccoli and cauliflower have also been found 
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to be independently associated with a decrease in lung cancer risk (Alberg et al., 2013). In 
particular, this reduction seems to be stronger for certain histological types (non-squamous cell 
carcinoma) (Deng et al., 2013). On the other hand, it has been suggested that a diet rich in saturated 
fats derived from animal sources increases lung cancer risk but the evidence is limited to a few 
observational studies. Even so, it has been suggested that for individuals with a high risk of 
developing lung cancer, a diet low in red meat and processed meat might be preferable (Deng et 
al., 2013). Alcohol intake in large amounts has also been associated with an increase in lung cancer 
risk (De la Cruz et al., 2011).  
Last but not least, physical activity has been strongly associated with a reduction in the risk 
of several cancer types, especially breast and colon, and an improvement in cancer-related and 
overall mortality in cancer survivors. Moderate to high physical activity can significantly reduce 
cancer risk by approximately 16% to 30% (Tardon et al., 2005, Shi et al., 2015, Emaus and Thune, 
2011). After a cancer diagnosis, maintaining appropriate levels of physical activity results in a 
significant reduction in mortality and disease recurrence (Li et al., 2015, Zhong et al., 2014, Je et 
al., 2013, Meyerhardt et al., 2006). In the lung cancer setting, moderate to high levels of physical 
activity have been shown to reduce the risk of lung cancer by 13% and 23%, respectively (OR = 
0.87; 95% CI: 0.83–0.90 and OR = 0.77; 95% CI: 0.73–0.81, respectively) (Sun et al., 2012). Some 
studies have reported different results for males and females. Emus et al., in a systematic review 
conducted in 2011, reported that while four out of six studies had found a statistically significant 
reduction in lung cancer risk among physically active men, only one of the four studies reported 
the same association among women (Emaus and Thune, 2011). However, these differences could 
be just due to the histological type of lung cancer, the percentage of smokers versus non-smokers 
in both males and females and other confounding factors. 
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1.4 Classification of lung cancer 
Tumours of the lung include a wide range of different histopathological features. The WHO 
and the International Association for the Study of Lung Cancer (IASLC) distinguish four main 
histological types, which are divided into small- and non-small-cell lung cancer. The former 
accounts for around 15% of all lung cancer diagnoses and has been traditionally classified as 
limited disease or extensive disease. Non-small-cell lung cancer encompasses several histological 
types, with the most common being adenocarcinoma, squamous-cell carcinoma and large-cell 
carcinoma (Figure 1.6). Squamous-cell carcinoma (SCC) was traditionally the most frequent 
histologic type but recently there has been a shift and adenocarcinoma has now replaced SCC as 
the most diagnosed type of lung cancer, especially among women, accounting for approximately 
40% of all NSCLCs (Houston et al., 2014, Leiro-Fernández et al., 2014) (Figure 1.7). Carcinoid 
tumours are neuroendocrine growths that can also be found in the lungs, although they represent a 
minority of lung cancer diagnoses (2%) (Iglesias et al., 2004). This slow-growing tumour is more 
likely to affect young people and is frequently found in non-smokers. The prognosis is very good 
and most patients manage to survive 15 years and more (Iglesias et al., 2004). 
 
 Figure 1.6: Classification of lung cancer.  
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Figure 1.7: Changes in histological features over two decades in Spain; Leiro-Martinez, 2014. 
NSCLC is further classified according to the TNM Staging System developed by the 
IASLC, which takes into consideration three parameters: tumour size (T), number of lymph nodes 
affected (N) and the presence of distant metastases (M). A summary of the description of each 
component is shown in Table 1.3.  
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The current TNM classification was updated in 2009 with the introduction of some changes 
in the T and N components. Compared to the previous version, the new TNM included a 
subdivision of the T1 and T2 classification resulting in 5 different categories, and a reclassification 
of some special conditions (Table 1.4).  
Descriptors Definitions 
T 
Tx 
Tis 
T0 
T1 
 
T1a 
T1b 
T2 
 
 
 
T2a 
T2b 
T3 
 
 
 
 
 
T4 
Primary tumour 
The primary tumour cannot be measured 
Tumour in situ 
No primary tumour 
Tumour ≤ 3 cm, surrounded by lung or visceral pleura, not more 
proximal than the lobar bronchus 
Tumour ≤ 2 cm 
Tumour ≥ 2 cm but ≤ 3 cm 
Tumour > 3 cm but ≤ 7 cm or tumour with any of the following: 
invades visceral pleural, involves main bronchus ≥ 2 cm distal to 
the carina, atelectasis/obstructive pneumonia extending to hilum 
but not involving the entire lung 
Tumour > 3 cm but ≤ 5 cm 
Tumour > 5 cm but ≤ 7 cm 
Tumour > 7 cm or 
invading chest wall, diaphragm, phrenic nerve, mediastinal 
pleural or parietal pericardium; 
or tumour in the main bronchus < 2 cm distal to the carina; 
or atelectasis/obstructive pneumonitis of the entire lung 
or separate tumour nodules in the same lobe 
Tumour of any size with invasion of heart, great vessels, trachea, 
recurrent laryngeal nerve, oesophagus, vertebral body or carina, 
or separate tumour nodules in a different ipsilateral lobe 
N 
Nx 
N0 
N1 
 
 
N2 
N3 
Regional lymph nodes 
Lymph nodes cannot be assessed 
No evidence of regional node metastasis 
Metastasis in ipsilateral peribronchial and/or perihilar lymph nodes 
and intrapulmonary nodes, including involvement by direct extension 
Metastases in ipsilateral mediastinal and/or subcarinal lymph nodes 
Metastases in contralateral mediastinal, contralateral hilar, ipsilateral 
or contralateral scalene or supraclavicular lymph nodes 
M 
Mx 
M0 
M1a 
 
M1b 
Distant metastases 
Distant metastases cannot be assessed 
No evidence of distant metastases 
Separate tumour nodules in contralateral lobe 
or tumour with pleural nodules or malignant pleural 
dissemination 
Distant metastases 
Table 1.3: 7th edition of the TNM staging system 
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Table 1.4: Updates in the 7th TNM Staging System 
Component Changes 
T T1: 
T1a: ≤ 2 cm 
T1b: > 2 cm ≤ 3 cm 
T2: 
T2a: > 3 cm ≤ 5 cm 
T2b: > 5 cm ≤ 7 cm 
T2 > 7 cm changes to T3 
T4 for additional nodule(s) in the same lobe 
changes to T3 
T4 for malignant pleural effusion changes to M1a 
M1 for additional nodule(s) in the ipsilateral side 
changes to T4 
N No change 
M M1: 
M1a: additional nodule(s) in the contralateral side 
or malignant pleural effusion  
M1b: distant metastases 
Once the tumour size, lymph nodes affected and the presence of metastases have been assessed, 
the TNM system provides a distribution of the tumours for stages of the disease. This classification 
was made according to the prognosis and five-year survival rates for each category and is 
summarized in Table 1.5 and Figures 1.8 and 1.9 (Detterbeck et al., 2013a). 
Table 1.5: TNM Staging System; ACCP, 2013 
T/M N0 N1 N2 N3 
T1a 
T1b 
IA 
IA 
IIA 
IIA 
IIIA 
IIIA 
IIIB 
IIIB 
T2a 
 
T2b 
IB IIA IIIA 
IIIA 
IIIB 
IIIB 
IIA IIB 
T3 IIB IIIA IIIA IIIB 
T4 IIIA IIIA IIIB IIIB 
M1 IV IV IV IV 
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  Figure 1.8: Illustration of localized disease (stage I and II) according to the 7th edition of the TNM classification; 
Detterbeck, 2013. 
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Before the latest update, the TNM classification was only recommended for NSCLC, but 
according to the retrospective analysis performed using the new version, it can also be used to 
classify other intrathoracic malignancies such as small-cell lung cancer (SCLC) and carcinoid 
tumours (Rami Porta, 2009, Howington et al., 2013).  
1.5 Screening and diagnosis for lung cancer  
1.5.1 Screening for lung cancer 
One of the main challenges in lung cancer is the difficulty in obtaining an early diagnosis. 
Individuals with lung cancer rarely experience any symptoms in the early stages of the disease, 
Figure 1.9: Illustration of locally advanced disease (stage III) according to the 7th edition of the TNM 
classification; Detterbeck, 2013. 
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which minimizes the chances of detecting the illness on time. As a matter of fact, the vast majority 
of the cases diagnosed with stages I and II are made incidentally during a workup for other 
purposes. 
The primary purpose of a screening test is to reduce the chance of dying from one 
particular disease without causing any harm in the process (Detterbeck et al., 2013b). In the lung 
cancer context, this raises two main concerns: first, there is currently no definitive cure for lung 
cancer, and second, a systematic screening for lung cancer would involve some form of radiation, 
which is potentially harmful for the individual.  
Several screening tests have been studied over the last few years in an attempt to improve 
the number of cases diagnosed with early stage. A chest X-ray (CXR) is usually the first step in the 
workup of lung cancer, although they provide little proof of the disease. Increasing the frequency 
of CXRs has been proposed as a plausible and economic strategy for enhancing an early diagnosis 
in individuals at high risk of lung cancer; however, this approach has shown no effectiveness in 
reducing the mortality and therefore is currently not recommended by the main guidelines 
(Detterbeck et al., 2013b). Sputum analysis is an inexpensive and harmless procedure that can be 
added to a conventional CXR during screening for lung cancer. Some studies have suggested that 
performing a sputum analysis every four months might help detect some forms of NSCLC, 
especially in heavy smokers (Detterbeck et al., 2013b). However, these results were not statistically 
significant and thus it was concluded that a sputum analysis did not provide any additional benefit 
to an annual CXR. Screening with low-dose computed tomography (LCTD) has shown the best 
results so far. A large meta-analysis conducted by the National Lung Screening Trial found a 
dramatic 20% reduction in lung cancer mortality with LCTD compared to those screened with a 
CXR (RR: 0.80; 95% CI, 0.73–0.93) (Aberle et al., 2011). The risk of radiation-induced cancer 
was estimated to be only one cancer death for every 2,500 screened participants, thus LCTD is 
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currently the only recommended screening test for patients at high risk of lung cancer (Detterbeck 
et al., 2013a, Detterbeck et al., 2013b). 
1.5.2 Diagnosis of lung cancer 
As reported previously, patients with lung cancer may not exhibit any symptom at the time 
of diagnosis. In those cases, the suspicion of lung cancer arises from an abnormal CXR or CT scan 
despite clinical evidence of the disease. A pulmonary nodule is defined as a single, well-
circumscribed, radiographic opacity surrounded by aerated lung (Gould et al., 2013b) and 
constitutes the typical form of presentation of lung cancer. However, it is also frequently the result 
of an old inflammatory or infectious disease (such as tuberculosis or pneumonia); in this case, a 
review of an old CXR is recommended before proceeding with further analysis (Gould et al., 
2013b). In the case that a nodule has shown no growth in the past two years, no more additional 
evaluation is recommended. The size of the nodule as well as the morphology are two basic features 
to look at before moving to the next step. Usually, nodules measuring less than 8 mm or showing 
smooth borders are more likely to be benign in nature than those bigger than 8 mm or with 
spiculated borders. In Figure 1.10 an algorithm of the recommended management of an individual 
with pulmonary nodule(s) is shown. 
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 Approximately 80–85 % of lung cancer cases corresponds to NSCLC (Rivera et al., 2013, 
de Cos Escuín et al., 2006, León-Atance et al., 2011, Jones et al., 2009a). In patients suspected of 
having NSCLC, the preferred diagnostic technique is usually based on the presumed stage of the 
disease (Rivera et al., 2013). Sputum cytology, bronchoscopy (including flexible bronchoscopy), 
endobronchial ultrasound (EBUS) and transthoracic needle aspiration are the most common 
methods besides surgical biopsy for diagnosing lung cancer. Sputum cytology is the least invasive 
and is more recommended for central tumours (SCLC and squamous-cell carcinoma), especially in 
high-risk patients (heavy smokers, low pulmonary function, etc.). Bronchoscopy and flexible 
bronchoscopy are also recommended for central tumours and constitute an excellent alternative to 
mediastinoscopy for the assessment of lymph nodes. Plus, the addition of an endobronchial needle 
aspiration to obtain cytology or histology samples substantially improves the sensitivity of the test 
(Rivera et al., 2013). In contrast, for peripheral tumours, bronchoscopy has proved to be less 
Figure 1.10: Algorithm in the management of individuals with pulmonary nodules; Gould, 2013. 
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effective and sensitivity is considerably lower (Rivera et al., 2013). Furthermore, bronchoscopy is 
also greatly affected by the size of the lesion (the larger the better). In those tumours, radial EBUS 
has shown more sensitivity and specificity than bronchoscopy (73% and 100%, respectively) 
(Rivera et al., 2013). Finally, transthoracic needle aspiration has also shown good sensitivity in the 
diagnosis of peripheral nodules (90%). Importantly, even if these tests come up negative, in the 
context of a clinical suspicion of lung cancer further investigations are warranted. The next step 
would involve a surgical biopsy of the tissue (usually by means of thoracoscopy) to provide final 
pathologic diagnosis or lung resection with exploratory/therapeutic intent (Rivera et al., 2013).  
1.6 Treatment for stages I and II of NSCLC(Swanson et al., 2007) 
1.6.1 Surgery 
Surgery is the treatment of choice for early stages of lung cancer (I and II) since it presents 
the best chance of cure (Benzo et al., 2007, Jones et al., 2009a, Ilonen et al., 2011). Selected patients 
with locally advanced disease (stage IIIA) can also be potentially treated with surgery and adjuvant 
chemotherapy to achieve complete remission (Crandall et al., 2014, Wilson, 1997). Unfortunately, 
stages I and II of NSCLC only account for 20% to 40% of lung cancer diagnoses (Howington et 
al., 2013, Leiro-Fernández et al., 2014, Gullón et al., 2012, de Cos Escuín et al., 2006). In those 
few cases, the presence of co-morbid diseases, advanced age, low cardiorespiratory fitness and 
poor pulmonary function can prevent patients from undergoing surgery safely (Beckles et al., 2003, 
Sekine et al., 2002, Luchtenborg et al., 2012). As a result, surgical rates for lung cancer are 
strikingly low, ranging from 11% in the UK to 27% in the US (Jones et al., 2009a, Lim et al., 2010). 
In Spain, the EPIClip Study of 2003 found a surgical rate of 14.8%, similar to the rates reported in 
most European countries (de Cos Escuín et al., 2006, Sánchez De Cos Escuín, 2009).     
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Lobectomy plus systematic lymphadenectomy has been the gold standard for lung cancer 
surgery since 1995, when a randomized controlled study conducted by the Lung Cancer Study 
Group found less cancer recurrence after lobectomy than after smaller resections (Ginsberg and 
Rubinstein, 1995). However, for those patients considered unfit to tolerate a lobectomy, the 
international guidelines recommend that a sublobar resection (wedge resection or segmentectomy) 
is preferred over no surgical treatment (Howington et al., 2013), since similar overall and cancer-
specific survival rates have been achieved after adjusting for age, stage and other influencing 
factors (Howington et al., 2013). At the other end, in the presence of large tumours (> 7 centimetres) 
or extensive lymph node invasion (N2), a pneumonectomy (removal of the whole lung) may be 
necessary. The decision to proceed with one or another should not only be justified in terms of 
oncological safety but also take into consideration the short- and long-term impairments associated 
with the procedure and the patient’s baseline functional status (this topic will be discussed in more 
detail in chapter three).     
The traditional approach to lung resection surgery consists of a posterolateral 
thoracotomy, which involves opening the ribcage and separating the adjacent muscles to access the 
lungs (Figure 1.11). However, over the past two decades, minimally invasive techniques have been 
steadily replacing the traditional approach and are now routinely performed around the world for 
the treatment of several respiratory diseases. Video-assisted thoracic surgery (VATS) has been 
inconstantly defined in the studies affecting the generalization of the results obtained. Today, 
VATS standard definition includes the use of video screen for guidance, two to three ports, and 
the absence of a retractor or rib spreading (Swanson et al., 2007). The technique, initially 
described for exploratory procedures, was used for the first time to perform a lobectomy in 1992 
in Italy (Landreneau et al., 1992, Roviaro et al., 1992). Since then, the surgical approach has been 
gaining acceptance thanks to the results published by some of the largest series (McKenna Jr et al., 
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2006, Gonzalez-Rivas et al., 2011, Loscertales et al., 2009) and is now the treatment of choice for 
early stages of lung cancer (Howington et al., 2013). Despite the initial misgiving among the 
cardiothoracic community, the technique has demonstrated identical oncological results when 
compared with open thoracotomy (Flores et al., 2011, Flores et al., 2009, Scott et al., 2010, Higuchi 
et al., 2014) and even less economic costs (Swanson et al., 2012).  
Although there is no standardized technique for the VATS approach, most surgeons make 
an anterior incision measuring three to five centimetres and then add one or two more ports so they 
can have better access to the lung (Figure 1.11). In 2010, surgeons at the Thoracic Surgery 
Department at the hospital of A Coruña went a little further and performed the first lobectomy 
using a single-port VATS with overall good short-term results (Gonzalez-Rivas et al., 2013). 
 
The main advantage of the videothoracoscopic approach over a conventional thoracotomy 
is that the incision to the patient’s chest is relatively minor, which leads to reductions in post-
operative infection and wound dehiscence. This hastens post-operative recovery and allows the 
Figure 1.11: VATS incision vs. posterolateral thoracotomy; Harris, 2012. 
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patient to return to full activity in a shorter time (Fan et al., 2013). For this reason, VATS could be 
an alternative to open thoracotomy for patients at high risk of developing post-operative 
complications and/or those denied surgery based on their cardiorespiratory fitness, poor pulmonary 
function or general frailty (Table 1.6). The specific benefits of the VATS approach will be 
discussed in detail in chapter three. 
Table 1.6: Special situations for which VATS may be preferable; Demmy, 2008 
  
Despite the large body of evidence supporting the superiority of VATS over the traditional 
approach, the number of videothoracoscopic lobectomies performed worldwide is still very low, 
accounting for only 16 to 20 % in the US and most European countries (Boffa et al., 2008, Begum 
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et al., 2014). Denmark has the highest VATS resection rates across Europe with 55% of 
lobectomies being performed using this approach (Begum et al., 2014). Spain also has extensive 
experience with more than 2000 cases performed. Out of the 46 hospital units surveyed in our 
country, three did not perform VATS and 22 responded positively (Begum et al., 2014), including 
our centre, where the vast majority of lung cancer patients (≥80%) are operated on using this 
approach.       
1.6.2 Radiation therapy 
Although surgical resection is the treatment of choice for localized disease, there are other 
plausible non-surgical options for those not able or willing to undergo surgery. International 
guidelines recommend that for high-risk patients with stage I NSCLC, conventional radiotherapy 
is an appropriate treatment option with curative potential, but five-year regional and overall 
survival remains suboptimal (Donington et al., 2012). Stereotactic body radiotherapy (SBRT) has 
been proposed as an effective alternative to conventional radiotherapy for treating stages I and II 
in patients who are unfit to tolerate sublobar resection or refused operation. SBRT differs from 
conventional radiotherapy in that it delivers shorter, more convenient regimens that involve smaller 
fields and higher doses delivered to the field (Howington et al., 2013). There are some advantages 
to this approach over surgical resection, including no need for hospitalization, better preservation 
of lung function, shortened waiting times and a faster return to daily life activities (Howington et 
al., 2013, Aragón et al., 2015). In addition, SBRT appears to have similar long-term outcomes to 
surgical resection of the tumour. For instance, an observational study comparing propensity-
matched patients with stage IA treated with surgical resection versus SBRT found no difference in 
local recurrence or overall three-year survival (Crabtree et al., 2010). Another recent study, 
however, found that after a median follow-up of 48 months, VATS offered better outcomes than 
SBRT in patients with pathologically proved stage I NSCLC (Hamaji et al., 2015). Plus, SBRT 
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cannot provide a pathologic confirmation of the tumour; given this, whenever possible sublobar 
resection is usually preferred over SBRT (Howington et al., 2013).  
Hadron therapy is another alternative to conventional radiotherapy for treating early but 
otherwise inoperable NSCLC, although it is extremely costly (Molina et al., 2008). The five-year 
survival rate for this treatment appears to be very similar to the rates observed after lung resection 
(60 to 65 %), thus it can be regarded as a good option for patients with non-resectable disease.  
Radiotherapy is also frequently administered in the form of post-operative radiotherapy 
(PORT), but the results found in the literature are quite controversial. Patients with resected stage 
I NSCLC appear to have worse survival after PORT, although the reasons for this are not 
completely clear (Howington et al., 2013). In contrast, a randomized controlled trial (RCT) 
published in 1996 found that in stage I NSCLC, PORT increased the five-year survival rate in 9% 
of patients in comparison to those who underwent surgery alone (p =0.048) (Trodella et al., 2002). 
Given the lack of consistent results, PORT is not currently recommended for stages I and II NSCLC 
unless there is a positive bronchial margin (Howington et al., 2013).    
1.6.3 Chemotherapy 
Lung cancer patients are at risk of developing local recurrence after lung resection surgery 
(Molina et al., 2008). Since the publication of a meta-analysis in 1995 showing a marginal increase 
in the five-year survival rates with adjuvant chemotherapy, several studies have been conducted 
comparing surgery alone with surgery plus chemotherapy (Molina et al., 2008). In an updated 
version of the meta-analysis, a 4% increase in the five-year survival rates was found (HR = 0.86; 
95% CI: 0.81–0.92) with little variation regarding the type of chemotherapy used (Burdett et al., 
2015). The problem with adjuvant chemotherapy lies in the difficulty of delivering the whole 
treatment, with some studies showing that only 70% of patients submitted to adjuvant 
chemotherapy finish their treatment (Howington et al., 2013). One alternative proposed to 
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overcome this issue is the delivery of the chemotherapy agents prior to lung resection. A Cochrane 
systematic review published in 2008 suggests that preoperative chemotherapy versus surgery alone 
can provide a slight increase in the five-year overall survival across all stages of NSCLC (Burdett 
SS, 2008). Another more recent meta-analysis found a significant benefit of preoperative 
chemotherapy on survival of 5% at five years (HR = 0.87; 95% CI: 0.78–0.96) and a 13% decrease 
in the relative risk of death (NSCLC Meta-analysis Collaborative Group, 2014). However, 
neoadjuvant therapy has also been identified as a risk factor for post-operative complications (Amar 
et al., 2010), hence the importance of conducting an exhaustive individual preoperative evaluation 
of surgical candidates to prevent potential mortality and morbidity. There is solid consensus in the 
literature not recommending chemotherapy for patients with stage IA since it doesn’t provide any 
additional benefit (Howington et al., 2013). This seems less obvious when dealing with patients 
with stage IB and further investigation is needed to draw definitive conclusions. For patients with 
stage IIA onwards, post-operative chemotherapy is clearly advocated whenever there is N1 node 
involvement (Howington et al., 2013).  
In summary, the current international recommendations for the treatment of resectable IA 
to IIIA NSCLC are the following: 
 For stages I and II NSCLC and no medical contraindications, surgical resection 
(lobectomy) is the preferred treatment (Grade 1B). 
 For patients with clinical stage I NSCLC, a minimally invasive approach is preferred 
over a thoracotomy (Grade 2C). 
 For patients with stages I and II who may not tolerate a lobectomy, sub-lobar 
resection (segmentectomy or wedge resection) is preferred over no surgical 
treatment (Grade 1B). 
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 For patients with stage I and II who cannot tolerate a sub-lobar resection 
(segmentectomy), SBRT plus wedge resection is suggested (Grade 2C). 
 Post-operative radiotherapy (PORT) is recommended to clear surgical margins after 
wedge resection (Grade 1C). 
 For stage I NSCLC, adjuvant therapy is not recommended outside of a clinical trial 
(Grade 1B). 
 For stages II to IIIA, adjuvant platinum-based chemotherapy is advocated (Grade 
1A). 
1.6.4 Complementary therapies in lung cancer: the role of exercise training 
Complementary therapies in individuals with lung cancer refer to those evidence-based 
techniques that are related to an improvement in physical and emotional well-being, HRQoL and 
alleviation of cancer-related symptoms (Deng et al., 2013). Those therapies include, but are not 
limited to, yoga, meditation, acupuncture, nutritional support, physical activity and exercise (Deng 
et al., 2013).  
Pulmonary rehabilitation (PR) is a comprehensive intervention designed to improve the 
physical and psychological condition of people with chronic respiratory diseases (Spruit et al., 
2013). PR has been raised to the category of gold standard therapy in the management of patients 
with COPD, where it has been shown to improve exercise and functional capacity, dyspnoea, 
muscular fatigue and HRQoL and reduce exacerbations and hospital admissions (Nici and 
ZuWallack, 2014, Ries et al., 2007). However, evidence of the effectiveness of PR, and particularly 
exercise, in other respiratory diseases is still limited. In the early 2000s, the first studies looking at 
the effects of PR on lung cancer started to emerge. Given the rationale for PR in COPD patients, it 
seemed logical to assume that PR could also result in significant improvements in people with lung 
cancer (Venturelli, 2010). Indeed, preliminary studies have shown an increase in exercise tolerance 
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and functional capacity in individuals with lung cancer, but inconsistent results have been found in 
other relevant outcomes such as HRQoL and pulmonary function.  
In patients with lung cancer, respiratory rehabilitation may play an important role across 
the whole continuum, from pre- to post-operative care (Bozonne, 2004) and in advanced disease. 
In the preoperative setting, exercise training could increase exercise capacity (peak oxygen 
consumption), which is associated with a lower incidence of post-operative complications and 
overall better surgical outcomes (Benzo et al., 2007). However, before implementing a preoperative 
PR programme in the context of lung cancer, the safety and feasibility of the intervention must be 
assessed. Throughout this thesis, we will examine the current literature on this topic and provide 
new evidence to support the implementation of such interventions in the lung cancer population.   
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CHAPTER TWO: CLINICAL AND SOCIO-ECONOMIC IMPACT OF LUNG CANCER 
2.1 Economic and health-care burden 
Lung cancer is a major public health issue. Economic costs incurred by lung cancer include 
those derived from its screening, diagnosis and therapeutic management but also those caused by 
the associated physical and psychosocial impairments (e.g. sick leave and labour incapacity) and 
early death. A recent study conducted among the 27 countries of the European Union estimated 
that in 2009 the costs originating from cancer were 126 billion euros, which accounted for 4% of 
the total health-care expenditure and 1% of gross domestic product (Luengo-Fernández et al., 
2013). Interestingly, the majority of the costs (60%) were attributed to productivity losses caused 
by cancer morbidity and mortality (Table 2.1).  
Table 2.1: Cost of cancer in the European Union in 2009 by country; Luengo-Fernández et al., 2013. 
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In Spain, the mean health-care cost per person was 90 euros, slightly under the European 
mean (102€) but higher than other close countries such as Portugal and the United Kingdom. Of 
all the cancer types included in the study, lung cancer had the highest economic impact in the whole 
of the European Union (18.8 billion, 15% of total cost). In sharp contrast, in Spain the cost per 
person for lung cancer was among the lowest across the 27 countries studied, representing only 
half of the money spent on other common cancer types (colorectal, breast and prostate) (Table 2.2) 
(Figure 2.1).  
Table 2.2: Health-care cost of all cancers and selected cancers in the EU in 2009, by country; Luengo-Fernández 
et al., 2013. 
 
  
Inpatient care was the major component of health-related costs in lung cancer (68%) followed by 
drugs expenses and primary care (Figure 2.1). The elevated cost derived from productivity losses 
in lung and other cancer types is partially caused by a delayed diagnosis; hence it is essential to 
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develop strategies to enhance physical and psychological functioning in cancer survivors to 
minimize the expenses derived from sick leave and early retirement.  
 
 
Figure 2.1: Health-care cost of lung cancer per person in 2009, by health-care service category; Luengo-
Fernández et al, 2013. 
2.2 Clinical manifestations  
Lung cancer is often a silent disease, especially in the early stages. Thanks to the advances 
in screening tools and early detection, the number of patients who are asymptomatic at the time of 
diagnosis is slowly increasing (Sánchez De Cos Escuín, 2009, Leiro-Fernández et al., 2014). Data 
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extracted from the latest series published in Spain showed that around one-third of patients were 
asymptomatic at the time of diagnosis (Leiro-Fernández et al., 2014). Symptoms experienced by 
individuals with lung cancer can be linked to the primary site of the tumour, derived from metastatic 
disease, a result of the anti-cancer treatment or manifestations of underlying conditions (Simoff et 
al., 2013). Cancer-related symptoms are a burden to patients and a major detriment to their HRQoL 
(Martins et al., 2005). In particular, patients with lung cancer often complain of higher levels of 
fatigue, dyspnoea and worse HRQoL than those with other cancer types, which can persist for five 
or more years after the initial diagnosis (Walling et al., 2015, Shi et al., 2011, Walker et al., 2014). 
The symptom experience is based on two different entities: symptom occurrence and 
symptom distress (Cooley et al., 2002). The first refers to the frequency and duration of the 
symptomatology while the second relates to the intensity and subjective perception of the 
symptoms. Both are affected by diverse factors stemming from the clinical status (type of cancer, 
stage, treatment received, number of co-morbidities) and socio-demographic and patient-related 
characteristics (age, gender, race, smoking history, education, marital status, dwelling status, 
employment) (Sarna et al., 2008, Shi et al., 2011, Cooley et al., 2002, Lowery et al., 2014, Hung et 
al., 2011). Typically, patients with advanced disease are at high risk of experiencing severe 
symptom distress, but even early-stage functional patients can suffer from disabling symptoms 
such as dyspnoea or cancer-related fatigue across the lung cancer continuum (Temel et al., 2006, 
Walling et al., 2015, Cooley et al., 2002). At the time of diagnosis, the symptoms most frequently 
reported by lung cancer patients are fatigue (37–80 %), cough (31.5–75 %), chest pain or chest 
discomfort (22–50 %), dyspnoea (33%), haemoptysis (19–35%) and anorexia/weight loss (23.8–
45 %)  (Koczywas et al., 2013, Sánchez De Cos Escuín, 2009, Leiro-Fernández et al., 2014, Yoder, 
2006, Shim et al., 2014, Walling et al., 2015) (Figure 2.2). 
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Figure 2.2: Common symptoms in lung cancer at the time of diagnosis; Leiro-Fernández et al, 2014. 
Other less common manifestations include hoarseness, wheezing, nausea/vomiting, 
swelling, bone pain (from bone metastases), clubbing, headache and seizures (Yoder, 2006). The 
majority of the symptoms are quite unspecific and commonly found in other chronic respiratory 
diseases, thus they should be only regarded as a clinical suspicion for further testing. The only 
symptom that has actually proved to be a strong predictor of lung cancer is the presence of 
haemoptysis (Shim et al., 2014).  
 2.2.1 Fatigue 
Fatigue is the most common symptom reported by cancer patients (Temel et al., 2006). The 
prevalence and severity of fatigue usually increase with the progression of the disease and the 
administration of anti-cancer therapies but it can also be found in early stages of the disease and in 
long-term cancer survivors. In a study conducted by Hung et al., 57% of stage I NSCLC survivors 
reported some degree of fatigue. Of those, almost 17% had moderate or severe fatigue, which led 
to significant functional impairment in one-quarter of them (Hung et al., 2011). 
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Cancer-related fatigue (CRF) is defined as a distressing, persistent, subjective sense of 
physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment 
that is not proportional to recent activity and that interferes with usual functioning (Berger et al., 
2015). In comparison to the typical fatigue reported by the healthy population, CRF is more 
distressing and less likely to be alleviated with rest (Berger et al., 2015). As a matter of fact, patients 
report CRF as the most distressing symptom associated with cancer and/or its treatment, greater 
even than pain or nausea/vomiting, which can generally be controlled with medication (Berger et 
al., 2015, Cykert et al., 2010). Despite its high prevalence and severity, oncologists usually neglect 
the clinical importance of fatigue and therefore it remains undertreated (Temel et al., 2006).  
 The mechanisms behind CRF are diverse and not entirely known. The possible 
pathophysiology includes a proliferation of pro-inflammatory cytokines, hypothalamic-pituitary-
adrenal (HPA) axis dysregulation, circadian rhythm desynchronization, skeletal muscle wasting 
and genetic dysregulation (Berger et al., 2015). There are also a number of potentially reversible 
causes of CRF including anaemia, metabolic abnormalities, sleep disorders, psychosocial stress 
and side effects of medications (Temel et al., 2006). In fact, most frequently CRF is a result of anti-
cancer treatments. Any local or systemic therapy used in the management of lung cancer is 
associated with an increase in fatigue, but it appears to be especially frequent after radiotherapy. In 
a longitudinal study looking at the symptom prevalence and evolution pattern after treatment for 
NSCLC and SCLC, 73% of NSCLC patients treated with radiotherapy exhibited a ≥ 10% 
worsening of fatigue compared to only 44% after chemotherapy (Rolke et al., 2010). Besides the 
type of treatment, the prevalence and severity of fatigue in lung cancer patients are also affected 
by the presence of other psychological and clinical features. For instance, in two studies conducted 
in NSCLC survivors, they found that functional status, concurrent lung disease and clinical 
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symptoms of depression and anxiety were risk factors associated with increased fatigue one to five 
years after surgery (Hung et al., 2011, Huang et al., 2015b).  
 Patients with NSCLC are particularly at risk of developing physical deconditioning and 
functional impairment because of co-morbid cardiovascular and pulmonary disease secondary to 
tobacco abuse (Temel et al., 2006, Granger et al., 2014). Low levels of physical activity have been 
reported for patients with lung cancer at the time of diagnosis, which further deteriorated during 
and after treatment (Granger et al., 2014). Physical activity has been identified as a protective factor 
against functional decline and CRF in NSCLC survivors (Hung et al., 2011, Huang et al., 2015b). 
In this line of treatment, exercise has been proposed as a non-pharmacological intervention to 
ameliorate fatigue and increase physical functioning and HRQoL. A systematic review and meta-
analysis looking at the effects of exercise in cancer patients undergoing or following treatment 
found a significant reduction in CRF (MD = 0.32; 95% CI: 0.21, 0.43 and 0.38; 95% CI: 0.21, 0.54, 
respectively) after an exercise-based intervention (Puetz and Herring, 2012). Among those studies 
conducted following treatment, there were greater improvements for trials with longer periods 
between treatment completion and exercise initiation, those with shorter exercise programme 
lengths and studies using waiting list comparison (Puetz and Herring, 2012). In another meta-
analysis including cancer survivors, the authors found a significant reduction in fatigue, especially 
for older cancer survivors engaging in moderate to intense exercise (MD = 0.31 (95% CI = 0.22–
0.40) (Brown et al., 2011). This finding is of particular interest given that most cancer patients 
(including those with lung cancer) are typically old. Globally, this data suggest that both physical 
activity and structured exercise interventions should be considered for patients with cancer to 
reduce CRF and improve functional and psychological well-being.     
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2.2.2 Dyspnoea 
 Respiratory symptoms are common among patients with lung cancer or metastatic disease 
to the lung (Temel et al., 2006). Dyspnoea and cough are the two respiratory symptoms most 
frequently reported at the time of diagnosis (Leiro-Fernández et al., 2014, Walling et al., 2015). 
Dyspnoea affects approximately 60% of patients with early disease and up to 87% of patients with 
advanced disease (Feinstein et al., 2010, Smith et al., 2001). Dyspnoea is clinically defined as an 
uncomfortable sensation or awareness of breathing (Temel et al., 2006) and is commonly reported 
by patients as being ‘out of breath’, ‘suffocated’ or as ‘having trouble with breathing’. The 
pathophysiology of dyspnoea in lung cancer is not completely understood, and there are several 
potential mechanisms involved (Koczywas et al., 2013) (Figure 2.3). The most common causes of 
dyspnoea in lung cancer are tied to the location of the tumour, anti-cancer therapies or to the 
presence of underlying respiratory conditions (Temel et al., 2006) (Table 2.3). 
CHAPTER TWO: clinical and socio-economic impact of lung cancer 
47 | P a g e  
 
 
 
 
Figure 2.3: Potential mechanisms of dyspnoea in patients with cancer; Koelwyn et al., 2012. 
In patients with early NSCLC, predictors of dyspnoea include impaired pulmonary 
diffusion capacity, clinical anxiety or depression symptoms and lack of moderate to strenuous 
physical activity (Feinstein et al., 2010). Males and older patients typically refer more severe 
dyspnoea than females or younger individuals (Smith et al., 2001) (Feinstein et al., 2010, Smith et 
al., 2001). Surgery is more intensely associated with an increase in dyspnoea in comparison to other 
systemic treatments, probably because of the loss in lung tissue and the disruption of the oxygen 
cascade (Rolke et al., 2010, Jones et al., 2009a).  
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Table 2.3: Common aetiologies of dyspnoea in lung cancer; adapted from Temel, 2006 
Common Aetiologies of Dyspnoea in Lung Cancer 
Related to Cancer 
Parenchymal lung involvement 
Lymphangitic spread of tumour 
Pleural Effusion 
Pericardial Effusion 
Airway Obstruction 
Superior vena cava syndrome 
Not-related to Cancer 
Pulmonary Embolus 
Pneumonia 
Anaemia 
Paraneoplastic syndromes 
Underlying respiratory disease 
Related to Cancer Therapy 
Lobectomy/Pneumonectomy 
Radiation pneumonitis 
Chemotherapy-related pneumonitis 
Pulmonary Fibrosis 
Dyspnoea has a strong impact on HRQoL, particularly on physical functioning and social 
functioning. Patients complaining from dyspnoea often exhibit other concurrent physical 
symptoms, including weakness, suffocation, tightness, congestion and pain, which further 
aggravate the feeling of breathlessness (Smith et al., 2001). Patients with dyspnoea are also at 
higher risk of developing panic attacks and anxiety (Shin et al., 2014, Temel et al., 2006). A 
relationship between dyspnoea and anxiety is common among lung cancer patients and may 
exacerbate the intensity and severity of breathlessness (Temel et al., 2006). Furthermore, the 
clinical manifestations of the two entities are very close and most patients experience difficulties 
in distinguishing one from the other. 
 Adequate management of dyspnoea includes both pharmacological and non-
pharmacological interventions. Opioids are the most effective pharmacologic agent for improving 
dyspnoea (Temel et al., 2006). On the other hand, non-pharmacological interventions include 
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oxygen, cognitive/behavioural therapies, breathing and relaxation techniques and exercise (Temel 
et al., 2006, Zhao and Yates, 2008). Like CRF, dyspnoea can be improved by increasing physical 
activity and structured exercise training programmes. Moderate to strenuous physical activity has 
been shown to be inversely correlated with the prevalence and severity of dyspnoea in lung cancer 
patients (Feinstein et al., 2010). Exercise training has been shown to significantly reduce dyspnoea 
in patients with COPD and other chronic respiratory diseases (McCarthy et al., 2015) but the results 
found in lung cancer patients are still controversial (Koczywas et al., 2013). An RCT conducted by 
Gattlik et al. found large improvements in exertional dyspnoea after a pulmonary rehabilitation 
programme conducted in lung cancer survivors (Glattki et al., 2012). Cesario et al. also observed 
an improvement in both exertional and baseline dyspnoea after a 4-week PR programme in post-
surgical lung cancer patients (Cesario et al., 2007b). However, Spruit et al., in a single-arm study, 
found no difference in exertional dyspnoea or leg fatigue after a post-thoracotomy rehabilitation 
programme (Spruit et al., 2006). The type of exercise prescribed (endurance vs. resistance or both), 
the timing of the intervention and the measurement tools chosen can explain the variation found in 
the results.   
 2.2.3 Pain 
 Pain is another frequent symptom found in cancer patients across the trajectory of the 
disease. Up to 50% of individuals with lung cancer report pain to some degree at the time of 
diagnosis (Yoder, 2006, Walling et al., 2015) and this percentage rises to 75% in individuals with 
advanced disease (Di Maio et al., 2004). Pain in lung cancer can be due to peripheral growth of the 
tumour, nerve involvement or dissemination of the disease (Di Maio et al., 2004). The two most 
common sites for pain presentation in lung cancer are the chest and spine (from bone metastasis or 
spine compression) (Temel et al., 2006). In individuals with advanced disease, pain is regarded as 
among the most distressing symptoms affecting their ability to carry out most activities of daily 
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living (Di Maio et al., 2004, Wang et al., 1999). Surgery can also cause significant pain by 
damaging the muscles, nerves and ribs. Plus, in the immediate post-operative period, the thoracic 
cavity suffers major trauma because of the use of chest tubes and other drainage devices (Hopkins 
and Rosenzweig, 2012). Post-thoracotomy pain syndrome (PTPS) is a condition occurring in as 
many as 50% of post-surgical patients with lung cancer (Rolke et al., 2010, Hopkins and 
Rosenzweig, 2012). The potential causes of PTPS include: a) trauma and compression of the 
intercostal nerves during surgery; b) fractures and compressed ribs from the use of separators 
during surgery; c) inflammation of the chest muscles and adjacent structures; d) atrophy of the 
chest muscles; and e) scar tissue rubbing the pleural cavity (Hopkins and Rosenzweig, 2012). Even 
after less invasive techniques such as VATS, the removal of lung tissue can damage the nerves and 
ribs, causing PTPS. On top of that, PTPS can be aggravated by the presence of other symptoms 
including anxiety, depression, fatigue and dyspnoea.  
 There are other intrinsic factors that can affect the prevalence and perception of pain in lung 
cancer patients. In a cross-sectional study, Gonzalez et al. examined the prevalence and severity of 
pain in patients with lung and colorectal cancer according to their smoking status (current, former 
or non-smoker). They observed that among lung cancer patients, current smokers reported pain 
more often than former smokers (48.8% vs. 38.5%, respectively; p <.001) and that smoking was 
also associated with the intensity of pain, with former smokers and lifetime non-smokers reporting 
less pain severity than current smokers (Gonzalez et al., 2014) (Figure 2.4). Other features 
associated with pain severity in this study were depression, black or Hispanic race and female 
gender (Gonzalez et al., 2014). 
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Figure 2.4: Prevalence of pain according to smoking history; Gonzalez et al., 2014. 
Pain management is important in oncologic care for maximizing patient outcomes (Bao et 
al., 2014). The current body of literature suggests that unrelieved pain significantly affects HRQoL 
and survival (Bao et al., 2014). In the cancer setting, the assessment and management of chronic 
pain are performed according to the WHO pain ladder developed in the mid 1980s (Figure 2.5). 
This simple visual scale divides cancer pain into three categories (mild, moderate and severe) and 
establishes the most appropriate pharmacological treatment for each one according to the current 
evidence. 
 
Figure 2.5: World Health Organization analgesic pain ladder. 
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 Unfortunately, there are several side effects associated with long-lasting use of pain 
medication, which have driven physicians to investigate the effectiveness of non-pharmacological 
interventions for controlling cancer pain. Currently, there is some evidence claiming that 
acupuncture can be beneficial for patients with cancer pain, although the number of investigations 
is small and there are some methodological issues that prevent solid conclusions being drawn 
(Paley et al., 2011). A recent overview of all the systematic reviews examining the effects of 
complementary therapies in pain management concluded that although there might be some 
symptom alleviation related to these interventions, no formal recommendations could be extracted 
due to the lack of homogeneity and high risk of bias of the studies included (Bao et al., 2014).  
 2.2.4 Anorexia, weight loss and cancer-related cachexia  
 Cancer-related cachexia is a well-known issue in cancer patients and is strongly associated 
with a poor prognosis. Cancer cachexia is a multifactorial symptom characterized by the co-
occurrence of anorexia and involuntary weight loss as a result of low calorie intake, muscle and 
adipose catabolism or both (Gould et al., 2013a). It is a progressive state of the body that cannot be 
fully reversed and that eventually leads to progressive functional impairment (Blum et al., 2011).  
Although cachexia can be found in all types of cancer, it mostly affects those individuals 
with gastrointestinal tract and lung tumours (Gould et al., 2013a). Cancer cachexia is typically 
associated with progression of the disease and therefore it has been mostly studied in advanced 
patients. Nevertheless, anorexia and weight loss, which are initial manifestations of cachexia, are 
also common at the time of diagnosis in lung cancer patients (Leiro-Fernández et al., 2014, Sánchez 
De Cos Escuín, 2009, Muscaritoli et al., 2006).  
As with CRF and dyspnoea, the pathophysiology of cachexia has not been entirely 
uncovered. It appears that different mechanisms are involved in the development of cancer 
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cachexia, including dysregulations in several hormones and appetite mediators (such as leptin, 
ghrelin and neuropeptide Y among others), the release of pro-inflammatory cytokines (TNF-α, IL-
1, IL-6 and IFN-γ), insulin resistance, and certain side effects derived from medications and anti-
cancer treatments (Suzuki et al., 2013, Muscaritoli et al., 2006) (Figure 2.6). The most common 
manifestations of cachexia are weight loss (due to depletion of lipid stores and muscle mass), 
malnutrition (due to loss of appetite, nausea and vomiting, and post-radiation dysphagia) and 
muscle dysfunction (due to muscle catabolism and atrophy) (Muscaritoli et al., 2006, Suzuki et al., 
2013). The progressive loss of muscle mass is by far the most prominent phenotypic feature of 
cancer cachexia and is related to major functional impairment (Muscaritoli et al., 2006). In the 
absence of stimuli (i.e. exercise), muscle mass remains constant and protein synthesis (anabolism) 
and degradation (catabolism) are balanced (Suzuki et al., 2013). During cancer cachexia, however, 
this state of balance is disrupted and the amount of muscle catabolism outstrips muscle anabolism, 
causing weight loss, weakness and fatigue (Suzuki et al., 2013). 
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Figure 2.6: Pathogenesis of cancer cachexia; Muscaritoli, 2006. 
The clinical consequences of cancer cachexia are severe. Weight loss at presentation is a 
well-known strong predictor of cancer outcomes. Both the amount of weight loss and the rate at 
which it occurs significantly affect prognosis and survival in the cancer population (Gould et al., 
2013a). In patients with NSCLC and SCLC, weight loss significantly correlates with poor physical 
and cognitive functioning and results in shorter overall survival (Mohan et al., 2007, Temel et al., 
2006). In particular, the progressive destruction of the muscle mass results in muscle dysfunction 
and atrophy, which eventually lead to reduced physical activity and physical functioning, increased 
fatigue and dyspnoea, and worsening of HRQoL (Muscaritoli et al., 2006, Gould et al., 2013a). 
Cancer cachexia also affects surgical risk as well as responsiveness and tolerability to first- and 
second-line chemotherapy/radiotherapy (Muscaritoli et al., 2006). Malnutrition, which can occur 
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as a result of untreated anorexia, is also associated with impaired wound healing, immune 
dysfunction, respiratory muscle fatigue and tissue wasting following surgery (Jones et al., 2013).  
To reverse cancer cachexia, the ultimate goal would be to cure cancer, but since this is not 
a reasonable scenario for the vast majority of cases, health professionals must develop other 
strategies to at least maintain optimal weight and prevent further deterioration. A comprehensive 
treatment for cancer cachexia should start by identifying the potential causes and include specific 
measures for all mechanisms involved, from anorexia and a lack of appetite to loss of muscle mass 
and muscle dysfunction. An adequate nutritional support that ensures enough calorie intake as well 
as the prescription of appetite stimulants and medication to reduce nausea and vomiting should be 
the selected approach to treat anorexia and loss of appetite. Unfortunately, improving muscle mass 
and reversing muscle dysfunction seems more challenging to achieve due to all the 
pathophysiological mechanisms involved. Theoretically, there are two potential lines of action that 
can be used to reverse muscle wasting: a) preventing muscle catabolism and b) stimulating muscle 
protein anabolism. Numerous pharmacological agents and supplements have been tested to reach 
those goals, including the prescription of anti-inflammatory cytokines, proteasome inhibitors and 
anabolic steroids and other anabolic hormones (Muscaritoli et al., 2006). Interestingly, both could 
potentially be achieved by engaging in conventional exercise training, thanks to its role in reducing 
inflammation and its ability to grow muscle mass by stimulating protein synthesis (Gould et al., 
2013a). The potential pathways involved in the effectiveness of exercise for reducing and 
preventing cancer cachexia are beyond the scope of this thesis, but briefly, repeated exercise 
training is associated with increased levels of anti-inflammatory IL-10 and other cytokine 
inhibitors, which contribute to fighting the pro-inflammatory status observed in patients with 
cachexia. Exercise is also known for generating an antioxidant effect, which can protect from the 
damage derived from reactive oxygen species. Finally, exercise has also been shown to increase 
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insulin sensitivity, which facilitates the transport and catchment of glucose and amino acid into the 
muscle cells (Gould et al., 2013a).     
2.2.5 Mood and symptom distress 
 Patients’ initial response to a cancer diagnosis is influenced by the type and stage of the 
disease but also by pre-existing psychological factors (Zabora et al., 2001, Sarna et al., 2008). 
Compared to other cancer types, patients with lung cancer have the highest level of emotional 
distress (Zabora et al., 2001). For instance, the prevalence of depression is higher in patients with 
lung cancer than in those with cancers in other primary sites (Walker et al., 2014), and it persists 
even after successful surgical resection of the tumour (Sarna et al., 2008). In one study investigating 
the changes in the prevalence of anxiety and depression before and after surgical treatment, 
researchers found that after surgery, depression was significantly higher than at baseline and 37.5% 
of patients needed supportive therapy and/or pharmacologic intervention (Park et al., 2015). The 
percentage of lung cancer patients suffering from major depression has been reported to be 5.8% 
three months after surgery, which although not high, is not too low either to be neglected (Uchitomi 
et al., 2000). Depression in patients with cancer is associated with worse anxiety, pain, fatigue and 
physical functioning (Walker et al., 2014). As previously mentioned, anxiety is also common in 
lung cancer patients. Epidemiological studies have shown that 15–40 % of individuals with NSCLC 
have clinically significant levels of anxiety (Dean et al., 2013). Risk factors associated with 
depression and anxiety in the lung cancer population include younger age, low income, female 
gender, having more co-morbidities, poor performance status and functional impairment 
(Hopwood and Stephens, 2000, Walker et al., 2014, Uchitomi et al., 2000, Shi et al., 2011).  
 Symptom severity and distress tend to be reduced over time. A study looking at the 
symptom burden in lung cancer patients over the first year after diagnosis found that a substantial 
increase was observed in most symptoms at six weeks (approximately at the beginning of the 
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planned treatment) but significant reductions were observed thereafter (Koczywas et al., 2013). In 
sharp contrast, in another longitudinal study involving individuals newly diagnosed with lung 
cancer, Cooley et al. observed that symptom distress was reduced three months after the diagnosis, 
but surprisingly it was intensified at six months (Cooley et al., 2002). This study also found 
significant differences in symptom distress according to the type of cancer treatment. Thereby, 
patients undergoing surgery reported less symptom distress both at three and six months in 
comparison to radio- and chemotherapy. It is worth noting, though, that patients undergoing 
surgery are mostly diagnosed with early stages of the disease and therefore are most likely to 
experience less symptom burden.   
2.2.6 Symptom clusters and prognosis value 
In the context of almost any illness, symptoms are rarely unique manifestations. Most of 
the time, the symptom burden experienced by patients results from the simultaneous occurrence of 
symptoms, also known as ‘clustering’ of symptoms (Fox and Lyon, 2006). The term ‘symptom 
cluster’ was first used by Dodd et al. in 2001 to refer to the coexistence of three or more symptoms 
together that may or may not share a common aetiology (Dodd et al., 2001). Since then, other 
authors have made minimal changes to this definition, including the consideration of only two or 
more symptoms together as a cluster as long as they have an impact on a major outcome. Because 
individual symptoms in lung cancer are associated with worsening HRQoL and poor performance, 
it seems reasonable to deduce that the combination of two or more symptoms may result in a more 
severe deterioration.   
In consequence, there has been an escalating body of research conducted in cancer 
populations to identify potential clusters of symptoms and examine their prognosis value. As an 
example, nausea and vomiting have been described as a gastrointestinal symptom cluster in most 
cancer patients, including those with lung cancer (Wang et al., 2008). Dyspnoea, cough and fatigue 
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are another persistent cluster in lung cancer patients even up to 5 years after diagnosis (Cheville et 
al., 2011a). This particular cluster was found to be inversely associated with survival, especially 
when presenting during the first two years after diagnosis (Cheville et al., 2011b). The combination 
of dyspnoea and fatigue with mood disorders such as anxiety and depression has also been 
frequently acknowledged in the lung cancer population as a symptom cluster (Cheville et al., 2011a, 
Fox and Lyon, 2006). Pain, fatigue, disturbed sleep and distress shape another cluster reported in 
a study involving post-operative lung cancer patients, with three-quarters of the patients displaying 
the four symptoms at the same time (Lin et al., 2013). Other clusters associated with poor prognosis 
are depression, fatigue and pain (Shin et al., 2014) and anxiety, fatigue and dyspnoea (Cheville et 
al., 2011a).    
Recognizing the presence of symptom clusters in specific populations is a big step in 
understanding a patient’s symptom experiences (Chen et al., 2011a). Hopefully, this would help 
health professionals involved in cancer management to specifically address patients’ issues, 
thereby improving their physical and psychological well-being.  
 2.3 Co-morbid diseases 
 Lung cancer patients often present with co-morbidities that can extensively affect the 
decision-making process regarding treatment options (Cykert et al., 2010, Blanco et al., 2008, 
Colinet et al., 2005). Individuals diagnosed with lung cancer are frequently old and carry a history 
of smoking, both intimately linked with the incidence of respiratory and cardiovascular disorders. 
In one study examining the prevalence and severity of co-morbidities in lung cancer, the authors 
found that almost 90% of the patients had at least one co-morbidity and 40% had three or more 
(Grose et al., 2014). The most frequent coexisting conditions were COPD (43%) and renal 
impairment (28%). In other epidemiological studies, the prevalence of cardiovascular and 
CHAPTER TWO: clinical and socio-economic impact of lung cancer 
59 | P a g e  
 
 
 
respiratory diseases in a population with lung cancer ranged from 36 to 44 % (Colinet et al., 2005, 
Sánchez de Cos Escuin et al., 2013).  
 Aging is associated with a higher incidence and prevalence of several co-morbid diseases 
due to the metabolic changes taking place as a consequence of senescence. During the early 1970s, 
patients with lung cancer who were ≥ 70 years old were considered unfit to undergo surgery based 
solely on their age, as increased age was a risk factor for thoracic surgery. However, the number 
of patients with advanced age diagnosed with lung cancer has exponentially increased in recent 
decades with the current average surpassing 65 years (Schulte et al., 2010, de Cos Escuín et al., 
2006, Sánchez De Cos Escuín, 2009). Thanks to the multiple advances in the perioperative 
management of patients with lung cancer, elderly people can now safely undergo surgical resection 
with similar post-operative and oncological outcomes to younger individuals. Yet the pre-existence 
of co-morbidities is a potential risk factor for post-operative complications and a torpid recovery. 
Therefore, although advanced age should not be regarded as an isolated factor for precluding 
surgery, older patients (especially ≥ 75 years old) should be evaluated and monitored closely to 
avoid potential complications and enhance surgical recovery (Agostini et al., 2010).   
The presence of an underlying respiratory disease is a well-established risk factor for lung 
resection surgery. Severe airway obstruction (FEV1 < 40%) has been traditionally viewed as a 
contraindication for anatomic surgical resection (Beckles, 2003). However, advances in 
perioperative management, and in particular the introduction of minimally invasive techniques that 
minimize chest trauma, have allowed patients with poor pulmonary function to undergo surgery, 
although significant morbidity is still reported (Wang et al., 2014). COPD is the fourth leading 
cause of death worldwide and is a major source of respiratory morbidity and mortality (Zhai et al., 
2014). COPD is often found among patients diagnosed with lung cancer, especially men, affecting 
between 50 and 75 % of cases (Nakajima et al., 2009, Montero et al., 2003, Loganathan et al., 
CHAPTER TWO: clinical and socio-economic impact of lung cancer 
60 | P a g e  
 
 
 
2006). Several hypotheses have been proposed to explain the high prevalence of COPD 
encountered in lung cancer patients. Some epidemiological studies have shown a link between 
airway obstruction and the risk of lung cancer, particularly for squamous-cell carcinomas (Mayne 
et al., 1999). Chronic inflammation present in COPD and other obstructive diseases such as asthma 
could affect the mucociliary clearance efficacy for expelling the carcinogenic substances found in 
cigarette smoke (Raviv et al., 2011) (Figure 2.7). Conversely, other studies suggest that the 
relationship between COPD and lung cancer is mostly explained by the shared smoking history 
and is not related to the physiopathology of COPD (Powell et al., 2013). Irrespectively of the nature 
of the relationship, the presence of COPD in lung cancer has been identified as an independent 
predictor factor for both PPCs and disease-free and overall survival (Agostini et al., 2010, Sekine 
et al., 2002, Okami et al., 2009, Zhai et al., 2014, Nakajima et al., 2009).   
 
 
Figure 2.7: Postulated mechanisms for the link between COPD and lung cancer; Raviv et al., 2010. 
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Given the important role that co-morbidities play as a prognostic factor in the short- and 
long-term outcomes of lung cancer, several instruments have been developed to quantify the 
severity and hazard of each particular one. The most widely used clinical score for assessing co-
morbidities is the Charlson Co-morbidity Index (CCI), which encompasses 19 medical and surgical 
conditions weighted according to their risk of death. The CCI has been used in lung cancer patients 
and it has been shown to predict post-operative mortality and morbidity (Moro-Sibilot et al., 2005, 
Strand et al., 2007, Asmis et al., 2008). However, due to the number of multiple conditions 
included, a simplified alternative was sought. In 2005, Colinet et al. designed a simplified co-
morbidity score specifically for patients with NSCLC (Colinet et al., 2005). This score system was 
developed in a multicentre cohort of 735 patients with histologically proven untreated NSCLC and 
was then prospectively validated in another population of 136 patients. Co-morbidities were 
divided into seven categories and scored according to their contribution to the relative risk of death 
(Table 2.4). 
Table 2.4: Summary of changes in physiological function and body composition with advancing age in healthy 
humans; adapted from Chodzko-Zajko et al., 2009 
Variable Typical Changes Functional Significance 
Muscle Strength Isometric, concentric and 
eccentric strength decline from 
age 40 year, accelerate after age 
65-70 years. Lower body 
strength declines at a faster rate 
than upper body strength. 
Declines in strength and power 
predict disability in old age and 
mortality risk. 
Cardiac function HRmax stroke volume and cardiac 
output decline. Slowed HR 
response at exercise onset. 
Reduced left ventricular ejection 
fraction %. 
Reduced exercise capacity with 
ageing 
Vascular function Aorta and its major branches 
stiffen. Vasodilator capacity and 
endothelium-dependent 
dilatation of most peripheral 
arteries (brachial, cutaneous) 
decrease 
Arterial stiffening and 
endothelial dysfunction increase 
CVD risk 
Maximal O2 Uptake Overall decline averages 0.4-
0.5ml/kg-1/min-1/yr-1 (9% per 
decade) in healthy sedentary 
Disease and mortality risk 
factor. 
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adults. Decline accelerates with 
advancing age. 
FFM FFM declines 2-3% per decade 
from 30 to 70 years of age. 
Losses of total body protein and 
potassium likely reflect the loss 
of metabolically active tissue 
(i.e: muscle). 
FFM seems to be an important 
physiological regulator 
MQ Lipid and collagen content 
increase. Peak-specific force 
declines. Oxidative capacity per 
kg muscle declines. 
Changes may be related to 
insulin resistance and muscle 
weakness. 
Regional adiposity Body fat increases during 30-50s 
with a preferential accumulation 
in the visceral (intra-abdominal) 
region, especially in men. After 
age 70 years, fat decreases 
Accumulation of visceral fat is 
linked to CVD and metabolic 
disease.  
*HRMax= Maximal Heart Rate; HR = Heart rate; CVD = Cardiovascular Disease; O2 = Oxygen; FFM = Free Fat Mass.  
The presence of an underlying respiratory disease is a well-stablish risk factor for lung 
resection surgery. Severe airway obstruction (FEV1 < 40%) has been traditionally viewed as a 
contraindication for anatomic surgical resection (Beckles, 2003). However, advances in 
perioperative management and in particular, the introduction of minimally invasive techniques 
which minimizes chest trauma, has allowed patients with poor pulmonary function to undergo 
surgery, although significant morbidity is still reported (Wang et al., 2014). COPD is the fourth 
leading cause of death worldwide and is a major source of respiratory morbidity and mortality 
(Zhai et al., 2014). COPD is often found among patients diagnosed with lung cancer, especially 
men, affecting between 50 - 75% of the cases (Nakajima et al., 2009, Montero et al., 2003, 
Loganathan et al., 2006). Several hypotheses have been proposed to explain the high prevalence of 
COPD encountered in lung cancer patients. As presented in Chapter 1, some epidemiological 
studies have shown a link between airway obstruction and the risk of lung cancer, particularly for 
SCC (Mayne et al., 1999). In addition, chronic inflammation present in COPD and other obstructive 
diseases such as asthma, could affect the mucociliary clearance efficacy to expel the carcinogenic 
substances found in cigarette smoke (Raviv et al., 2011) (Figure 2.7). Conversely, other studies 
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claim that the relationship between COPD and lung cancer is basically due to the intimately link 
between smoking and the development of both diseases and not related to the physiopathology of 
COPD (Powell et al., 2013). Irrespectively of the nature of the relationship, the presence of COPD 
in lung cancer has been identified as an independent predictor factor for both PPCs and disease-
free and overall survival (Agostini et al., 2010, Sekine et al., 2002, Okami et al., 2009, Zhai et al., 
2014, Nakajima et al., 2009).   
Several instruments have been developed to assess the prognosis role of a wide range of co-
morbidities in the lung cancer setting. The most widely used in clinical practice and research is the 
Charlson Co-morbidity Index (CCI), which encompasses 19 medical and surgical conditions 
weighted according to their risk of death. The CCI has been used in lung cancer patients and it has 
demonstrated to predict post-operative mortality and morbidity (Moro-Sibilot et al., 2005, Strand 
et al., 2007, Asmis et al., 2008). However, due to the multiple conditions included, a shortened 
alternative was sought. In 2005, Colinet et al., designed a simplified co-morbidity score specifically 
for patients with NSCLC (Colinet et al., 2005). This score system was developed in a multicentre 
cohort of 735 patients with histologically proven untreated NSCLC and was then prospectively 
validated in another population of 136 patients. Co-morbidities were divided in seven categories 
and were scored according to their contribution to the relative risk of death (Table 2.5). 
Table 2.5: Colinet Co-morbidity Score; Colinet et al, 2005 
Co-morbidity Weighting 
Tobacco Consumption 
Diabetes Mellitus 
Renal insufficiency 
Respiratory Co-morbidity 
Cardiovascular Co-morbidity 
Neoplastic Co-morbidity 
Alcoholism 
7 
5 
4 
1 
1 
1 
1 
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In this research, the Colinet Co-morbidity Score (CCS) was found to be an independent 
factor of poor prognosis and reduced five-year survival in patients with NSCLC, especially for 
those with a CCS ≥ 9. The authors also concluded that the CCS was more informative than the CCI 
in predicting patients’ outcomes.   
2.4 Cardiorespiratory fitness 
 Cardiorespiratory fitness (or exercise tolerance) reflects the integrative capacity of the 
components in the oxygen cascade to supply adequate oxygen for adenosine triphosphate (ATP) 
resynthesis (Jones, 2011). Peak oxygen consumption (VO2peak) is the gold standard in the 
assessment of cardiopulmonary fitness (Jones, 2011). It has been acknowledged that patients with 
lung cancer exhibit low cardiopulmonary fitness across the whole lung cancer continuum in 
comparison to age- and sex-matched populations. In a study conducted among patients with lung 
cancer awaiting lung resection surgery, VO2peak was found to be reduced by 25 to 44 % in 
comparison to normative data (Loewen et al., 2007). The reasons for this marked reduction in 
exercise tolerance are diverse and relate to cancer pathophysiology (tumours in the lungs directly 
affect the oxygen cascade), patients’ baseline status (presence of co-morbidities, advanced age, low 
physical activity levels) and the effects of the anti-cancer therapies (Jones, 2011, Jones et al., 
2009a) (Figure 2.8).  
 
Figure 2.8: Proposed causes of reduced exercise tolerance in cancer patients; Jones, 2009. 
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In the lung cancer setting, the role of VO2peak is critical as it provides valuable information 
regarding surgical tolerability and prognosis of the disease. The ability of the preoperative VO2peak 
to predict post-operative complications has been extensively acknowledged in the literature (Jones 
et al., 2010, Loewen et al., 2007, Benzo et al., 2007, Brunelli et al., 2014). Postoperatively, reduced 
VO2peak has also been associated with physical decline and worsening HRQoL (Jones et al., 2008). 
In advanced disease, Jones et al. found that VO2peak was 33% below age- and sex-predicted values. 
In this population, functional exercise capacity has been shown to predict survival in addition to 
other well-established factors such as performance status (PS) (Jones et al., 2012).  
Given the prognostic role of exercise tolerance in the perioperative setting of lung resection 
surgery, it’s not surprising that VO2peak has been proposed as an attractive modifiable therapeutic 
target to reduce surgical risk, hasten recovery, and improve symptom control and hopefully cancer-
specific outcomes (Jones, 2011). Repeated exercise training is regarded as the most effective way 
to increase VO2peak in healthy people (Jones, 2011) and has also been successfully prescribed in 
people with COPD and other chronic respiratory diseases. Therefore, it is reasonable to believe that 
exercise training could yield similar results in the cancer population and, more specifically, in lung 
cancer. Consequently, a systematic review and meta-analysis conducted in people with cancer 
found a statistically significant increase in VO2peak after an exercise-based intervention (WMD = 
2.90 ml.kg-1.min-1; 95% CI: 1.16; 4.64) (Jones et al., 2011). In lung cancer patients, preliminary 
pilot RCTs and cohort studies have also found significant improvements in VO2peak after an exercise 
intervention (Stefanelli et al., 2013, Jones et al., 2009c, Jones et al., 2007). Altogether, this data 
constitutes proof or principle that exercise can improve cardiopulmonary fitness in lung cancer 
patients, which could be used as a means to improve physical functioning and enhance post-
operative recovery.   
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2.5 Health-related quality of life 
Quality of life is a subjective and multidimensional concept that refers to an individual’s 
physical health, perception of symptom distress, functional status and ability to carry out activities 
of daily living (Anant et al., 2005). HRQoL is a serious concern for lung cancer patients. Although 
traditionally post-operative outcomes and long-term survival have been robust indicators of success 
after treatment for lung cancer, from the patient’s point of view those statistics deal inadequately 
with important functional issues that may arise after cancer treatments (Balduyck et al., 2011). In 
particular, for patients undergoing lung surgery, reduction in self-care and limited physical function 
may be more worrisome issues than post-operative complications (Cykert et al., 2000).  
There are multiple instruments designed to evaluate HRQoL in the context of health and 
illness. Several health profiles are used to assess HRQoL in people with cancer, which are further 
classified into generic and disease-specific. Among the latter, the European Organization for 
Research and Treatment of Cancer’s (EORTC) QLQ-C30 questionnaire is one of the most widely 
administered for evaluating HRQoL in cancer populations. This questionnaire covers general 
aspects of quality of life as well as symptom prevalence and symptom distress in a variety of cancer 
patients. In 1994, a subscale of 13 items (the LC-13) was added to specifically evaluate lung cancer 
symptomatology and side effects derived from conventional chemo- and radiotherapy in this 
population (Bergman et al., 1994). The Functional Assessment of Cancer Therapy (FACT) is 
another disease-specific instrument for measuring HRQoL in patients with cancer, which also 
includes a lung cancer module (FACT-L). On the other hand, there are other generic instruments 
that were designed to evaluate HRQoL in a broader sample of individuals. The Short Form 36 
Health Survey (SF-36), developed in 1992, is a self-administered questionnaire that includes 36 
items evaluating eight major health domains, which are then further summarized into two major 
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categories (the Physical and Mental Component Summaries (PCS and MCS, respectively)) to 
provide a wider overview of physical and psychological status (Ware and Sherbourne, 1992).  
Studies have shown that individuals with lung cancer exhibit low levels of HRQoL across 
the lung cancer continuum, from the time of diagnosis to active treatment and post-treatment. 
Several investigations have shown that self-reported quality of life for newly diagnosed lung cancer 
patients is below normative data (Granger et al., 2014, Coats V, 2013, Moller and Sartipy, 2010, 
Möller and Sartipy, 2012) and declines further during and after treatment (Dean et al., 2013, Paull 
et al., 2006, Koczywas et al., 2013), especially after major surgical resection (Kenny et al., 2008, 
Ilonen et al., 2010, Handy Jr et al., 2002).  
Treatment efficacy in lung cancer should then be measured by its effects on quantity of life 
but also quality of life (Ediebah et al., 2014). Performance status and HRQoL have been identified 
as strong predictors of overall survival, both in patients undergoing surgery and 
chemotherapy/radiotherapy (Li et al., 2012, Ediebah et al., 2014, Pompili et al., 2013, Lemonnier 
et al., 2014). Several studies have found a correlation between preoperative PCS and overall 
survival in patients with NSCLC (Pompili et al., 2013, Brunelli et al., 2013b, Moller and Sartipy, 
2010). In particular, Pompili et al. found that a preoperative PCS ≤ 50 was associated with a 
significant reduction in overall survival in patients with stage I NSCLC (HR = 2.3; 95% CI: 1.44–
4.4; P=0.01). Also, Ediebah et al. found that for every 10-point improvement in physical function 
in the EORTC-CQC at baseline, there was a 7% reduction in the risk of lung cancer death (HR = 
0.93; 95% CI: 0.88, 0.98). Post-operative PCS and MCS have also been found to predict long-term 
survival in patients with lung cancer (HR for a 10-point increment 0.649; 95% CI: 0.45, 0.937 and 
0.701; 95% CI: 0.519, 0.946 for the PCS and MCS, respectively (Moller, 2012)). Furthermore, 
having an MCS below normative data six months after surgery was significantly associated with a 
higher risk of death (HR = 2.90; 95% CI: 1.18, 7.17). These findings are genuinely important since 
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mental and physical well-being are potentially modifiable factors to target in the perioperative 
period of lung cancer and could lead to significant improvements in overall and cancer-specific 
survival.
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CHAPTER THREE: PERIOPERATIVE MANAGEMENT IN PATIENTS UNDERGOING 
LUNG RESECTION 
 3.1 Preoperative evaluation of the lung resection candidate 
 As previously mentioned, lung resection surgery provides the best chance of survival in 
individuals with NSCLC (Ilonen et al., 2011, Benzo et al., 2007, Toker et al., 2007). However, the 
side effects associated with lung surgery have been extensively acknowledged and may influence 
the decision-making process regarding the appropriate treatment. Patients considered at high risk 
of experiencing severe physical and psychological deconditioning after surgery might be 
considered unfit to undergo standard lobectomy and offered sublobar resection or even non-
surgical treatment, which would reduce their long-term survival. The potential negative effects 
associated with lung resection may be triggered by the patient’s clinical status, the surgical features 
(duration, blood loss, etc.) and/or the suitability of the perioperative measures adopted. Individuals 
with lung cancer are frequently old and with a long history of smoking, which predisposes them to 
severe chronic co-morbidities such as COPD and cardiovascular disorders that significantly 
increase the risk of post-operative complications. The chest trauma caused by the surgery along 
with the anaesthetic agents administered can lead to hypoventilation during the first 24 hours, 
reduce coughing and increase sputum retention, leading to respiratory complications (Escribano 
Martin et al., 2009). For these reasons, patients with confirmed or suspected early-stage lung cancer 
who are candidates to undergo surgery with curative intent should be submitted to a comprehensive 
evaluation of the potential risks associated with surgery and the results must be counterbalanced 
against the long-term survival if an oncological suboptimal treatment is chosen (Brunelli et al., 
2013a).  
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There are three major pillars in the physiologic preoperative evaluation of the lung resection 
candidate: evaluation of the cardiac risk, assessment of the pulmonary function and measurement 
of the cardiorespiratory fitness. 
3.1.1 Cardiovascular risk 
The risk of major cardiovascular events after lung resection surgery has been estimated to 
be between 2 and 3 % (Brunelli et al., 2011). The main international associations recommend the 
use of the Recalibrated Thoracic Revised Cardiac Risk Index (ThRCRI) as the preferred risk-
scoring tool for assessing cardiac risk in patients undergoing non-cardiac procedures (Brunelli et 
Figure 3.1: Thoracic Revised Cardiac Risk Index (ThRCRI); Brunelli et al., 2013a. 
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al., 2013a) (Figure 3.1). This assessment tool stratifies patients into four categories: 0 (A), 1–1.5 
(B), 2–2.5 (C) and above (D) (Choi and Mazzone, 2015). A ThRCRI score of two or more should 
be derived in a cardiology consultation for further evaluation before lung resection surgery (Choi 
and Mazzone, 2015). 
3.1.2 Pulmonary function 
 Spirometry, and particularly preoperative FEV1, has traditionally represented the key test 
in the functional evaluation of the lung resection candidate (Brunelli et al., 2013a). Several cut-off 
values have been proposed in the literature but a preoperative FEV1 < 60% was found to be the 
most accurate for predicting post-operative complications after lung resection surgery (Licker et 
al., 2006). Nevertheless, the ability of the FEV1 to predict post-operative morbidity has been 
questioned in the literature after patients with FEV1 ≤ 40% of predicted have been operated on, 
with relatively low mortality and acceptable post-operative outcomes. In light of this, the post-
operative predicted (PPO) FEV1 has been proposed as a more precise alternative to preoperative 
FEV1 for predicting post-operative outcomes after lung surgery and therefore it should be 
calculated in patients with FEV1 < 80% according to the international guidelines (Brunelli et al., 
2013a). In a retrospective study examining the role of PPO FEV1 in predicting post-operative 
respiratory complications, Alam et al. demonstrated that the OR for developing PPCs increased as 
the PPO FEV1 decreased (with a 10% increase in morbidity for every 5% decrease in PPO lung 
function) (Alam et al., 2007). Generally, a PPO FEV1 > 40% is considered to be safe for performing 
lung resection surgery; however, what happens to patients under this threshold is not so clear. 
Multiple studies have suggested that individuals with poor pulmonary function could safely 
undergo lung surgery by means of a sublobar resection with similar short- and long-term outcomes 
(Brunelli et al., 2013a, Brunelli et al., 2009b, Solli et al., 2003). As a matter of fact, in those patients 
with a FEV1 < 70%, PPO FEV1 is not even considered a reliable predictor of complications since 
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individuals with poor lung function experience only a mild deterioration in FEV1 compared to non-
obstructed patients due to the so-called ‘lung volume reduction effect’ (Brunelli et al., 2002, 
Brunelli et al., 2009b, Brunelli et al., 2007a). In  contrast to patients with normal pulmonary 
function, those with severe airway obstruction can even experience an improvement in their FEV1 
after lung resection (Brunelli et al., 2007a). In addition, although PPO FEV1 may be accurate for 
estimating the residual definitive FEV1 three to six months after lung resection, it appears that it 
actually overestimates the FEV1 during the first post-operative days, when most of the 
complications occur (Brunelli et al., 2007a, Varela et al., 2007). All these findings suggest that 
pulmonary function should not be used alone as a stratification tool to select patients for thoracic 
surgery.   
The diffusing capacity of the lung for carbon monoxide (DLCO) is a valuable measurement 
for alveolar oxygen exchange in the assessment of the lung resection candidate (Brunelli et al., 
2009b). Calculation of PPO DLCO is currently recommended by the main guidelines for patients 
with either preoperative FEV1 or DLCO < 80%. A PPO DLCO of less than 40% is consensually 
regarded as the cut-off to distinguish between normal- and higher-risk resection patients (Brunelli 
et al., 2009b). Both DLCO and PPO DLCO have shown a good correlation with pulmonary 
complications, better than PPO FEV1. A preoperative DLCO < 60% has been associated with a 25% 
risk of mortality and 40% risk of pulmonary morbidity (Ferguson et al., 1988). Similarly to PPO 
FEV1, PPO DLCO has also been shown to correlate significantly with the risk of pulmonary 
complications and mortality after lung resection, even in patients with otherwise normal pulmonary 
function (FEV1 > 80%) or without COPD (Ferguson and Vigneswaran, 2008). According to some 
observational studies, at least 40% of individuals may have an abnormal DLCO with an otherwise 
normal FEV1. Consequently, measurement of DLCO has been systematically recommended in the 
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preoperative evaluation of the lung resection candidate regardless of the preoperative FEV1 
(Brunelli et al., 2013a).   
3.1.3 Cardiorespiratory fitness 
 Patients at moderate to high risk of post-operative complications according to their 
pulmonary function should undergo further examinations before being submitted to lung resection 
surgery. The European Respiratory Society and the European Society of Thoracic Surgeons 
(ERS/ESTS) guidelines recommend that all patients with a preoperative FEV1 or DLCO <80% 
should undergo exercise testing to measure their VO2peak (Figure 3.2) (Brunelli et al., 2009b). The 
American College of Chest Physicians (ACCP), however, advocates that for patients with a PPO 
Figure 3.2: ERS/ESTS algorithm for assessment of cardiopulmonary reserve before lung resection in 
lung cancer patients; Brunelli et al., 2009.  
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FEV1 or DLCO of between 30 and 60 % a low-technology exercise testing is enough to estimate 
their cardiopulmonary fitness while those with a pulmonary function lower than 30% should 
perform a high-standardized cardiopulmonary exercise testing with direct VO2peak measurement 
(Choi and Mazzone, 2015, Brunelli et al., 2013a) (Figure 3.3).  
Cardiopulmonary exercise testing (CPET) is the gold standard for assessing exercise 
capacity both in healthy individuals and people with chronic diseases (Jones, 2011). CPET is a 
sophisticated physiologic testing technique that includes recording the exercise electrocardiogram, 
heart rate response to exercise, minute ventilation and oxygen uptake per minute among other 
physiological responses to strenuous exercise (Brunelli et al., 2013a). The aim of the test is to stress 
the whole cardiopulmonary/systemic oxygen delivery system and estimate the physiological 
reserve that may be available after surgery (Brunelli et al., 2009b). 
 
Figure 3.3: ACCP algorithm for thoracotomy and major anatomic resection (lobectomy or greater); Brunelli 
et al., 2013. 
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It is assumed that the test simulates the physiological stress experienced after surgery and 
therefore patients who are unable to perform adequately in the exercise test may respond similarly 
to surgical stress or adverse post-operative events (Brunelli et al., 2009b). A VO2peak of 20 ml/kg
-
1/min-1 (or 75% of predicted) has been established as safe for undergoing lung resection up to a 
pneumonectomy (Brunelli et al., 2009b, Brunelli et al., 2013a). Patients with a VO2peak of between 
35 and 75 % of predicted are considered to be at some risk of post-operative mortality and 
morbidity and those under 35% (or 10 ml/kg-1/min-1) should be offered alternative options to 
surgery due to the high risk of post-operative death and long-term disabilities. In a meta-analysis 
of the relationship between cardiopulmonary fitness and post-operative complications, Benzo et al. 
found that those who experienced post-operative complications after surgery had a lower mean 
preoperative VO2peak than those without complications, both in ml/kg
-1/min-1 and percentage of 
predicted (MD = 3; 95% CI: 2–4.1 and MD = 8.1; 95% CI: 3.3–12.8, respectively) (Benzo et al., 
2007). In an observational study conducted in 204 patients undergoing lung resection, Brunelli et 
al. found that the mortality rate in those patients with a VO2peak < 12 ml/kg
-1/min-1 was tenfold 
higher than those with a peak VO2peak > 12 ml/kg
-1/min-1. Therefore, they concluded that the best 
cut-off value for pulmonary complications was 12 ml/kg-1/min-1 or 40% of predicted (Brunelli et 
al., 2009a). In a recent propensity-matched comparison of patients undergoing thoracic surgery by 
VATS or open lobectomy, morbidity and mortality were also significantly higher in those patients 
with a VO2peak < 15 mml/kg
-1/min-1 (morbidity: 35% vs 31% and mortality: 7.6% vs. 3.7%, 
respectively; p <.05) (Begum et al., 2015). 
The main inconvenience with CPET is the difficulty in performing it in most centres due to 
the sophisticated equipment required and the need for experienced and trained personnel to conduct 
the test. In those cases, field tests have been proposed as an alternative to conventional CPET, and 
they have shown a good correlation with the measured VO2peak in populations with chronic diseases 
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such as COPD. The Stair Climb Test (SCT) has been successfully used as a surrogate for CPET in 
the preoperative evaluation of the lung resection candidate (Brunelli et al., 2013a). This 
inexpensive and easy-to-administer test was first used in the preoperative setting of thoracic surgery 
in 1968 and has proven to effectively discriminate patients at risk of developing post-operative 
complications (Wilson, 1997). In a prospective cohort of 640 patients who underwent lung 
resection surgery, Brunelli et al. found that the altitude reach with the SCT was a strong 
independent predictor of post-operative morbidity and mortality and increased hospital costs 
(Brunelli et al., 2012). Furthermore, patients who were unable to climb more than 12 m 
(approximately two flights of stairs) had a 13-fold increase of mortality than those who climbed 14 
m or more. Other factors that have proved to be associated with a higher rate of post-operative 
complications are the speed of the test, heart rate difference pre- to post-test and oxygen 
desaturation during the performance (Dong et al., 2014). A desaturation greater than 4% has been 
associated with an increased risk of perioperative complications, including respiratory failure, 
intensive care unit (ICU) admission, prolonged hospital stay, home oxygen requirement and 
mortality (Toker et al., 2007, Dong et al., 2014). Low preoperative oxygen saturation at rest has 
also been acknowledged as an independent predictor of post-operative morbidity (Toker et al., 
2007). The main issue with the SCT is the lack of standardization. The height of the step, number 
of steps per flight and the speed in conducting the SCT can drastically influence the results 
obtained. In a study conducted by Bernasconi et al., the SCT was only significantly correlated with 
the measured VO2peak in those patients who were able to climb the equivalent of 20 m with an 
average speed of ≥ 15 m/min (Bernasconi et al., 2012). Finally, heart rate recovery following the 
SCT has also been suggested as another factor to pay attention to when assessing cardiorespiratory 
fitness. Dong et al. found that post-operative complications were more common in those patients 
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who had a heart rate difference pre-post SCT of less than 55 beats per minute than in those with 
more than 55 (35.1% vs. 18.1%, respectively) (Dong et al., 2014).  
 Other common field tests have been suggested as an alternative to CPET in the preoperative 
evaluation of thoracic surgery. The Incremental Shuttle Walk Test (ISWT) is a standardized, 
external-pace test that has shown a good correlation with VO2peak in people with chronic respiratory 
disorders (van Tilburg et al., 2009, Win et al., 2006). During the test, patients must complete as 
many shuttles as possible between two cones separated by 10 metres at an incrementally 
progressive speed. In a study comparing four common field tests, Granger et al. found that the 
ISWT has moderate criterion validity with the CPET VO2peak and was the most promising field test 
for stratifying patients in the perioperative setting of lung cancer (Granger et al., 2015a). It has been 
reported that 25 shuttles are equivalent to a VO2peak of approximately 10 ml/kg
-1/min-1 and thus this 
has been established as the cut-off for a higher risk of post-operative mortality and morbidity (van 
Tilburg et al., 2009, Brunelli et al., 2012). On the other hand, a total distance of 450 metres is 
considered equivalent to a VO2peak > 15 ml/kg
-1/min-1 and therefore is considered as being safe for 
performing surgery. However, the role of the ISWT in predicting post-operative complications is 
limited and is not supported by the current evidence. Erdogan et al. found no statistically significant 
correlation between the risk of post-operative complications and the ISWT in 20 patients 
undergoing lung cancer surgery (Erdogan et al., 2013). Win et al. found no significant difference 
either in the endurance or Incremental Shuttle Walk Test between those patients with and without 
post-operative complications (Win et al., 2004).   
The most widespread field test for assessing functional exercise capacity in individuals with 
chronic respiratory diseases including lung cancer is the 6MWT (Granger et al., 2013a). The test 
has shown good validity and reproducibility and a good correlation with VO2peak (Nakagawa et al., 
2014), being equivalent to approximately 15 ml/kg-1/min-1 when a distance of 450 metres is reached 
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(van Tilburg et al., 2009). Although the test has shown little validity with the CPET VO2peak in 
patients with lung cancer (Granger et al., 2015a), it has demonstrated the ability to predict more 
accurately post-operative complications after lung resection surgery. For instance, one study found 
that those individuals who could not reach 500 metres in the preoperative assessment for a 
lobectomy were at higher risk of developing post-operative complications and a prolonged hospital 
stay (Marjanski et al., 2015). In another retrospective study conducted in Japan, the authors 
concluded that an oxygen saturation < 91% at baseline or a decrease in oxygen saturation of > 4% 
during the 6MWT were both correlated with a VO2peak of < 15 ml/kg
-1/min-1 and therefore could 
be used as a replacement for CPET in the absence of more sophisticated equipment. In a 
retrospective analysis, Ha et al. reported that an impaired heart rate recovery (defined as a reduction 
of less than 18 beats in one minute) after a 6MWT was associated with an increase in post-operative 
cardiopulmonary complications in patients who underwent lung cancer surgery (Ha et al., 2015). 
Altogether, these data suggest that field tests are a powerful alternative for selecting potentially 
operable lung cancer patients with borderline lung function. However, for those unable to reach the 
proposed cut-offs, formal CPET with VO2peak assessment must be undertaken prior to making any 
final decision (Choi and Mazzone, 2015). 
  3.1.4 Development of aggregate scores to predict post-operative outcomes 
 None of the previous measurements are enough to predict the risk of post-operative 
complications alone (van Tilburg et al., 2009). As a result, researchers have developed aggregate 
scores to quantify more effectively the risk of post-operative complications. A predictive model 
can define a composite of complications or may focus on a particular complication due to its clinical 
relevance and/or frequency (for instance, pneumonia or respiratory failure). For example, Falcoz 
et al. developed a risk prediction model (the Thoracoscope) using data from 15,183 patients that 
include age, sex, dyspnoea score, ASA score, performance status, priority of surgery (elective or 
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urgent), diagnosis (malignant or benign), procedure class and co-morbid disease as predictive 
factors of post-operative mortality and morbidity (Falcoz et al., 2007). The model was found to be 
extremely reliable and accurate for predicting in-hospital mortality, showing an almost perfect 
correlation between the expected and the observed deaths, thus it is currently the most common 
assessment tool for predicting post-operative complications. In a retrospective analysis, Amar et 
al. found that PPO DLCO and the need for neoadjuvant chemotherapy could also predict post-
operative complications with moderate accuracy (Amar et al., 2010). Finally, Agostini et al., in a 
cohort of 234 patients undergoing thoracic surgery, reported that advanced age (≥ 75 years old), 
BMI ≥ 30, American Society of Anesthesiologists (ASA) score ≥ 3, smoking history and COPD 
were independent risk factors for developing PPCs. Finally, Simonsen et al., in a retrospective 
analysis of 7,479 patients undergoing thoracic surgery for lung cancer, found that advanced age > 
80 years, obesity, history of previous pneumonia, COPD, alcoholism and atrial fibrillation were 
risk factors for post-operative pneumonia (Simonsen et al., 2015).    
In summary, although predicted models and algorithms are useful in assessing the 
perioperative risk of lung resection, an individualized, comprehensive evaluation should be 
provided for all patients being considered for lung resection surgery in order to guarantee the best 
possible outcomes. Finally, it is worthy noting that the recommendations described in this chapter 
have been made for patients undergoing open thoracotomies. It is unclear whether the same 
guidelines are encouraged in patients undergoing minimally invasive techniques such as VATS or 
robotic thoracic surgery. Preliminary studies have shown controversial results. Zhang et al., using 
a prospective cohort of patients undergoing lobectomy by VATS or open thoracotomy, 
demonstrated that in both procedures, PPO DLCO and PPO FEV1 were good predictors of post-
operative complications (Zhang et al., 2015). However, in a retrospective study, neither a 
preoperative FEV1 nor DLCO < 60% were found to be good predictors of post-operative 
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complications in patients undergoing VATS (Berry et al., 2010). The role of cardiopulmonary 
fitness and VO2peak is also not clear, but a recent study conducted using the ESTS database found 
that in patients undergoing VATS, low VO2peak was not associated with an increased surgical risk 
(Begum et al., 2015). Further research is needed in this new surgical context to elucidate which 
factors could influence the post-operative trajectory in patients undergoing VATS. 
3.2 Impact of lung resection surgery on patients’ outcomes 
 3.2.1 Post-operative mortality and morbidity 
 The most common reported outcomes after thoracic surgery are hospital morbidity and 
mortality (Donington et al., 2012). Mortality following lung resection is affected by the type of 
operation performed, the presence of co-morbidities, the expertise of the surgeon, the volume of 
the institution and the stage of the disease (Shaw et al., 2008). Mortality after lung surgery has been 
steadily declining over the past decade (Shaw et al., 2008, Rosen et al., 2014) and is currently 3.7 
to 11.5 % for pneumonectomy and 1–5 % for lobectomy (Rosen et al., 2014, Shaw et al., 2008, 
Otake et al., 2011). However, for patients with co-morbid disease, advanced age or poor 
cardiopulmonary fitness, mortality has been reported to be as high as 60% (Brunelli et al., 2013a). 
Respiratory failure is the leading cause of mortality after lung resection surgery (Donington et al., 
2012). The current established factors associated with increased in-hospital mortality are male 
gender, older age, co-morbidities, surgery on the right side of the lung and a more extensive 
procedure (Strand et al., 2007). In a large series of patients operated on for lung cancer in the USA, 
a higher mortality rate was found among right-side pneumonectomies without neoadjuvant therapy 
(12.1%) (Rosen et al., 2014). Mortality also seems to be slightly higher in those patients undergoing 
sublobar resections compared to standard lobectomy, probably due to pre-existing co-morbidities 
and/or low cardiopulmonary reserve (Rosen et al., 2014, Shaw et al., 2008). In addition, highly 
experienced thoracic surgeons, high hospital case volume and teaching status are also associated 
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with lower 30-day mortality rates (Shaw et al., 2008, Rosen et al., 2014). However, perioperative 
mortality might not be an adequate quality indicator for lung cancer resection after all. In a study 
comparing 30-day mortality with 90-day mortality, authors found that whereas the former was 
fairly low (3.69%), the latter was almost double (Hu et al., 2014). In most cases, death was due to 
the primary cancer, but coexistent COPD, cardiovascular diseases, renal failure and infection were 
also common causes of mortality in this period. In the multivariate analysis, a preoperative 
diagnosis of congestive heart failure was the most statistically significant predictor of 90-day 
mortality (Hu et al., 2014). These results are consistent with another similar study comparing the 
30- and 90-day mortality according to hospital volume, where the authors also reported that the 
latter was almost double the former (Pezzi et al., 2014). This data confirms that the current 
measures of in-hospital or 30-day mortality rates underestimate the actual mortality risk after lung 
resection surgery.  
 Despite the reduction in in-hospital and 30-day mortality rates, morbidity is still very 
frequent after thoracic surgery (Donington et al., 2012). In particular, post-operative pulmonary 
complications (PPCs) are the leading cause of death and increased hospital cost in cardiothoracic 
and non-cardiothoracic surgery (Cassidy et al., 2013, Sabate et al., 2014). According to the National 
Surgical Quality Improvement Programme, the attributable cost of PPCs was more than 52,000 US 
dollars per patient (Dimick et al., 2004). The incidence of PPCs ranges from 2 to 40 % depending 
on the type of procedure, the extent of resection, the surgical approach and the patient baseline 
status (Sabate et al., 2014, Cassidy et al., 2013, Begum et al., 2015). Furthermore, the lack of 
standardization in the definition highlights the disparities found across studies in the PPC rates. In 
theory, the term ‘post-operative pulmonary complication’ encompasses any pulmonary 
abnormality occurring during the post-operative period producing an identifiable disease or 
dysfunction that is clinically significant (Agostini et al., 2011). Under the umbrella of PPCs are 
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included events of different severity and management such as respiratory failure, reintubation, 
weaning failure, pneumonia, atelectasis, bronchospasm, pneumothorax, pleural effusion and 
various forms of upper-airway obstruction (Sabate et al., 2014). Several evaluation tools have been 
proposed for accurately assessing the frequency and severity of post-operative complications after 
thoracic surgery. In 2008, Reeve et al. developed the Melbourne Group Scale (MGS), which was 
primarily designed to identify those pulmonary complications more likely to be prevented by a 
physiotherapy intervention. A positive score of four points out of eight was considered to be a 
positive diagnosis of PPC (Reeve et al., 2008). Other common scales used to assess PPCs are the 
Brooks-Brunn Score and the Gosselink Score (Table 3.1). In a prospective study comparing the 
three scoring systems, the incidence of PPC according to the MGS, the Gosselink Score and the 
Brooks-Brunn score was 13, six and 39 %, respectively. The clinical incidence of PPC as described 
in the cohort was 12%, thus the MGS was shown to have the strongest correlation and the highest 
specificity and sensitivity (99 and 100 %, respectively), demonstrating large superiority (Agostini 
et al., 2011). Finally, the ESTS has published a special report in an attempt to standardize the 
definition of the most common PPCs after thoracic surgery (Fernandez et al., 2015). However, 
unlike the previous instruments, this statement only provides a list of definitions and therefore 
cannot be used to assess severity and frequency of PPCs.  
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Table 3.1: Post-operative pulmonary complications criteria according to three common scales; Reeve et al., 2011 
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 PPCs are a major concern both for the patient and for the health system. In the immediate 
post-operative period, PPCs are responsible for a prolonged hospital stay and increased health-care 
costs, delaying the patient’s recovery to full activity (Stephan et al., 2000, Varela et al., 2006, 
Branson, 2013). In the long term, they can also affect physical functioning and HRQoL. In a cross-
sectional study investigating the correlates of physical activity among long-term lung cancer 
survivors, Coups et al. found that those patients who had had post-operative complications were 
less likely to engage in leisure physical activity (Coups et al., 2009). Furthermore, post-operative 
complications can also impact on overall and disease-free survival. In a retrospective analysis 
performed in 2010 by Rueth et al., the authors found that among those patients who had at least 
one post-operative complication, the five-year cancer-specific and overall survival was lower than 
in patients with no complications (p <.001) (Rueth et al., 2011). The same tendency was found 
when comparing patients with and without pulmonary complications alone (overall survival 52.7% 
vs. 68.9%, respectively, p <.001). These findings were maintained even after adjusting for 
confounding variables, thereby highlighting the important role of assessing perioperative risk in 
surgical lung cancer patients. Similar results have been reported for some particular complications; 
for instance, Simonsen et al. found that those patients diagnosed with post-operative pneumonia 
after lung cancer surgery had decreased disease-free survival compared with those without a 
clinical diagnosis of pneumonia (Simonsen et al., 2015).  
  3.2.2 Pulmonary function 
 Alterations in pulmonary function and respiratory mechanics are frequent after lung 
resection surgery and can substantially impact on a patient’s immediate recovery and/or quality of 
life (Choi and Mazzone, 2015). Pulmonary function decreases dramatically by around 30–50 % 
during the first post-operative days compared to baseline (Donington et al., 2012). The loss of 
pulmonary function is influenced by several factors, but the most significant is the extent of the 
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resection. For instance, a pneumonectomy can decrease the FEV1 by 34–36 %, a lobectomy by 9–
17 % and a segmentectomy by 5% (Choi and Mazzone, 2015). The surgical approach also 
influences changes in pulmonary function after surgery, with minimal-access techniques proving 
superior to traditional approaches for preserving pulmonary function and hastening recovery (Che 
et al., 2013, Ueda et al., 2006, Endoh et al., 2010).  
The vast majority of the literature suggests that it takes approximately three to six months 
for the pulmonary function to return to baseline values but some discrepancies have been found. 
Early studies found a persistent reduction in FEV1 beyond this time frame (Bolliger et al., 1996, 
Nezu et al., 1998, Miyazawa et al., 1999, Nomori et al., 2003, Wang et al., 2006, Kushibe et al., 
2008a), which could last up to two years after lobectomy (Miyazawa et al., 1999) and beyond five 
after pneumonectomy (Deslauriers et al., 2011, Vainshelboim et al., 2015). Conversely, more 
recent investigations have found a return to baseline (≥ 80% predicted) within the first three months 
(Brunelli et al., 2007b, Win et al., 2007, Saito et al., 2014), particularly after VATS (Che et al., 
2013, Ueda et al., 2006). Along with FEV1 and FVC, DLCO and respiratory muscle strength could 
also be significantly impaired immediately after surgery and persist beyond the first post-operative 
month (Laurent et al., 2013). The long-term implications of pulmonary function loss have not been 
examined in the literature but it is likely that they can affect a patient’s HRQoL and functional 
capacity. 
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Table 3.2: Long-term effects of surgical resection on pulmonary mechanics 
Study Participants Extent of resection Outcomes Time of 
evaluation 
Results 
Pelletier, 
1990 
47 NSCLCi Lobectomy  (L) and 
pneumonectomy (P) 
FEV1  
MIP 
MEP 
2 months post-
surgery 
L: FEV1 ↓ from baseline to post-surgery 
89±22 to 74±10 
P: FEV1 decreased from 79±22 to 53±11 
No changes in MIP and MEP 
Bollinger, 
1996 
68 patients after 
lung resection 
Lobectomy (L) and 
pneumonectomy (P) 
FVC  
FEV1  
3 and 6 months 
post-surgery 
L: FVC ↓ 7.3% and FEV1 ↓ 8.8% at 6 months 
P: FVC ↓36.2% and 34% at 6 months 
Nezu, 1998 82 lung cancer 
patients 
Lobectomy (L) and 
pneumonectomy (P) 
FEV1 
VC 
3 and 6 months 
post-surgery 
L: FEV1 ↓ 11.2% and VC ↓ 11.6% at 6 
months 
P: FEV1 ↓ 36.1% and VC 40.7% at 6 months 
Nugent, 
1999 
106 lung cancer 
patients 
Thoracotomy alone, wedge 
resection, lobectomy (L) and 
pneumonectomy (P) 
FEV1 
FVC 
3 and 6 months 
post-surgery 
L: FVC ↓ 11.4% but no changes in FEV1 
P: FEV1 and FVC significantly decrease by 
26.1% and 32.2% respectively  
Miyazawa, 
1999 
8 lung cancer 
patients 
Lobectomy  or bilobectomy  FEV1 
FVC 
VC 
DLCO 
6 months and up 
to 4 years 
VC ↓ from 3.47±0.5 to 2.41±0.34 at 6 months 
and 2.67±0.46 at 4 years 
FVC ↓ from 3.26±0.63 to 2.31±0.3 and 
2.62±0.41 respectively 
FEV1 ↓ from 2.19±0.56 to 1.8±0.47 and 
1.88±0.48 at 4 years 
DLCO ↓ from 85.46.9% to 79.5% at 3 months 
but increased to 106.9±14.7 in the late postop 
Nomori, 
2003 
112 lung cancer 
patients 
Lobectomy FEV1 
VC 
1, 2, 4, 12 and 24 
weeks post-
surgery 
VC values at 6 months ranged from 
88.3±10.6% of baseline after VATS to 
74.1±14.1% after standard thoracotomy 
Bobbio, 
2005 
11 NSCLC Lobectomy and bilobectomy FEV1 
TLC 
DLCO 
3 months FVC, FEV1 and DLCO did not decrease after 
surgery (p >.05); TLC ↓ from 120% of 
predicted to 99% 
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Wang, 2006 28 undergoing 
LRS 
Lobectomy, pneumonectomy 
and wedge resection 
FEV1 
 
12 months post-
surgery 
After 1 year, FEV1 ↓ from 86±18 of predicted 
value to 74±15% (p <.001) 
Brunelli, 
2007 
200 patients with 
lung cancer 
Lobectomy (L) and 
pneumonectomy (P) 
FEV1 
DLCO 
Discharge, 1 and 
3 months post-
surgery 
L: FEV1 79.5% and 84% of the preoperative 
values at 1 and 3 months respectively; DLCO 
was 81.5% and 88.5% of baseline at 1 and 3 
months respectively 
P: FEV1 was 65% and 66% of baseline 1 and 
3 months respectively; DLCO was 75% at 1 
month and 80% at 3 months. 
Win, 2007 110 patients with 
lung cancer 
Lobectomy (L) and 
pneumonectomy (P) 
FEV1 
FVC 
1, 3 and 6 months L: FEV1 was 75% and 85% of baseline at 1 
and 6 months while FVC was 69% and 81% 
respectively 
P: FEV1 was 61% and 65% of baseline at 1 
and 6 months respectively while FVC was 
56% and 61% respectively. 
Nagamatsu, 
2007 
18 NSCLC Lobectomy FEV1 
FVC 
VC 
1, 3, 6 and 6 
months post-
surgery 
FVC was 78.5%, 81.6% and 82.7% of 
baseline at 3, 6 and 12 months respectively; 
VC was 82.6% of baseline at 12 months 
FEV1 was 83.6% and 82.4% at 6 and 12 
months respectively 
Kushibe, 
2008 
106 NSCLC Lobectomy FEV1 
FVC 
6 – 12 months FEV1 ↓ 9.2±16.7 to 14.9±9.8 depending on 
the lobe resected; FVC ↓ between 8.9±9.9 
and 17.3±12.1 
Kushibe, 
2008 
100 individuals 
with and without 
COPD 
Lobectomy FEV1 
FVC 
6 – 12 months FVC ↓ 14.6±10.5 in the non-COPD group 
and between 8.6±16.3 to 11.1 in the severe 
and moderate COPD groups respectively 
FEV1 ↓ 14.7±11.5 in the non-COPD group 
and 11.6±10.7 in the moderate COPD group 
but ↑ 4.7±15.8 in the severe COPD group 
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Deslauriers, 
2011 
100 lung cancer 
patients 
Pneumonectomy FEV1 
FVC 
DLCO 
>5 years after 
surgery 
FEV1 ↓ 44±16% from baseline and FVC ↓ 
38±21%. DLCO was 34±11% reduced 
comparing to baseline 
Saito, 2014 178 I NSCLC Lobectomy (L) and 
segmentectomy (S) 
FEV1 
VC 
1 and 6 months 
post-surgery 
L: at 1 month VC was ↓ 17.5% and FEV1 
15.5%; at 6 months value had reached 80% of 
baseline 
S: at 1 month VC was ↓ 11.2% and FEV1 7%: 
at 6 month, value had reached 90% of 
baseline 
Kim, 2015 300 NSCLC Lobectomy and sublobar 
resection 
FEV1 
FVC 
DLCO 
3 and 12 months 
post-surgery 
 
L: at 3 months, ↓ in FVC, FEV1 and DLCO 
were 13.9±10.3%, 13.4±9.6% and 14.9±14.2. 
At 12 months, ↓ were 6.8±10.1, 9.4±10.1 and 
9.8±13.4 respectively 
S: at 3 months, ↓ in FVC, FEV1 and DLCO 
were 4.45±7.3, 4.8±8.7 and 3.4±11.5 
respectively. At 12 months, ↓ were 2±8.3, 
2.7±8.1 and 0.38±22.1 respectively 
iNSCLC = Non-Small Cell Lung Cancer; FEV1 = Forced Expiratory Volume 1 second; MIP = Maximal Inspiratory Pressure; MEP = Maximal 
Expiratory Pressure; FVC = Forced Vital Capacity; VC = Vital Capacity; DLCO = Diffusion Capacity of Carbon Monoxide; TLC = Total Lung 
Capacity; VATS= Video-Assisted Thoracic Surgery.
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3.2.3 Exercise and functional capacity  
 Exercise capacity (cardiorespiratory fitness) refers to the ability to perform a determinate 
task before reaching the level of exhaustion and is an excellent indicator of an individual’s general 
health. Patients with lung cancer have been shown to exhibit low cardiorespiratory fitness at the 
time of diagnosis, most likely associated with a long history of smoking, a sedentary lifestyle, 
advanced age and/or concurrence of cardiovascular and respiratory co-morbidities. Surgery is 
associated with a decrease in VO2peak during the early post-operative period, but this reduction is 
especially pronounced after resection of the lung parenchyma, because of the direct disruption of 
the oxygen cascade (Jones et al., 2009a, Jones, 2011). The pattern of decline in VO2peak after lung 
resection surgery has been documented in several longitudinal studies, showing a significant 
decrease during the first weeks followed by a progressive recovery thereafter (Brunelli et al., 
2007b, Nugent et al., 1999, Nagamatsu et al., 2007). However, other studies have shown a 
permanent reduction of up to 25% of VO2peak after lobectomy in NSCLC (Nezu et al., 1998, Win 
et al., 2007, Kushibe et al., 2008b). Changes in VO2peak after surgery may be influenced by several 
confounding factors including the extent of the resection and the surgical approach; similarly to 
what is seen in pulmonary function, individuals who undergo pneumonectomy experience more 
severe and persistent declines in exercise performance than those undergoing lobectomy or 
sublobar resection (Vainshelboim et al., 2015). 
Functional capacity determined with a field test has the advantages of being easier and 
cheaper to obtain and reflecting more accurately the patient’s ability to perform daily tasks than 
formal CPET. Functional exercise capacity is compromised after lung resection surgery and 
therefore can affect a patient’s self-care and HRQoL. Several studies have shown a decrease in 
6MWT immediately after surgery (Arbane et al., 2011, Nomori et al., 2003, Nomori et al., 2004) 
that can persist for up to six months (Granger et al., 2014). Again, this decline in physical 
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performance seems less severe after VATS and consequently performance returns faster to 
preoperative values (Nomori et al., 2003, Che et al., 2013, Ueda et al., 2006). A few studies have 
assessed the long-term impact of lung resection on functional capacity and found that somehow 
lung cancer survivors manage to maintain good levels of physical performance even in the presence 
of significant impaired pulmonary function, suggesting the development of several adaptive 
changes (Deslauriers et al., 2011, Vainshelboim et al., 2015). 
 
CHAPTER THREE: Preoperative evaluation of the lung resection candidate  
91 | P a g e  
 
 
 
Table 3.3: Long-term impact of lung resection on (functional) exercise capacity 
Study Participants Extent of resection Outcomes Time of 
evaluation 
Results 
Pelletier, 
1990 
47 NSCLCi Lobectomy  (L) and 
pneumonectomy (P) 
Wmax 2 months post-
surgery 
L: Mean Wmax ↓ 12% comparing to 
baseline 
P: Mean Wmax ↓ 26% comparing to 
baseline 
 
Bollinger, 
1996 
68 patients after 
lung resection 
Lobectomy (L) and 
pneumonectomy (P) 
VO2max  3 and 6 months 
post-surgery 
L: VO2max ↓ from 18.6±4.8 to 16.9±4.9 (p 
<.05) at 3 months and increased to 
18.8±5.4 at 6 months  
(p <.05) 
P: VO2max ↓ from 18.9±5.6 to 14.2±2.5 at 
3 months and to 15.1±2.7 at 6 months 
Nezu, 1998 82 lung cancer 
patients 
Lobectomy (L) and 
pneumonectomy (P) 
VO2max 3 and 6 months 
post-surgery 
L: VO2peak was ↓ 13.3% at 6 months 
P: VO2peak was ↓ 28.1 at 6 months 
Nuggent, 
1999 
106 lung cancer 
patients 
Thoracotomy alone, wedge 
resection, lobectomy (L) and 
pneumonectomy (P) 
VO2peak 6 months post-
surgery 
L: VO2peak ↓ 1.91 ml/kg-1/min-1  
(p >.05) 
P: VO2peak ↓ 6.72 ml/kg-1/min-1 (p <.01) 
Miyazawa, 
1999 
8 lung cancer 
patients 
Lobectomy  and bilobectomy  Wmax 6 months and up 
to 4 years 
Wmax ↓ from 62.5±13.7 to 45.8±10.2 at 6 
months and didn’t improve thereafter 
Bobbio, 
2005 
11 NSCLC Lobectomy and bilobectomy VO2max 3 months VO2max ↓ from 17.8±3.2 ml/kg-1/min-1 to 
14.1±3 (p =.003) 
Wang, 2006 28 undergoing LRS Lobectomy, pneumonectomy 
and wedge resection 
VO2max 
Wmax 
 
12 months post-
surgery 
After 1 year, VO2max ↓ from 18.5±4 to 
16.3±4.8 (p <.001) and Wmax from 111±31 
Watts to 99.36 (p <.001) 
Brunelli, 
2007 
200 patients with 
lung cancer 
Lobectomy (L) and 
pneumonectomy (P) 
VO2peak Discharge, 1 and 
3 months post-
surgery 
L: VO2Peak was 96% and 97% of baseline 
at 1 and 3 months respectively 
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P: VO2peak was 82% and 89% at 1 and 3 
months respectively 
Win, 2007 110 patients with 
lung cancer 
Lobectomy (L) and 
pneumonectomy (P) 
SWT (%) 1, 3 and 6 months L: SWT was 70%, 83% and 84% at 1, 3 
and 6 months respectively 
P: SWT was 60%, 71% and 77% 
respectively. 
Nagamatsu, 
2007 
18 NSCLC Lobectomy VO2peak 1, 3, 6 and 12 
months  
VO2peak was 90% and 97% at 6 and 12 
months respectively 
Kushibe, 
2008 
106 NSCLC Lobectomy VO2peak 6 – 12 months VO2peak was reduced between 9.4±12.7% 
and 18.1±12.3% according to the resected 
lobe 
Kushibe, 
2008 
100 individuals 
with and without 
COPD 
Lobectomy VO2peak 
Wmax 
6 – 12 months VO2peak ↓ 9.2±12.1% in the non-COPD 
group and from 9.7±18.3 to 12.2±10.4 in 
the severe and moderate COPD groups 
respectively 
Wmax also ↓ 9.4±15.3% in the non-COPD 
and from 6±34.5 to 9.2±13.3 in the severe 
and moderate COPD group respectively  
i NSCLC = Non-small Cell Lung Cancer; Wmax = Maximal Workload; VO2max = Maximal oxygen consumption; VO2Peak = Peak of oxygen 
consumption; 6MWT = 6 Minute Walk Test; SWT = Shuttle Walk Test; COPD = Chronic Obstructive Pulmonary Disease; VATS = Video-Assisted 
Thoracic Surgery.
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 3.2.4 Muscle strength 
 There is a relative paucity of literature regarding the potential consequences of pulmonary 
resection on muscle strength and it is mostly limited to patients in the perioperative period of lung 
transplantation or lung volume resection surgery (LVRS). Although pulmonary resection does not 
directly cause muscle deconditioning, reduction in physical functioning and functional capacity 
after surgery can lead to a decrease in physical activity, muscle atrophy and increased dyspnoea, 
which further decrease physical functioning, leading to a vicious circle of functional decline. In a 
longitudinal study conducted by Granger et al., lung cancer patients showed a decrease in muscle 
strength (quadriceps, rotator cuff and tibialis anterior) both during active treatment and four months 
post-treatment in comparison to baseline (Granger et al., 2014). In a randomized controlled trial 
investigating the effects of an early post-operative pulmonary rehabilitation programme on muscle 
strength after lung cancer surgery, Salhi et al. observed that three months after radical therapy, 
there were significant reductions in muscle mass and quadriceps muscle force (p <.01) and that at 
six months, only those patients randomized to the training group had recovered their preoperative 
values (Salhi et al., 2014). Arbane et al. studied the effects of an early resistance and mobility 
intervention (starting on post-operative day 1) in post-surgical NSCLC in comparison to the 
standard care and found that there was a significant group effect (i.e, a decrease in muscle strength 
in the control group but an increase in the active group at post-operative day five; p <.05) (Arbane 
et al., 2011). On the other hand, Maruyama et al., in an observational study, looked at the effects 
of lung resection performed via mini-thoracotomy on respiratory muscle strength, quadriceps force 
and 6MWT during the first two weeks after surgery and found that only quadriceps force was 
significantly decreased by post-operative day (POD) 7 but recovered to baseline at POD 14 
(Maruyama et al., 2011). These data suggest that there is most likely a negative effect of lung 
resection surgery on muscle strength and muscle mass; however, more studies are needed to 
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corroborate the potential effects of resistance training on preventing and/or restoring this 
deterioration. 
 3.2.5 Health-related quality of life  
 Health-related functional status and quality of life assessment are important and under-
reported in the treatment of patients with early stages of NSCLC and should be incorporated into 
clinical decisions (Donington et al., 2012). Deterioration of physical functioning has been identified 
as one of the main concerns for patients undergoing lung resection surgery and thus should be 
specifically addressed before and after the surgery (Cykert et al., 2010). HRQoL is worse in patients 
who have undergone pulmonary resection than in age- and sex-matched subjects (Handy Jr et al., 
2002) and is also significantly impaired comparing to baseline for the majority of dimensions 
(Kenny et al., 2008). In a systematic review published in 2013, Poghosyan et al. reported that six 
out of seven studies examining HRQoL six months after lung resection surgery found a significant 
decline in the PCS (Poghosyan et al., 2013) (Table 3.4). Only one study reported no change in the 
six-month follow-up, and this included only women undergoing thoracotomy (Sarna et al., 2010). 
Granger et al., in a longitudinal follow-up study, found that at the time of diagnosis, individuals 
with lung cancer had an HRQoL below normative data, which further deteriorated during and after 
treatment (Granger et al., 2014). In long-term lung cancer survivors (one to six years post-surgery), 
Ostroff et al. reported that HRQoL was also inferior to that among a cohort of matched smokers 
(Ostroff et al., 2011). Clinical and socio-demographic factors associated with significant declines 
in the PCS after surgery include age, extent of resection and post-operative adjuvant therapy 
(Möller and Sartipy, 2012). More strikingly, Pompili et al. found that patients with better 
preoperative physical functioning and bodily pain scores were at higher risk of a relevant physical 
deterioration after surgery, while those with lower PPO FEV1, higher preoperative social 
functioning and better mental health were at higher risk of a significant emotional deterioration 
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(Pompili, 2011). In lung cancer survivors (one to six years post-surgery), being non-employed, the 
presence of dyspnoea, symptoms of depression and the number of co-morbid conditions were 
associated with poor PCS scores in the SF-36 (Ostroff et al., 2011). Other well-known factors that 
have been associated with changes in HRQoL after surgery are age (Schulte et al., 2010), the extent 
of lung parenchyma resected (lobectomy or bilobectomy versus pneumonectomy) (Schulte et al., 
2009) and the surgical approach (VATS versus open) (Demmy and Nwogu, 2008), which will be 
covered in detail in the next section.     
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Table 3.4: Effects of lung resection surgery on HRQoL 
Study Population Outcome Time of evaluation Results 
Handy, 2002 139 NSCLCi SF-36 6 months postop Significant ↓ pre to post-surgery in PF, RP, SF, BP and MH 
Sartipy, 2009 117 NSCLC 
(lobectomy vs. 
pneumonectomy) 
SF-36 6 months postop L: the PCS↓ from 46.6±11 at baseline to 38.1 post-surgery and the MCS from 
39.5±13 to 43.4±13   
P: the PCS ↓ from 47.8±9 to 33±10 and the MCS ↑ from 36.5±13 to 37.8±13 
(p <.05) 
Sartipy, 2010 198 NSCLC (men 
vs. women) 
SF-36 6 months postop M: the PCS ↓ from 45.2±11 to 40.5±11  and the MCS ↑ from 42.3±13 to 
44.8±12 (p <.001) 
W: the PCS ↓ from 46.1±11 to 39.5±11 and the MCS ↑ from 36.4±14 to 
42.3±14 (p <.001) 
Pompili, 2010 100 NSCLC SF-36 3 months postop COPD: the PCS ↓ from 50.9±7.1 to 49.3±7.2 and the MCS ↑ from 45.4±11.7 
to 46±12.5 
Non-COPD: the PCS ↓ from 51.9±5 to 49.4±7.7 and the MCS ↑ from 45.7±11.1 
to 47.8±10.6 
Moller, 2010 198 NSCLC 
(Young vs. old 
patients) 
SF-36 6 months postop Y: the PCS ↓ from 46.4±10.9 to 41±11.1 and the MCS ↑ from 38.3±14.1 to 
43.4±13.5 (p <.001) 
O: the PCS ↓ from 43.9±11.6 to 38±9.7 (P<.001) and the MCS ↑ from 
41.8±12.8 to 43.8±12 (p =NS) 
Pompili, 2011 172 NSCLC SF-36 3 months postop The PCS ↓ from 52.4 to 46.6 and the MCS ↑ from 46.6 to 48.2. 48 patients 
(27.9%) experienced a decline in PCS pre to post-surgery. 
Moller, 2012a 170 NSCLC SF-36 6 months postop The PCS ↓ 9 points pre to post-surgery and the MCS ↑ 4 points 
Moller, 2012b 213 NSCLC SF-36 6 months postop 60% of the patients reported a ↓ in PCS and 33% in MCS pre to post-surgery 
Granger, 2014 50 NSCLC SF-36 10 weeks and 6 months 
postop 
The PCS ↓ from 42.7±1.7 to 38.1±1.4 (P<.01) and 39.7±2 at 10 and 6 months 
respectively (p =NS); the MCS ↓ from 45±1.9 to 41.5±2.2  and 42.7±2.1 at 10 
weeks and 6 months respectively (p =NS) 
iNSCLC=Non-small Cell Lung Cancer; SF-36=Short-From 36 Health Survey; PF= Physical Functioning, RP=Role Physical; SF=Social Functioning; BP=Bodily Pain; 
COPD=Chronic Obstructive Pulmonary Disease; PCS=Physical Component Summary; MCS=Mental Component Summary; M=Men; W=Women; Y=Young patients (<70 years); 
O=Old patients (>70 years); NS=Non-significant.
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3.3 Post-operative outcomes and surgical approach: VATS versus open thoracotomy 
 Since the first successful VATS lobectomy in the early 90s, the number of thoracoscopic 
procedures performed for lung cancer has been progressively increasing and it is now recognized 
as the preferable approach for stage I NSCLC, especially in those patients with a high risk of post-
operative morbidity and mortality (Ceppa et al., 2012, Howington et al., 2013). Despite the 
outstanding results of this minimally invasive approach, acceptance has been slow and frustrating 
(Begum et al., 2014). Most cardiothoracic surgeons refuse to embrace the technique, alluding to its 
great complexity and being sceptical about its oncological safety and equivalence to the traditional 
approach. Consequently, numerous studies have been conducted addressing these and other 
important outcomes comparing both surgical methods to demonstrate the safety and effectiveness 
of the minimally invasive approach, although, given the ethical implications, very few randomized 
controlled trials have been undertaken and they are not expected in the future (Begum et al., 2014). 
In one of those RCTs, Kirby et al. allocated 55 patients with early-stage NSCLC to undergo either 
video-assisted or conventional lobectomy. The authors found a significant decrease in the number 
of post-operative complications but no difference in hospital stay, operation time, intraoperative 
complications or blood loss (Kirby et al., 1995). In 2000, Sugiura et al. conducted a pseudo-RCT 
involving 44 patients (22 per arm), examining the short- and long-term outcomes of the two 
approaches (Sugiura et al., 1999). They reported no significant difference in hospital mortality, 
morbidity or post-operative length of hospital stay but less post-operative pain and a shorter time 
to return to the preoperative level of activity. They also found less recurrence and overall better 
survival at maximal follow-up. Since these early and controversial studies, the majority of the 
research has consistently demonstrated a significant reduction in length of hospital stay and post-
operative complications with VATS versus open thoracotomy. In the long-term outcomes, some 
studies have shown less recurrence after VATS than after open surgery (Higuchi et al., 2014, Flores 
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et al., 2011, Luo et al., 2014) and better overall survival (Fan et al., 2013), but the results are not 
consistent or disappear after propensity-matched scoring (Berry et al., 2014). The latest studies 
published in 2015 confirmed the superiority of VATS for reducing hospital stay, but conflicting 
results are still found in post-operative complications, recurrence, and cancer-specific and overall 
survival (Kuritzky et al., 2015, Murakawa et al., 2015, Cai et al., 2015, Begum et al., 2015). 
Altogether, this data seems to indicate that VATS may be superior to the traditional approach in 
the short-term outcomes (including length of hospital stay and most likely pulmonary 
complications) but provides no additional benefit in the long term. Nonetheless, it is important to 
acknowledge here that the VATS approach requires a long learning curve and some of the 
comparisons may be biased because of surgeon inexperience in performing the technique. This is 
reflected somehow in the studies reporting fewer dissected nodes with the VATS approach, longer 
operation times or higher rates of intraoperative complications and conversions to thoracotomies 
(Kawachi et al., 2009, Pan et al., 2012).     
 With regard to the functional outcomes, the majority of the research agrees that the 
minimally invasive access technique is superior to the conventional approach in terms of the 
incidence and severity of post-operative and chronic pain, the need for pain medication, functional 
capacity, exercise capacity and HRQoL. In a meta-analysis published by Cheng et al., the number 
of patients who were dependent at discharge was significantly reduced by VATS compared to open 
thoracotomy, as well as the time to return to full activity and the functional capacity (Cheng et al., 
2007). Another study comparing early recovery of pulmonary function and cardiorespiratory 
fitness between VATS and open thoracotomy found that there were significant differences in the 
6MWT between groups one week and one month post-surgery and pulmonary function was also 
better preserved in patients operated on by VATS (Che et al., 2013). Similar results were reported 
by Ueda et al., who found that following a fast-track rehabilitation protocol, patients undergoing 
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VATS return to preoperative values (≥ 80%) only three days after surgery (Ueda et al., 2006). In 
terms of quality of life, Handy et al. found that patients after VATS reported higher levels of 
HRQoL six months post-surgery than those undergoing the conventional approach (Handy, 2010). 
These differences have also been reported in the long term but the results are inconsistent (Li et al., 
2002, Aoki et al., 2007). In light of these findings, it seems that VATS provides better functional 
outcomes, especially in the short term, but the evidence on this topic is less extensive and has 
received comparatively less attention than the other outcomes, thus larger propensity-matched 
cohort studies are required to further assess the influence of the surgical approach on the short- and 
long-term functional recovery after lung cancer surgery.    
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Table 3.5: Post-operative and functional outcomes in VATS vs open thoracotomy 
Author, 
year 
Design Participants Mortality Complications Length 
of stay 
Recurrence Survival Functional outcomes  
Kirby, 1995 RCTi 55 Stage I-IIIA 
NSCLC (25 
VATS) 
- ↓ in VATS NS - - - 
Sugiura, 
2000 
Cohort 44 stage I 
NSCLC (22 
VATS) 
NS NS NS ↓ in VATS - VATS patients 
experienced less post-
operative pain. Time to 
return to preoperative 
activity was also shorter 
in VATS 
Li, 2002 Cross-
sectional 
51 (27 VATS) - - - - - Overall, NS in any 
HRQoL domain except 
for less constipation in 
VATS group 
Park, 2007 RMC 244 stage I 
NSCLC (122 
VATS) 
- ↓ VATS ↓ VATS - - - 
Whitson, 
2007 
RC 147 stage I 
NSCLC (59 
VATS) 
NS ↓ pneumonia in 
VATS 
NS - NS in 5-year 
survival 
- 
Sakuraba, 
2007 
PC 140 stage IA 
NSCLC (84 
VATS) 
NS - - NS NS in 5-year 
survival 
- 
Watanabe, 
2008 
RC 69 I-IIIA 
NSCLC (37 
VATS) 
- - - NS NS in 5-year 
survival 
- 
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Cattaneo, 
2008 
RMC 164 Stage I 
NSCLC > 70 
years (82 
VATS) 
NS ↓VATS ↓ VATS - - - 
Kawachi, 
2009 
RC 249 stage I 
NSCLC (VATS 
73) 
NS NS - - - - 
Handy, 2009 RC 241 NSCLC (49 
VATS) 
NS NS ↓ VATS - - Better HRQoL in 
VATS. No difference in 
6MWT 
Flores, 2009 PC 741 stage IA 
NSCLC (398 
VATS)  
NS ↓ VATS ↓VATS - NS in 5-year 
survival 
- 
Yang, 2009 RC 621 NSCLC 
(113 VATS) 
NS - NS ↓ - - 
Gopaldas, 
2010 
RC 13619 lung 
resection (759 
VATS) 
NS NS NS - - - 
Scott, 2010 PMC 752 Stage I-II 
NSCLC (66 
VATS) 
NS ↓ VATS ↓VATS - - - 
Flores, 2011 PC 1172 Stage IA 
NSCLC (520 
VATS) 
- - - ↓ VATS - - 
Ilonen, 2011 RMC 328  stage I 
NSCLC (116 
VATS) 
NS ↓VATS ↓VATS - NS 2-year 
survival 
- 
Swanson, 
2012 
RC 3961 (1054 
VATS) 
- ↓ VATS - - - - 
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Pan, 2012 RC 180 stage I-
IIIA(83 VATS) 
- - ↓VATS ↓ VATS - - 
Papiashvilli, 
2012 
RC 389 NSCLC (63 
VATS) 
NS ↓ AF in VATS ↓VATS - - - 
Papiashvilli, 
2013 
RC 103 early stage 
NSCLC (63 
VATS) 
NS ↓ VATS NS - - - 
Fan, 2013 PC 148 stage I-II 
NSCLC (71 
VATS) 
 ↓ Chest tube 
duration, AF and 
chylothorax 
↓VATS  ↑ survival 
rate at the 
end of 
follow-up in 
VATS 
 
Lee, 2013 RMC 416 (208 
VATS) 
- ↓ VATS - - NS in 5-year 
survival 
- 
Subroto, 
2013 
RMC 68350 
lobectomies 
(10554 VATS) 
NS ↓ VATS ↓VATS - - - 
Che, 2013 PC 138 lung cancer 
(68 VATS) 
- - - - - ↓ Pulmonary function 
loss and 6MWT in 
VATS 
Cao, 2013 PMC 2916 stage I-
IIIA (1458 
VATS) 
- - - - NS in 5-year 
survival 
- 
Higuchi, 
2014 
PC 160 Stage IA 
NSCLC (114 
VATS) 
NS ↓ VATS ↓VATS ↓ NS in 5-year 
survival 
- 
Subroto, 
2014 
RMC 6008 NSCLC 
(1293 VATS) 
- - - - NS in 5-year 
survival 
- 
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Luo, 2014 RC 240 NSCLC 
(120 VATS) 
- NS NS ↓ systemic 
recurrence for 
VATS 
NS in 1 and 
3-year 
survival 
- 
Jeon, 2014 RMC 182 stage I 
NSCLC and 
COPD (91 
VATS) 
NS ↓ PPCs in VATS ↓ VATS - - - 
Berry, 2014 RMC 1087 NSCLC 
(610 VATS) 
↓ VATS ↓ VATS - - ↑VATS; NS 
after 
matching 
- 
Murakawa, 
2015 
RMC 285 Stage I-II 
NSCLC (101 
VATS) 
- ↓ VATS NS - NS after 
matching 
- 
Kuritzky, 
2015 
PMC 298 Stage I 
NSCLC (74 
VATS) 
NS ↓ VATS NS - NS in 5-year 
survival 
- 
Cai, 2015 RC 138 stage I-II 
NSCLC (71 
VATS) 
NS ↓ VATS ↓ VATS NS - ↓ Post-operative pain in 
VATS 
iRCT=Randomized Controlled Trial; VATS=Video-Assisted Thoracic Surgery; NSCLC=Non-small Cell Lung Cancer; NS=Non significant; 
HRQoL=Health Related Quality of Life; RMC=Retrospective Matched Cohort; RCH=Retrospective Cohort; PCH=Prospective Cohort; 
PMC=Prospective Matched Cohort; 6MWT=6-Minute Walk Test; AF=Atrial Fibrillation; PPCs=Post-operative Pulmonary Complications. 
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CHAPTER 4: Prehabilitation vs. Rehabilitation. The role of preoperative exercise training on 
functional capacity, pulmonary function, HRQoL and post-operative outcomes in lung cancer 
patients: systematic review and meta-analysis 
1.1 INTRODUCTION AND RATIONALE 
There is growing evidence suggesting that individuals with lung cancer would greatly 
benefit from engaging in exercise training across the disease spectrum, from diagnosis to active 
treatment and also in palliative care (Jones, 2011). Cancer treatments add a significant burden to 
patients who are already exposed to the debilitating effects of the disease, leading to physical and 
psychological declines and affecting self-care and self-management. Patients undergoing lung 
resection surgery are particularly prone to physical deconditioning during the first few weeks. If 
this situation is not properly tackled, it can lead to permanent disabilities and HRQoL deterioration. 
Post-operative rehabilitation programmes have been recently proposed as a mean to restore 
functional fitness after surgery. Indeed, preliminary studies have shown an improvement in 
exercise tolerance, functional capacity, muscle strength and HRQoL in postthoracotomy patients 
after a comprehensive rehabilitation programme (Spruit et al., 2006, Stigt et al., 2013, Glattki et 
al., 2012, Salhi et al., 2014, Arbane et al., 2011). However, after lung resection surgery, patients 
often complain of significant dyspnoea and fatigue as well as experience high levels of anxiety and 
depression regarding their prognosis. Furthermore, a considerable percentage of them would be 
referred to neoadjuvant chemo- radiotherapy which could decrease adherence to the intervention 
and minimize the results obtained. In light of this, the preoperative period has been suggested as a 
more appropriate time to implement an exercise intervention given that patients have not seen 
compromised yet their physical functioning (Gillis et al., 2014). In addition, active engagement of 
the individual in the preparation process is likely to alleviate some of the emotional distress 
surrounding the anticipation of surgery and the recovery process (Carli et al., 2010). Finally, a 
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combination of pre and post-rehabilitation could lead to greater improvements in functional 
capacity than post-operative rehabilitation alone (Gillis et al., 2014).  
Prehabilitation is defined as the process of enhancing functional capacity of an individual 
to enable him or her to withstand a stressful event (Ditmyer et al., 2002). In the preoperative phase, 
prehabilitation refers to the implementation of measures of diverse nature with the aim of reducing 
post-operative complications and improving the post-operative course (Debes et al., 2014). A 
generic prehabilitation programme may incorporate a warm-up, an endurance or resistance training, 
flexibility exercises and practicing functional task (Ditmyer et al., 2002). The rationale behind 
preoperative rehabilitation lies on the fact that surgery is a stressful event which usually involves 
bed rest for several days (Valkenet et al., 2011). Because bed rest is correlated with loss of muscle 
mass, physical deconditioning, longer hospitalization and a torpid post-operative course, 
optimizing physical functioning at baseline may contribute to improve post-operative outcomes 
and hasten recovery (Valkenet et al., 2011).  
The effectiveness of preoperative exercise training in a wide range of patients has been 
extensively acknowledged in the literature. For instance, in abdominal and cardiac surgery, 
prehabilitation has shown to decrease 50% the incidence of PPCs and reduce hospital length of stay 
in one day (Valkenet et al., 2011). In patients undergoing Coronary Artery Bypass Graft (CABG) 
surgery, adding a preoperative exercise-based intervention twice weekly for ten weeks significantly 
reduced total hospital stay and days in the ICU. Plus, after the intervention, patients showed an 
increase in the PCS which was maintained at least six months after the surgery (Arthur et al., 2000). 
In a systematic review and meta-analysis involving cardiac surgical patients, participants in the 
prehabilitation groups showed a significant reduction in PPCs and time to extubation. In addition, 
older patients significantly reduced their hospital length of stay (MD = -1.32; 95% CI: -2.36 to -
0.28) (Snowdon et al., 2014). Alone with preoperative exercise training, inspiratory muscle training 
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(IMT) has been suggested as another form of prehabilitation given the potential role of the 
respiratory muscles in preventing PPCs. In a meta-analysis including patients undergoing 
cardiothoracic and upper abdominal surgery, preoperative IMT effectively improved maximal 
inspiratory pressure (MD = 15 cmH2O; 95% CI: 9 – 21) and reduced PPCs (OR = 0.48; 95% CI: 
0.26 – 0.89) although no significant difference was observed in length of hospital stay (Mans et al., 
2015). On the contrary, in the meta-analysis conducted by Snowdon et al., IMT significantly 
reduced both PPCs and length of hospital stay in patients undergoing cardiac surgery (Snowdon et 
al., 2014). 
 Unfortunately, evidence of the effectiveness of prehabilitation in thoracic surgery has 
received comparatively less attention. In one longitudinal study, Nomori et al. examined the effects 
of IMT on maximal inspiratory and expiratory pressures (MIP and MEP respectively) in patients 
undergoing thoracic surgery. They found that patients who had a positive diagnosis of PPCs were 
those with lower MIP and MEP at baseline and furthermore, they didn’t show any improvement 
after the training (Nomori et al., 1994). In a RCT evaluating the effects of IMT and incentive 
spirometry for two weeks in patients with COPD undergoing lung cancer surgery, Weiner et al. 
reported an increase in FEV1 and inspiratory muscle strength prior to surgery but no differences in 
PPCs (Weiner, 1997). Some systematic reviews have also been published in the topic but most 
were conducted in a mix cohort of cancer patients or included pre and post-operative interventions 
(Rodriguez-Larrad et al., 2014, Granger et al., 2011, Crandall et al., 2014, Singh et al., 2013). Only 
one systematic review focused on the effects of preoperative exercise training in patients 
undergoing lung cancer surgery. After examining the studies included, the authors concluded that 
preoperative training might have a positive effect on post-operative complications, mortality, 
length of hospital stay, physical fitness and quality of life but no definitive conclusions could be 
drawn due to the heterogeneity of the programmes (Pouwels et al., 2015). Therefore, in this 
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systematic review and meta-analysis we aim to study the effectiveness of preoperative exercise 
training in lung cancer patients undergoing surgery and to quantify the effect of the intervention on 
each of the selected outcomes. 
4.2 OBJECTIVES 
The specific aims of this study were: 
1) To examine the effectiveness of a preoperative exercise-based intervention in patients 
awaiting lung cancer surgery on the following outcomes: exercise capacity, functional capacity, 
pulmonary function and HRQoL. 
 2) To determine the impact of the intervention on the post-operative outcomes (post-
operative complications and hospital length of stay) in comparison to the standard care (no 
prehabilitation).  
3) To perform a meta-analysis and pool results to measure the effects of the intervention on 
each of the outcomes examined.  
4.3 MATERIALS AND METHODS 
4.3.1 Protocol 
A protocol for this systematic review was registered in the PROSPERO database 
(registration number CRD42015024283). The Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) statement guidelines were applied (Liberati et al., 2009).  
4.3.2 Eligibility criteria 
 Articles were deemed eligible if they were 1) randomized or non-randomized controlled 
trials (RCTs and nRCTs), cohort studies or case – control studies including individuals with 
suspected or confirmed NSCLC; 2) described a pre-operative exercise based intervention, focused 
on endurance and/or resistance training and 3) reported results on at least one of the following 
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outcomes: exercise capacity, functional capacity, health-related quality of life (HRQoL), 
pulmonary function, post-operative complications or length of hospital stay. Systematic or 
narrative reviews, abstracts and conference papers were excluded as well as non-preoperative 
interventions and studies involving other cancer patients. Only articles published in English, 
Spanish or French were included. 
4.3.3 Type of interventions 
 Studies must evaluate an exercise-based intervention focused on endurance or resistance 
training or a combination of both. Additionally, studies could include other components such as 
breathing exercises with or without incentive spirometry, inspiratory muscle training, stretching, 
relaxation and education regarding exercise and physical activity.  
4.3.4 Outcomes 
 Studies must report results from at least one of the following outcomes 1) exercise capacity 
or functional exercise capacity; 2) pulmonary function; 3) health-related quality of life or 4) post-
operative outcomes. 
4.3.5 Information sources and search strategy 
 Prior to conduct this systematic review, the Cochrane Library, PROSPERO and PEDro 
were searched to ensure that no other similar meta-analysis was published or being undertaken at 
the moment. The following databases were searched to identify potentially eligible records: 
CINAHL (1982 – 2014), EMBASE (1974 – 2014), MEDLINE (1950 – 2014), PEDro (1990 – 
2014), PUBMED (1974 – 2014) and SCOPUS (1975 – 2014). A manual crossed search was also 
conducted among the previous identified records. No restrictions were applied. The following 
terms were combined in the database search: “Exercise Therapy” OR ‘Exercise Training” OR 
“Pulmonary Rehabilitation” AND “Lung Neoplasms” OR “Lung Cancer”. The full description of 
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the search terms can be found in the Table 4.1. The last search was conducted on 17th September, 
2015. 
Table 4.1: Search Strategy 
DATABASE Search Fields DESCRIPTORS 
MEDLINE 
PUBMED 
MESH and subject 
headings 
1. Exercise Therapy 
2. Pulmonary 
Rehabilitation 
3. Lung Neoplasms 
4. (#1 OR #2) AND #3  
CINHAL MESH and subject 
headings 
1. Therapeutic, Exercise 
2. Pulmonary 
Rehabilitation 
3. Lung Neoplasms 
4. (#1 OR #2) AND #3 
 EMBASE All fields 1. Exercise Training 
2. Rehabilitation, 
Pulmonary 
3. Lung Cancer 
4. (#1 OR #2) AND #3 
SCOPUS Title, Abstract, Key 
Words 
1. Exercise Training 
2. Pulmonary 
Rehabilitation 
3. Lung Cancer 
4. (#1 OR #2) AND #3 
PEDro All fields 1. “Lung Cancer “ 
4.3.6 Study selection 
One reviewer (RS) performed the search and initial eligibility assessment based on title 
and/or abstract against the inclusion criteria. After removing for duplicates and not relevant records, 
two independent reviewers (RS and MY) assessed all abstracts and identified the potentially 
eligible records. Full-text analyses of those deemed eligible were conducted by two independent 
reviewers (RS and MY). In the presence of a disagreement, this was settled by a third reviewer 
(EG). All references were stored in Endnote X7 (Thomson Reuters, Thomson Corporation, USA) 
during the study period.  
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4.3.7 Data collection process 
 Data from each article were extracted by one reviewer (RS). Another review author checked 
the extracted data to ensure that all the key points were included (MY). Disagreements were 
resolved by discussion between the two authors. If no agreement was achieved, it was planned for 
a third author to decide (CG). Data extracted were stored in a Microsoft Office Excel 2010 
(Microsoft Corporation®, Redmond, Washington, USA) spreadsheet.  
4.3.8 Data items 
 Relevant information from each study was collected in the following aspects: 1) design, 2) 
participants, 3) intervention and 4) outcomes. A complete list of the items included can be found 
in Table 4.2. Authors were contacted by e-mail when any of the listed items was missing or was 
insufficiently described. Sixteen authors were reached and after two attempts, six (37.5%) 
responded. 
Table 4.2: Study Data Collection 
 Design 
 Location (country) 
 Participants 
 Number of participants 
 Mean Age 
 Cancer type, stage and anti-cancer treatment 
 Type of surgery and extent of resection 
 Intervention 
 Setting 
 Timing (preoperative alone or preoperative + post-operative) 
 Type of intervention (endurance, resistance, both) 
 Intensity and duration  
 Frequency and length of intervention 
 Adherence 
 Adverse events 
 Outcomes 
 Primary and secondary outcomes 
 Measurement Tools 
 Results 
 Limitations 
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4.3.9 Risk of bias in individual studies 
 Assessment of risk of bias was conducted using the PEDro Scale for randomized controlled 
trials and the Newcastle – Ottawa Quality Assessment Scale (NOS) for cohort studies. The 
evaluation was conducted independently by two reviewers for each article (RS and EG). In case of 
a disagreement, this was settled by a third reviewer (MY). 
4.3.10 Summary measures 
 The principal summary measures of this systematic review were mean change of exercise 
capacity (VO2peak) and functional capacity (in meters) before and after a preoperative rehabilitation 
programme. Secondary summary measures include mean differences in pulmonary function (pre – 
post intervention) and inter-group differences in hospital LOS and Risk Ratio (RR) of post-
operative complications. Two articles (Bradley et al., 2013, Morano et al., 2013) reported data as 
median and range (or interquartile range (IQR)) and thus estimations of the mean and standard 
deviation (SD) were made according to the available formulas (Wan et al., 2014). 
4.3.11 Synthesis of results and statistical analysis  
 For each outcome of interest, the standardized (SMD) or mean difference (MD) for 
continuous variables and RR for dichotomous variables was calculated and 95% Confident 
Intervals (CI) were computed for statistical significance. Forest plots were generated to illustrate 
the study-specific effect size. Meta-analyses and pooled estimated effect sizes were undertaken 
when considered appropriate according to the number of studies included, measurements properties 
and between-studies variability. Heterogeneity was assessed using the X2 and the I2. A p value of ≤ 
0.1 for the X2 or I2 ≥ 50% was considered as substantial heterogeneity and a subgroup analysis was 
run to explore possible causes. All analyses were performed using the Review Manager (RevMan) 
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version 5.3 for Windows (Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014) based on a random-effects model.  
4.4 RESULTS 
4.4.1 Study selection  
A flow diagram of the study selection is shown in Figure 4.1. Six databases were screened 
yielding a total of 1.656 studies. Additionally, 12 studies were identified from cross-manual search 
and personal records, accounting for a total of 1.668 references. After removing from duplicates 
and non-relevant records, 234 articles were assessed by title and abstract and 51 were selected for 
full-text analysis. Finally, 21 articles involving 17 participant samples fulfilled the inclusion criteria 
and were included in the review.  
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search  
(n = 1656) 
Additional records identified through 
other sources  
(n = 12) 
Records after duplicates removed  
(n = 1338) 
Abstracts screened  
(n = 234) 
Excluded (n = 160) 
- Review: 76 
- No Preoperative 
intervention: 50 
- No exercise-based: 
21 
- Other outcomes: 5 
- No NSCLC: 3 
- Other: 5 
Full-text articles assessed for 
eligibility (n= 74) 
 
 
Full-text articles excluded  
(n = 53) 
- Conference papers 
and abstracts: 24 
- Language: 12 
- Not preoperative 
intervention: 10 
- Not exercise  
intervention: 4 
- Protocols: 3  Studies included in 
qualitative synthesis  
(n = 21) 
Studies included in 
quantitative synthesis (meta-
analysis)  
(n =14) 
Excluded from the meta-
analyses: 
- Data not retrievable 
or computable: 3   
- Meta-analysis not 
appropriate for 
selected outcome: 4  
Figure 4.1: Flow diagram of the studies included in the systematic review and meta-analysis. 
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4.4.2 Study characteristics 
 The main characteristics of each study included are summarized in Table 4.3. 
Design 
This systematic review included five RCTs (Pehlivan et al., 2011, Benzo et al., 2011, 
Stefanelli et al., 2013, Morano et al., 2013, Morano et al., 2014), three non-RCTs or pseudo-RCTs 
(Fang et al., 2013, Li et al., 2013, Gao et al., 2014), three retrospective cohort studies (Sekine et 
al., 2005, Harada et al., 2013, Tarumi et al., 2015), one prospective cohort study (Bradley et al., 
2011) and nine prospective case-series (Jones et al., 2009c, Jones et al., 2007, Peddle et al., 2009a, 
Cesario et al., 2007a, Bobbio et al., 2008, Bagan et al., 2013, Divisi et al., 2013, Coats V, 2013, 
Mujovic et al., 2014). Eight studies compared a rehabilitation programme vs. no intervention 
(control group) (Benzo et al., 2011, Bradley et al., 2013, Pehlivan et al., 2011, Stefanelli et al., 
2013, Li et al., 2013, Gao et al., 2014, Fang et al., 2013, Sekine et al., 2005) while three studies 
compared two different interventions (Morano et al., 2013, Morano et al., 2014, Harada et al., 
2013). One study evaluated two randomized controlled trials at the same time but only one of them 
was finally included (study #2) because data from the first study was missing (Benzo et al., 2011).  
Participants 
A total of 1,189 patients participated in the studies including 595 subjects engaging in the 
rehabilitation programmes and 594 acting as controls. Mean age was 64.8±5.28 in the experimental 
groups and 64.3±6.3 in the controls, and almost 62% were men in both groups. All studies included 
patients with NSCLC or a mixed cohort of lung cancer types (Jones et al., 2009c, Jones et al., 2007, 
Peddle et al., 2009a). Most patients were diagnosed with early stage of the disease (I – IIIA) and 
three studies included individuals who had underwent or were undergoing neoadjuvant therapy (Li 
et al., 2013, Tarumi et al., 2015, Coats V, 2013). Lung resection was mostly performed by an open 
thoracotomy (Bobbio et al., 2008, Bradley et al., 2013, Stefanelli et al., 2013, Fang et al., 2013, Li 
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et al., 2013, Sekine et al., 2005, Divisi et al., 2013, Mujovic et al., 2014) while other studies also 
included a small percentage of patients operated by VATS (Benzo et al., 2011, Morano et al., 2013, 
Gao et al., 2014, Harada et al., 2013). Only in one study patients were operated by means of VATS 
alone (data provided by the authors) (Coats V, 2013). The extent of parenchyma resected varied 
across studies with lobectomy being the most common procedure according to the international 
guidelines (Molina et al., 2008, Howington et al., 2013).  
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Table 4.3: Characteristics of the studies included in the systematic review 
 Study Design Participants Type of Cancer Stage Surgical 
Approach 
Extent of resection Neo-
adjuvant 
Therapy 
1 Sekine et al., 
2005 
Retrospective 
Cohort Study 
22  (rehab) + 60 
(historical 
controls) 
NSCLC I – IV Open Lobectomy  NR 
2 Jones et al., 
2007 
Prospective case 
series 
20 Lung Cancer and 
lung metastases 
I – 
IIIA 
NR All types NO 
3 Cesario et al., 
2007 
Prospective case 
series 
12 NSCLC + severe 
COPD 
IA - 
IIB 
NR Lobectomy NR 
4 Bobbio et al., 
2008  
Prospective case 
series 
12 NSCLC I – 
IIIA 
Open Lobectomy NO 
5 Peddle et al., 
2009  
Prospective case 
series 
9 Lung Cancer and 
lung metastases 
I – IV NR All types NO 
6 Jones et al., 
2009 
Prospective case 
series 
20 Lung Cancer and 
lung metastases 
I – 
IIIA 
NR All types  NO 
7 Pehlivan et al., 
2011 
RCT 60 NSCLC IA-
IIIB 
NR Lobectomy/ 
pneumonectomy 
NR 
8 Benzo et al., 
2011 (Study 
#2) 
RCT 19 (rehab 10 + 9 
controls) 
NSCLC + COPD NR VATS/Open All types NR 
9 Harada et al., 
2013 
retrospective 
cohort study 
50 (CVPR 29 + 
CHPR 21) 
NSCLC + 
impaired PF 
IA – 
IV 
VATS/Open Lobectomy NR 
10 Bagan et al., 
2013 
Prospective case 
series 
20 NSCLC IA – 
IIB 
VATS/Open Lobectomy/ bilobectomy/ 
pneumonectomy 
NO 
11 Stefanelli et 
al., 2013 
RCT 40 (20 rehab. + 20 
controls) 
NSCLC + COPD I – II Open Lobectomy NR 
12 Fang et al., 
2013 
pseudo-RCT 61 (39 rehab + 22 
controls) 
NSCLC + COPD NR Open Lobectomy/ bilobectomy NO 
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13 Divisi et al., 
2013 
Prospective case 
series 
27 NSCLC + COPD IA – 
IIB 
Mini-
thoracotomy 
Lobectomy NR 
14 Morano et al., 
2013 
RCT 24 (12 PR + 12 
CPT) 
NSCLC + 
impaired PF 
IA – 
IIIA 
VATS/Open NR NR 
15 Bradley et al., 
2013 
Prospective cohort 
study 
363 (58 rehab. + 
305 controls) 
NSCLC NR Open NR NR 
16 Coats et al., 
2013 
Prospective case 
series 
16 NSCLC IA – 
IV 
VATS Lobectomy/wedge resection  YES 
17 Xu-Hong Li et 
al., 2013 
nRCT 48 (24 rehab. + 24 
controls) 
NSCLC IIA – 
IIIB 
Open All types YES 
18 Morano et al., 
2014 
RCT 24 (12 PR + 12 
CPT) 
NSCLC + 
Impaired PF 
IA – 
IIIA 
NR NR NR 
19 Mujovic et al., 
2014 
Prospective case 
series 
83 NSCLC + COPD NR Open All types NR 
20 Gao et al., 
2014 
nRCT 142 (71 rehab + 71 
controls) 
NSCLC + High 
Surgical Risk 
IA– 
IV 
VATS/Open NR NR 
21 
 
Tarumi et al., 
2015 
Restrospective 
Cohort Study 
82 NSCLC + chemo-
radiotherapy 
IIB – 
IV 
Open Lobectomy/Pneumonectomy YES 
 NSCLC: Non-Small Cell Lung Cancer; RCT=Randomized Controlled Trial; nRCT=Non-randomized Controlled Trial; NR=Non Reported; COPD=Chronic Obstructive Pulmonary Disease; 
VATS=Video-Assisted Thoracic Surgery; PF=Pulmonary Function; CVPR=Conventional Pulmonary Rehabilitation; CHPR=Comprehensive Pulmonary Rehabilitation; PR=Pulmonary Rehabilitation; 
CPT=Chest Physical Therapy. 
  
CHAPTER FOUR: prehabilitation versus rehabilitation 
118 | P a g e  
 
 
 
 Type of interventions 
A detailed description of the interventions is shown in Table 4.4.  
 Studies were undertaken in Europe (Cesario et al., 2007a, Bobbio et al., 2008, Pehlivan et 
al., 2011, Bagan et al., 2013, Stefanelli et al., 2013, Divisi et al., 2013, Bradley et al., 2013, Mujovic 
et al., 2014), Asia (Sekine et al., 2005, Fang et al., 2013, Li et al., 2013, Gao et al., 2014, Tarumi 
et al., 2015) and north and south America (Jones et al., 2009c, Jones et al., 2007, Peddle et al., 
2009a, Benzo et al., 2011, Morano et al., 2013, Morano et al., 2014, Coats V, 2013). The majority 
of them were conducted as an out-patient intervention at a hospital or training facility. Only one 
investigation delivered a home-based programme (Coats V, 2013). Four studies resumed the 
rehabilitation programme after surgery (Bradley et al., 2013, Pehlivan et al., 2011, Li et al., 2013, 
Sekine et al., 2005) and three studies provided standard post-operative physiotherapy care until 
hospital discharge (Tarumi et al., 2015, Bagan et al., 2013, Mujovic et al., 2014).  
 The modality of exercise prescribed was predominantly endurance training for lower and/or 
upper limbs (Stefanelli et al., 2013, Fang et al., 2013, Sekine et al., 2005, Harada et al., 2013, 
Tarumi et al., 2015, Jones et al., 2009c, Jones et al., 2007, Peddle et al., 2009a, Cesario et al., 2007a, 
Bagan et al., 2013, Divisi et al., 2013) or a combination of endurance plus resistance training 
(Bobbio et al., 2008, Benzo et al., 2011, Bradley et al., 2013, Coats V, 2013). Only two studies 
focused on resistance training alone (Li et al., 2013, Mujovic et al., 2014). Breathing exercises with 
or without incentive spirometry were performed in 15 of the 21 studies (Benzo et al., 2011, Bobbio 
et al., 2008, Bradley et al., 2013, Pehlivan et al., 2011, Stefanelli et al., 2013, Fang et al., 2013, Li 
et al., 2013, Sekine et al., 2005, Harada et al., 2013, Tarumi et al., 2015, Cesario et al., 2007a, 
Bagan et al., 2013, Divisi et al., 2013, Mujovic et al., 2014).  
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Table 4.4: Description of interventions included in the studies 
Study Setting Timing Type of intervention 
 
Intensity Duration of 
session 
(duration 
RT) 
Frequency Length of 
intervention 
Adherence 
ETi RT BE IMT Otherii 
Sekine et al., 
2005 
Supervised + 
unsupervised 
Pre + post – 
op 
* - * - - NR 45’ (30’) Everyday 2 weeks 
 
NR 
Jones et al., 
2007, Peddle et 
al., 2009; Jones 
et al.2009 
Supervised Preoperative * - - - - Continuous and 
interval: 60 - 
100% of 
VO2peaki 
20 – 30’ 5/week 4 – 10 weeks 72, 88 and 
78% 
respective. 
Cesario et al., 
2007 
Supervised Preoperative * - * - * 80% Wmax 3 hours (NR) 5/week 4 weeks NR 
Bobbio et al., 
2008 
Supervised + 
Unsupervised 
Preoperative * * * - * 50 – 80% of Wmax 90’ (40’) 5/week 4 weeks 
 
80% 
Pehlivan et al., 
2011 
Supervised (in-
patient) 
Pre + post – 
op 
* - * - - %HRmax 
(Karvonen 
Formula) 
NR  3/day 1 week  NR 
Benzo et al., 
2011 (Study #2) 
Supervised + 
unsupervised 
Preoperative * * * * -  
Borg Scale 
NR (20’) 5/week 2 weeks (10 
sessions) 
100% 
Harada et al., 
2013 
Supervised Preoperative * - * - * Borg Scale NR CHPR: 
2/week 
CVPR: 
1/week 
2 – 5 weeks NR 
Bagan et al., 
2013 
Supervised Pre + postop * - * - * Continuous: 20 – 
30 W 
 
NR (30’) Daily 2 weeks MR 
Stefanelli et al., 
2013 
Supervised Preoperative * - * - - Continuous; at 
least 70%WMax 
3 hours (30) 5/week 3 weeks NR 
Fang et al., 2013 Supervised Preoperative * - * - - Interval; 60 – 
80%WMax 
NR (40’) 5/week 2 weeks NR 
Divisi et al., 
2013 
Supervised Preoperative * - * * - Incremental up to 
100% of Wmax 
90’ (40’) 6/week 4 – 6 weeks NR 
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Morano et al., 
2013 & Morano 
et al., 2014 
Supervised Preoperative * * - * * 80% Wmax 
 
NR (30’) 5/week 4 weeks NR 
Bradley et al., 
2013 
Supervised Pre and post 
– op 
* * * - - Up to 60% Wmax 60’ (NR) 2/week Variable NR 
Coats et al., 2013 Home – based Preoperative * * - - - Continuous (60 – 
80% Wmax) 
NR (30’) 3 to 5/week 4 weeks 75% 
Xu – Hong Li et 
al., 2013 
Supervised Preoperative - * * - * NR NR NR NR NR 
Mujovic et al., 
2014 
Supervised Preoperative - * * - * NR 45’(NA) 3/day; 
5/week 
2 – 4 weeks  NR 
Gao et al., 2014 Supervised Preoperative * - * - - Borg Scale (5 – 7) 1.5 – 2 hours 
(30-40’) 
2/day 3 – 7 days NR 
Tarumi et al., 
2015 
Supervised (in-
patient) 
Pre and post-
op 
* - * - * ? NR (45’) 5 times per 
week 
10 weeks NR 
iET = Endurance Training; RT=Resistance Training; BE=Breathing Exercises; NR=Not Reported; CHPR=Comprehensive preoperative pulmonary rehabilitation; CVPR=Conventional preoperative 
pulmonary rehabilitation; VO2Peak=Oxygen Consumption Peak; Wmax=Maximal Workload; HRmax=Maximal Heart Rate; IMT=Inspiratory Muscle Training.  
ii Education, Relaxation, Stretching and/or nutritional support 
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IMT was also performed in four studies (Benzo et al., 2011, Morano et al., 2013, Morano et al., 
2014, Divisi et al., 2013). Other minority interventions included educational sessions (Bradley et 
al., 2013, Cesario et al., 2007a, Bagan et al., 2013, Mujovic et al., 2014), relaxation techniques (Li 
et al., 2013, Tarumi et al., 2015, Bagan et al., 2013), stretching (Bobbio et al., 2008, Morano et al., 
2013, Morano et al., 2014), Non-Invasive Ventilation (NIV) (Bagan et al., 2013) and Functional 
Electrical Stimulation (FES) of the abdominal muscles (Cesario et al., 2007a). 
 The total duration of the interventions ranged from one to ten weeks (median four) with a 
median frequency of five sessions per week (range two – 14). Intensity was described in the studies 
as moderate to high and was mostly individually tailored according to the patient’s tolerance. 
Adherence was poorly assessed (Jones et al., 2009c, Jones et al., 2007, Peddle et al., 2009a, Coats 
V, 2013) and only two adverse events were recorded (abnormal decline in systolic blood pressure 
in both cases) which were solved after exercise was discontinued (Jones et al., 2007). 
4.4.3 Outcomes 
Primary outcomes 
Cardiopulmonary fitness (measurement of VO2peak) was the main (Bobbio et al., 2008, 
Stefanelli et al., 2013, Jones et al., 2007, Coats V, 2013) or the secondary (Fang et al., 2013, Jones 
et al., 2009c, Peddle et al., 2009a, Bagan et al., 2013, Divisi et al., 2013) outcome in nine studies. 
Functional capacity was also assessed in 11 studies (Benzo et al., 2011, Bradley et al., 2013, 
Morano et al., 2013, Morano et al., 2014, Pehlivan et al., 2011, Jones et al., 2009c, Jones et al., 
2007, Cesario et al., 2007a, Divisi et al., 2013, Coats V, 2013, Mujovic et al., 2014).  
 Pulmonary function was measured in 13 studies as the primary (Morano et al., 2013, Fang 
et al., 2013, Tarumi et al., 2015, Cesario et al., 2007a, Bagan et al., 2013, Divisi et al., 2013, 
Mujovic et al., 2014) or secondary study endpoint (Bobbio et al., 2008, Bradley et al., 2013, 
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Stefanelli et al., 2013, Sekine et al., 2005, Harada et al., 2013, Jones et al., 2007). FVC, FEV1 and 
DLCO were the most frequently reported respiratory parameters. MIP and MEP were also examined 
in one study (Morano et al., 2013).  
 Only four articles assessed the impact of the preoperative rehabilitation programme on 
HRQoL as the primary (Li et al., 2013, Peddle et al., 2009a) or the secondary outcome (Morano et 
al., 2014, Coats V, 2013), using a lung cancer specific questionnaire or a generic instrument 
respectively.  
 Nine studies reported the post-operative outcomes as the primary (Benzo et al., 2011, 
Pehlivan et al., 2011, Gao et al., 2014, Sekine et al., 2005, Harada et al., 2013) or the secondary 
study endpoint (Bradley et al., 2013, Morano et al., 2013, Fang et al., 2013, Mujovic et al., 2014). 
Post-operative morbidity (frequency of post-operative complications) and post-operative length of 
stay (LOS) were recorded.  
 Secondary outcomes 
Other additional outcomes assessed in the studies were the feasibility (Coats V, 2013) and 
cost-effectiveness of the intervention (Bradley et al., 2013, Gao et al., 2014), muscle strength 
(Coats V, 2013), fatigue (Peddle et al., 2009a), inflammatory markers (Jones et al., 2009c) and 
fibrinogen and albumin levels (Morano et al., 2014). 
4.4.4 Risk of bias within studies  
Risk of bias for individual studies was assessed by two independent reviewers (RS and EG) 
achieving a total agreement of 69.8% according to the Kappa Index, with the largest difference 
between raters being two points. The results are shown in Tables 4.5 and 4.6. The first displays the 
quality evaluation of the RCTs and pseudo-RCTs using the PEDro scale, while the latter depicts 
the results of the NOS for the quasi-experimental and cohort studies. The median score for the 
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RCTs and non-RCTs was five (range two – eight). This falls just below the published score in 
PEDro for moderate to high quality studies (6/10 points) but it is similar to the mean reported in 
the cardiothoracic research field (Geha et al., 2013). On the other hand, the median score for the 
observational studies according to the NOS was six (range four - eight) which is classified 
according to the literature as high risk of bias (Lo et al., 2014). 
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Table 4.5: Quality assessment of RCTs and nRCTs according to the PEDro scale 
Study 
Eligibility 
criteria 
Random 
Allocation 
Concealed 
Allocation 
Baseline 
Comparability 
Blind 
Subjects 
Blind 
Therapist 
Blind 
Assessors 
Adequate 
follow-up 
Intention-
to-treat 
analysis 
Between-
group 
comparisons 
Point 
estimate and 
variability 
TOTAL 
SCORE 
Benzo, 
2011 (Study 
2) 
YES YES NO YES NO NO YES YES NO YES YES 6/10 
Pehlivan, 
2011 
NO YES NO YES NO NO NO YES NO YES YES 5/10 
Stefanelli, 
2013 
NO YES NO YES NO NO NO NO NO YES YES 4/10 
Fang, 2013 NO NO NO NO NO NO YES YES NO YES YES 4/10 
Morano, 
2013 
YES YES YES YES NO NO YES YES YES YES YES 8/10 
Morano, 
2014 
YES YES YES YES NO NO NO YES YES YES YES 7/10 
Gao, 2014 
 
NO NO NO NO NO NO NO YES NO YES YES 3/10 
GLOBAL 
SCORE 
(Median) 
 5/10 
*Eligibility Criteria item des not contribute to total score 
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Table 4.6: Quality assessment of cohort studies and case series studies according to the Newcastle-Ottawa Scale for cohort studies 
Study Selection Comparability Outcome Total Score 
Sekine, 2005 XXXX XX XX 8/9 
Cesario, 2007 XX NA XXX 5/9 
Jones, 2007 XXX NA XXX 6/9 
Bobbio, 2008 XXX NA XXX 6/9 
Peddle, 2009 XXX NA XXX 6/9 
Harada, 2013 XXXX XX X 7/9 
Bagan, 2013 XXX NA X 4/9 
Divisi, 2013 XXX NA XXX 6/9 
Bradley, 2013 XXX XX XX 7/9 
Coats, 2013 XXX NA XXX 6/9 
Mujovic, 2014 XXX NA XXX 6/9 
Tarumi, 2015 XXX NA XXX 6/9 
GLOBAL SCORE (Median)  6/9 
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4.4.5 Results from individual studies 
A summary of the main results of this systematic review can be found in Table 4.7. 
Seven out of eight studies reported a statistically significant mean change in VO2peak pre to 
post-interventions (Jones et al., 2009c, Jones et al., 2007, Peddle et al., 2009a, Bagan et al., 2013, 
Fang et al., 2013, Stefanelli et al., 2013, Divisi et al., 2013). The study from Coats et al., (Coats V, 
2013) found no difference in VO2peak but they reported a significant and clinically meaningful 
improvement in the Constant-load Endurance Test (CCET) after four weeks of a home-based 
endurance and strength training. Two studies also registered an increase in the maximal workload 
(Wmax) achieved during the CPET (Bobbio et al., 2008, Fang et al., 2013).  
Changes in functional capacity measured with the 6MWT demonstrated an improvement 
from baseline to post-intervention (Jones et al., 2007, Peddle et al., 2009a, Cesario et al., 2007a, 
Divisi et al., 2013, Morano et al., 2013, Bradley et al., 2013, Coats V, 2013). The study from Benzo 
et al., (Benzo et al., 2011) failed to find any significant difference after the training using an ISWT 
but data from this study was not retrievable and therefore it was not possible to calculate the mean 
difference and 95% C.I. The study from Pehlivan et al. (Pehlivan et al., 2011) found a significant 
improvement in exercise performance but since they used a non-standardized test the results were 
not incorporated into the analysis. 
Both FVC and FEV1 were significantly enhanced after the intervention comparing to 
baseline (Cesario et al., 2007a, Pehlivan et al., 2011, Harada et al., 2013, Bagan et al., 2013, Fang 
et al., 2013, Divisi et al., 2013, Morano et al., 2013, Bradley et al., 2013, Mujovic et al., 2014, 
Tarumi et al., 2015). The study from Jones et al., (Jones et al., 2007) found no differences in any 
of the pulmonary function parameters after eight weeks of intense aerobic exercise training. Only 
two studies compared the pulmonary function between groups after the surgery. Sekine et al., 
(Sekine et al., 2005) using an historical control group found that patients who had completed the 
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prehabilitation programme experienced a smaller reduction in FEV1 one month after surgery (p 
=.023). On the contrary, Stefanelli et al. (Stefanelli et al., 2013) compared both groups 60 days 
postoperatively and found no significant differences.  
Assessment of HRQoL after the training yielded no significant improvement in any of the 
health domains (Peddle et al., 2009a, Coats V, 2013, Morano et al., 2014). However, in comparison 
to a control group, Xu-Hong Li et al., (Li et al., 2013) found that patients engaging in the 
rehabilitation programme reported better scores in several domains of the EORTC QLQ-LC30 both 
at three and six months after the surgery. Due to the small number of studies and uniqueness 
measurement properties of the questionnaires, mean differences and 95% CI were not calculated 
for this outcome. 
Finally, in terms of post-operative outcomes, post-operative hospital LOS  was significantly 
reduced in comparison to the standard care with the exception of the study conducted by Benzo et 
al., (Benzo et al., 2011) where the authors were only able to find a trend towards a reduction which 
was almost statistically significant (p =.058). Post-operative morbidity was also significantly 
reduced, although studies showed significant heterogeneity (Benzo et al., 2011, Pehlivan et al., 
2011, Harada et al., 2013, Fang et al., 2013, Morano et al., 2013, Bradley et al., 2013, Gao et al., 
2014, Sekine et al., 2005). Again, the study conducted by Benzo et al., reported only a significant 
difference in the chest tube duration and the incidence of prolonged air leak while the study by 
Harada et al., found that the differences were only significant among patients with several co-
morbidities (CCI ≥ 3).  
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Table 4.7: Results from individual studies 
Study Outcomes Results Limitations 
Sekine et al., 
2005 
(retrospective 
cohort study) 
LOSi 
PPC  
Pulmonary Function (post-
operative FEV1) 
 
↓ LOS between groups (p =.003) 
Less change in FEV1 after surgery  
(p =.023) 
No differences in PPCs 
Historical control group. 
Intervention was not fully described. 
Study limited to patients with poor lung function. 
Jones et al., 2007 
(prospective case 
series) 
Exercise Capacity (VO2Peak) 
Functional Capacity (6MWT) 
Pulmonary function (FEV1, 
FVC, DLCO) 
↑VO2peak (ml/kg-1/min-1 and % predicted); p =.002 and 
p <.001 
↑6MWT (m and % predicted) pre – post intervention 
(p =.003) 
No difference in lung function 
No control group. 
Small sample size. 
Mix of cancer types. 
Cesario et al., 
2007 
(prospective case 
series) 
Pulmonary Function 
Functional capacity (6MWT) 
↑FVC (L, % of predicted); p <.01 FEV1 (% 
predicted);  p<.05 
↑ 6MWT (m) pre – post intervention (p<.05) 
No control group. 
Small sample size. 
Protocol was not fully described. 
Bobbio et al., 
2008 
(prospective case 
series) 
Exercise capacity (VO2Max, 
Wmax) 
Pulmonary Function (FEV1, 
FVC, DLCO) 
↑ VO2max (ml/kg-1/min-1) and L;  
p =.001 
↑VO2max@AT (ml/kg-1/min-1) and L; p <0.02 
↑Wmax; p =.001 
No control group. 
Small sample size. 
Study limited to patients with poor lung function. 
Peddle et al., 
2009 
(prospective case 
series) 
HRQoL (FACT-L; TOI; LCS)  
Exercise capacity (VO2Peak) 
No changes in HRQoL pre – post intervention  
Correlation between changes in VO2peak and ↑fatigue 
↓HRQoL pre – post surgery 
No control group. 
Small sample size. 
Mix of cancer types. 
Inadequate Follow-up 
Jones et al., 2009 
(prospective case 
series) 
Exercise Capacity (VO2Peak) 
Functional Capacity (6MWT) 
Inflammatory markers 
↓ inflammatory markers 
↑ VO2Peak (mean change +0.13 L.min-1; p=.002 
↑6MWT (mean +62m; p =.004) 
No control group. 
Small sample size. 
Mix of cancer types. 
Pehlivan et al., 
2011 
(RCT) 
LOS 
PPC  
↓ LOS and PPC (p <.001 and <.05 respectively) 
↑ FEV1 (L), FVC (L), PaO2, PaCO2 and DLCO (p 
<.01) 
↑ Exercise performance  (P<.001) 
Patients in the rehab group were significantly worse 
in lung function comparing to the control group.  
There is no description of how exercise capacity 
was measured (non-standardized test). 
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Pulmonary Function (FEV1, 
FVC, PaO2, PaCO2, SaO2, 
DLCO) 
Exercise performance (non-
standardized test) 
Benzo et al., 
2011 
(RCT) 
PPC  
LOS 
Functional Capacity (SWT) 
↓ of chest tube duration in the rehab group and ↓ PAL 
(p =.03) 
↓ in LOS (p =.058) 
No difference in SWT (p >.05) 
Sample size. 
Low intensity training; duration per session not 
specified. 
Harada et al., 
2013 
(retrospective 
cohort study) 
Post-operative complications 
Pulmonary Function (VC, 
FEV1) 
↓ of post-operative complications only in patients 
with CCI ≥ 2; p =.0362 
↑FEV1 and VC pre – post intervention (p <.01) 
Historical control group. 
There were no differences in the preoperative 
exercise programme between groups except in 
frequency. 
The programme was not fully described.  
Bagan et al., 
2013 
(prospective case 
series) 
Exercise Capacity (VO2Max) 
Pulmonary Function (FEV1) 
↑ VO2max (3.5 ml/kg-1/min-1); ↑ PPOVO2max (p 
<.0001) 
↑ FEV1 (12%); ↑ PPOFEV1 (p<.0001) 
 
No control group. 
Patients shown poor cardiopulmonary fitness at the 
beginning. 
Intensity of the endurance training was not 
individually tailored. 
Stefanelli et al., 
2013 
(RCT) 
Exercise Capacity (VO2peak) 
Pulmonary Function (FEV1, 
FVC, FEV1/FVC, DLCO) 
↑ VO2peak (ml/kg-1/min-1) pre-post intervention and in 
comparison to the control group (p <0.001) both pre 
– post training and 60 days after surgery; 
No changes in Pulmonary Function at any point 
(intra-group or inter-group) 
 
Patients were younger than other series (age <75) 
and had no severe co-morbidities. 
Quality assessment was poor. 
Fang et al., 2013 
(pseudo-RCT) 
Pulmonary Function (FVC, 
FEV1, FEV1/FVC, DLCO, 
MVV) 
Exercise Capacity (VO2peak) 
Post-operative complications  
LOS 
HRQoL (results not reported) 
↑ FVC (L), FEV1/FVC, MVV, DLCO and DLCO/VA 
pre – post intervention (p <.05); No change in FEV1 
↑ Wmax (Watts), VO2max (L) and SaO2 pre - post 
intervention (p <.01) 
↓ LOS in the rehabilitation group  
(p =.021) 
No difference in cardiopulmonary complications 
Randomization was done among patients who were 
fit for surgery, while training was performed both in 
surgical and non-surgical candidates. 
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59% patients of the non-operation group fulfilled 
operation criteria 
Divisi et al., 2013 
(prospective case 
series) 
Pulmonary Function (FVC, 
FEV1, FEV1/FVC, PEF, 
DLCO) 
Exercise Capacity (VO2peak) 
Functional Capacity (6MWT) 
↑ FEV1 (L and % predicted), FVC (% predicted), 
FEV1/FVC, PEF (l/s; % predicted) and DLCO (p 
<.05); 
↑ VO2max (l and l/kg-1/min-1),  
(p <.01) 
 ↑ 6MWT (m) pre – post intervention (p < .00001) 
No control group. 
Patients exhibited very low cardiopulmonary fitness 
and lung function at the beginning. 
Morano et al., 
2013 
(RCT) 
Lung Function (FVC, FEV1, 
MIP, MEP, PaO2, PaCO2, 
SaO2, MIP, MEP) 
Functional Capacity (6MWT) 
PPC  
LOS 
↑ FVC (L and % predicted); (p <.01), and ↑ MIP and 
MEP (pre – post intervention); (p <.001) 
↑ 6MWT (m) pre – post intervention (p <.001) 
↓ LOS and PPCs (p <.05) 
 
Bradley et al., 
2013 
(prospective 
cohort study) 
Functional Capacity (6MWT) 
Pulmonary Function (FEV1) 
PPC 
LOS 
↑ 6MWT pre – post intervention  
(p <0.001) 
↑ FEV1 pre-post intervention  
(p =.009 
↓ LOS in the rehab group (p =.05) 
No difference in PPCs 
Non-randomized study. 
Protocol was barely described. 
High rate of dropouts. 
Low frequency and total duration of the training. 
Coats et al., 2013 
(prospective case 
series) 
Exercise Capacity (VO2peak, 
endurance time) 
Functional Capacity (6MWT) 
Muscle Strength 
HRQoL (SF-36) 
No change in VO2peak 
↑ CET (s) (p <.05) 
↑ Muscle strength (p <.05) 
↑ 6MWT (m) (p <.05) 
No change in HRQoL 
No control group. 
Small sample size. 
 
Xu-Hong Li et 
al., 2013 
(non-RCT) 
HRQoL (EORTC QLQ-C30) At 3 months there were significant differences in 
global health, physical function and emotional role 
between groups (p <.05) and fatigue (p =.006) 
At 6 months HRQoL there was also a significant 
difference in other symptoms (pain, dyspnoea, 
constipation, insomnia and appetite loss); p <.0001 
The rehabilitation programme was not described.  
Only measured HRQoL. 
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Morano et al., 
2014 
(RCT) 
Levels of fibrinogen and 
albumin 
HRQoL 
HADS 
↑ fibrinogen levels intra and inter-group (p <.0001) 
but no changes in albumin levels 
↓ Anxiety and Depression (p <.05) 
No differences in HRQoL 
 
Mujovic et al., 
2014 
(prospective case 
series) 
Pulmonary Function (FVC, 
FEV1, FEF25,50%, SaO2) 
Functional Capacity (6MWT) 
PPC 
LOS 
↑ FEV1 (ml), VC (ml) and FEF50%  
(p <.001 and p =.006 respectively) 
↑ 6MWT (m); p <.01 
No control group. 
Intervention was not properly described (intensity, 
length of intervention). 
Gao et al., 2014 
(non-RCT) 
Post-operative Complications  
LOS 
Average hospital cost 
↓ post-operative complications; p <.05 
↓ LOS; p =.00 
No difference in hospital cost 
Patients were not randomized and only included 
high-risk patients. 
Intervention was very short (3 – 7 days) and 
intensity of the training was low.  
Complications were of minor severity and include 
several types. 
Tarumi et al., 
2015 
(prospective 
cohort study) 
Pulmonary Function ↑ FVC and FEV1 after the training  
(p <.001 and p <.0001 respectively) both in litres and 
% of predicted in patients with impaired pulmonary 
function only 
Retrospective study. 
No analysis of functional capacity or exercise 
performance. 
 LOS = Length of Hospital Stay; PPC = Post-operative Pulmonary Complications; FEV1 = Forced Expiratory Volume in 1 second; VO2peak = Peak Oxygen Consumption; 6MWT 
= Six Minute Walk Test; FVC = Forced Vital Capacity;  DLCO = Diffusion of Carbon Monoxide; Wmax = Maximal Workload; HRQoL = Health-Related Quality of Life; FACT – 
L: Functional Assessment of Cancer Therapy – Lung Cancer; TOI = trial outcome index; LCS = lung cancer subscale; SWT = Shuttle Walk Test; VC = Vital Capacity; CCI = 
Charlson Co-morbidity Index; PPOVO2peak = predicted post-operative VO2Peak; PPOFEV1 = predicted post-operative FEV1; MVV = Maximal Voluntary Ventilation; SaO2 = Oxygen 
Saturation; PaO2 = Partial Oxygen Pressure; PaCO2 = Partial Pressure of Carbon Dioxide; MIP = Maximal Inspiratory Pressure; MEP = Maximal Expiratory Pressure; CET = 
Constant Cycle-ergometry Test; SF-36 = Short Form 36 Health Survey; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire; HADS = Hospital and Anxiety Distress Scale; FEF25,50% = Forced Expiratory Flow at 25% and 50%.
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4.4.6 Synthesis of results 
For the primary outcomes (exercise and functional capacity) a large between-study 
heterogeneity was found and therefore it was consider not appropriate to conduct a meta-analysis 
and pooled results; to illustrate the results of each study, a forest plot with the standardized mean 
difference and 95% CI was generated (Figures 4.2 and 4.3). Due to the small number of studies 
included and the unique properties of the measurement tools, no forest plot was generated for the 
results on HRQoL. 
 
Figure 4.2: Forest plot with SMD and 95% C.I for the studies which examined VO2peak changes pre- to post- 
intervention. 
 
Figure 4.3: Forest plot with SMD and 95% C.I for the studies which examined 6MWT changes pre- to post- 
intervention. 
For each of the other outcomes of interest (FVC, FEV1, LOS and post-operative 
complications) a random-effect meta-analysis was performed to estimate the pooled effect size of 
the interventions. A significant increase for both FEV1 (SMD = 0.27, 95% CI: 0.11, 0.42) and FVC 
(SMD = 0.38, 95% CI: 0.14, 0.63) pre to post-intervention was found (Figure 4.4A and 4.4B). In 
the post-operative outcomes, a significant reduction both in hospital LOS (MD = -4.83, 95% CI: -
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5.90, -3.76) and post-operative complications (RR = 0.45, 95% CI: 0.28, 0.73) was obtained 
(Figures 4.5 and 4.6), although the latter showed substantial heterogeneity (X2=20.08, p =.005; 
I2=65%) (Figure 4.6A). To elucidate the possible reasons, we conducted a subgroup analysis 
according to the type of complications included (pulmonary alone vs. others) and found that when 
pulmonary complications were analysed separately, heterogeneity was significantly reduced 
without reducing the effect size (OR = 0.55; 95% CI: 0.34 - 0.89; p = .24 I2 = 27%) (Figure 4.6B). 
A 
 
 
 
 
B 
 
 
 
 
 Figure 4.4: Forest plot and pooled estimated effect size of the interventions on FVC (A) and FEV1 (B) . 
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Figure 4.5: Forest plot and pooled estimated effect size for post-operative LOS in the intervention and control 
groups. 
 
  
Figure 4.6: Forest plot and pooled estimated effect size of the interventions on overall post-operative 
complications (A) and pulmonary complications alone (B). 
B 
A 
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We also conducted a sub-group analysis in LOS and post-operative complications to 
compare the results obtained with randomized or pseudo-randomized controlled trials versus cohort 
studies. For the first outcome, we did not find any significant difference between both types of 
designs (MD = -4.06; 95% CI:-5.22, -2.90 and MD = -6.11; 95% CI: -7.85, -4.36 for RCTs and 
cohort studies respectively). In both cases, heterogeneity was low. For the post-operative 
complications however, the mean effect in terms of RR was almost identical but heterogeneity was 
significantly higher in the cohort studies (I2 = 82% vs. 0%) (Figure 4.7). 
4.5 DISCUSSION 
This systematic review aimed to examine the current body of evidence on the benefits of 
engaging in a preoperative exercise-based intervention for individuals with lung cancer. The results 
drawn support the hypothesis that preoperative exercise training can significantly reduce hospital 
stay and the incidence of PPCs, as well as minimize post-operative risk by enhancing pulmonary 
Figure 4.7: Forest plot and pooled effect size of the interventions on post-operative complications in RCTs and 
cohort studies. 
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function and most likely, exercise capacity. These findings are consistent with the other systematic 
review conducted in patients awaiting lung resection surgery (Pouwels et al., 2015) and strengthen 
the evidence for the implementation of such interventions in this population. 
When setting up a preoperative pulmonary rehabilitation programme in oncological patients 
there are several factors that should be taken into consideration. The individual components of the 
intervention including the modality of training, intensity, frequency and total duration as well as 
the clinical features of the participants (stage of the disease, presence of co-morbidities, 
performance status) and the instruments used to measure the intervention-related changes can 
significantly affect the results obtained. Given the paucity of research in this particular population, 
the current recommendations in lung cancer stem from those reported for COPD. For instance, 
duration of the intervention has been conventionally stablished in eight to 12 weeks, with longer 
training periods usually associated with larger improvements (Jenkins et al., 2010, Spruit et al., 
2013). However, in the oncologic setting, the urge to proceed with surgery as soon as possible 
demands for shorter interventions. In a recent systematic review of the effects of prehabilitation in 
post-operative outcomes, six to eight weeks have been proposed as an adequate balance between 
feasibility and efficacy (Debes et al., 2014). This suggestion is consistent with the available 
literature and the current therapeutic delay reported in lung cancer. According to a retrospective 
analysis conducted in the UK, the median waiting time in lung cancer to receive the first line of 
treatment was 48 days (6.8 weeks) which didn’t affect the long-term outcomes at any stage of the 
disease (Bozcuk and Martin, 2001). In another retrospective study, patients with stage I NSCLC 
undergoing surgical resection with a delay in care of more than eight weeks had an increase in 30-
day mortality and a decrease in median survival comparing to those receiving surgical resection 
within the first eight weeks (57.7±1 months versus 69.2±1.3; p <.001). Therefore the suggested 
time frame of six – eight weeks seems optimal for delivering a preoperative pulmonary 
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rehabilitation programme without affecting cancer-specific outcomes. In this systematic review, 
only one study assessed the feasibility of the intervention (Coats V, 2013) and concluded that a 
home-based rehabilitation programme for four weeks was safe and feasible. In contrast, study #1 
in the RCT of Benzo et al., (Benzo et al., 2011) was promptly closed after one year of recruitment 
mainly due to the fact that patients or providers were not willing to delay surgery for four weeks. 
However, based on the results found in some studies included in the systematic review, only two 
to three weeks of intense pulmonary rehabilitation seem to be enough to yield some improvements 
in exercise capacity and pulmonary function (Bagan et al., 2013, Fang et al., 2013, Mujovic et al., 
2014). Adherence was also scarcely assessed in the studies included ranging from 72 to 80 % (Coats 
V, 2013, Peddle et al., 2009a, Jones et al., 2009c, Jones et al., 2007) although two more 
investigations reported 100% of adherence (data provided by the authors upon request) (Bagan et 
al., 2013, Bobbio et al., 2008). One study recorded two adverse effects and both were reversed after 
discontinuing the training (Jones et al., 2007). Altogether, these findings suggest that exercise 
training can be safely achieved before surgery although further research is needed to examine 
patients’ preferences and perceived barriers to improve adherence an optimize results.  
Features of training including mode of delivery, duration, intensity and frequency are also 
crucial when designing a pulmonary rehabilitation programme to achieve the desirable results. 
Traditionally, endurance training has been the cornerstone of pulmonary rehabilitation but more 
recently resistance training has also been acknowledged as an essential component to prevent or 
reverse muscle atrophy and enhance physical functioning. Nowadays, a combination of both 
endurance and resistance training is regarded as the best strategy to treat peripheral muscle 
dysfunction in patients with chronic respiratory diseases (Nici et al., 2006). However, the mode of 
delivery for each component has been poorly assessed and therefore there are no solid 
recommendations to be made. For example, endurance training can be performed at a constant load 
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or combining bouts of different intensity. Interval training has been suggested as an alternative to 
constant training for those patient who are unfit to achieve the targeted intensity for the total 
duration of the training. Few studies have been published comparing both approaches but it seem 
that they are equally effective in terms of improving the peak power or VO2peak (Beauchamp et al., 
2010). However, interval training could be more easily tolerated given that it facilitates a decrease 
in end-expiratory lung volume resulting in lower ventilation and less dyspnoea (Andrianopoulos et 
al., 2014, Puhan et al., 2006). The majority of the studies included in this review used a continuous 
protocol to deliver the endurance training with intensity ranging from 60 to 100 % of the peak 
workload. The studies conducted by Jones et al. used a combination of constant and interval 
training up to 100% of the VO2peak where intensity and duration of the training were increased 
according to the patient’s progression (Peddle et al., 2009a, Jones et al., 2007, Jones et al., 2009c). 
Given that we could not perform a meta-analysis for this outcome, we cannot compare the effect 
size of each training modality and examine potential differences in terms of VO2peak but according 
to the results obtained in each individual study, it appears that there are no differences between the 
two approaches. Intensity was also very variable in the studies included but it generally achieved 
60% of the maximal workload as recommended by the international guidelines (Nici et al., 2006). 
Only the study by Bagan et al. delivered a low-intensity programme where patients trained for 30 
minutes at an intensity of 20 to 30 Watts (Bagan et al., 2013). Even so VO2max and PPO VO2max 
were significantly increased after the intervention. This demonstrates that cardiopulmonary fitness 
can be improved even with low-intensity programmes in patients with severe deconditioning and/or 
at high risk of post-operative morbidity and mortality. With regard to resistance training only five 
studies included strength exercises in their protocols (Bobbio et al., 2008, Benzo et al., 2011, 
Morano et al., 2014, Morano et al., 2013, Coats V, 2013). According to the current 
recommendations, in patients with chronic respiratory diseases, resistance training should be 
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delivered at medium intensity (55 – 60 % of maximal one repetition) and include two to four sets 
of 6 to 12 repetitions. Again, there is no current evidence of which training load and/or modality 
of resistance training provides the optimal results in patients with lung cancer. Overall, in the 
studies included, patients trained using free weights or elastic bands focusing on low loads and a 
relatively high number of repetitions. In summary, given the lack of consistency between the 
studies included in the review in terms of modality of training (continuous vs. interval), type of 
exercise prescribed (endurance vs. resistance or both), intensity and frequency no conclusions can 
be extracted and future research is needed to provide specific guidelines in the lung cancer 
population.   
Measurement tools in the lung cancer setting are diverse and their responsiveness is more 
likely related to the stage of the disease (Granger et al., 2013a). Peak Oxygen Consumption 
(VO2peak) provides the gold standard for evaluating cardiorespiratory fitness in healthy subjects 
(Jones et al., 2010) and is a key measurement in the preoperative evaluation of individuals 
undergoing lung resection surgery, especially for those who exhibit poor lung function (Benzo et 
al., 2007, Brunelli et al., 2009b, Brunelli et al., 2013a). In addition, it has been acknowledged that 
VO2peak is a strong and reliable predictor of post-operative mortality and morbidity, HRQoL and 
long-term survival in NSCLC (Benzo et al., 2007, Loewen et al., 2007, Bobbio et al., 2008, Jones 
et al., 2010, Brunelli et al., 2014, Bolliger et al., 1996). Endurance training is considered the best 
way to improve VO2peak in healthy subjects (Jones, 2011) and it has also been successfully 
prescribed to individuals with several chronic diseases (Gimenez, 2000, Corhay et al., 2012, Lan 
et al., 2013). The studies included in this systematic review support the premise that endurance 
training is also able to improve cardiopulmonary fitness in patients with NSCLC. However, due to 
the large heterogeneity found in the studies, estimated of pooled effect sizes were not obtained and 
we cannot draw any definitive conclusion. There was only one study that found no change in 
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VO2peak after the training (Coats V, 2013). In this investigation, Coats et al. examined the effects 
of a home-based rehabilitation programme consisted of three to five weekly sessions of aerobic 
and strength training for four weeks. We believe that there are two possible explanations for the 
lack of results in this study. One, the reported lack of responsiveness of an incremental exercise 
test to quantify intervention-related changes (Borel et al., 2013), which seems reasonable in this 
case given that  patients did improve their endurance time and functional performance (6MWT). 
Furthermore, in this study patients were already fit at baseline in terms of exercise capacity (VO2peak 
107% of predicted), therefore the intensity and/or total duration of the programme could have been 
insufficient to yield the physiological adaptations to exercise.   
Similarly to exercise capacity, functional capacity was significantly enhanced across studies 
but heterogeneity was also found to be substantial and thus a meta-analysis was considered not 
appropriate. The 6MWT was the most common field test used in the studies in consistent with the 
literature (Granger et al., 2013a). The test has shown a good correlation with VO2peak and perceived 
physical functioning in people with a variety of chronic diseases and cancer patients and has also 
proven effective to measure changes after a pulmonary rehabilitation programme (Ross et al., 2010, 
Schmidt et al., 2013). In this systematic review, four out of six studies reported an increment of 
more than 42 meters in the 6MWT, which is greater than the minimally clinical important 
difference (MCID) for individuals with lung cancer (Granger et al., 2015b). Only one study did not 
find any improvement in the functional capacity after the intervention. In this investigation, Benzo 
et al. examined the effects of a ten-session, twice-daily intervention of moderate aerobic and 
strength training using the Incremental Shuttle Walk Test (ISWT) (Benzo et al., 2011). Although 
the ISWT has shown moderate validity and correlation with the VO2peak measured with a CPET in 
individuals with lung cancer (Granger et al., 2015a), incremental test are less sensitive to detect 
changes after an exercise-based intervention (Borel et al., 2013). This has lead researchers to 
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asseverate that the ISWT can be a good surrogate to CPET to assess functional capacity and stratify 
patients in the preoperative setting of lung cancer surgery but constant-work rate protocols are 
probably more responsive to detect changes after a pulmonary rehabilitation programme. 
Pulmonary function is considered the key assessment in the physiologic evaluation of the 
lung resection candidate since both FEV1 and predicted PPO FEV1 have been traditionally applied 
for stratification of perioperative risk (Brunelli et al., 2013a). Similar findings have been reported 
for the diffusing capacity of carbon monoxide (DLCO) and particularly, for the PPO DLCO. Studies 
have shown that a PPO DLCO below 60% is a strong predictor of cardiopulmonary complications 
and mortality even in patients with otherwise normal pulmonary function (Brunelli et al., 2013a, 
Brunelli et al., 2007a). Optimizing FEV1 and DLCO through targeted exercises in the preoperative 
period of lung cancer might result in an increase in surgical rates, improving patients’ prognosis 
and prolonging disease-free and overall survival. In a preoperative randomized controlled trial 
published by Weiner et al., IMT plus incentive spirometry resulted in an improvement in 
pulmonary function in COPD patients awaiting lung resection surgery although this wasn’t 
translate into a reduction in hospital stay or post-operative pulmonary complications (Weiner, 
1997). Results of this meta-analysis showed that a significant increase both in FEV1 and FVC can 
be achieved after a preoperative exercise-based intervention. These findings are consistent with 
another systematic review and meta-analysis conducting in post-surgical lung cancer patients. In 
this study, breathing exercises improved pulmonary function in terms of FEV1 (SMD = 3.37; 95% 
CI: 1.97-4.77; p <.001) and FEV1/FVC (SMD = 1.77; 95% CI: 0.15-3.39; p =.032) (Liu et al., 
2013). In another systematic review involving patients with COPD, breathing exercises (including 
IMT, deep breathing exercises, pursed lips breathing and incentive spirometry) significantly 
enhanced functional capacity (MD = 45 meters; 95% CI: 29-61) but had no effect on HRQoL or 
dyspnoea (Holland et al., 2012). Despite this, breathing exercises are not systematically 
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recommended for patients with chronic respiratory diseases. It is worth noticing though, that 
breathing exercises have been insufficiently described in the literature and are arbitrarily used to 
refer to several interventions, which can lead to undesirable and biased results (Garrod and 
Mathieson, 2013).  
The HRQoL was infrequently assessed in the studies included. This is not entirely 
surprising since according to one systematic review of randomized trials for the treatment of lung 
cancer, only 36% of the studies published contained information about HRQoL (Sarna and 
Riedinger, 2004). However, a growing interesting in the subject has emerged given the prognostic 
role of HRQoL in lung cancer survival (Pompili et al., 2013, Li et al., 2012, Moller and Sartipy, 
2012). Unfortunately, studies examining the effects of exercise training on HRQoL have yielded 
disappointing results, showing little to no change in the majority of the domains (Jones et al., 2008, 
Arbane et al., 2011, Stigt et al., 2013). In this line, the studies included in our review have also 
failed to find any significant improvement in HRQoL after the prehabilitation (Peddle et al., 2009a, 
Morano et al., 2014, Coats V, 2013). More interestingly, the only study which compared HRQoL 
to a control group during the post-operative period found significant differences in global health, 
physical functioning and symptom severity both at three and six months after the surgery (Li et al., 
2013). However, this was a non-randomized study with several methodological flaws, so these 
findings should be interpreted carefully.  
Finally, post-operative morbidity is regarded as the main cause for increased hospital costs 
and long-term impairments. PPCs are particularly the most costly and are associated with 
prolonged hospital stay in comparison to patients without pulmonary complications (Cassidy et al., 
2013, Sabate et al., 2014, Branson, 2013). In the long-term, PPCs have been also shown to impact 
cancer-related survival reducing disease-free and overall survival across all stages (Rueth et al., 
2011). Risk factors associated with post-operative complications include advanced age (≥75 years 
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old), PPO FEV1 or PPO DLCO ≤60%, cardiovascular morbidity, neoadjuvant therapy, low 
cardiorespiratory fitness, smoking status, obesity and the presence of COPD (Brunelli et al., 2007a, 
Brunelli et al., 2013b, Jones, 2011, Stephan et al., 2000, Agostini et al., 2010, Amar et al., 2010). 
Several studies have been undertaken to assess the efficacy of perioperative interventions to prevent 
complications after cardiothoracic surgery but results are conflicting (Agostini et al., 2010, Reeve 
et al., 2010, Varela et al., 2006, Weiner, 1997, Yañez-Brage et al., 2009, Sobrinho et al., 2014). 
Yañez et al., in an observational study conducted in patients undergoing off-pump CABG found 
that preoperative chest physiotherapy including breathing exercises and incentive spirometry 
effectively reduced the incidence of atelectasis (17% vs. 36%; p =.01) (Yañez-Brage et al., 2009). 
Sobrinho et al., in another prospective study involving patients undergoing myocardial 
revascularization found a significant reduction in post-operative LOS in patients undergoing 
preoperative physiotherapy (IMT and breathing exercises) comparing to the control group 
(Sobrinho et al., 2014). In this meta-analysis, a significant reduction both in post-operative LOS 
and post-operative complications was found, with the latter showing a Relative Risk Reduction 
(RRR) of 55% in those patients undergoing prehabilitation in comparison to the standard care. 
Furthermore, when pulmonary complications were assessed separately, we observed that the mean 
effect size was maintained and heterogeneity across studies was remarkably reduced (from I2=65%; 
p =.02 to I2=27%; p =0.24). The lack of consensus in the definition of PPCs is most likely the main 
responsible for the controversial results found in the literature. Several diagnostic tools have been 
proposed to homogenously assess the frequency and severity of PPCs such as the MGS, which 
aims to identify those complications that are more likely to be prevented with a physiotherapy 
intervention (Reeve et al., 2010). Unfortunately, only one study in this review used this scale to 
assess post-operative complications (Bradley et al., 2013). The majority of the studies included as 
PPCs events of different severity and therapeutic management, such as pulmonary embolism, 
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bronchopleural fistula, atelectasis, prolonged air leak, pneumonia, respiratory failure or re-
intubation, which considerably hinder the comparison and generalization of results. 
4.6 LIMITATIONS 
This systematic review and meta-analysis has several limitations that must be 
acknowledged. First, given the lack of RCTs published in the field, we also included non-
randomized controlled trials and observational studies, which are more easily biased and can 
potentially affect the validity and reliability of the findings. Notwithstanding, in the sub-group 
analysis performed comparing RCTs with cohort study, both LOS and PPCs showed little change 
in the mean effect size. In addition, because most studies were series of cases, the principal 
summary measurements (exercise capacity and functional capacity) were calculated pre to post-
intervention, so it remains unclear whether a preoperative pulmonary rehabilitation programme 
provides better functional outcomes in the post-operative period in comparison to the standard care. 
Furthermore, the between-studies heterogeneity has prevented us from conducting a meta-analysis 
in those outcomes. Finally, assessment of publication of bias was not considered appropriate in the 
meta-analysis because of the small number of studies involved. However, the novelty of the 
research field (the oldest article being published in 2005), plus the differences found in the results 
(with some studies showing little to no results) suggest that most likely publication of bias has not 
influenced our findings. 
4.6 CONCLUSIONS 
The results of this systematic review are indicative that an exercise-based intervention 
performed in the preoperative period of lung cancer surgery improves pulmonary function and most 
likely exercise and functional capacity before surgery. Furthermore, prehabilitation of patients with 
lung cancer appears effective in reducing post-operative pulmonary complications and length of 
CHAPTER FOUR: prehabilitation versus rehabilitation 
145 | P a g e  
 
 
 
hospital stay in patients undergoing thoracotomies. However, further research involving larger 
RCTs are needed to validate these results and elucidate the effectiveness of the intervention on 
other outcomes such as HRQoL and survival.
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CHAPTER FIVE: Feasibility of a preoperative pulmonary rehabilitation programme in patients 
awaiting VATS for lung malignancies: a single-arm pilot study. 
5.1 INTRODUCTION AND RATIONALE 
 The main concern for implementing a prehabilitation programme in oncological patients is 
the need to proceed with surgery as soon as possible. As discussed in the previous chapter, 
traditional exercise programmes should last between eight to 12 weeks, with longer training periods 
usually leading to better results (Spruit et al., 2013, Nici et al., 2006, Ries et al., 2007). However, 
in individuals with cancer who are waiting to undergo surgery, the urge to proceed with the planned 
treatment calls for shorter interventions. Six weeks of pulmonary rehabilitation are the minimum 
recommended to achieve sustainable effects, although physiologic improvements have been seen 
as early as two – four weeks (Shannon, 2010). The Swedish Lung Cancer Study Group recommend 
that 80% of all diagnostic test should be completed within four weeks from the first consultation 
and treatment should start within two weeks thereafter (Myrdal et al., 2004). A therapeutic delay 
of > eight weeks has been associated with poor disease-free and overall survival in patients with 
stage I NSCLC undergoing lung resection surgery with curative intent (Samson et al., 2015). 
Consequently, six to eight weeks have been proposed as an optimal time frame to deliver a 
preoperative intervention both in terms of feasibility and efficacy (Debes et al., 2014).  
Feasibility refers to the ultimately capacity of something to be done or undertaken 
considering all the variables involved. Feasibility in the context of an exercise intervention is 
usually assessed in terms of cost-effectiveness, tolerability, safety, adherence to the protocol 
prescribed and preliminary responsiveness. Adherence is define by the WHO as the extent to which 
a person’s behaviour corresponds with agreed-on recommendations by the health care provider and 
is a crucial health behaviour in the management of chronic respiratory diseases (Nici et al., 2006). 
Feasibility studies are usually designed to determine if an intervention is appropriate for further 
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testing in a larger sample. These investigations are necessary when there is not enough evidence 
on the effectiveness of a particular treatment. There are eight major areas in which a feasibility 
study can be focused on (Table 5.1) (Bowen et al., 2009). In this pilot study, we specifically focused 
on the implementation, practicality and preliminary efficacy.  
Table 5.1: Key areas of focus of feasibility studies and possible outcomes; adapted from Bowen et al., 2010 
Area of focus Outcomes of interest 
Acceptability  Satisfaction 
 Intent to continue use 
 Perceived appropriateness 
 Perceived positive or negative effects on 
organization 
 Actual use 
 Perceived demand 
Demand 
Implementation  Degree of execution (recruitment rate, 
adherence) 
 Success or failure of execution 
 Amount, type of resources needed to 
implement 
 Factors affecting implementation ease or 
difficulty 
 Positive/negative effects on participants 
(safety) 
 Ability of participants to carry out the 
intervention 
 Cost analysis 
Practicality 
Adaptation  Degree to which similar outcomes are 
obtained in new format 
Integration  Perceived fit with infrastructure 
 Perceived sustainability 
 Cost to organization and policy bodies 
 Fit with organizational goals and culture 
 Positive or negative effects on 
organization Expansion 
Limited Efficacy  Intended effects or programme or 
process on key intermediate variables 
 Effect-size estimation 
 Maintenance of changes from initial 
change 
   Safety is also a critical aspect when implementing an exercise-based intervention, 
especially in frail populations such as COPD or cancer. Before starting an exercise programme, a 
comprehensive evaluation of the exercise capacity and health status is needed to individualize the 
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exercise prescription and explore potential limitations (Spruit et al., 2013). There is accumulating 
evidence that exercise in the context of cancer is effective and safe across all stages, although the 
majority of the research has been conducted in cancer survivors or patients undergoing active 
treatment (Granger et al., 2013b, Cheema et al., 2014, Jones et al., 2008, Hoffman et al., 2013, 
Schmitz et al., 2010). Few studies have been undertaken in patients with lung cancer awaiting 
surgery thus the feasibility and safety of the intervention in this particular context is still not clear 
(Jones et al., 2007). Moreover, no study has focused on patients undergoing videothoracoscopic 
surgery. Given these circumstances, we conducted a pilot single-arm study to test the feasibility, 
tolerability and safety of a supervised preoperative exercise intervention in patients awaiting VATS 
for lung malignancies. 
5.2 OBJECTIVES 
The primary aim of this study was to assess the feasibility and safety of a preoperative 
pulmonary rehabilitation programme in patients undergoing videothoracoscopic surgery for lung 
malignancies. Secondary objectives included: 
 To explore the changes in functional capacity, muscle strength and HRQoL before and 
after the intervention. 
 To depict the decline in physical and psychological functioning during the first post-
operative months after VATS. 
 To determine if three months after the surgery the patients have reached their baseline 
values in terms of fuctional capacity, muscle strength and HRQoL. 
5.3 HYPOTHESIS 
We hypothesized that 1) a preoperative exercise programme was feasible (patients achieved 
at least 80% of adherence) and safe (not associated with any severe adverse effect and 2) the 
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intervention was optimal in frequency and intensity to yield significant and clinical changes in the 
main outcomes. 
5.4 MATERIALS AND METHODS 
 5.4.1 Design 
 This was a non-randomized single-arm pilot study.  
 5.4.2 Participants 
From February 2013 to June 2013 we screened all patients being considered for lung 
resection surgery for lung malignancies at the University Hospital of A Coruña, Spain. Inclusion 
and exclusion criteria are shown in Table 5.2.   
Table 5.2: Inclusion and Exclusion Criteria 
INCLUSION CRITERIA EXCLUSION CRITERIA 
- Adults only (>18 years old) 
- Suspected or histological diagnosed of 
NSCLC either primary or metastatic 
- Health area of A Coruña 
- No contraindications for exercise therapy 
- Neoadjuvant therapy with chemotherapy or 
radiotherapy in the 6 months prior to surgery 
- Not signed the informed consent 
- Inability to perform the PPRP, no 
cooperation or no capacity to adhere the 
programme 
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Potentially eligible patients were initially contacted by phone and scheduled for an 
interview with a specialized physiotherapist. In this first interview, an information sheet was given 
to the patients explaining the purpose of the study (Supplemental file no.3). Those who agreed to 
participate gave written informed consent prior to any formal testing.  
The research protocol was approved by the local ethics committee in the context of a larger 
randomized controlled trial (CEIC Galicia, 2011/395) (Supplemental file no.1). 
5.4.3 Intervention 
The PPRP consisted of one and a half hour session, three to five times per week, during the 
preoperative waiting period (ranging from four to 12 weeks) including endurance and resistance 
training as well as conventional chest physiotherapy and breathing exercises.  
Endurance training 
Endurance training was performed using a calibrated cycle-ergometer (Monark 818 E, 
Monark Exercise AB, Sweden) with an initial targeted duration of 30 minutes.  
In the first session, an incremental exercise test was conducted according to the American 
College of Chest Physicians guidelines (ATS/ACCP, 2003) to determine the peak workload 
(Wpeak). Each training session patients completed an interval protocol combining four minutes at 
low intensity (45 – 50% of the Wpeak) with one minute at high intensity (80 - 85% of the Wpeak). A 
five-minute warm-up and a four-minute cool down at 30% of the Wpeak were also included in the 
30 minutes. After the first 10 sessions, intensity was maintained and the goal was to increase total 
duration to 40 minutes. 
Resistance training 
Resistance training was performed using elastic bands (Thera-Band®, The Hygienic 
Corporation, Akron, Ohio, USA) and bodyweight exercises. Patients performed six out of ten 
exercises proposed by the investigators targeting the main muscle groups involved in daily life 
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activities. A detailed description and illustration of the exercises can be found in the Supplemental 
file no. 7. The initial goal was to perform three sets of 15 repetitions of each exercise during the 
first 10 sessions; from the 10th session onwards number of sets increased to four – five if possible. 
Training load for the Thera-band® exercises was determined after a 25 maximal repetition test 
(Newsam, 2005) and patients were asked to maintain a moderate rate of exertion (five - six) 
according to the OMNI-Resistance Scale of Perceived Exertion during the training. The OMNI-
RES is a tool that helps to control intensity during strength training exercises that can be applied 
to men, women, boys and girls alike and has been validated to use with elastic bands (Figure 5.1) 
(Colado et al., 2012). 
Breathing exercises 
 Breathing exercises and airway clearance techniques were provided at the end of the session 
according to the patients’ needs. Participants were also encouraged to do breathing exercises at 
home with a volume-oriented incentive spirometer (Coach 2 Incentive Spirometer 22-4000 HD, 
Smith Medicals, USA). The protocol consisted of 30 sustained inspirations at 80% of the maximal 
Vital Capacity (VC) with an end-inspiratory hold of two to three seconds (Westerdahl et al., 2005, 
Figure 5.1: The OMNI-RES of perceived exertion with elastic bands; Colado, 2012. 
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Yañez-Brage et al., 2009). Patients were taught to perform six cycles of five repetitions each, with 
one minute rest between cycles. Participants were asked from time to time about the performance 
of the exercises to ensure compliance and understanding of the protocol.  
 Each training session was recorded and kept in a codified data sheet (Supplemental file no. 
4).  
 5.4.4 Outcomes 
 Patients were evaluated at four points during the study period: T1: at baseline; T2: after the 
preoperative rehabilitation programme; T2: immediately after surgery (one week after hospital 
discharge) and T3: three months after surgery. The results of each evaluation were kept in an 
individual, codified data collection sheet. 
Safety and feasibility 
 Feasibility of the intervention was determined using the following criteria: on one hand, we 
calculated the percentage of patients who consented from those who fulfilled the inclusion criteria 
(recruitment rate) and on the other hand, the percentage of sessions attended relatively to the 
number of sessions scheduled (adherence). Mean preoperative time was estimated in 6 weeks. 
Using a training frequency of at least 3 times per week, the number of sessions planned was 18.  
 Safety was described as the absence of any adverse events requiring medical consultation 
or additional treatment.  
Functional capacity  
 Functional Capacity refers to a person’s ability to perform daily life activities that require 
sustained aerobic metabolism and it’s a reflection of the integrated efforts and health status of the 
pulmonary, cardiovascular and skeletal muscle systems (Arena et al., 2007). The gold standard for 
the assessment of functional capacity is VO2peak using a CPET (Arena et al., 2007, Jones et al., 
2009a). However, the CPET is expensive and time-consuming and therefore is not available in 
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most clinical and rehabilitation settings. The 6MWT is a field test derived from the 12-minute run 
test developed by Cooper et al. in the late 1960’s, which was later adapted to fast walking and 
accommodated to patients with respiratory disease who found the 12-minute walk too exhausting. 
The test has proven to be safer, easier to administer, better tolerated and more reflective of the 
activities of daily living than other walk tests (American Thoracic Society, 2002, Enright, 2003). 
The 6MWT is a self-paced test and therefore is considered a submaximal test (contrary to the 
CPET); however, since the majority of the activities of daily living are performed at sub-maximal 
level of exertion, the test may be more adequate to measure functional capacity  (Enright, 2003, 
American Thoracic Society, 2002). The 6MWT has shown good correlation with the measured 
VO2Peak in patients with diverse cardiopulmonary disorders (correlation coefficient (r) ranging from 
.21 to .7) and cancer (r =.67) (Ross et al., 2010, Schmidt et al., 2013). In NSCLC, the 6MWT is the 
most common field test used to assess functional capacity (Granger et al., 2013a) and it has shown 
to predict post-operative complications and survival (Marjanski et al., 2015, Jones et al., 2012). 
The test has also shown good sensitivity to measure changes after a pulmonary rehabilitation 
programme in chronic respiratory diseases (Holland et al., 2014, Singh et al., 2014). 
 To perform the test, the Spanish Society of Respiratory Medicine and Thoracic Surgery 
(SEPAR) and the ATS guidelines were applied (American Thoracic Society, 2002, Burgos-Rincon 
and Casan Clara, 2004). Patients were asked to walk as fast as they could during six minutes 
between two marks on an inside 40-meter corridor. Heart rate, oxygen saturation, dyspnoea and 
fatigue were recorded at the beginning and at the end of the test. Oxygen saturation and heart rate 
were also monitored during the test using a portable pulse oximeter. Encouragement was given 
every one minute according to the international recommendations. Total walked distance was 
calculated once the test was finished. Duplicate tests were performed at baseline for reliability and 
the maximum distance covered was used for the analysis.  
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  Muscle strength 
 Muscle strength was assessed using a modified version of two items included in the Senior 
Fitness Test (SFT) developed and validated by Rikli and Jones (Rikli and Jones, 2013). The SFT 
is a battery of tests specifically designed to measure functional fitness in older adults. Functional 
fitness is defined as having the physiologic capacity to perform normal everyday activities safely 
and independently without undue fatigue (Rikli and Jones, 2013). Selection of the items included 
in the SFT was made basing on two principles: a) validity and reliability and b) easy to administer 
and feasible. With that in mind, two items were selected to measure muscle strength: the Arm Curl 
Test and the 30’s Chair to Stand Test. The first examines upper body strength by counting the 
number of times a hand weight of 5lb for women and 8lb for men can be curled through a full range 
of motion in 30 seconds (Figure 5.2A). In our study, two dumbbells of two and 3.5 kg were used 
for females and males respectively according to the estimated equivalence in the International Unit 
System (IUS). The 30’s Chair to Stand Test evaluates lower body strength by counting the number 
of times within 30 seconds that an individual can rise to full stand from a seated position without 
pushing off with the arms (Figure 5.2B). For this test chair height was 43.5 cm according to the 
metric equivalent of the original height (Rikli and Jones, 2013).  
 The SFT was performed in the same sequence for all the evaluations: first, the Arm Curl 
test followed by the Chair to Stand Test. Only one trial with partial practice the same day was 
allowed for each of the tests and the obtained values were compared to the normative scores (Rikli 
and Jones, 1999).   
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Health-related quality of life   
HRQoL was assessed using the second version of the Short Form 36 Health Survey (SF-
36). This generic questionnaire encompasses 36 items offering an overview of an individual’s 
health status in eight major dimensions: 1) limitations in physical activities because of health 
problems; 2) limitations in social activities because of emotional problems; 3) limitations in usual 
role activities because of physical health problems; 4) bodily pain; 5) general mental health 
(psychological distress and well-being; 6) limitations in usual role activities because of emotional 
problems; 7) vitality (energy and fatigue) and 8) general health perceptions (Ware and Sherbourne, 
1992). The test was developed in 1992 to be either self-administrated or by a trained interviewer in 
person or by telephone (Ware and Sherbourne, 1992). In 1996 the second version of the 
questionnaire was released which among other improvements included a summary of the eight 
dimensions into two major categories: the Physical Component Summary (PCS) and the Mental 
Component Summary (MCS) which provide an easiest evaluation of the physical and 
psychological well-being (Figure 5.4). 
Figure 5.2: Curl Arm (A) and Chair to Stand (B) to assess muscle strength with the SFT; Rikli and 
Jones, 2001. 
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The items in the SF-36 represent both positive and negative health status, so for each 
dimension they are codified, aggregated and transformed into a 0 – 100 score (where 0 represents 
the worst possible health status for that particular dimension). The questionnaire was validated into 
Spanish in 1995 and the normative data for the Spanish population including those over 60 years 
was extracted in two subsequent samples (Alonso et al., 1998, López-García et al., 2003). To 
facilitate the interpretation of the results, the scores are usually presented as the standardized mean, 
where 50 represent the general population mean and 10 the standard deviation (SD) (Vilagut et al., 
2008).  
Physical 
Functioning 
Role 
Physical 
Social 
Functioning 
 
General 
Health 
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Bodily 
Pain 
Role 
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Health 
Physical Component 
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Mental Component 
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Figure 5.3: SF-36 Health domains 
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 In this study, the questionnaire was self-administrated whenever possible but patients were 
assisted if they required further explanations of the questions. The SF-36 can be found in the 
Supplemental file no.6.   
 Post-operative outcomes 
 Data from the medical records was reviewed regarding the Length of Hospital Stay (LOS) 
and the number of Post-operative Pulmonary Complications (PPC) along with other perioperative 
features. 
5.4.5 Sample size calculation 
This study was not powered to detect any specific difference in the outcomes measured so 
there was no real estimation of the sample size. Instead, a pragmatic sample of ten patients was 
chosen to assess the feasibility of the study and preliminary effects of the intervention.  
5.4.5 Statistical analysis 
 Initially, a descriptive analysis of the participants regarding the main socio-demographic 
and clinical variables was performed. Despite the normal distribution of the main variables, non-
parametric tests were used due to the small sample size. At first, a Friedman Test was conducted 
to compare the main outcomes at T0, T1, T2 and T3. If a significant difference was found, then the 
Wilcoxon Signed rank Test was used in order to examine specific pairwise differences. 
Univariate and multivariate regression analysis were used to identify the potential risk 
factors associated with a decrease in the post-operative functional capacity.  
All statistical analyses were performed using the SPSS package for Windows (Version 20; 
IBM Corporation, Chicago IL, USA) and a p value of <.05 was considered statistically significant. 
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5.5 RESULTS 
During the study period, 23 potentially eligible patients were evaluated, and 12 met the 
inclusion criteria and provided informed consent (recruitment rate 56.2%). Reasons for exclusion 
were not interested (n=4), lack of transportation (n=2), severe musculoskeletal impairment (n=2), 
urgent surgery (n=2) and referral to neoadjuvant therapy (n=1). Two patients withdrew during the 
study due to difficulties to attend the PPRP and another patient was excluded because surgery was 
declared urgent. A flow diagram of the study is shown in Figure 5.4. Finally, nine patients were 
enrolled. Baseline characteristics are shown in Table 5.3.  
23 patients were evaluated 
12 patients signed 
informed consent and 
entered the study 
9 patients finished the 
intervention and were 
analysed 
3 patients were excluded: 
2 = withdrew due to lack of 
transportation 
1 = underwent urgent 
surgery 
Figure 5.4: Flow diagram of the study. 
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Table 5.3: Baseline characteristics 
VARIABLE VALUE (n=9) 
Age (years) 68.56 (10.36) 
Sex (% men) 88.9% 
BMI 29.15 (3.83) 
History of Smoking 
No 
Former 
Current 
 
1 (11.1%) 
6 (66.7%) 
2 (20.2%) 
Co-morbidities (%) 
COPD 
Arterial Hypertension 
Diabetes Mellitus 
Cardiovascular Disease 
Previous History of Cancer 
 
6 (66.6%) 
3 (33.3%) 
1 (11.1%) 
2 (22.2%) 
2 (22.2%) 
CCS 7.56 (3.35) 
Symptomatology (%) 
None 
Cough 
Dyspnoea 
Expectoration 
Other 
 
4 (50%) 
2 (25%) 
2 (25%) 
4 (50%) 
0 
Lung Function (% of predicted) 
FVC 
FEV1 
FEV1/FVC 
 
83.11 (14.45) 
69.89 (13.92) 
62.22 (9.74) 
6MWT (meters) 557.56 (74.43) 
6MWT (% predicted) 89.35% 
Curl Arm Test (nº) 16.89 (5.35) 
Chair Sit-to-Stand Test (nº) 14.56 (5.91) 
Maximal Workload Achieve (Watts) 72.77 (20.28) 
Extension of resection (%) 
Lobectomy 
Wedge Resection 
 
6 (66.7%) 
3 (33.3%) 
Post-operative Diagnosis (%) 
Adenocarcinoma 
Squamous Cell Carcinoma 
Lung Metastases 
 
2 (22.2%) 
4 (44.4%) 
2 (22.2%) 
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Benign 1 (11.1%) 
Stage of Disease 
IA-IB 
IIA-IIB 
Lung metastases 
 
4 (50%) 
2 (25%) 
2 (25%) 
Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; FVC: Forced Vital Capacity; 
FEV1: Forced Expiratory Volume in 1 second; CCS: Colinet Co-morbidity Score; 6MWT: 6 
Minute Walking Test 
 
Overall adherence was 109.9% with patients attending a median of 21 sessions of the 18 
initially scheduled (range 11 – 27). Only one patients achieved <80% of adherence. The 
improvement in the 6MWT and muscle strength experienced by this participant was similar than 
that observed in patients with overall adherence ≥80%. No adverse events were recorded.  
All patients underwent surgery by VATS through one or two ports. The mean waiting period 
before surgery was 71.44±17.55 days. Mean LOS was 5.11±4.01 days. Two patients (22.2%) 
experienced one or more PPC: prolonged air leak >7 days in both cases, and pneumothorax in one 
case.  
Results of the functional outcomes are summarized in Table 5.4 and Figures 4.4 and 4.5. A 
borderline significant improvement of 22.55±30.11 meters (p =.050) was achieved in the 6MWT 
after the PPRP (T0 to T1). Upper and lower body strength were significantly enhanced after the 
intervention, from 16.89±5.35 to 20.67±2.64 repetitions (p =.028) and from 14.56±5.92 to 
15.86±3.93 repetitions (p =.016) respectively. The Chair Sit-To-Stand Test was obtained only for 
seven patients because another participant was unable to complete the test due to knee discomfort.  
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Table 5.4: Results for the functional capacity and muscle strength 
Variable 
T0 T1 T2 T3 
6MWT (m) 557.56±74.43 580.11±80.67 489.67±98.69** † 529.63±83.23 
Curl Arm Test (nº) 16.89±5.34 20.67±2.64* 20±3.28** 19.25±3.19†† 
Chair Sit-To-
Stand Test (nº) 
 14.56±5.91 15.86±3.93* 16.11±4.98 13.22±6.98 
*p <.05 between T0 and T1; **between T0 and T2; †between T1 and T2† †between T0 and T3; 
After the surgery, all measurements significantly decreased both comparing to baseline and 
pre-surgery. Functional capacity decreased by 67.88±65.52 meters (p =.011) from T0 to T2 and by 
90.44±63.35 meters from T1 to T2 (p =.08). Upper body strength also decreased from T0 to T2 (p 
=.050) while no change was found for lower body strength (p >.05). At T3, functional capacity and 
muscle strength were fully recovered (the 6MWT was 105.5 ± 6.8% of the baseline values and 
upper and lower body strength were 80 ± 14% and 88±13.4% respectively) 
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Figure 5.5: Individual tendency for the 6MWT during the study period. 
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Results from the HRQoL are shown in Table 5.4. At baseline, HRQoL scores were below 
normative data. At T1 all items were improved, although the difference was only statistically 
significant for the Mental Health Subscale (72±11.3 to 80±10.2; p =.041). In the early post-
operative period (T2), all items decreased comparing to baseline and pre-surgery, especially the 
physical role (from 61.66±18.04 pre-surgery to 37.77±21.37 post-surgery; p =.012). Three months 
after surgery, all items were restored comparing to baseline (P>.05). A summary of tendency for 
PCS and MCS throughout the study period is shown in Figure 5.7. One patient did not complete 
the three-month follow-up due to hospitalization for other causes. 
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Figure 5.6: Individual changes for the Curl Arm Test (A) and The Chair to Stand Test (B) during the 
study period. 
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Table 5.5: Changes in HRQoL throughout the study period 
HRQoL 
Domain 
T0 T1 T2 T3 
Physical 
Functioning 
79.4±4.4 79.4±12.6 67.2±23.1 82.5±15.1 
Role Physical 56.1±26.2 62.2±18.1 37.8±21.4 ¥ 59.4±14.5 
Bodily Pain 71.8±28.8 76.5±28.1  64.4±30.1 74.5±23.7 
General Health 52.9±37.7 68.9 ±18.5 64.1±24.8 68.7±22.6 
Vitality 61.7±24.6 65.6±14.9 59.4±19.1 71.2±14.3 
Social 
Functioning 
83.3±25.8 91.7±16.5 84.7±25.6 87.5±22.2 
Role Emotional 71.8±13.2 71.85±13.2 54.8±24.2 ¥ 69.2±21.9 
Mental Health 72±11.3 80±10.2* 69.8±22.5 ¥ 73.5±18.4 
 
*p <0.05 T0 to T1; ¥p <0.05 T1 to T2 
 
Univariate analysis indicate that after surgery, the 6MWT was highly correlated to the 
baseline FEV1, baseline physical functioning and baseline PCS. In the multivariate analysis the 
PCS was identified as an independent factor for the post-operative 6MWT (R2 = .58). 
Figure 5.7: PCS and MCS tendency throughout the study period. 
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5.6 DISCUSSION 
 The results of this preliminary pilot study suggest that a PPRP for patients awaiting VATS 
is feasible, safe, and can potentially improve functional capacity and muscle strength, optimizing 
the patients’ baseline status before lung resection surgery.  
Eligibility and recruitment rate, adherence and completion rate are key components in 
assessing the feasibility of an exercise protocol. The eligibility rate is fundamentally affected by 
the inclusion and exclusion criteria established by the investigators but also by the designated 
location from where the participants are picked. For instance, Granger et al. in a pilot randomized 
trial in patients with NSCLC, reported an eligibility rate of only 18% in a general thoracic clinic, 
reflecting the heterogeneity of the institution and significantly affecting the potential number of 
participants eligible for the study (Granger et al., 2013b). The recruitment or consenting rate refers 
to the number of patients from those eligible who participate in the study and is a reflection of the 
willingness of the patients to exercise. In our study, we achieved a recruitment rate of 52.2% which 
although it could be considered as low, it is similar to other feasibility studies conducted in lung 
cancer patients (Coats V, 2013, Granger et al., 2013b, Jones et al., 2008, Kuehr et al., 2014). In 
contrast, completion rate was 75%, superior to some other studies including patients with NSCLC 
(Missel et al., 2015, Temel et al., 2009, Kuehr et al., 2014, Andersen et al., 2013) but certainly 
improvable. For instance, in the study conducted by Coats el at., a home-based programme in lung 
cancer patients awaiting surgery resulted in a 81% completion rate (Coats V, 2013). Jones et al. 
also reported a 90% completion rate in a preoperative exercise-based intervention and a 95% after 
a post-operative 14-week training programme (Jones et al., 2008, Jones et al., 2007). The modality 
of exercise prescribed, timing and setting of the intervention as well as the baseline status of the 
participants are features that can affect the completion rate in patients with lung cancer and need 
to be specifically addressed in the future.  
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For an exercise intervention to be successful it is fundamental that participants adhere to 
the prescribed programme. Adherence in the oncological setting is challenging to say the least and 
is most likely influenced by numerous clinical, demographical and socio-economic factors. In a 
meta-analysis looking at the factors influencing adherence in cancer survivors, inconsistent results 
were found in the majority of the factors studies. As a matter of fact, the only factor positively 
associated across studies was exercise history (referring to a past habit of engaging in exercise 
training or physical activity). Correlates of adherence in NSCLC have been scarcely investigated. 
According to a study conducted by Peddle et al. in NSCLC survivors, females were at higher risk 
of poor exercise adherence comparing to males (Peddle et al., 2009b). In another study looking at 
the adherence trajectory in patients undergoing treatment for breast cancer, the authors found that 
women with higher perceived importance of exercise, early-stage disease and employed status were 
more likely to be classified as good intensity adherents (Huang et al., 2015a). In our study 
adherence exceed our own expectations and achieved a mean of 109%, with only one patient 
attending <80% of the prescribed sessions. This adherence rate is better than reported in other 
preoperative studies (Jones et al., 2007, Peddle et al., 2009a, Peddle et al., 2009b) but we must 
acknowledge that the therapeutic delay observed in our study was longer than predicted 
(71.4±17.50 days). Again, timing of the intervention (pre, post- or during active treatment), setting 
and type of exercise prescribed can also significantly influence the compliance of the patients to an 
exercise intervention. For example, Hoffman et al. in a pilot investigation examining the adherence 
to a virtual reality home-based training programme in postthoracotomy lung cancer patients 
reported an 88% adherence (Hoffman et al., 2014). Most likely, exercise interventions which are 
designed to be conducted at home or using a combination of supervised and unsupervised exercise 
sessions would result in better overall adherence in this population across the cancer continuum.   
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Although this is the first preoperative intervention to include only patients undergoing 
VATS, other similar studies have been conducted in recent years in patients submitted to 
thoracotomy which allows us to compare our findings in the outcomes examined. Between 2007 
and 2009, Jones et al. published the results of a preoperative pulmonary programme on exercise 
tolerance, inflammatory markers and other functional variables. They found a significant increase 
both in the distance covered with the 6MWT and VO2peak after a median of eight weeks of aerobic 
training (Jones et al., 2009c, Jones et al., 2007). Cesario et al., in 2007, conducted a small pilot 
study evaluating the effects of a 4-week intervention in patients who were denied surgery because 
of their poor lung function and reported a significant increase of 79 meters in the 6MWT along 
with an improvement in pulmonary function (Cesario et al., 2007a). More recently, Mujovic et al. 
conducted an intense preoperative rehabilitation programme of three daily sessions of aerobic 
training lasting two to four weeks and found an improvement of 56 meters (p =.0001) in the 6MWT 
(Mujovic et al., 2014). In the same line, Divisi et al. examined the effects of a four-week 
preoperative pulmonary rehabilitation programme in patients with lung cancer and COPD and 
reported a significant improvement in the 6MWT from 220 to 390 meters (Divisi et al., 2013). 
Bradley et al. in a cohort study of patients undergoing lung resection surgery found a significant 
improvement in the 6MWT of 20 meters after a low frequency training programme (p =.001) 
(Bradley et al., 2013). Finally, Morano et al. in a randomized controlled trial comparing 
conventional chest physical therapy with pulmonary rehabilitation for four weeks, found that there 
was a significant change in the 6MWT of 50 meters only for the PR group (p <.001). These results 
are consistent with our research, since we also found an increase in the distance walked with the 
6MWT of 22.55±30.11 meters (p =.050) after the training. Although this difference did not reach 
statistical significant importance by a very small margin, the improvement was clinically 
meaningful according to the minimal clinical important difference (MCID) reported for lung cancer 
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patients (Granger et al., 2015b). Postoperatively, we found a significant decrease in the 6MWT 
comparing to baseline of 67.9±65.5 meters (p =.01). Even so, patients were over 80% of the 
preoperative values, which is consistent with previous research and demonstrates that in contrast 
to open surgery, functional exercise capacity is restored within the first week after VATS (Ueda et 
al., 2006).  
We also found a significant improvement in muscle strength after the PPRP according to 
the SFT. The SFT is a battery of test designed to measure functional fitness in older adults. 
Considering that the lung cancer population is mostly old and carries a significant history of co-
morbidities, the test seems an appropriate and affordable choice to measure changes in functional 
fitness after an exercise programme. Plus, each item included in the SFT has been successfully 
measured against the gold standard in the field. For example, both the Arm Curl Test and the 30’s 
Chair to Stand Test have been compared with the maximal one-repetition test (1RM) showing an 
intra-class correlation coefficient (ICC) of .79 and .77 respectively (Rikli and Jones, 2013). The 
SFT has been used in several populations, including dwelling elderly people and individuals with 
chronic diseases. Alexander et al. in a study comparing the effectiveness of two training modalities 
in older patients with COPD observed that both groups improved all SFT items with no significant 
differences between groups (Alexander et al., 2008). Peddle et al., in a study conducted in post-
surgical lung cancer patients, reported significant improvements in several items of the SFT (Arm 
curl, Chair sit to stand and 6MWT) after a resistance training programme with weight machines 
(Peddle-McIntyre et al., 2012). Finally, Fahlman et al. studied the effects of a 16-week semi-
supervised strength training programme using elastic bands on functional fitness in older but 
otherwise healthy individuals and found significant improvements both in the Arm Curl and the 
30’s Chair To Stand Test pre to post intervention and in comparison to a control group (Fahlman 
et al., 2011). These findings are consistent with our results since we also reported significant 
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improvements in both items of the SFT, but especially in the Arm Curl Test, which shows that 
elastic bands can improve muscle strength and that the SFT is sensitive to change after an exercise-
based intervention in the lung cancer population. 
  Another secondary endpoint in this study was changes in HRQoL after the training. As 
previously reported, lung cancer patients frequently exhibit low levels of quality of life both in 
comparison to healthy individuals and other cancer survivors and are also considered at higher risk 
of experience functional decline after surgery (Granger et al., 2014). Unfortunately, as discussed 
in the previous chapter, so far the effects found after an exercise-based intervention are inconsistent 
and not very encouraging. Riesenberg et al. in a study conducted in patients with lung cancer after 
surgery and/or after radio- or chemotherapy found overall significant improvements in HRQoL 
according to the EORTC QLQ-C30 L13 and the SF-36 (Riesenberg and Lubbe, 2010). In another 
longitudinal single-arm study involving patients after lung cancer surgery, participants improved 
their HRQoL from 56.3 to 65.9 (p <.05) and more importantly, the improvements were maintained 
six months after the rehabilitation (Vandenbos et al., 2015). On the contrary, Arbane et al. in a 
randomized controlled trial in postthoracotomy patients found no changes in HRQoL pre to post 
intervention or between groups (Arbane et al., 2011). Morano et al. in another randomized 
controlled trial in preoperative lung cancer patients found an improvement of eight points in the 
PCS after four weeks of endurance and resistance training but the interaction effect between time 
and group was not statistically significant (Morano et al., 2014). Features of the training including 
intensity, frequency, mode of delivery and the number of participants could partially explain the 
variation observed across studies. Also, the instrument selected to measure HRQoL can 
substantially affect the results obtained. In our study, we chose the SF-36 given the heterogeneity 
of the lung resection candidate and to facilitate the external comparison of our results (Nici et al., 
2006). Our results showed an overall improvement in HRQoL but only the mental health domain 
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achieved statistical significance. Nevertheless, our sample size was too small to detect any 
significant improvement in HRQoL. Given that most studies conducted in cancer patients have 
reported positive changes in quality of life after the interventions, larger sample sizes would likely 
result in both statistical and clinically meaningful improvements. Therefore, we encourage 
researchers to undertake powered randomized controlled trials to confirm the effects of exercise on 
HRQoL.  
5.7 LIMITATIONS 
This is study has several limitations that must be addressed. First, this was a non-
randomized single-arm study, so we lack of a control group to confirm that our results are due to 
the prescribed intervention. Second of all, our sample size was too small to detect significant 
differences in some of the outcomes of the study, such as functional capacity and HRQoL. Also, 
inclusion criteria were broad and thus the baseline characteristics of the patients were 
heterogeneous, especially in terms of age and pulmonary function. Finally, due to lack of financial 
support we weren’t able to obtain a more accurate measurement of the selected outcomes although, 
as previously discussed, the instruments used instead have been extensively validated in the 
literature and therefore they shouldn’t affect the validity of our results. 
5.8 CONCLUSIONS 
 In conclusion, we believe that a preoperative rehabilitation programme for patients 
awaiting lung resection for VATS is safe and feasible and has the potential to improve functional 
fitness and enhance exercise performance. Larger randomized controlled trials are warrant to 
determine whether or not these findings can enhance post-operative functional recovery and reduce 
length of hospital stay and post-operative complications.
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CHAPTER SIX: Effectiveness of a preoperative pulmonary rehabilitation programme to improve 
exercise capacity and enhance post-operative recovery in patients undergoing VATS: a 
randomized, single-blind controlled trial. 
6.1 INTRODUCTION AND RATIONALE 
 Throughout this thesis, it has been well-documented that individuals with NSCLC 
frequently experience functional deconditioning across the lung cancer continuum which can lead 
to increased dyspnoea, decreased physical activity and impaired HRQoL. Additionally, these 
clinical features can be further aggravated by anti-cancer therapies, especially after lung resection 
surgery. Fortunately, low exercise capacity and functional deconditioning are two modifiable risk 
factor in the onset of thoracic surgery (Jones et al., 2009a); therefore, interventions designed to 
improve pre-surgical exercise capacity should be of clinical benefit in lung cancer (Shannon, 2010). 
Pulmonary Rehabilitation (PR) is a comprehensive, interdisciplinary intervention aimed to 
restore the patient to his or hers highest possible level of independent function  (Ries et al., 2007). 
One salient aspect of this definition is that the programme must be individually tailored according 
to the patient’s baseline status (Celli, 2003). Plus, rather than only focusing on reversing the 
progress of the disease, a pulmonary rehabilitation programme is designed to reduce the symptoms 
and disabilities associated with the disease and enhance functionality.  
In 1974 the American College of Chest Physicians (ACCP) defined PR for the first time. 
In 1980, the American Thoracic Society (ATS) issued its first official statement on the topic in 
which the pulmonary rehabilitation components were described in detail and the list of benefits 
were specified. More recently, a task force from the European Respiratory Society (ERS) and the 
ATS updated the pulmonary rehabilitation definition to “a comprehensive intervention based on a 
thorough patient assessment followed by patient-tailored therapies that include, but are not limited 
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to, exercise training, education and behaviour change, designed to improve the physical and 
psychological condition of people with chronic respiratory disease and to promote the long-term 
adherence to health-enhancing behaviours”. This new definition entails two important 
modifications regarding the previous one stated in 2006. First, the shift from a multidisciplinary to 
an interdisciplinary intervention, in the sense that the latter involves analysing, synthetizing and 
harmonizing links between disciplines into a coordinated and coherent whole instead of them 
working separately. Secondly, the new definition highlights the importance of behaviour changes 
as a mean to achieve long-term results and promote a new lifestyle.  
The ultimately goals of PR are a) to control, alleviate and as much as possible reverse the 
symptoms and pathophysiologic processes leading to respiratory impairment and b) to enhance the 
patient’s physical and psychological well-being. To achieve those goals, PR includes several 
components such as exercise training, nutrition, self-management education and psychological 
support. Exercise is considered the cornerstone of PR and therefore is an essential, mandatory 
aspect of the programme (Ries et al., 2007, Nici et al., 2006, Nici and ZuWallack, 2014, Wilson, 
1997, Celli, 2003). Conventionally, exercise training in PR was delivered in the form of endurance 
training for the lower limbs, given their role in performing the majority of the daily life activities 
such as walking. Endurance training can be defined as an activity in which the body’s large muscle 
groups are moved in a rhythmic manner for sustained periods of time (Chodzko-Zajko et al., 2009). 
The specific aims of endurance training are to re-condition the muscles of ambulation and improve 
cardiorespiratory fitness to increase physical activity and eventually reduce breathlessness and 
fatigue (Spruit et al., 2013). Endurance training is most commonly prescribed in the form of cycling 
or walking (Figure 6.1). Walking has the benefit of being a more functional exercise and benefits 
can be easily translated into daily life. Biking, on the other hand, places a greater specific load on 
the quadriceps muscles and results in less exercise-induced oxygen desaturation, thus is usually 
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advocated for patients with moderate to severe chronic respiratory diseases (Spruit et al., 2013). 
Aerobic training at high intensity (≥60% of peak exercise capacity) for at least 30 minutes three 
times per week is the minimum recommended by the main guidelines to elicit physiologic changes 
(Nici et al., 2006, Andrianopoulos et al., 2014). However, less than 20% of patients with severe 
chronic disease may be able to sustain this continuous high-intensity exercise throughout the PR 
(Andrianopoulos et al., 2014). In this case scenario, interval training can be a more reasonable 
alternative for this population. This modality of training consists of repeated short periods of 
exercise at high intensity alternated with rest (Andrianopoulos et al., 2014). Both regimes have 
shown to elicit similar physiologic improvements in healthy individuals but interval training could 
be a better choice for those patients with severe respiratory impairment or advanced muscle atrophy 
that have difficulty in achieving their targeted intensity or total duration.  
More recently, resistance training has been acknowledged as another key component in PR 
given the peripheral muscle dysfunction shown by patients with COPD. Resistance training is a 
type of exercise modality in which local muscle groups are trained by repetitive lifting of relatively 
heavy loads and it is designed to enhance several aspects of muscle performance (such as maximal 
strength, muscle endurance or muscle mass) (Andrianopoulos et al., 2014, Spruit et al., 2013). It is 
Figure 6.1: Training modalities in PR; Andrianopoulos et al., 2014. 
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well-established that COPD also affect the peripheral muscles by decreasing muscle mass and 
muscle force, aggravating general weakness, fatigue and dyspnoea. The role of resistance training 
in PR to reverse this muscle deconditioning is crucial since aerobic training alone is only able to 
induce suboptimal increases in muscle mass or muscle strength. However, resistance training 
should never be regarded as a replacement for endurance training. Given this rationale, the 
combination of endurance and strength training is probably the best strategy to treat peripheral 
muscle dysfunction in chronic respiratory disease (Nici et al., 2006).  
The minimum duration of exercise training in pulmonary rehabilitation has not been 
specifically investigated but current recommendations agreed that a minimum of 20 sessions or 8 
to 12 weeks are preferable, with longer training periods resulting in overall larger improvements, 
especially in exercise capacity. Patients should exercise at least three times per week, and regular 
supervision is strongly advocated to achieve optimal physiologic benefits (Nici et al., 2006, Jenkins 
et al., 2010). General recommendations for endurance training are shown in Table 6.1. 
 
Table 6.1: Recommendations for endurance training; Jenkins et al. 2010 
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PR is a relatively inexpensive, low-tech therapy for patients with chronic diseases. 
However, when setting up a pulmonary rehabilitation programme there are minimum requirements 
that should be fulfilled. In addition to an adequate space to perform the exercise training such as a 
rehabilitation room or a gym, minimal equipment is required to perform the training and monitor 
basic vitals (Table 6.2).  
 
Evidence of the effectiveness of PR fundamentally stems from studies in COPD and other 
chronic respiratory diseases. During the past decade, a growing interest in the potential role of PR 
in lung cancer patients has emerged and preliminary results are promising (Edvardsen et al., 2015, 
Shannon et al., 2010, Granger et al., 2013b). Patients with lung cancer could benefit from PR across 
the whole lung cancer continuum (Jones et al., 2009a). Particularly, in the preoperative period, PR 
could increase exercise and functional capacity leading to an improvement in lung resection 
outcomes (Benzo, 2007, Rivas-Perez and Nana-Sinkam, 2015). PR has also been recommended for 
patients who are considered unfit to undergo surgery in an attempt to improve their baseline 
cardiorespiratory fitness with satisfactory results (Jones et al., 2013, Cesario et al., 2007a). In a 
Table 6.2: Equipment required for a pulmonary rehabilitation programme; Jenkins et al., 2010 
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retrospective study involving post-pneumonectomy patients, the lack of preoperative 
physiotherapy was also an independent predictor of post-operative pulmonary complications 
(Algar et al., 2003). Combining PR with conventional chest physiotherapy also decreases the 
incidence of relevant respiratory complications such as atelectasis (Nagarajan et al., 2011). As a 
result of fewer post-operative complications, length of hospital stay can also be shortened in 
patients undergoing PR (Morano et al., 2013, Pehlivan et al., 2011). However, these studies have 
been mostly conducted in patients undergoing thoracotomy. With the advent of VATS, new 
randomized controlled trials are warrant to examine the effects of a preoperative pulmonary 
rehabilitation programme (PPRP) in this surgical context. 
6.2 OBJECTIVES 
The two main purposes of this randomized controlled trial were 1) to assess the effects of a 
PPRP on exercise tolerance (endurance time) in patients awaiting VATS and 2) to compare the 
effectiveness of the intervention to enhance post-operative recovery in comparison to the standard 
care (no intervention). 
Secondary study endpoints included: 
1. To measure changes in muscle strength and HRQoL before and after the 
intervention. 
2. To compare functional capacity, muscle strength and HRQoL in the rehabilitation 
and control groups in the post-operative period to assess the effectiveness of the 
intervention to enhance functional recovery after VATS. 
3. To compare the incidence of post-operative pulmonary complications (PPCs) and 
length of hospital stay between the rehabilitation and the control group. 
4. To examine the risk factor associated with a decrease in functional capacity and 
exercise tolerance after VATS for lung cancer. 
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6.3 HYPOTHESIS 
Our hypothesis for this study was that a preoperative exercise-based pulmonary 
rehabilitation programme would improve exercise tolerance, muscle strength and health-related 
quality of life in patients with confirmed or suspected lung cancer awaiting VATS. We also 
hypothesized that patients in the intervention group would performed better in the exercise testing 
in the post-operative period in comparison to the control group. 
6.4 MATERIAL AND METHODS 
This research protocol was designed according to the Consolidated Standard of Reported 
Trials (CONSORT) guidelines and was registered in the database of clinical trials 
(clinicaltrials.gov) under the registration number NCT01963923. The protocol was approved by 
the local Ethics Committee (CEIC Galicia, 2011/395). 
6.4.1 Design 
This was a randomized (1:1 ratio), assessor-blinded controlled trial conducted at the 
University Hospital of A Coruña (Spain) serving a population of 550.000 inhabitants.  
6.4.2 Participants 
From October 2013 to April 2015 (18 months) patients who were scheduled for lung 
resection surgery at the Thoracic Department of the hospital were assessed for eligibility. Inclusion 
and exclusion criteria are summarized in Table 6.3. 
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Table 6.3: Inclusion and exclusion criteria 
INCLUSION CRITERIA EXCLUSION CRITERIA 
- Adults only (>18 years old) 
- Suspected or histological diagnosis of 
NSCLC. 
- Having, at least, one of the following 
conditions: FEV1≤80% of predicted value; 
and/or BMI ≥ 30; and/or age ≥ 75 years and/or 
having two or more co-morbidities such as 
AH, Diabetes, COPD, cardiovascular disease, 
renal impairment and/or past history of 
cancer. 
- Distance to the facility centre ≤ 80 km. 
- Neoadjuvant therapy with chemo- or 
radiotherapy in the 6 months prior to surgery. 
- Reconversion to open thoracotomy during 
surgery.  
- Bilobectomies or pneumonectomies.  
- Inability to perform the exercise training; no 
cooperation or lack of adherence. 
- Not signed the informed consent. 
 
 
*NSCLC = Non-Small Cell Lung Cancer; FEV1 = Forced Expiratory Volume in the 1 second; 
BMI = Body Mass Index; AH = Arterial Hypertension; COPD = Chronic Obstructive Pulmonary 
Disease 
Patients were considered eligible if they have confirmed or suspected resectable NSCLC 
and presented at least with one of the conditions listed in table 6.3. The clinical features selected 
as inclusion criteria were chosen based on the current evidence of the potential risk factors 
associated with poor post-operative outcomes and/or poor prognosis (Amar et al., 2010, Barrera et 
al., 2005, Agostini et al., 2010, Wilson, 1997).  
Potentially eligible patients were initially contacted by phone and scheduled for an 
interview with a specialized physiotherapist. After carefully reading the information sheet and 
posed any questions they might have, those who agreed to participate gave written informed 
consent prior to any formal testing (Supplemental file no.3). 
Patients were randomized using a 1:1 ratio after they completed the baseline assessments. 
Group allocation was revealed to the patient by same investigator responsible of the PPRP but only 
after the initial evaluations were completed. 
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6.4.3 Intervention 
Patients were randomly allocated to receive either a PPRP (rehabilitation group) or standard 
care (control group). Patients in the control group were monitored by their general practitioners 
during the preoperative period and only if required. Meanwhile, patients in the experimental group 
engaged in a 1-hour, three to five times per week exercise-based intervention including the 
following: 
Endurance training 
The general principles of exercise training in individuals with chronic diseases are no 
different from those for healthy individuals or even athletes. These basic principles are: a) overload 
(only loads higher than those imposed in daily life activities will provoke physiological changes); 
b) specificity (the acquired physiological changes are only shown in the exercise practiced); c) 
periodization and variation of the training (in order to achieve progress as the physiologic changes 
occur) and d) reversibility (meaning the total or partial loss of the effects achieved after 
discontinuing the training) (Spruit et al., 2013, Celli, 2003).  
Intensity is an important determinant of the physiological responses to exercise training 
(Garber et al., 2011). According to the principle of overload, intensities below a minimum threshold 
will not result into the physiological changes required to increase VO2peak and exercise capacity. 
As aforementioned, a training intensity that exceeds 60% of the peak exercise capacity is 
empirically considered sufficient to elicit some physiologic training effects when the total effective 
training exceeds 30 minutes (Nici et al., 2006). Lower intensities (50% of peak work rate) have 
also shown to improve symptom management and HRQoL, and could also increase exercise 
capacity in more deconditioned patients (Garber et al., 2011).  However, in some cases, it may be 
impossible for the patient to achieve the targeted intensity and/or duration due to severe ventilatory 
limitation and/or muscle atrophy. Interval training has been proposed as a more suitable alternative 
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in this population given that the placement of rest periods decreases ventilatory requirements and 
exercise-associated dyspnoea (Andrianopoulos et al., 2014). A recent meta-analysis conducted in 
healthy individuals aged 18 to 45 found that both continuous and interval training elicit large 
improvements in VO2max when comparing to no training. In addition, the authors observed that for 
subjects with typically lower baseline fitness, the improvements were greater with the interval 
training. Furthermore, when comparing both training modalities, there was an increased benefit of 
the high interval training comparing to continuous modality on VO2max (MD: 1.2 ml/kg-1/min-1 
±0.9) (Milanović et al., 2015). In contrast, in patients with COPD interval training appears equally 
effective to continuous training to increase cardiorespiratory fitness (Beauchamp et al., 2010). 
Additionally, attendance rates and dropouts did not differ between groups. The variation in the 
modality used to deliver the interval training including work: rest ratio, peak intensity and total 
duration of the exercise could largely affect the results of the comparison.      
In this study, endurance training was performed using a calibrated cyclo-ergometer 
(Monark 818 E, Monark Exercise AB, Sweden) with an initial targeted duration of 30 minutes 
according to the previous recommendations. Training load (Watts) was determined after a 
symptom-limited incremental cycle test. The test was performed according to the American 
Figure 6.2: Square-Wave Endurance Exercise Test; adapted from Giménez et al., 1982. 
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College of Chest Physicians (ACCP) guidelines (ATS/ACCP, 2003): after a two-minute unload 
cycling at 50 - 70 rpm, intensity was increased by 12.5 W each minute until maximal exhaustion 
was achieved. Patients were asked to discontinue if they couldn’t maintain the rhythm of cycling 
due to increased dyspnoea, muscle fatigue or any symptom of discomfort. The maximal load 
maintained for at least 30 seconds was recorded as the Peak Work Load (Wpeak). Heart rate and 
oxygen saturation were monitored during the test whilst blood pressure, dyspnoea and leg fatigue 
were recorded only before and after the assessment. Each training session patients were encouraged 
to perform 30 minutes of interval aerobic training adapting the principles of the SWEETraining 
developed by Giménez et al. for chronic respiratory diseases, which consisted of a one-minute bout 
at a high intensity load (≥80% Wpeak) combined with a four-minute, low-intensity active rest (50% 
Wpeak) (Figure 6. 2) (Giménez et al., 1982). A five-minute warm-up and a four-minute cool down 
were also included in the 30 minutes time frame. 
At the beginning and at the end of the test dyspnoea and leg fatigue were logged using the 
modified version of the Borg Scale (Table 6.4). After the 10th session, if either dyspnoea or leg 
fatigue were below the targeted intensity (four to five), a new incremental cycle test was conducted 
in order to re-evaluate the peak work rate and maintain an optimal training stimuli.   
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Table 6.4: Modified version of the Borg Scale; Borg, 1982 
 
Resistance training 
The same principles of overload, specificity and variation also apply for resistance or 
strength training (Ratamess et al., 2009, Andrianopoulos et al., 2014). Resistance training is 
oriented to enhance muscle mass, maximal strength or muscle endurance. According to this, the 
addition of resistance training to a PR programme can help preventing or reversing peripheral 
muscle weakness in patients with respiratory chronic diseases who suffer from muscle weakness 
or atrophy. Intensity is considered the most important variable and should be inversely related to 
the training volume (Andrianopoulos et al., 2014). Depending on the specific goal, training volume 
(which encompasses intensity, number of repetitions and sets and frequency of the training) can 
slightly vary. Conventionally, resistance training is performed using weight machines or free 
weights as they allow clinicians to accurately measure the intensity of the training. International 
guidelines recommend that for healthy adults, an intensity of ≤50% of the maximal one repetition 
Rating of Perceived Exertion Intensity 
0 Nothing at all 
0.5 Extremely light (just noticeable) 
1 Very Light 
2 Light 
3 Moderate 
4 Somewhat severe 
5 Severe 
6  
7 Very Severe 
8  
9 Extremely Severe (almost maximal) 
10 Maximal 
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(1RM) is the optimal to improve muscle endurance and it could also be beneficial for improving 
muscle strength and power in sedentary and older people beginning a resistance programme 
(Garber et al., 2011). Two to four sets of 10 – 15 repetitions each, at least two times per week are 
recommended in this population (Garber et al., 2011). Progression can be achieved by increasing 
the intensity, the number of repetitions per set, the number of sets, decreasing the rest between sets 
or increasing speed of the movement (Ratamess et al., 2009). Unfortunately, the availability of free 
weights or weight machines is limited in many clinical settings thus other alternatives are warrant. 
Elastic bands have been recently acknowledged as a valid training modality by the international 
guidelines (Garber et al., 2011, Nici et al., 2006). Studies have shown that elastic bands induce 
similar muscle activation than traditional equipment and are as effective as weight machines or free 
weights to increase muscle strength in sedentary but otherwise healthy individuals (Colado and 
Triplett, 2008, Colado et al., 2009, Andersen et al., 2010). The main disadvantage of elastics bands 
is the difficulty to accurately measure training intensity and progression. According to the first 
manufacturer (Thera-Band®, The Hygienic Corporation, Akron, Ohio, USA) there are eight band 
colours each one providing different resistance (tan – yellow – red – green – blue – black – silver 
and gold). In 2000, Page et al. measured the specific force developed by each one of the bands and 
generated regression equations according to the percentage of elongation (Page et al., 2000) (Table 
6.5). The results provided clinicians and researchers with a more precise estimation of the real 
intensity generated by each band and enable comparison to other training modalities.    
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In our study, four different bands (yellow – red – green – blue) of 1.25-m long were used. 
Percentage of elongation ranged from 50 to 125 % depending on the exercise performed and the 
height of the patient. Training load was determined during the first session after a 25 maximal 
repetition test, meaning that the patient could not perform more repetitions with the correct 
technique (Newsam, 2005). They started with the lightest resistance available and performed a 
maximal number of three consecutive attempts with a one-minute rest between to choose the 
adequate resistance. 
Functional exercises that strengthen the lower and upper limbs are recommended for 
pulmonary rehabilitation programmes with limited equipment (Jenkins et al., 2010). According to 
this, ten exercises were selected targeting individual muscles or muscle groups involved in daily 
life activities: shoulder lateral raise, straight arm shoulder flexion, elbow flexion, row, chest press, 
latissimus row, single leg press, heel raise, step-up and/or squat. Upper and back exercises were 
Table 6.5: Resistance in Kilograms of Thera-Band® according to the percentage of elongation; 
Page et al., 2000. 
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performed using the elastic bands while bodyweight exercises were used to train the lower body 
(Supplemental file no.7). 
During each training session, patients performed six out of the ten proposed exercises 
according to their personal limitations and preferences balancing upper and lower body exercises. 
During the first session, patients performed one set of 15 repetitions of each exercise to familiarize 
with the technique. In the subsequent training sessions, the goal was to perform three sets of 15 
repetitions for each exercise with a 40-second rest between sets (Chodzko-Zajko et al., 2009, 
Ratamess et al., 2009). From the 10th onwards, number of repetitions was maintained and the 
number of sets was increased to four if tolerable. Patients were encourage to maintain a moderate 
perceived rate of exhaustion of (five to six) according to the OMNI-Resistance Scale described in 
the previous chapter (Colado et al., 2012).  
Breathing exercises 
As early as 1915, physiotherapists were including breathing exercises as part of their 
conventional regimes (Grant-Paterson and Buchholtz-Moodie, 1985). Breathing exercises aim to 
correct breathing errors, re-establish a proper breathing pattern, increase diaphragm activity, 
elevate the amount of alveolar ventilation, reduce work-imposed breathing and relieve shortness of 
breath in patients with respiratory diseases (Liu et al., 2013). The addition of a respiratory 
biofeedback to perform the exercises enables clinicians to select a determinate goal and provides 
the patients with more autonomy and self-evaluation of the progress. Incentive Spirometry (IS) was 
introduced by Bartlett and colleagues as a method to encourage deep breathing inhalations in post-
operative patients (Bartlett et al., 1973). IS is accomplished when the patient inhales a pre-
determinate flow and/or volume using the device and sustains the inspiration for three to six 
seconds (Restrepo et al., 2011). IS is usually recommended in the perioperative period of major 
surgery (especially abdominal, thoracic and cardiac) to prevent and/or reverse atelectasis and other 
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post-operative pulmonary complications. Despite the almost universal widespread of the technique, 
the evidence so far is at least controversial. There are several factors that could explain the 
inconsistent results found across studies. For instance, breathing exercises are insufficiently 
described in the literature, the terminology used to define them is arbitrary, and more frequently, 
the same name is given to different interventions (Garrod and Mathieson, 2013). Lack of 
standardization to perform the IS, the type of incentive spirometer used as well as the diaphragmatic 
and thoracic motion can contribute to the absence of consistent results (Grant-Paterson and 
Buchholtz-Moodie, 1985, Chang et al., 2010, Westerdahl, 2014, Weindler and Kiefer, 2001).  
In this randomized controlled trial, patients in the experimental group were taught 
breathing exercises using a volume-oriented incentive spirometer (Coach 2 Incentive Spirometer 
22-4000 HD, Smith Medicals, USA). Participants were asked to perform the exercises at home 
twice daily. The protocol consisted of 1) slow exhalation outside the device until the reserve 
volume was reached; 2) a deep, slow inhalation through the device up to 80% of the maximal vital 
capacity (flow rate approximately 0.5 – 1.5L/min); 3) an end-inspiratory hold of three seconds and 
4) a normal exhalation outside the device. The sequence was repeated 30 times distributed in six 
cycles of five repetitions each, with a one-minute rest between cycles.   
Also, when considered appropriate and according to the patients’ baseline 
symptomatology, airway clearance techniques were provided at the end of the session.  
Each training session was recorded and kept in a codified data sheet (Supplemental file no. 
4).  
  
CHAPTER SIX: effectiveness of a preoperative pulmonary rehabilitation programme in VATS 
186 | P a g e  
 
 
 
6.4.4 Outcomes 
The two main outcomes of the study were: 1) changes in exercise capacity (endurance time) 
before and after the PPRP and 2) mean difference between groups in endurance time in the post-
operative period (early and late post-operative period).  
Other secondary outcomes included 1) changes in muscle strength and HRQoL before and 
after the intervention; 2) mean difference between groups in muscle strength and HRQoL in the 
early and late post-operative period and 3) differences in length of hospital stay and post-operative 
pulmonary complications between groups. Patients in both groups were evaluated at three points 
during the study period: at baseline prior to randomization (T0) and in the early (T1) and late post-
operative period (T2). The experimental group was also evaluated after the PPRP prior to surgery. 
The post-operative evaluations (T1 and T2) were undertaken by two blinded therapist who were 
not aware of the allocation of the participants.  
Patients were evaluated at baseline on two separated days by one of the investigators. On 
the first day, medical and socio-demographic data were collected during a personal interview 
including: smoking history, symptomatology, number of medications, height, weight and BMI. 
Heart rate, blood pressure and oxygen saturation at rest were also recorded. An incremental 
symptom-limited exercise test was then performed followed by a Constant-load Cycle-Endurance 
Test (CCET) at 80% of the Wpeak. On the second day, patients completed the rest of the assessment 
including determination of muscle strength, HRQoL and functional exercise capacity. Participants 
were asked not to drink alcohol or other caffeinated drinks the previous day of the tests. They were 
also encouraged not to perform any strenuous exercise 24 hours before the exercise capacity 
evaluation. Patients in the intervention group were re-evaluated prior to surgery to measure changes 
after the exercise programme (endurance time, muscle strength and HRQoL). Finally, post-
operative evaluations including exercise capacity, functional capacity, muscle strength and HRQoL 
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were obtained at three weeks and three months (Figure 6.3). The results of the evaluations were 
kept individually in a codified data collection sheet shown in the Supplemental file no.5. 
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Figure 6.3: Chronogram of the study. 
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Exercise capacity 
The principle of specificity in exercise training entails that individuals engaging in a 
training programme would only show improvements in the exercise practiced. According to this, 
it is essential both in clinical practice and in research to select the most sensitive tool to measure 
changes after an exercise training. Traditionally, incremental exercises tests were used both to 
assess cardiopulmonary fitness and to quantify the improvements after a given intervention. 
However, today we have sufficient data to believe that incremental protocols are not the most 
sensitive tool to evaluate the impact of an exercise-based intervention. As acknowledged by the 
ATS and the ACCP, although the incremental tests are the most widely used in clinical practice, 
constant-work rate protocols (6MWT, ESWT, Constant-Load Cycle-Endurance Test) are gaining 
popularity because of their clinical applicability for monitoring responses to therapy (ATS/ACCP, 
2003). In 2009, the ERS statement on Pulmonary Rehabilitation recognized the superiority of the 
constant endurance test over the measurement of VO2peak to quantify the effects of therapeutic 
interventions in COPD (Brunelli et al., 2009b). This asseveration is based on the results of some 
comparative studies showing that in patients with chronic diseases, endurance time has shown the 
largest improvement after a pulmonary rehabilitation programme (Ong et al., 2004). Given these 
findings, it appears that maximal exercise tests are more appropriate to assess the nature of the 
exercise limitation in patients with pulmonary diseases while constant protocols performed at a 
percentage of the maximal intensity should be used to measure changes after an intervention 
(Whipp and Ward, 2009, van 't Hul et al., 2003).  
Constant-load Cycle Endurance Test (CCET) has shown to yield higher fractioned 
increases in exercise tolerance than other constant protocols (Casaburi, 2009). Intensity and 
duration of the CCET are the two more important features for the validity and reliability of the test. 
Optimal duration should fall between four and seven minutes (Casaburi, 2009) since durations 
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greater than the upper limit imply that the work rate is not much above the critical power while 
durations less than four minutes don’t allow enough time to the cardiorespiratory system to adopt 
the physiological adaptations to exercise. Intensity, on the other hand, is a subject of continuous 
discussion. It is generally accepted that a higher intensity (≥60%) is preferred over a moderate one 
(≤60%), given that it has shown shorter exercise time, less variability and higher sensitivity (Oga 
et al., 2004). The most common intensities for the CCET vary between 75 and 85 % of the peak 
workload achieved during an incremental maximal test but no final consensus has been reached. 
The CCET has shown good intra-test reliability and validity in patients with COPD (Intra-class 
Correlation Coefficient ≥ .85 (van 't Hul et al., 2003) but further confirmation is needed in other 
chronic diseases.  
Given the superiority of the constant endurance tests and the arguable responsiveness of the 
6MWT reported by some authors (Borel et al., 2013), in our study, a CCET was used to measure 
changes in exercise tolerance after the PPRP. To perform the test, an incremental symptom-limited 
cycle-ergometry test was firstly performed to determine the peak workload (Wpeak) according to 
the ATS/ACCP recommendations (ATS/ACCP, 2003) (a full description of the test is provided in 
the previous chapter). After a 45-minute rest, the CCET was performed at 80% of the Wpeak: after 
two minutes of unloaded cycling, intensity was rapidly increased until the targeted percentage was 
reached. Patients were instructed to exercise for as long as possible at 50 - 70 revolutions per minute 
(rpm) until maximal exhaustion was achieved or the patient was unable to maintain the minimal 
pedalling rate. Encouragement was given every two minutes. If exercise time exceeded more than 
15 minutes the test was terminated (van 't Hul et al., 2003). Heart rate, oxygen saturation, dyspnoea 
and leg fatigue were recorded at the beginning and at the end of the test. Heart rate and oxygen 
saturation were also monitored during the test. Reasons to discontinue the test were logged in the 
data collection sheet (Supplemental file no.5).   
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Functional capacity 
Functional capacity was assessed at three points during the study period (at baseline and in 
the early and late post-operative period) using a 6MWT.  
The 6MWT was performed in an indoor flat corridor with patients walking at self-pace 
between two marks separated by 30 meters according to the national and international guidelines 
(American Thoracic Society, 2002, Burgos-Rincon and Casan Clara, 2004).  Patients were asked 
to walk as fast as they could for six minutes between the two marks (Figure 6.3). Heart rate, oxygen 
saturation, dyspnoea and fatigue were recorded at the beginning and at the end of the test. Oxygen 
saturation and heart rate were monitored during the test using a portable pulse oximeter. Total 
walked distance was calculated once the test was finished. Duplicate tests were performed at 
baseline for reliability and the maximum distance covered was used for the analysis. 
The values achieved during the test were compared to the reference equations for the 
Spanish population (Gimeno-Santos et al., 2015) (Table 6.6). 
  
Figure 6.4: Trajectory of the 6MWT; Burgos-Rincón et al., 2004. 
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Table 6.6: Reference equations for the Spanish population aged 45 - 85; Gimeno-Santos et al., 2015 
 Reference Equation 
Males 6MWD = 478 – (5.51*Ageyears) + 
(4.15*Heightcm) – (1.78*Weightkg) – 
(1.18*HRbaseline) + 84 
Females 6MWD = 1107 – (5.78*Ageyears) – 
1.48*Weightkg) – (1.27*HRbaseline) + 67 
  
Muscle strength 
Muscle strength was assessed using two items of the Senior Fitness Test (SFT) designed 
and validated by Rikli et al.: the Curl Arm Test and the 30’s Chair-Stand Test (Rikli and Jones, 
2013). The test was performed in the same sequence for every assessment: first the Arm Curl test 
followed by the 30’s Chair to Stand Test. Only one trial with partial practice the same day was 
allowed for each of the tests. For more details of how the test was performed refer to Chapter 5. 
Health-related quality of life 
HRQoL was assessed using the second version of the Short Form 36 Health Survey (SF-
36) described in Chapter 5. The test as self-administrated whenever possible; if the patient was 
unable to read or understand the test, one of the investigators was responsible for reading the 
questionnaire and provide the participant with further explanations of the questions.  
Post-operative outcomes 
Post-operative outcomes included: a) length of post-operative hospital stay (LOS) from the 
day of surgery to hospital discharge and b) incidence of post-operative pulmonary complications 
(PPCs) assessed with the Melbourne Group Scale (MGS). As described in previous chapters, the 
MGS is a tool specifically designed to identify post-operative respiratory complications which are 
more likely to be prevented by a physiotherapy intervention (Reeve et al., 2008). Post-operative 
outcomes were retrospectively reviewed by using the medical records. We also recorded other 
common complications (prolonged air leak, atrial fibrillation, pneumothorax, pleural effusion) and 
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other perioperative relevant data: number of post-operative physiotherapy interventions, 
pathological diagnosis, stage and post-operative adjuvant therapy.  
6.4.5 Sample size estimation 
This study was powered to detect a clinically minimal important difference between groups 
of 100s in the exercise capacity assessment (endurance time) (Casaburi, 2009, Laviolette et al., 
2008). To detect this difference with a probability of α = .05 and power = .8 using a bilateral 
hypothesis and estimating a 10% of dropouts 11 patients per arm were required. The standard 
deviation of the whole sample was taken from a recent study conducted in patients with NSCLC 
awaiting lung resection surgery (Coats V, 2013). Sample size calculation was performed using the 
Epidat® v3.1 Xunta de Galicia, 2005. 
6.4.6 Randomization 
Randomization was undertaken using a random-based computer programme (Epidat® 
v3.1 Xunta de Galicia, 2005) with an allocation ratio of 1:1. 22 patients were initially randomized 
and individual allocations were placed in consecutively numbered and sealed opaque envelopes by 
a third person not involved in the study. Once the first 22 patients were randomized, if the targeted 
sample size was not achieved, subsequent randomization was performed in blocks of six patients 
until the desirable sample was achieved.  
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6.4.7 Blinding/Masking 
Participants were not blinded to group allocation since they knew if they were training or 
not. The physiotherapist responsible for the PPRP was also aware of the group allocation since she 
knew which participants were involved in the training. The baseline assessment was conducted by 
the same physiotherapist who supervised the training programme; however, group allocation was 
only revealed after the evaluations were completed, this way the investigator was also blinded when 
performing the initial assessments. All of the post-operative evaluations were performed by two 
blinded therapists who were unaware of the allocation of the patients.  
6.4.8 Statistical analysis 
Quantitative data are presented as mean and standard deviation (SD) while qualitative data 
are described in absolute numbers and percentage of the total. Normality was assessed using the 
Kolmogorov – Smirnov Test for each variable in each group. Initially, a comparative analysis of 
the participants regarding the main demographic and clinical variables was undertaken using an 
independent t-test or a Mann Whitney Test and the Chi Square Test. Changes in the primary and 
secondary variables (exercise capacity, functional capacity, muscle strength and HRQoL) for each 
group were evaluated using a general linear model of repeated measures. Inter-group comparisons 
were performed using independent t-tests for the primary and secondary outcomes including post-
operative length of stay. Comparison of the incidence of post-operative complications was done 
using a Chi Square Test. Univariate correlations were analysed to identify factors influencing 
exercise performance in the early and late post-operative period. A multivariate regression was 
then performed to further confirm the results of the univariate analysis. 
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All statistical analyses were calculated using the SPSS® package for Windows® (Version 
22, IBM Corporation, Chicago IL, USA) and a p value of <.05 was considered statistically 
significant.  
6.5 RESULTS 
This randomized single-blind controlled trial took place from October 2013 to October 
2015 at the University Hospital of A Coruña. The recruitment period went on for 18 months, 
starting in October 2013 and finishing in April 2015. During that period, 319 patients joined the 
waiting list for lung resection surgery at the Thoracic Department. 68 eligible patients (21.3%) 
were contacted and 46 (67.6%) signed the informed consent. Six patients (13%) withdrew before 
randomization therefore 40 patients were randomized during the recruitment period; of those, 22 
(55%) completed at least one of the post-operative evaluations and were analysed. A flow diagram 
of the study selection process is shown in Figure 6.5. Baseline characteristics of both groups are 
shown in Table 6.7.  
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Assessed for eligibility (n=319) 
Excluded (n=279) 
  Not meeting inclusion criteria 
(n=174) 
  Surgery scheduled within one week 
(n=14) 
  Not NSCLC (n=11) 
  Contraindications to exercise (n=10) 
  Declined to participate (n=16) 
  Neoadjuvant Therapy (n=24) 
  Other reasons (n=30) 
Analysed (n=10): 
- Lost to follow up (n= 2) 
 
 
Analysed (n=12) 
Lost to follow-up (give reasons) (n=2) 
- Not evaluated (n=2) 
Excluded (n=3) 
- Reconversion to thoracotomy 
(n=1) 
- Not Surgery (n=1) 
- Not malignant disease (n=1) 
CONTROL GROUP (n=20) 
 Received allocated intervention (n=18) 
 Did not receive allocated intervention 
(n=2) 
- Referred to preoperative 
physiotherapy (n=2) 
Analysed (n=10) 
Lost to follow-up (n=2) 
- Not evaluated (n=1) 
- Surgery re-scheduled (n=1) 
Discontinued intervention (n=8) 
- Not malignant disease: 2 
- Neoadjuvant therapy (n=1) 
- Abandoned intervention (n=2) 
- Surgery moved forward (n=1) 
- Tumor declared unresectable 
(n=1) 
- Unable to continue with the 
training (n=1) 
 
REHABILITATION GROUP (n=20) 
 Received allocated intervention (n=20) 
 Did not receive allocated intervention 
(give reasons) (n=0) 
Analysed (n=9): 
- Clinical Deterioration (n=1) 
 
Allocation 
3 Months (T2 
Post-Surgery 
Randomized (n=40) 
Enrolment 
Figure 6.5: Flow diagram of the study. 
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Table 6.7: Baseline characteristics of the patients included in the study 
VARIABLE 
GROUP 
CONTROL 
(n=12) 
REHABILITATION 
(n=10) 
Age (years) 69.4±9.4 70.9±6.1 
Sex (M/F) 9/2 11/1 
BMI 25.7±2.8 29.4±4.3 
History of Smoking (n, %) 
No 
Former 
Current 
 
2 (16.7%) 
7 (58.3%) 
3 (25%) 
 
2 (20%) 
8 (80%) 
0 
Package/Year 39.5±32.1 50.7±34.8 
CCS 
Respiratory Disease (n, %) 
Cardiovascular Disease (n, %) 
Renal Impairment (n, %) 
Diabetes Mellitus (n, %) 
Alcoholism (n, %) 
PHx Cancer (n, %) 
8.7±4.2 
4 (33.3%) 
9 (75%) 
0 
3 (25%) 
0 
6 (50%) 
9.3±4.9 
7 (70%) 
8 (80%) 
0 
1 (10%) 
0 
4 (40%) 
Symptomatology (n, %) 
Cough 
Dyspnoea 
Expectoration 
Other 
8 (66.7%) 
3 (25%) 
3 (25%) 
7 (58.3%) 
4 (33.3%) 
10 (100%) 
3 (30%) 
7 (70%) 
4 (40%) 
2 (20%) 
SBP 15.12±2.7 13±1.7 
DBP 7.1±0.9 7.7±1.2 
FEV1 (%) 87.6±26.1 69.2±15.1 
FVC (%) 80.1±18 71.2±15 
FEV1/FVC 68.8±6 61.2±9.4 
6MWT (m) 507.7±9 420.2±116.3 
6MWT (%) 79.8±11.4 70.1±18.2 
Maximal Workload (W) (median, 
IQR) 
75 (67.5 – 84.4) 67.5 (50 – 75) 
Maximal Workload (% predicted) 55.4±16.7 51.35±15.18 
CCET (s) 366.83±205 322.40±96 
Curl Arm (no. repetitions) 17.3±3.5 13.4±3 
Sit To Stand (no. repetitions) 12.7±2.5 11.5±3.7 
*BMI=Body Mass Index; CCS=Colinet Co-morbidity Score; PHx=Past History; SBP=Systolic 
Blood Pressure; DBP=Diastolic Blood Pressure; FEV1=Forced Expiratory Volume in 1 second; 
FVC=Forced Vital Capacity; 6MWT=Six Minute Walk Test; IQR=interquartile range 
CCET=Constant-load Cycle Endurance Test 
CHAPTER SIX: effectiveness of a preoperative pulmonary rehabilitation programme in VATS 
198 | P a g e  
 
 
 
The mean preoperative period was 53.9±17.7 days. There was no significant difference in 
the therapeutic delay between groups (p =.89). Patients in the rehabilitation group attended a 
median of 16 sessions (range eight – 25) achieving a mean adherence of 100.2±32.6 %. Three 
patients reached less than 80% of the adherence. No adverse events were recorded during the 
training.  
All patients underwent VATS through one or two ports performed by highly experienced 
surgeons. There was only one reconversion to thoracotomy (control group) and the patient was 
excluded from the analysis. Ten patients in the control group and six in the rehabilitation group 
underwent a lobectomy while the others received a sublobar resection. No significant differences 
were found between groups in the type of resection (p =.229). The pathologic diagnosis confirmed 
eight NSCLC and four lung metastases in the control group and eight cases of NSCLC, one 
carcinoid and one lung metastasis in the rehabilitation group (p =.89). One patient in the control 
group was diagnosed with benign disease and was also excluded from the analysis. The majority 
of the patients were diagnosed with an early stage of the disease and only two patients were stage 
IIIA. A registered specialized physiotherapist performed conventional chest physiotherapy in those 
patients requiring assistance to improve their respiratory status (three vs four patients in the control 
and rehabilitation groups respectively; p =.452).  
Median time from surgery to T1 was 24.5 days (IQR: 10.7 – 34.2) or 3.5 weeks (IQR: 1.5 
– 4.9). Median time from surgery to T2 was 98 days (IQR: 92 – 110) or 14 weeks (IQR: 13.1 – 
15.7). No significant differences were found between groups (p =.093 and p =.842 respectively). 
All 22 patients completed the early post-operative (T1) evaluation. However, from T1 to 
T2 two patients were lost to follow-up in the control group (one patient refused and the other was 
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out of town) and one in the rehabilitation group (the participant had severely deteriorated from T1 
to T2), leaving 19 patients for analysis at T2.   
6.5.1 Intra-group comparison 
Rehabilitation group 
 Results for the main variables in the intervention group are shown in Table 6.8 and Figures 
6.6 to 6.14. In brief, pre to post-intervention, patients in the rehabilitation group experienced a 
significant increase in the three main variables studied: endurance time, muscle strength and 
HRQoL (role physical and PCS). Exercise capacity (endurance time) experienced both a statistical 
and a clinically meaningful improvement from baseline to pre-surgery, with patients increasing 
123% their baseline time (p <.001) (Figure 6.6). Upper and lower body strength also improved 
significantly (p =.002 and .041 respectively) (Figure 6.7 and Table 6.8). 
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Table 6.8: Changes in main outcomes pre to post intervention in the rehabilitation group 
VARIABLE N BASELINE PRE-Surgery  P value 
CCET (s) 10 322.4±96.2 719±211.2 <.001 
Arm Curl (no.) 10 13.40±3 16.30±2.9 .002 
Chair to Stand (no.) 10 11.5±3.7 12.40±4.5 .041 
Physical Functioning 10 63.5±20.8 71±14.9 .110 
Role Physical 10 48±30.6 65.9±12.8 .038 
Bodily Pain 10 64.5±26.3 69.2±23.8 .518 
General Health 10 41.9±20.2 52.2±14.3 .072 
Vitality 10 52±16.5 55±15.6 .526 
Social Functioning 10 87.5±22 97.5±5.3 .223 
Role Emotional 10 60.6±19.2 72.7±12.3 .098 
Mental Health 10 63.2±13.6 64.4±19.2 .771 
PCS 10 40.77±8 45.2±6.8 0.08 
MCS 10 45.7±8.3 47.4±7.4 .511 
 *CCET= Constant-load Cycle Endurance Test; PCS= Physical Component Summary; MCS= 
Mental Component Summary 
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Figure 6.6: Changes in endurance time pre- to post-intervention in the rehabilitation group. 
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At baseline, HRQoL was below normative data across all health dimensions. After the 
training, all items increased but only significantly for the role physical and the PCS (p =.038 and 
.008 respectively). However, except for the social functioning, all of the items were still below 
normative data (<50). 
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Figure 6.7: Changes in the SFT pre- to post-intervention in the rehabilitation group. 
Figure 6.8: Changes in PCS and MCS pre- to post-intervention in the rehabilitation group. 
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At T1, exercise capacity decreased comparing to pre-surgery but continued over the 
baseline values (+137.3±268.2; p =.14). At T2, there was a recovery in the endurance time 
comparing to T1 (p =.16) (Figure 6.9). Curl Arm remained over the baseline values in almost 2 
repetitions at T1 while the 30’s Chair-to-Sit Test slightly decreased (MD: -0.55±3.5). None of the 
parameters were significantly decreased comparing to baseline and were fully recovered at T2 
(Figure 6.10 and 6.11). Functional capacity measured with the 6MWT slightly decreased at T1 and 
recovered at T2 (Figure 6.12). The HRQoL changes are shown in Table 6.9 and Figures 6.13 and 
6.14.  
Figure 6.9: Changes in CCET during the study period in the rehabilitation group. 
* 
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Figure 6.10: Changes in the Arm Curl Test during the study period in the rehabilitation group. 
Figure 6.11: Changes in the Chair to Stand Test during the study period in the rehabilitation group. 
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Table 2.9: Changes in HRQoL across time in the rehabilitation group 
HRQoL Domain Baseline Post-Surgery (T1) 
95% Confident Interval 
3 Months (T2) 
95% Confident Interval 
Lower Limit Upper Limit Lower Limit Upper Limit 
Physical Functioning 63.5±20.8 -10±17.3 -22.4 +2.4 -2.2±9.4 -9.4 +5 
Role Physical 48±30.6 -19.5±26.3* -38.3 -0.7 +6.1±40.2 -24.8 +37 
Bodily Pain 64.5±26.3 +3.2 -13.2 +19.4 +26.3±26.6* +5.9 +46.8 
General Health 41.9±20.2 -12.4±23.5 -29.2 +4.4 -3.1±17.3 -16.4 +10.3 
Vitality 52±16.5 -12±12.9* -21.3 -2.7 -1.7±15.6 -13.7 +10.3 
Social Functioning 87.5±22 -16.2±30.6 -38.2 +5.7 -8.3±24.2 -26.9 +10.3 
Role Emotional 60.7±19.2 +8±21.3 -7.2 +23.2 +8.1±28.6 -13.9 +30.2 
Mental Health 63.2±13.6 0±10.1 -7.9 +7.9 -2.2±16 -14.5 +10.1 
PCS 40.8±7.8 -2.8±5.8 -6.9 +1.3 +4.3±4* +1.3 +7.4 
MCS 45.7±8.3 -0.6±8.9 -6.9 +5.8 -2.1±6.4 -7.1 +2.9 
*p <.05
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Figure 6.13: Changes in PCS during the study period in the rehabilitation group. 
Figure 6.12: Changes in the 6MWT during the study period in the rehabilitation group. 
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Control Group 
 The results of the intra-group comparison for the control group are presented in Table 6.10 
and Figures 6.15 and 6.16. Exercise tolerance decreased slightly in the early post-operative period 
but continue to decline at T2 (MD = 137.8±221.7 seconds) which was statistically and clinically 
significant (Figure 6.13). The same tendency although less pronounced was seen in the functional 
capacity measured with the 6MWT (Figure 6.14). The decrease in the post-operative functional 
capacity at T1 was also clinically and statistically significant comparing to baseline (p =.016). 
There were no significant changes in neither of the SFT items included in the study.  
HRQoL in the control group was also below normative data except for the Bodily Pain and 
the Vitality dimensions. At T1, patients significantly decreased their Physical Functioning, Role 
Physical, Bodily Pain and PCS (p <.05). Furthermore, the decline was clinically meaningful (>10 
points) in the physical functioning, role physical, bodily Pain, vitality and social functioning (Table 
6.10). 
 
Figure 6.14: Changes in MCS during the study period in the rehabilitation group. 
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Figure 6.15: Changes in endurance time during the study period in the control group. 
  
Figure 6.16: Changes in the 6MWT during the study period in the control group. 
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Table 6.10: Changes in HRQoL across time in the control group 
SF-36 Domain Baseline T1 95% Confident Interval T2 95% Confident Interval 
Lower Limit Upper Limit Lower Limit Upper Limit 
Physical Functioning 79.6±16.6 -13.3±17.7* -2 -24.6 -12±19.9 -26.2 +2.2 
Role Physical 64.6±20 -13.7±15.8* -3.7 -23.8 -11±22.3 -27 +5 
Bodily Pain 89.7±13.9 -24.4±32.7* -5.7 -47.2 -15.7±30.8 -37.7 +6.3 
General Health 53.8±28.5 +.3±24.2 +15.7 -15.1 +4.4±14.1 -5.7 +14.5 
Vitality 68.3±18.5 -11.7±18.4 +.01 -23.3 -11.5±18.1 -24.5 +1.5 
Social Functioning 83.3±30.3 -14.6±24.3 +.9 -30 -5±27.1 -24.4 +14.4 
Role Emotional 60.6±18.7 +7.8±19.2 +20 -4.4 +1.3±11.7 -7 +9.7 
Mental Health 67.3±19.3 -.37±14.4 +5.5 -12.8 -2.8±15.1 -13.6 +8 
PCS 49.5±5.5 -7.4±5.3* -4 -10.8 -4.8±5.8* -8.9 -0.7 
MCS 44.2±9.9 +.5±8.4 +5.8 4.8 -.04±8 -5.8 +5.7 
*p <.05 
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6.5.2 Inter-group comparison 
 Results of the inter-group comparison for the primary and secondary study endpoints are 
shown in Table 6.11 and 6.12. 
Results for the main outcomes  
There were no statistically significant differences in exercise capacity, functional capacity 
or the SFT between groups in the early post-operative period (p >.05) (Table 6.11). Mean 6MWT 
in both groups was 95±10.2 % of the preoperative values. Only one patient in the rehabilitation 
group was below 80% of his baseline distance. This patient was a complex case under the effects 
of psychiatric medication that could most likely interfered with the recovery. In the HRQoL 
assessment, the only difference was found in bodily pain, with patients in the rehabilitation group 
exhibiting an improvement in three points while the control group had a mean reduction of 26 
points (p =.026) (Table 6.12 and Figure 6.17).  
In contrast, three months after surgery (T2), results showed a statistically significant 
difference between groups in endurance time (MD = 288.9±91.8; p =.006) and in the mean change 
for the Curl Arm Test (p =.045) and the number of Chair-to-Sit repetitions (p =.004) (Table 6.11). 
Patients in the rehabilitation group also showed an improvement in the 6MWT comparing to 
baseline (mean difference 8.14%) while the control group remained stable, but the differences were 
not statistically significant (p >.05). In the HRQoL assessment mean change in Bodily Pain and 
PCS also showed statistically significant differences between groups (p =.006 and .001 
respectively). In particular, the control group had a mean decrease in PCS of almost five points 
comparing to baseline while participants in the rehabilitation group improved by four points (p 
=.001) (Table 6.12 and Figure 6.18). Both groups improved their bodily pain from T1 to T2, but 
the improvement was larger for the rehabilitation group and the differences were still significant 
(p =.006).   
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Table 6.11: Changes in exercise capacity, functional capacity and SFT across time in the rehabilitation and control groups 
VARIABLE GROUP Baseline Post-Surgery  
(mean difference)  
P value 3 Months  
(mean difference) 
p value 
CCET (s) Rehabilitation 322.4±96.2 +137.7±268.2 
.097 
+226±269.4* 
.005 
Control 366.8±205 -25.8±16.71 -137.8±221.7 
6MWT (m) Rehabilitation  420.11±116.3 -15.55±47.731 
.500 
1.88±34.7 
.186 
Control 514.5±100.9 -27.7±33.7* -31.5±64.6 
Arm - 
Curl (n) 
Rehabilitation  13.4±3 +1.9±3 
.105 
+1.8±3.3 
.045 
Control 17.3±3.5 -0.25±2.9 -1.8±3.5 
Chair-to-Stand 
(n) 
Rehabilitation  11.5±3.7 -0.55±3.5 
 
.531 
+2±2.2* 
.002 
Control 12.7±2.5 +0.5±3.9 -1.3±1.8* 
*Intra-group statistically significant difference (p <.05) 
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Table 6.12: Changes in HRQoL across time in the rehabilitation and control groups 
HRQoL 
Domain 
GROUP Baseline Post-Surgery 
(mean 
difference) 
p value 3 Months 
(mean 
difference) 
p value 
Physical 
Functioning 
Control  79.6±16.6 -13.3±17.7* 
.662 
-12±19.9 
.197 
Rehabilitation 63.5±20.8 -10±17.3 -2.2±9.4 
Role 
Physical 
Control 64.6±22. -13.7±15.8* 
.533 
-11±22.3 
.261 
Rehabilitation 48±30.6 -19.5±26.3* +6.1±40.2 
Bodily Pain Control 89.7±13.9 -26.4±32.7* 
.026 
-15.7±30.8 
.006 
Rehabilitation 64.5±26.3 +3.2±23 +26.3±26.6* 
General 
Health 
Control 53.8±28.5 +0.3±24.2 
.252 
+2±21.2 
.328 
Rehabilitation 41.9±20.2 +12.4±23.5 +11.2±18.4 
Vitality 
Control 68.3±18.5 -11.7±18.4 
.962 
-11.5±18.1 
.225 
Rehabilitation 52±16.5 -12±12.9* -1.7±15.6 
Social 
Functioning 
Control 83.3±30.3 -14.6±24.3 
.888 
-5±27.1 
.782 
Rehabilitation 87.5±22 -16.2±30.6 -8.3±24.2 
Role 
Emotional 
Control 60.5±18.7 +7.8±19.2 
.980 
+1.33±11.7 
.520 
Rehabilitation 60.6±19.2 +8±21.3 +8.1±28.6 
Mental 
Health 
Control 67.3±19.3 -3.7±14.4 
.517 
-2.8±15.1 
.936 
Rehabilitation 63.2±13.6 +0±11 -2.2±16 
PCS 
Control 49.48±5.5 -7.4±5.3* 
.067 
-4.8±5.8* 
.001 
Rehabilitation 40.77±8 -2.8±5.8 +4.3±4* 
MCS 
Control 44.2±9.9 -0.5±8.4 
.782 
-.04±8 
.555 
Rehabilitation 45.7±8.3 +0.6±8.9 -2.1±6.4 
*Intra-group statistically significant difference (p <.05)  
CHAPTER SIX: Effectiveness of a PPRP in patients with lung cancer undergoing VATS 
212 | P a g e  
 
 
 
0
10
20
30
40
50
60
70
80
90
100
Sc
o
re
CONTROL
REHABILITATION
Figure 6.18: Inter-group comparison of HRQoL domains at T2. 
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Figure 6.17: Inter-group comparison of HRQoL domains at T1. 
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  Post-operative outcomes: hospital stay and incidence of complications 
 Comparison of the post-operative hospital stay and rate of post-operative complications are 
shown in Figures 6.19 and 6.20. Post-operative length of stay (LOS) was similar between groups 
and the difference was not statistically significant (three vs. two median days in the rehabilitation 
and control group respectively; p =.539). 
There were no significant differences in any of the post-operative complications recorded 
although we observed more cases of prolonged air leak, pneumothorax, chest infection and 
desaturation in the rehabilitation group than in the control group (Figure 6.9). Nevertheless, any 
patient achieved a score of four in the MGS indicating a positive diagnosis of PPC.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.19: Comparison of LOS in the rehabilitation and control groups. 
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Figure 6.20: Comparison of PPCs in rehabilitation and control groups. 
In the univariate analysis, the endurance time measured in the late post-operative period 
(T2) was correlated with the BMI, baseline FEV1 (L and % of predicted), baseline FVC (L), 
endurance time pre-surgery, the Peak Workload and the number of PPRP sessions attended. In the 
multivariate analysis, FEV1 (L) and the endurance time achieved pre-surgery were the only two 
independent factors associated with the endurance time achieved at three months, explaining up to 
76% of the variation (Table 6.13 and 6.14). On the other hand, the three-month PCS was correlated 
with the PCS pre-surgery, the PCS post-surgery, the presence of cough, dyspnoea and other 
symptomatology at baseline, the occurrence of post-operative pneumothorax and the role physical 
of the SF-36. In the multivariate analysis, the two factors independently associate with PCS were 
the PCS pre-surgery and the presence of dyspnoea at baseline, accounting for 87% of the variation 
(Table 6.14).  
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Table 6.13: Correlation Coefficients for CCET and PCS measured three months post-surgery 
 Variable Coefficient P value 
CCET BMI .555 .017 
FEV1 (L) -.576 .012 
FEV1 (%) -.485 .041 
FVC(L) -.593 .010 
FEV1 (l) post-surgery -.601 .018 
No. Sessions .616 .007 
CCET Pre-Surgery .757 .018 
PCS PCS Pre-Surgery .707 .033 
PCS Post-Surgery .633 .004 
Role Physical Baseline .430 .066 
Cough -.364 .66 
Dyspnoea -.381 .041 
Other symptomatology -.329 .096 
Pneumothorax -.474 .016 
 
Table 6.14: Multivariate analysis for the endurance time (CCET) measured three months post-surgery 
Model Unstandardized Coefficients Sig. 95.0% Confidence Interval for B 
B Std. Error Lower Bound Upper Bound 
1 (Constant) -44.416 250.318 .864 -636.326 547.493 
CCET Pre-Surgery .841 .334 .040 .051 1.631 
2 (Constant) 502.380 226.026 .068 -50.685 1055.445 
CCET Pre-Surgery .970 .215 .004 .445 1.496 
FEV1 (L) Baseline -352.930 104.104 .015 -607.664 -98.196 
 
Table 6.15: Multivariate analysis for the PCS at T2 (3 months post-surgery) 
 
Model 
Unstandardized Coefficients 
Sig. 
95.0% Confidence Interval for B 
B Std. Error Lower Bound Upper Bound 
1 (Constant) 50.512 1.767 .000 46.333 54.692 
Dyspnoea -4.744 1.286 .008 -7.785 -1.703 
2 (Constant) 30.563 5.090 .001 18.110 43.017 
Dyspnoea -3.885 .757 .002 -5.737 -2.033 
PCS PRE .420 .105 .007 .163 .677 
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6.6 DISCUSSION  
This study was designed to evaluate the effects of a preoperative pulmonary rehabilitation 
programme on exercise capacity before VATS and to investigate whether or not the intervention 
would help to preserve post-surgical exercise and functional capacity to a greater extent than the 
standard care. Our results demonstrate that a PPRP in patients awaiting lung resection effectively 
improve exercise capacity, muscle strength and the physical component of the HRQoL which most 
likely minimize the functional decline observed after surgery and hasten post-operative recovery 
during the first three months after VATS.  
Exercise training is considered the cornerstone of PR. The reported benefits of exercise 
training in chronic respiratory adults include an improvement in exercise tolerance, functional 
capacity, symptom control, mood and HRQoL (Holland et al., 2013). To optimize the results 
obtained, the instruments used to measure changes after the intervention must be sensitive to the 
exercise prescribed and responsive to change. There are three major categories of instruments to 
measure changes in exercise capacity in patients with chronic diseases: questionnaires, activity 
monitors and exercise testing (Casaburi, 2009). Within the latter, the constant-load protocols have 
demonstrated its superiority to detect such changes (Casaburi, 2009) but there is little consensus in 
the literature in terms of which particular exercise testing is better for patients with lung cancer. 
Granger et al., in a systematic review of the most common instruments used to measure functional 
capacity in patients with NSCLC concluded that the 6MWT was the most frequently used in this 
population (Granger et al., 2013a). However, the sensitivity and responsiveness of the test to 
quantify changes after a given intervention has been questioned and other submaximal exercise 
tests have been proposed instead (Borel et al., 2013, Granger et al., 2015a). In particular, the 
Constant-load Cycle Endurance Test (CCET) has gained popularity in patients with chronic 
obstructive pulmonary disease to monitor the effectiveness of several pharmacological and non-
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pharmacological interventions. For instance, Ong et al. in a comparison of three exercise-testing 
protocols to measure intervention-related improvements after a pulmonary rehabilitation 
programme, found a 16% increase in the 6MWT, a 53% in VO2peak, a 30% in the Wpeak and a 144% 
improvement in the CCET (Ong et al., 2004). Porszasz et al. also reported a statistically significant 
increase in endurance time of 11.6±8.1 minutes after seven weeks of high-intensity endurance 
training in patients with COPD (Porszasz et al., 2005). Interestingly, the authors did not find any 
improvement in the VO2peak. In a similar study, Laviolette et al. also found an improvement of 198 
seconds in the endurance time measured with the CCET at 80% of the Wpeak (Laviolette et al., 
2008) and more importantly, the observed that the effects were maintained up to one year after the 
rehabilitation. Finally, the study by Coats et al. in patients awaiting lung cancer surgery found no 
change in VO2peak after a four-week home-based exercise programme but a significant 
improvement in endurance time of 60% (Coats V, 2013). In our study, we found a significant 
increase in endurance time of 369.6±197 seconds measured at 80% of the Wpeak which corresponds 
to an increment of 123% comparing to baseline. Notably, the improvement was sustained after the 
surgery although to a lesser extent (+137.3±268.2 seconds at T1 and +226±269.4 seconds at T2). 
One limitation of the test is that the magnitude of the improvement is strongly influenced by the 
power/duration relationship properties which dictates that the increments seen in endurance time 
are influenced by the baseline pre-treatment value (Borel et al., 2013, Whipp and Ward, 2009). In 
our study, patients in the rehabilitation group performed the CCET at a median workload of 54W 
while patients in the control group did the same at 60W (p =.021). This finding can explain why 
patients in the rehabilitation group experienced such a dramatic improvement in endurance time 
but it cannot justify the tendency observed in both groups, with the control group showing a 
progressive functional decline contrary to the rehabilitation group who improved their exercise 
capacity and sustained it for the total duration of the follow-up.  
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Resistance training has become an essential component of pulmonary rehabilitation given 
that aerobic training is less effective to improve muscle mass, muscle strength and muscle 
endurance than strength training. In cancer patients, resistance training can help to prevent cancer-
cachexia and maintain patient’s autonomy and self-care. The results drawn by a systematic review 
and meta-analysis in cancer survivors demonstrated that resistance training effectively increases 
lower and upper limb muscle strength (SMD = 14.57; 95% CI: 4.78-9.03, p <.001) and reduces 
fatigue (SMD: 1.86; 95% CI: -0.03 to -3.75; p =0.05) (Strasser et al., 2013). In the prehabilitation 
studies conducted in lung cancer patients, strength training was associated with improvements in 
functional capacity (6MWT) and HRQoL (Li et al., 2013, Mujovic et al., 2014). Although 
resistance training is more commonly delivered using free weights or weight machines, the use of 
less expensive and sophisticated equipment is gaining popularity. New evidence has arisen 
supporting the effectiveness of low-equipment pulmonary rehabilitation programmes for people 
with chronic respiratory diseases in the absence of traditional high-tech equipment (Alison and 
McKeough, 2014). One example of low-tech equipment is elastic bands, which are an affordable, 
practical and versatile way of improving muscle strength in sedentary population (Colado and 
Triplett, 2008, Colado et al., 2009). They have also demonstrated to be safe and effective to 
improve muscle strength, functional fitness and functional capacity in older frail people (Fahlman 
et al., 2011, Oesen et al., 2015). In patients with chronic respiratory diseases, the use of elastic 
bands is also expanding. In COPD, a minimally supervised training programme using elastic bands 
three times per week for 12 weeks significantly improved knee extensor strength by 4.9kg (95% 
CI: 1.1 – 8.7) (O'Shea et al., 2007). In another study comparing elastic tubing resistance training 
versus conventional training the authors found significant improvements in the distance covered 
with the 6MWT in both groups but to a larger extent in the elastic tubing group (p <.05). Muscle 
strength and HRQoL also improved in both groups but the differences were not statistically 
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significant (Ramos et al., 2014). In the same line, Nyberg et al. demonstrated that a low-load, high-
repetition resistance training using elastic bands in COPD patients significantly improved 6MWT 
by 34 meters in comparison to a control group (Nyberg et al., 2014). In the lung cancer setting, 
Mujovic et al. also found a significant improvement in functional capacity (6MWT increased 53 
meters by average) after a short, intense preoperative pulmonary rehabilitation programme 
including breathing exercises plus resistance training with elastic bands (Mujovic et al., 2015). 
Importantly, the improvement in the 6MWT was also statistically significant in comparison to a 
control group who did not exercise. In our study, both the Arm Curl Test and the 30’s Chair to Sit 
Test were significantly improved after the training. Although the improvements were small in 
magnitude specially if compared to longer interventions (Peddle-McIntyre et al., 2012), they were 
sustained over the three-month follow-up period. Altogether, these findings support the use of 
elastic bands as an effective alternative to traditional weight machines and free weights to improve 
muscle strength and functional capacity both in healthy people and in frail individuals with chronic 
respiratory diseases. 
As discussed in previous chapters, HRQoL is becoming more relevant in the 
interdisciplinary management of individuals with lung cancer given its role in predicting long-term 
outcomes in this population. In an observational longitudinal study, Pompili et al. found that the 
physical component of the HRQoL was strongly associated with overall and cancer-specific 
survival in patients with stage I NSCLC (Pompili et al., 2013). Particularly, a PCS < 50 was 
associated with a hazard ratio of 2.3 for overall survival (95% CI: 1.1-4.4; p =.01). This finding is 
of great interest since the PCS is another modifiable factor in the perioperative period of lung 
resection surgery. However, several systematic reviews have highlighted the lack of consistency 
across studies when assessing the effectiveness of exercise-based interventions to improve HRQoL 
(Granger et al., 2011, Rodriguez-Larrad et al., 2014, Singh et al., 2013, Pouwels et al., 2015). In 
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contrast, our results demonstrate that a PPRP focused on endurance and strength training can 
significantly improve the PCS prior to lung resection surgery which was sustained at three months 
postoperatively. Similar results were also reported in another randomized controlled trial conducted 
in 249 patients undergoing CABG (Arthur et al., 2000). After 10 weeks of PR, patients in the 
rehabilitation group improved their PCS from baseline to pre-surgery in +1.55±7.48 points. 
Furthermore, the improvement was sustained throughout the first six post-operative months. In our 
investigation, we observed a significant increase of almost five points in the PCS which was also 
maintained at three months postoperatively. These results are proof of principle that prehabilitation 
can effectively improve PCS in a lung cancer population. 
This study is, to our knowledge, the first to examine the effects of a PPRP on the post-
operative outcomes after VATS for lung cancer. Only one previous study has evaluated a 
preoperative exercise-based intervention in patients undergoing VATS (Coats V, 2013) but this 
was a single-arm study and the patients were not followed up after the surgery thus the effects of 
the intervention in the post-operative period remain unknown in this surgical context. It is well-
known that functional capacity is reduced after lung resection surgery but it appears to return to 
baseline during the first weeks. As seen in chapter three, the type of surgery performed including 
the extent of resection and the surgical approach can notably influence the pattern of recovery. For 
instance, Nomori et al. found that immediately after thoracotomy, the 6MWT was significantly 
reduced the first week but substantially improved by the second week reaching 93% of the baseline 
value (Nomori et al., 2004). In another study, however, the same authors found that patients 
undergoing VATS experienced only a 7% decrease in the 6MWT comparing to a 35% decrease in 
those undergoing thoracotomy (Nomori et al., 2003). Ueda et al. observed that in patients 
undergoing VATS, the 6MWT was ≥80% of the preoperative value only three days after the surgery 
(Ueda et al., 2006). These results are consistent with our investigation, since we observed that three 
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weeks after surgery the 6MWT was recovered by 94.6% and 97.6% of the baseline values in the 
control and rehabilitation group respectively. Interestingly, at three months, only patients in the 
rehabilitation group had improved their 6MWT and were slightly over the baseline, but the change 
was not statistically significant.  
In addition to better preserve functional capacity after surgery, VATS has demonstrated to 
significantly reduce post-operative length of stay and post-operative pulmonary complications in 
several cohort studies and meta-analyses (Park et al., 2007, Cattaneo et al., 2008, Flores et al., 2009, 
Scott et al., 2010, Ilonen et al., 2011, Paul et al., 2013, Zhang et al., 2013, Cheng et al., 2007). In 
chapter four, we concluded that a preoperative exercise-based programme reduced post-operative 
length of stay (MD = -4.83; 95% CI: -5.9 to -3.76) and the risk for post-operative complications 
(RR = 0.45; 95% CI: 0.28, 0.74). However, the majority of the patients in those studies were 
operated using an open approach so it is not known whether such interventions could yield the 
same results in patients undergoing VATS. In our study, we could not find any significant 
differences in post-operative LOS or post-operative complications between groups. The median 
LOS was very low (two and three days in the rehabilitation and control groups respectively) even 
when comparing to other series (Nwogu et al., 2015, Cai et al., 2015, Kuritzky et al., 2015). In 
addition, any patient was diagnosed with a PPC according to the MGS, although up to 60% of the 
patients presented at least one isolated complication. The most common were persistent air leak 
with or without associated pneumothorax and atelectasis but none of the cases required further 
treatment and they were managed conservatively. Contrary to what we could have expected, 
patients in the rehabilitation group were more likely to be diagnosed with persistent air leak, 
pneumothorax, desaturation or chest infection. However, if we consider the baseline status of the 
patients, those in the rehabilitation group had worse pulmonary function and higher BMI which 
CHAPTER SIX: Effectiveness of a PPRP in patients with lung cancer undergoing VATS 
222 | P a g e  
 
 
 
can explain these findings to some extent. Also, both persistent air leak and pneumothoraxes are 
not particularly preventable from a physiotherapy point of view.  
6.7 LIMITATIONS 
Our study has important limitations that need to be discussed. First of all, we included 
patients with suspected or confirmed NSCLC, which resulted in some patients being diagnosed of 
lung metastases instead of lung cancer. Even though, any tumour found in the lungs can affect the 
oxygen cascade irrespectively of the origin of the tumour, so from a functional point of view those 
patients with lung metastases who undergo lung resection surgery can equally experience 
functional and psychological declines after surgery and thus could benefit from a perioperative 
rehabilitation intervention. Second of all, in order to guarantee an optimal recruitment rate, the 
inclusion criteria was broad resulting in a heterogeneous sample, especially in terms of pulmonary 
function (FEV1 at baseline range from 41 to 131% of predicted). Also, despite the randomization, 
patients in the rehabilitation group had lower pulmonary function and a higher BMI. This resulted 
in more patients in the rehabilitation group undergoing a sublobar resection than those in the control 
group, which can obviously determine the pattern of recovery after the surgery. However, the 
differences were not statistically significant and a univariate general linear model showed no 
interaction with the extent of the resection thus we don’t believe that this factor have had a major 
impact in the results obtained. Finally, we need to consider the number of dropouts during the 
investigation and the potential implications of this. Of the 20 patients randomized to the 
intervention group only 50% completed the study. However, this low completion rate had little to 
do with the PPRP and more with other perioperative features (changes in surgery, tumour found 
unresectable at the time of surgery or further testing showing no malignancy). In fact, adherence 
rate to the protocol was very good and only two participants discontinued the intervention by choice 
therefore we consider that the programme was well-accepted and tolerated by the patients. 
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6.7 CONCLUSIONS 
The results of this randomized single-blind controlled trial show that a preoperative, 
supervised pulmonary rehabilitation programme consisted of endurance and resistance training 
plus breathing exercises effectively improved exercise capacity, muscle strength and the physical 
component of HRQoL in patients awaiting VATS. Furthermore, the results found both at three 
weeks postoperatively but especially at three months suggest that the preoperative intervention 
enhanced post-operative recovery by preserving functional and exercise capacity and HRQoL to a 
greater extent than the standard care. We encourage researchers to undertake future randomized 
controlled trials to evaluate the effects of such interventions on the post-operative outcomes in 
high-risk surgical patients undergoing VATS.  
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CHAPTER SEVEN: CONCLUSIONS AND FUTURE DIRECTIONS 
 7.1 SUMMARY OF THE THESIS 
 The studies included in this thesis were designed to assess whether a prehabilitation 
exercise-based intervention for patients undergoing VATS for lung cancer was feasible, safe, well-
tolerated and effective to enhance physical functioning and prevent deterioration after surgery. As 
a whole, or findings suggest that: 
 There is enough evidence to asseverate that patients after lung cancer surgery exhibit 
significant deterioration in exercise capacity and exercise which affects self-care and 
HRQoL. 
 Prehabilitation of patients undergoing thoracic surgery by means of thoracotomy enhances 
pulmonary function and accelerates post-operative recovery. Furthermore, it is possible that 
a preoperative exercise-based intervention is more effective than conventional post-
operative physiotherapy alone to reduce post-operative pulmonary complications. 
 A pulmonary rehabilitation programme in the preoperative period of video-assisted thoracic 
surgery for lung cancer is feasible, well-tolerated and can be achieved without any further 
delay in the therapeutic management. Furthermore, the intervention can enhance the 
preoperative status by improving exercise capacity, functional capacity, muscle strength 
and the physical component of HRQoL 
 In comparison to the standard care, a preoperative pulmonary rehabilitation programme can 
prevent functional deterioration after surgery and even increase physical performance 
comparing to baseline. 
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7.2 FUTURE DIRECTIONS 
There have been numerous advances in the treatment of patients with lung cancer in recent 
years. For example, low-dose CT screening has increased the number of patients diagnosed with 
early disease; chemo- and radiotherapy regimes have been significantly optimized and the surgical 
management has experienced an outstanding improvement thanks to the development of minimally 
invasive approaches such as video-assisted surgery and robotic-assisted surgery. However, 
comparing with other cancer types, the evidence regarding exercise and physical activity in the 
context of lung cancer is scarce and somehow inconsistent. Exercise intolerance is a reality in 
cancer patients and profoundly affects their functional capacity and quality of life. There is a large 
body of knowledge on the limitations in exercise performance in healthy individuals and people 
with chronic obstructive respiratory diseases. However, as we have established throughout this 
thesis, the underlying mechanisms for the limitation of exercise capacity in patients with cancer is 
barely known and should be addressed in further investigations (Jones et al., 2009b). Exercise and 
physical activity both pre and post-diagnosis have shown to decrease the risk of cancer and improve 
disease-free survival and overall survival in several cancer types (Meyerhardt et al., 2006, Chen et 
al., 2011b, Tardon et al., 2005, Sun et al., 2012, Je et al., 2013). Yet, there is insufficient data to 
allow for formal recommendations in this population. According to a recent Cochrane systematic 
review, it appears that moderate and vigorous exercise during cancer treatment provides greater 
improvements in HRQoL, physical functioning, anxiety, fatigue and sleep disturbances than light 
exercise (Cavalheri et al., 2014). It has also been reported in another meta-analysis that an inverse 
non-linear dose-response exists between physical activity and cancer mortality (Li et al., 2015). In 
cancer survivors, engaging in 15 Metabolic Equivalents of Task (METs) per week can reduce the 
risk of cancer death by 27% (Li et al., 2015). The best modality of exercise in this population is 
also not established. In a retrospective study including 2,863 cancer survivors, physical activity 
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was not associated with a lower risk of all-cause mortality but those engaging in resistance training 
lowered their risk of mortality by 33% (95% CI: 0.45-0.99) even after adjusting for physical activity 
levels and other confounders (Hardee et al., 2014).  
In the perioperative context of lung cancer, we have shown that preoperative exercise 
training can reduce post-operative complications and accelerate post-operative recovery after 
thoracotomy. However, there is no evidence at the moment that similar results would be achieved 
in patients undergoing minimally invasive procedures. Given the remarkable results obtained with 
this technique in the post-operative outcomes, it seems unlikely that improving the preoperative 
status of the patients would provide any further benefit in this population. Notwithstanding, with 
the progressive ageing of the lung cancer patient and the clinical and co-morbid diseases associated 
with smoking, the role of preoperative exercise training could be justified to enhance post-operative 
recovery and prevent functional decline especially in high-risk surgical patients.  
In light of this, the future of exercise in the context of lung cancer is linked to uncover the 
underlying mechanisms of exercise limitation to determine the optimal modality, frequency, 
intensity and timing as well as analysing its role in increasing disease-free and overall survival.        
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SUPPLEMENTAL FILE NO.3 – INFORMATION SHEET AND INFORMED 
CONSENT 
HOJA DE INFORMACIÓN AL PARTICIPANTE EN UN ENSAYO CLÍNICO SIN 
MEDICAMENTOS NI PRODUCTOS SANITARIOS 
 
TÍTULO: 
Efectividad de un programa de rehabilitación pulmonar preoperatorio sobre la tolerancia al 
esfuerzo y la calidad de vida en pacientes sometidos a videocirugía. 
 
CÓDIGO: RSG-RPC-2011  
 
INVESTIGADOR/A PRINCIPAL: 
Esther Giménez Moolhyzen   
Diplomada en Fisioterapia. Experta en Fisioterapia Respiratoria por la UDC 
Servicio de Cirugía Torácica. Hospital Universitario de A Coruña. As Xubias, nº 84 - 15006 A 
Coruña 
Teléfono de contacto: 981178286 
E-mail: emoolhui@hotmail.com 
 
Este documento tiene por objetivo ofrecerle información sobre un estudio de investigación 
de tipo experimental (ensayo clínico) en el que se le invita a participar. Este estudio se realizará en 
el Hospital Clínico Universitario de A Coruña (CHUAC) y ha sido aprobado por el Comité Ético 
de Investigación Clínica de Galicia. 
Si decide participar en el mismo, debe recibir información personalizada del investigador, 
leer antes este documento y realizar todas las preguntas que necesite para comprender los detalles 
sobre el mismo. Si lo desea, puede llevarse consigo el documento, consultarlo con otras personas 
y tomarse el tiempo necesario para decidir si participa o no. 
La participación en este estudio es completamente voluntaria. Usted puede decidir no 
participar o, si acepta, cambiar de parecer retirando su consentimiento en cualquier momento sin 
que sea necesario dar ningún tipo de explicación. Le aseguramos que su decisión no afectará a la 
relación con su clínico ni a la asistencia sanitaria a la que usted tiene derecho. 
¿Cuál es el propósito del estudio? 
Este estudio se propone evaluar la efectividad de una intervención de fisioterapia en cuanto 
a mejorar la condición física y funcional así como la calidad de vida percibida en los pacientes que 
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se encuentran en lista de espera para resección pulmonar. El objetivo final es conocer si esta mejoría 
alcanzada durante el preoperatorio se traduce en una mejor recuperación postoperatoria, 
incrementando la tolerancia al esfuerzo y su capacidad para realizar las tareas básicas diarias de 
forma independiente. 
¿Cómo se llevará a cabo la investigación? 
Durante el periodo que dure el estudio, todos los pacientes que cumplan los criterios de 
inclusión y presten su consentimiento serán distribuidos aleatoriamente en dos grupos: un grupo 
experimental que acudirá a las sesiones de rehabilitación pulmonar en el CHUAC, y un grupo 
control que cumplirá con las instrucciones facilitadas por su facultativo. 
Este es un estudio unicéntrico, que se llevará a cabo en la Sala de Rehabilitación Pulmonar 
del Hospital Clínico Universitario de A Coruña a lo largo de 18 meses. 
El programa de Rehabilitación Pulmonar será dirigido por una de las investigadoras, 
mientras que las mediciones y las pruebas funcionales serán realizadas por una persona diferente 
ajena al grupo asignado al paciente, para que evitar que puedan influir en la interpretación de los 
resultados posibles expectativas previas de los investigadores. 
¿Por qué me ofrecen participar? 
La selección de las personas invitadas a participar en este estudio depende de unos criterios 
que están descritos en el protocolo de investigación. Estos criterios sirven para seleccionar a la 
población en la que se responderá al interrogante planteado en la investigación. Se le invita a 
participar en el estudio porque usted cumple con esos criterios. 
En este estudio se espera una participación de un total de 22 personas, 11 por cada grupo 
que se forma. 
¿En qué consiste la participación? 
Los pacientes serán asignados al azar a uno de los dos grupos que se formarán para el 
estudio, teniendo un 50% de posibilidades de ser incluidos en uno o en otro. El grupo experimental, 
acudirá a la sala de Rehabilitación Pulmonar del CHUAC entre dos y cuatro días a la semana (según 
disponibilidad y lista de espera), durante las semanas previas a la cirugía. La duración aproximada 
de cada sesión de tratamiento es de 1 hora y en ella el paciente deberá realizar una serie de ejercicios 
de fuerza y de resistencia así como técnicas de fisioterapia respiratoria en caso de ser necesario. 
Así mismo, debe saber que se le solicitará información de carácter personal sobre sus datos 
antropométricos y clínicos y deberá completar algunos test físicos para evaluar sus valores de 
resistencia, función pulmonar, capacidad funcional y calidad de vida. 
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El grupo control continuará con las instrucciones facilitadas por su facultativo y solamente 
deberá facilitarnos sus datos demográficos y clínicos así como completar las mediciones sobre los 
aspectos a evaluar con el estudio. 
Tras la cirugía, todos los pacientes deberán acudir a la sala de Rehabilitación Pulmonar para 
poder repetir las mediciones indicadas anteriormente. Finalmente, serán contactados para una 
última valoración a los tres meses de recibir el alta hospitalaria. 
La investigadora principal o alguno de los miembros del equipo podrán decidir finalizar el 
estudio antes de lo previsto o interrumpir su participación en el mismo por aparición de nueva 
información relevante, por motivos de seguridad, o por incumplimiento de los procedimientos del 
estudio. 
Recuerde que toda la información que nos facilite se haya protegida por la Ley Orgánica 
15/1999, de 13 de diciembre, de protección de datos de carácter personal, que todos los 
investigadores nos comprometemos a cumplir y respetar. 
¿Tiene algún riesgo la participación? 
Los riesgos asociados a un Prográmame de Rehabilitación Pulmonar son muy bajos. Estos 
programas han sido diseñados para ser aplicados específicamente en pacientes con patologías 
respiratorias crónicas, teniendo en cuenta sus características fisiopatológicas especiales y sin 
haberse desencadenado en ningún caso efectos adversos graves.  
Debido a que el perfil de los pacientes participantes en el estudio puede incluir la presencia 
de enfermedades como hipertensión arterial, diabetes mellitus, Enfermedad Pulmonar Obstructiva 
Crónica o patologías cardiovasculares, durante la realización de los ejercicios, se monitorizará la 
frecuencia cardíaca, saturación de oxígeno y la tensión arterial, con el objetivo de prevenir 
cualquier tipo de episodio de mayor gravedad que pudiera producirse.  
En cualquier caso, cualquier acontecimiento considerado de gravedad será notificado al 
Comité de Ética de Investigación Clínica de Galicia.  
¿Obtendré algún beneficio por participar? 
No podemos asegurarle que exista un beneficio directo por participar en el estudio, pero en 
base a los resultados obtenidos con estos programas en otras patologías respiratorias, consideramos 
que existe una gran posibilidad de lograr la mejoría de los aspectos señalados al inicio y por lo 
tanto, creemos que su estado físico y funcional mejorará tras las sesiones de rehabilitación 
recibidas. 
¿Recibiré la información que se obtenga del estudio? 
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Si usted lo desea, se le facilitará un resumen de los resultados del estudio. También podrá 
recibir los resultados de las pruebas que se le practiquen si así lo solicita.  
¿Se publicarán los resultados de este estudio? 
Los resultados serán presentados en publicaciones científicas para su difusión, pero en 
ningún caso se transmitirá dato alguno que pueda llevar a la identificación de los participantes 
¿Cómo se protegerá la confidencialidad de mis datos? 
El tratamiento, comunicación y cesión de sus datos se hará conforme a lo dispuesto en la 
Ley Orgánica 15/1999, de 13 de diciembre, de protección de datos de carácter personal y por su 
regulación (RD 1720/2007). En todo momento, usted podrá acceder a sus datos, corregirlos o 
cancelarlos. 
Sus datos llevarán un código que no permite identificarlos directamente. La relación entre 
los códigos y su identidad será custodiada por el investigador. Sólo el equipo investigador y las 
autoridades sanitarias que tienen el deber de guardar la confidencialidad, tendrán acceso a todos 
los datos recogidos por el estudio. En situaciones de urgencia médica o requerimiento legal, las 
personas indicadas podrán consultarlos. Se podrá transmitir a terceros información que no pueda 
ser identificada, exclusivamente para los fines del estudio. En el caso de que alguna información 
sea transmitida a otros países, se realizará con un nivel de protección de los datos equivalente, 
como mínimo, al exigido por la normativa de nuestro país.  
Su médico especialista y médico de cabecera pueden, si lo desea, recibir información sobre 
su participación en este estudio 
Si usted decide interrumpir la participación, puede ser importante seguir utilizando los datos 
recogidos hasta ese momento para disponer de mayor información posible sobre la seguridad y la 
efectividad de la técnica investigada. Llegada esta circunstancia, se le pedirá autorización para 
utilizar dichos datos. 
¿Qué pasará con los datos obtenidos? 
Los datos obtenidos serán guardados de forma codificada, que quiere decir que poseen un 
código que se puede relacionar, mediante una información con el donante.  Esta información está 
a cargo del investigador principal y sólo pueden acceder a ella los miembros del equipo y las 
autoridades sanitarias en el ejercicio de sus funciones. 
¿Qué ocurrirá si hay alguna consecuencia negativa de la participación? 
Como ya se mencionó con anterioridad, los riesgos asociados a un programa de 
Rehabilitación Pulmonar son muy bajos y no se han descrito efectos adversos graves. Se trata por 
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lo tanto de una intervención segura, supervisada en todo caso por personal especializado y que 
cuentan con una monitorización continua para evitar posibles episodios adversos.  
¿Quién me puede proporcionar más información? 
Puede contactar con uno de los investigadores colaboradores del proyecto a través del 
correo electrónico (raquel.sebio@udc.es) o en el siguiente número de teléfono: 668860237. Muchas 
gracias por su participación. 
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DOCUMENTO DE CONSENTIMENTO INFORMADO PARA EL PARTICIPANTE EN UN 
ENSAYO CLÍNICO SIN MEDICAMENTOS NI PRODUCTOS SANITARIOS  
 
TÍTULO:  
Efectividad de un programmea de rehabilitación pulmonar preoperatorio sobre la tolerancia al 
esfuerzo y la calidad de vida en pacientes sometidos a videocirugía. 
 
CÓDIGO: RSG-RPC-2011 
Yo,  (nombre y apellidos) ………………………………………… 
 He leído la hoja de información al participante del estudio que se me ha entregado 
anteriormente, he podido hablar con Raquel Sebio García del estudio y hacer todas las 
preguntas sobre el estudio necesarias para comprender las condiciones en las que se realiza 
y considero que he recibido suficiente información sobre el estudio.  
 Comprendo que mi participación es voluntaria, y que puedo retirarme del estudio 
cuando lo desee, sin tener que dar explicaciones y sin que esto repercuta en mis cuidados 
médicos. 
 Accedo a que se utilicen mis datos en las condiciones detalladas en la hoja de 
información al participante.  
 Presto libremente mi conformidad para participar en el estudio. 
En canto a los resultados de las pruebas realizadas, yo: 
DESEO conocer los resultados de mis pruebas 
NO DESEO conocer os resultados de mis pruebas 
 
El/la participante,    El/la investigador/a, 
     
 
Fdo.:      Fdo.:  
Fecha:      Fecha:  
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SUPPLEMENTAL FILE NO.4 – TRAINING LOG TEMPLATE 
CODIGO: 
SESIÓN: 
FECHA: 
A. ENTRENAMIENTO DE FUERZA – RESISTENCIA: 
EJERCICIO COLOR THERA BAND  NÚMERO DE 
REPETICIONES 
NÚMERO DE 
SERIES 
Abducción Hombro    
Flexión Hombro    
Flexión de codo    
Chest Press    
Remo    
Lateral Pull Down    
Empuje Pierna    
Sentadilla    
Set Up    
Gemelos    
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B. PROGRAMMEA DE ENTRENAMIENTO AL ESFUERZO: 
 PMT (W): 
 INTENSIDAD BASE (W): 
 INTENSIDAD PICO (W): 
 FRECUENCIA CARDÍACA MÁX. TEÓRICA:  
 Nº DE PICOS: 7 
TIEMPO WATT SATURACIÓN FC 
1- 5’ 30% PMT   
5 –- 6’ 80% PMT   
6 – 10’  50% PMT   
10 – 11’ 80% PMT   
11 – 15’ 50% PMT   
15 – 16’ 80% PMT   
16 – 20’ 50% PMT   
20 – 21’ 80% PMT   
21 – 25’ 50% PMT   
25 – 26’ 80% PMT   
26 – 30’ 50% PMT   
30 – 31’ 80% PMT   
31 – 35’ 50% PMT   
35 – 36’ 80% PMT   
36 – 40’ 30% PMT   
 
SENSACIÓN DE DISNEA AL INICIO (Escala Borg Modificada): 
SENSACIÓN DE DISNEA MÁXIMA ALCANZADA: 
SENSACIÓN DE FATIGA EN MMII (Escala Borg Modificada): 
FATIGA ALCANZADA EN MIEMBROS INFERIORES:   
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SUPPLEMENTAL FILE no.5 – DATA COLLECTION SHEET 
CODIGO DEL SUJETO: 
SEXO: 
EDAD: 
PESO: 
TALLA: 
LUGAR DE RESIDENCIA: 
ANTECEDENTES PERSONALES 
HISTORIA DE TABAQUISMO  SÍ  NO  EXFUMADOR 
Nº PAQUETES/AÑO  
ALCOHOLISMO    SÍ  NO    
OTRAS PATOLOGÍAS 
ENFERMEDAD CARDIOVAS  NO  SI 
EPOC     NO  SI  GRADO1 
ENFERMEDAD RESPIRATORIA NO  SÍ    
INSUFICIENCIA RENAL  NO  SI    
DIABETES    NO  SI    
CÁNCER    NO  SÍ  
COLINET CO-MORBIDITY SCORE:  
DATOS CLÍNICOS 
DIAGNÓSTICO PRE-OPERATORIO: 
SÍNTOMAS ASOCIADOS 
 TOS     SÍ  NO 
 DISNEA    SÍ   NO GRADO2 
 ANOREXIA    SÍ  NO 
 ASTENIA    SÍ  NO 
 EXPECTORACIÓN   SÍ  NO ASPECTO  
                                                          
1 Según Escala GOLD 2011 
2 Según Medical Research Council 
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 OTROS:  
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VALORACIÓN 
ESPIROMETRÍA 
 
 VFC FEV1 FEV1/VFC 
BASAL    
POST-QX    
  
TEST DE CALIDAD DE VIDA 
 BASAL PRE-QX POST-QX SEGUIMIENTO 
FECHA DE 
CUMPLIMENTACIÓN 
    
 
PRUEBA DE RESISTENCIA MÁXIMA EN CICLOERGÓMETRO 
Fecha: 
Potencia Máxima Teórica:   Frecuencia Cardíaca Máxima Teórica: 
Tiempo Potencia Sat FC  Borg 
Disnea 
Borg Fatiga TA 
Basal       
1’       
2’       
3’       
4’       
5’       
6’       
7’       
8’       
9’       
10’       
11’       
12’       
Rec 1’       
Rec 2’       
Rec 3’       
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Motivo de parada: 
PRUEBA DE 6 MINUTOS MARCHA 
 T0(1) 
Fecha: 
T0(2) 
Fecha: 
T2 
Fecha: 
T3 
Fecha: 
Sat O2 Basal     
Sat O2 Final     
FC Basal     
FC Final     
Disnea Basal     
Disnea Final     
Fatiga 
Muscular Basal 
    
Fatiga 
Muscular Final 
    
Distancia 
recorrida (m) 
    
Número de 
Paradas 
    
Tiempo de 
Recuperación 
    
Val Ref3     
 
TEST DE APTITUD FÍSICA 
 Val Ref4 T0 T1 T2 T3 
30’s Arm 
Curl  
     
30’s Chair to 
Sit 
     
                                                          
3 P.Enright, 1995 Reference Equations 
4 Rikli and Jones, 2001(Heyward 2008, pp. 135-6) 
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PRUEBA DE RESISTENCIA SUBMÁXIMA 
 T0 
Fecha: 
T1 
Fecha: 
T2 
Fecha: 
T3 
Fecha: 
FC Basal     
FC Final     
Saturación de 
O2 Basal 
    
Saturación de 
O2 Final 
    
Potencia de 
Prueba (80% 
PMT) 
    
Tiempo 
Mantenido 
    
Disnea Final     
Fatiga MMII 
Final 
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INFORME QUIRÚRGICO 
FECHA INGRESO: 
FECHA DE LA CIRUGÍA: 
EQUIPO QUIRÚRGICO: 
PROCEDIMIENTO: 
COMPLICACIONES POSTOPERATORIAS   
 VENTILACIÓN MECÁCICA > 48H  SÍ  NO 
 DRENAJE TORÁCICO  > 5 DÍAS  SI  NO  
 ATELECTASIA    SÍ  NO  
 NEUMONÍA     SÍ  NO 
 NEUMOTORAX    SI  NO 
 DERRAME PLEURAL   SI  NO   
 INFECCION RESPIRATORIA/ 
INFILTRADOS     SI  NO 
 CAMBIOS EN EL ESPUTO   SI  NO 
 ANALISIS DE ESPUTO   SI  NO 
 FIBRILACIÓN ATRIAL   SI  NO 
 READMISION REA    SI  NO 
 DESATURACIÓN    SI  NO 
 LEUCOCITOSIS    SI  NO 
NUMERO DE SESIONES DE FTR: 
ALTA HOSPITALARIA: 
DIAGNOSTICO POSTOPERATORIO: 
ADYUVANCIA:     SI  NO 
 
 
  
SUPPLEMENTAL FILES 
270 | P a g e  
 
 
 
SUPPLEMENTAL FILE no.6 – SHORT FORM 36 HEALTH SURVEY (Spanish 
version) 
 
CODIGO DEL PACIENTE: 
FECHA DE CUMPLIMENTACION:  
 
 
 
 
 
 
 
 
Institut Municipal d´Investigació Mèdica (IMIM-IMAS) 
Unidad de Investigación en Servicios Sanitarios 
C/ Doctor Aiguader, 80 E-8003 Barcelona 
Tel. (+34) 93 225 75 53, Fax (+34) 93 221 40 02 
www.imim.es 
 
 
 
 
 
 
 
 
 
 
 
Cuestionario de Salud SF-36 
(versión 2) 
 
 
 
Su Salud y Bienestar 
 
Por favor conteste las siguientes preguntas. Algunas preguntas pueden 
parecerse a otras pero cada una es diferente. 
 
Tómese el tiempo necesario para leer cada pregunta, y marque con una X la 
casilla que mejor describa su respuesta. 
 
¡Gracias por contestar a estas preguntas! 
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1. En general, usted diría que su salud es: 
 1   Excelente 
 2   Muy buena 
 3   Buena 
 4   Regular 
 5   Mala 
2. ¿Cómo diría que es su salud actual, comparada con la de hace un año? 
 1   Mucho mejor ahora que hace un año 
 2   Algo mejor ahora que hace un año 
 3   Más o menos igual que hace un año 
 4   Algo peor ahora que hace un año 
 5   Mucho peor ahora que hace un año 
3. Las siguientes preguntas se refieren a actividades o cosas que usted podría hacer en un día normal. Su salud actual, 
¿le limita para hacer  esas actividades o cosas? Si es así, ¿cuánto? 
a. Esfuerzos intensos, tales como correr, levantar objetos pesados, o participar en deportes agotadores. 
 1   Sí, me limita mucho 
 2   Sí, me limita un poco 
 3   No, no me limita nada 
b. Esfuerzos moderados, como mover una mesa, pasar la aspiradora, jugar a los bolos o caminar más de 1 hora. 
 1   Sí, me limita mucho 
 2   Sí, me limita un poco 
 3   No, no me limita nada 
c. Coger o llevar la bolsa de la compra. 
 1   Sí, me limita mucho 
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 2   Sí, me limita un poco 
 3   No, no me limita nada 
d. Subir varios pisos por la escalera. 
 1   Sí, me limita mucho 
 2   Sí, me limita un poco 
 3   No, no me limita nada 
e. Subir un sólo piso por la escalera. 
 1   Sí, me limita mucho 
 2   Sí, me limita un poco 
 3   No, no me limita nada 
f. Agacharse o arrodillarse. 
 1   Sí, me limita mucho 
 2   Sí, me limita un poco 
 3   No, no me limita nada 
g. Caminar un kilómetro o más. 
 1   Sí, me limita mucho 
 2   Sí, me limita un poco 
 3   No, no me limita nada 
h. Caminar varios centenares de metros. 
 1   Sí, me limita mucho 
 2   Sí, me limita un poco 
 3   No, no me limita nada 
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i. Caminar unos 100 metros. 
 1   Sí, me limita mucho 
 2   Sí, me limita un poco 
 3   No, no me limita nada 
j. Bañarse o vestirse por sí mismo. 
 1   Sí, me limita mucho 
 2   Sí, me limita un poco 
 3   No, no me limita nada 
4. Durante las 4 últimas semanas, ¿con qué frecuencia ha tenido alguno de los siguientes problemas en su trabajo o en 
sus actividades cotidianas, a causa de su salud física? 
a. ¿Tuvo que reducir el tiempo dedicado al trabajo o a sus actividades cotidianas? 
 1   Siempre 
 2   Casi siempre 
 3  Algunas veces 
 4  Sólo alguna vez 
 5  Nunca 
b. ¿Hizo menos  de lo que hubiera querido hacer? 
 1   Siempre 
 2   Casi siempre 
 3  Algunas veces 
 4  Sólo alguna vez 
 5  Nunca 
c. ¿Tuvo que dejar de hacer algunas tareas en su  trabajo o en sus actividades cotidianas? 
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 1   Siempre 
 2   Casi siempre 
 3  Algunas veces 
 4  Sólo alguna vez 
 5  Nunca 
d. ¿Tuvo dificultad para hacer su trabajo o sus actividades cotidianas (por ejemplo, le costó más de lo normal)? 
 1   Siempre 
 2   Casi siempre 
 3  Algunas veces 
 4  Sólo alguna vez 
 5  Nunca 
5.  Durante las 4 últimas semanas, ¿con qué frecuencia ha tenido alguno de los siguientes problemas en su trabajo o 
en sus actividades cotidianas, a causa de algún problema emocional (como estar triste, deprimido o nervioso? 
a. ¿Tuvo que reducir el tiempo dedicado al trabajo o a sus actividades cotidianas por algún problema emocional? 
 1   Siempre 
 2   Casi siempre 
 3  Algunas veces 
 4  Sólo alguna vez 
 5  Nunca 
b. ¿Hizo menos de lo que hubiera querido hacer por algún problema emocional? 
 1   Siempre 
 2   Casi siempre 
 3  Algunas veces 
 4  Sólo alguna vez 
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 5  Nunca 
c. ¿Hizo su trabajo o sus actividades cotidianas menos cuidadosamente que de costumbre, por algún problema 
emocional? 
 1   Siempre 
 2   Casi siempre 
 3  Algunas veces 
 4  Sólo alguna vez 
 5  Nunca 
6. Durante las 4 últimas semanas, ¿hasta qué punto su salud física o los problemas emocionales han dificultado sus 
actividades sociales habituales con la familia, los amigos, los vecinos u otras personas? 
 1   Nada 
 2   Un poco 
 3   Regular 
 4   Bastante 
 5   Mucho 
7. ¿Tuvo dolor en alguna parte del cuerpo durante las 4 últimas semanas? 
 1   No, ninguno 
 2   Sí, muy poco 
 3   Sí, un poco 
 4   Sí, moderado 
 5   Sí, mucho 
 6   Sí, muchísimo 
8. Durante las 4 últimas semanas, ¿hasta qué punto el dolor le ha dificultado su trabajo habitual (incluido el trabajo 
fuera de casa y las tareas domésticas)? 
 1   Nada 
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 2   Un poco 
 3   Regular 
 4   Bastante 
 5   Mucho 
9. Las preguntas que siguen se refieren a cómo se ha sentido y cómo le han ido las cosas durante las 4 últimas semanas. 
En cada pregunta responda lo que se parezca más a cómo se ha sentido usted. Durante las 4 últimas semanas ¿con qué 
frecuencia… 
a. se sintió lleno de vitalidad? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
 4   Sólo alguna vez 
 5   Nunca 
b. estuvo muy nervioso? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
 4   Sólo alguna vez 
 5   Nunca 
c. se sintió tan bajo de moral que nada podía animarle? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
 4   Sólo alguna vez 
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 5   Nunca 
d. se sintió calmado y tranquilo? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
 4   Sólo alguna vez 
 5   Nunca 
e. tuvo mucha energía? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
 4   Sólo alguna vez 
 5   Nunca 
f. se sintió desanimado y deprimido? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
 4   Sólo alguna vez 
 5  Nunca 
g. se sintió agotado? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
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 4   Sólo alguna vez 
 5   Nunca 
h. se sintió feliz? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
 4   Sólo alguna vez 
 5   Nunca 
i. se sintió cansado? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
 4   Sólo alguna vez 
 5   Nunca 
10. Durante las 4 últimas semanas, ¿con qué frecuencia la salud física o los problemas emocionales le han dificultado 
sus actividades sociales (como visitar a los amigos o familiares)? 
 1   Siempre 
 2   Casi siempre 
 3   Algunas veces 
 4   Sólo alguna vez 
 5   Nunca 
11. Por favor diga si le parece CIERTA o FALSA cada una de las siguientes frases: 
a. Creo que me pongo enfermo más fácilmente que otras  personas. 
 1   Totalmente cierta 
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 2   Bastante cierta 
 3   No lo sé 
 4   Bastante falsa 
 5   Totalmente falsa 
b. Estoy tan sano como cualquiera. 
 1   Totalmente cierta 
 2   Bastante cierta 
 3   No lo sé 
 4   Bastante falsa 
 5   Totalmente falsa 
c. Creo que mi salud va a empeorar. 
 1   Totalmente cierta 
 2   Bastante cierta 
 3   No lo sé 
 4   Bastante falsa 
 5   Totalmente falsa 
d. Mi salud es excelente. 
 1   Totalmente cierta 
 2   Bastante cierta 
 3   No lo sé 
 4   Bastante falsa 
 5   Totalmente falsa 
Gracias por contestar a estas preguntas. 
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SUPPLEMENTAL FILE no.7 - RESISTANCE TRAINING EXERCISE BOOKLET  
A) Upper Body and Back 
 
1) Thera-Band Shoulder Front Raise in 
Standing: Stand on the middle of the 
band under your feet. Grasp the ends of 
the band. Lift upward, keeping your 
elbows straight and thumbs up. Stop at 
shoulder level. Hold and slowly return. 
2) Thera-Band Shoulder Lateral 
Raise in Standing: Stand on the 
middle of the band. Grasp the ends of 
the band. Lift the band upward, 
keeping your elbows straight. Stop at 
shoulder level. Hold and slowly 
return. 
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3) Thera-Band Elbow Biceps Curl 
(Standing): Stand on the middle of the 
band. Grasp the ends of the band. Lift 
the band upward, bending your elbows 
and palms up. Keep your elbows by 
your side. Hold and slowly return. 
4) Thera-Band Upright Row in 
Standing: Place middle of the band 
under both feet and grasp each end 
of the band with palms facing down. 
Pull the ends of the band upward 
toward your chin, lifting your 
elbows upward. Hold and slowly 
return to the starting position. 
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5) Thera-Band Chest Flies: Secure the 
middle of the band to a stationary object 
at shoulder level. Face away from the 
attachment. Use a staggered step with 
one leg slightly in front of the other. 
Grasp the bands at shoulder height with 
your elbows straight. Keep your elbows 
straight and pull bands inward with 
palms facing each other. Slowly return. 
6) Thera-Band Shoulder Lat Pull 
Down (standing):  Secure the 
middle of a long band or tubing to a 
stationary object above shoulder 
level, facing the attachment. Grasp 
the ends of the tubing above 
shoulder height with your elbows 
extended. Bend your elbows and 
bring your hands to your chest, 
pulling the bands down and back. 
Hold and slowly return. 
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B) Lower body 
 
 
 
  
7) Thera-Band Knee Leg Press in 
Supine:  Lay on your back with 
your knee bent and middle of band 
looped around the bottom of the 
foot. Grasp the ends of the band in 
each hand near your shoulders. 
Extend your hip and knee against 
the band until straight. Hold and 
slowly return. 
8) Calf raise: Place your feet at 
shoulder width. Keep your hands by 
your side and go up onto your toes. 
Hold and slowly return  
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9) Exercise Ball Wall Squat: Begin 
with ball behind your back and 
stabilized on wall. Keep neck and 
pelvis in neutral. Perform a squat by 
bending knees, lowering pelvis and 
rolling ball downward. Hold and 
slowly return. 
10) Step-Up: Step up onto stairs or 
steps facing forward. Use the railing 
or other sturdy object for balance if 
needed. 
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SUPPLEMENTAL FILE no. 8 – SUMMARY OF THE THESIS IN SPANISH 
INTRODUCCIÓN 
El cáncer de pulmón es la primera causa de muerte por cáncer en el mundo. En España, 
según el último informe publicado por el Instituto Nacional de Estadística, en el 2013 21.664 
personas fallecieron a consecuencia de este tumor, situándose como la tercera causa de muerte tras 
las enfermedades cardiovasculares (Instituto Nacional de Estadistica, 2015). En los próximos años, 
se espera que el cáncer de pulmón supere a éstas últimas como la primera causa de muerte en el 
mundo.  
Aproximadamente, el 85% de los casos de cáncer de pulmón corresponden a la estirpe de 
células no pequeñas (CPCNP) para el cual, el tratamiento quirúrgico es el más indicado y el que 
mayores posibilidades de supervivencia aporta (Howington et al., 2013). Sin embargo, únicamente 
el 20 – 25% de los pacientes con CPCNP se encuentran en un estadio operable en el momento del 
diagnóstico, de los cuales, muchos no podrán someterse a una cirugía de resección tumoral por ser 
considerados pacientes de alto riesgo quirúrgico debido a su edad avanzada, la presencia de 
comorbilidades cardíacas y/o respiratorias graves o a sub-óptima función física y/o pulmonar, lo 
que conlleva un peor pronóstico y disminuye su supervivencia a largo plazo. El concepto de pre-
habilitación ha surgido recientemente en contraposición a la rehabilitación convencional como una 
manera de preparar a los pacientes ante una cirugía mayor, especialmente a aquellos que tienen 
mayor riesgo de padecer complicaciones postoperatorias y por lo tanto de experimentar una 
recuperación más larga y tórpida. Así mismo, la pre-habilitación podría incluso reconducir a 
pacientes con muy baja función pulmonar y/o tolerancia al ejercicio considerados como de alto 
riesgo quirúrgico a enfrentarse a la cirugía en óptimas condiciones. Lamentablemente, existe muy 
poca evidencia en relación a la eficacia de estos programas especialmente en el contexto de cirugía 
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torácica y la mayor parte de los estudios han sido llevados a cabo en pacientes sometidos a una 
toracotomía convencional (Jones et al., 2007, Cesario et al., 2007, Morano et al., 2013, Sekine et 
al., 2005). Con el auge de la cirugía mínimamente invasiva, nos encontramos en un momento de 
relajación de los criterios quirúrgicos lo que ha llevado a pacientes con un peor estado basal a ser 
operados, lo que en último caso podría conllevar un aumento de la morbimortalidad perioperatoria. 
En este nuevo contexto quirúrgico, se desconocen los efectos que la pre-habilitación podría tener 
sobre la tolerancia al esfuerzo de los pacientes así como a nivel postoperatorio sobre la incidencia 
de complicaciones postoperatorias y la recuperación física y funcional durante los primeros meses 
tras la cirugía.  
OBJETIVOS 
En vista del rápido incremento de la videocirugía así como de la falta de estudios sobre el 
papel de la rehabilitación pulmonar y en concreto de la pre-habilitación en este contexto quirúrgico, 
los objetivos principales de esta tesis son: 
1. Identificar, sintetizar y analizar la evidencia científica actual sobre los programas de pre-
habilitación en pacientes con cáncer de pulmón sometidos a cirugía de resección pulmonar. 
2. Examinar la viabilidad, seguridad y eficacia preliminares de un programa de rehabilitación 
pulmonar preoperatorio en pacientes con sospecha clínica o diagnóstico confirmado de 
cáncer de pulmón sometidos a resección pulmonar por videocirugía. 
3. Analizar la eficacia de un programa de rehabilitación pulmonar preoperatorio en esta 
población para incrementar la función física y la calidad de vida así como para mejorar la 
recuperación postoperatoria. 
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4. Proporcionar una base sólida de donde partan futuras investigaciones en el campo de la pre-
habilitación de cirugía torácica y otras cirugías mayores para reducir la morbilidad 
postoperatoria y acelerar la recuperación funcional y psicológica. 
MATERIAL Y MÉTODO 
Esta tesis se encuentra estructurada en tres estudios, cada uno de los cuales cuenta con una 
metodología propia en función del tipo de investigación y los objetivos propuestos: una revisión 
sistemática y meta-análisis, un estudio piloto de viabilidad y un ensayo aleatorizado controlado a 
simple ciego. Los estudios fueron llevados a cabo en el periodo comprendido entre Febrero de 2013 
y Noviembre de 2015. En el siguiente apartado se expone un breve resumen de cada uno de los 
estudios incluidos en esta tesis en cuanto a su objetivo, metodología y principales resultados. 
RESULTADOS 
ESTUDIO #1: 
Diseño: revisión sistemática y meta-análisis acerca de los efectos de la rehabilitación pulmonar 
preoperatoria en pacientes con cáncer de pulmón sometidos a resección pulmonar. 
Objetivo: el objetivo principal del estudio era examinar los efectos de la rehabilitación 
preoperatoria en pacientes con cáncer de pulmón en cuanto a tolerancia al esfuerzo, capacidad 
funcional, función pulmonar y calidad de vida relacionada con la salud (CVRS). Como objetivos 
secundarios se encontraban: 1) comparar la incidencia de complicaciones postoperatorias y la 
estancia hospitalaria en los pacientes sometidos a pre-habilitación en comparación con el 
tratamiento estándar (no pre-habilitación) y 2) llevar a cabo un meta-análisis con el fin de 
cuantificar el tamaño del efecto de la intervención en cada una de las variables de medición 
seleccionadas. 
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Material y método: esta revisión sistemática se llevó a cabo conforme a las recomendaciones de 
PRISMA (the Preferred Reporting Items for Systematic Reviews and Meta-analisys). Así mismo, 
el protocolo fue registrado en la base de datos de PROSPERO bajo el código de identificación 
CRD42015024283. Seis bases de datos (CINAHL, EMBASE, MEDLINE, PEDro, Pubmed y 
SCOPUS) fueron sistemáticamente revisadas dando lugar a 1,656 referencias. 12 artículos fueron 
también identificados a través de una búsqueda manual. La búsqueda inicial fue realizada por una 
de las investigadoras y una vez eliminados los duplicados y las referencias no relevantes, dos 
investigadoras analizaron de forma independiente las referencias restantes en función de los 
criterios de inclusión pre-establecidos. Los artículos fueron incluidos si: 1) incluían pacientes con 
cáncer de pulmón; 2) evaluaban algún tipo de intervención preoperatoria relacionada con el 
ejercicio aeróbico o de fuerza o una combinación de ambos; 3) medían los resultados del programa 
en alguna de las siguientes variables: tolerancia al esfuerzo, capacidad funcional, función 
pulmonar, calidad de vida y/o complicaciones postoperatorias y estancia hospitalaria. El análisis 
de calidad fue realizado de forma independiente por dos investigadoras utilizando la escala 
proporcionada por PEDro para ensayos clínicos y la Newcastle-Ottawa Scale (NOS) para estudios 
de cohortes y series de casos. Finalmente, en aquellas variables en las que se consideró oportuno, 
además de un análisis descriptivo de los resultados se llevó a cabo un meta-análisis para cuantificar 
el tamaño del efecto y generar los correspondientes intervalos de confianza al 95% (I.C 95%). El 
programa utilizado fue el Review Manager© (RevMan) versión 5.3 para Windows©. 
Resultados: tras aplicar los criterios de inclusión y exclusión 21 estudios fueron finalmente 
incluidos en la revisión sistemática (ocho ensayos clínicos, cuatro estudios de cohortes y nueve 
series de casos) pero únicamente 14 entraron en el posterior meta-análisis. La modalidad de 
ejercicio predominante en los estudios fue el entrenamiento aeróbico seguido de una combinación 
entre el entrenamiento aeróbico y de fuerza. Sólo dos estudios centraron sus intervenciones en el 
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entrenamiento de fuerza muscular periférica. Otros componentes frecuentes en los programas 
fueron los ejercicios respiratorios con o sin incentivador, el entrenamiento de la musculatura 
respiratoria o las técnicas de relajación. El análisis de calidad mostró un nivel metodológico medio 
(5/10 para los ensayos clínicos según la escala PEDro y 6/9 para los estudios de cohortes y series 
de casos según la escala NOS).  
 En cuanto a las variables analizadas, la mayoría de los estudios mostraron un aumento 
significativo pre – post intervención en la tolerancia al esfuerzo (consumo máximo de oxígeno) y 
la capacidad funcional (test de 6 minutos marcha). Sin embargo, los estudios mostraron una alta 
heterogeneidad y por lo tanto se consideró inapropiado realizar un meta-análisis. Solo cuatro 
estudios incluyeron un análisis sobre la calidad de vida y los resultados fueron inconsistentes, por 
lo que debido a esto y a la variabilidad encontrada en los instrumentos de medición se consideró 
de nuevo inapropiado calcular el tamaño del efecto. Por otro lado, la función pulmonar experimentó 
un aumento significativo en los dos principales parámetros estudiados (Capacidad Vital Forzada 
(CVF) y Volumen Espirado Máximo en el primer segundo (VEMS)). En este caso, el meta-análisis 
mostró un aumento significativo pre – post intervención (diferencia de medias estandarizada = 
0,38; I.C 95%: 0,14 - 0,63 y 0,27; I.C 95%: 0,11 – 0,42 respectivamente). De la misma manera, la 
duración de la estancia hospitalaria fue significativamente menor en los grupos de pre-habilitación 
en comparación con el tratamiento estándar (diferencia de medias = -4,83 días; C.I 95%: -3,76 -
5,9) así como la incidencia de complicaciones postoperatorias (riesgo relativo (RR) = 0,45; C.I 
95%: 0,34 – 0,89). Sin embargo, en esta última variable el nivel de heterogeneidad fue sustancial 
(I2 = 65%) por lo que se llevó a cabo posteriormente un sub-análisis para examinar las posibles 
causas. Así, encontramos que al clasificar las complicaciones postoperatorias según el origen (sólo 
respiratorio versus respiratorio y/u otros), los estudios que incluyeron sólo complicaciones 
postoperatorias respiratorias mostraron un tamaño del efecto similar (RR = 0,55; I.C 95%: 0,34 – 
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0,89) pero significativamente menos heterogeneidad (I2 = 27%). También el tipo de diseño influyó 
en el nivel de  heterogeneidad de forma que al separar los ensayos clínicos aleatorizados versus los 
no aleatorizados y los estudios de cohortes, de nuevo el tamaño del efecto se mantenía estable 
mientras que el nivel de heterogeneidad se reducía totalmente (RR = 0,46; I.C 95: 0,26 – 0,82; I2 = 
0%).       
Conclusiones: en conjunto, los resultados de esta revisión sistemática y meta-análisis demuestran 
que la pre-habilitación en pacientes con cáncer de pulmón sometidos a resección pulmonar reduce 
de forma significativa la morbilidad postoperatoria así como la estancia hospitalaria. Así mismo, 
la realización de un programa basado en el ejercicio físico resulta efectiva para incrementar la 
función pulmonar y podría mejorar además la tolerancia al esfuerzo y la capacidad funcional 
aunque en estos casos los resultados no son concluyentes. Finalmente, se necesitan más estudios 
para analizar el papel de estos programas sobre la calidad de vida de los pacientes.   
ESTUDIO #2: 
Diseño: estudio piloto para evaluar la viabilidad, tolerancia y eficacia preliminares de un programa 
de rehabilitación pulmonar preoperatorio en pacientes con sospecha clínica o diagnóstico 
confirmado de cáncer de pulmón sometidos a resección pulmonar por videocirugía. 
Objetivos: el principal objetivo de este estudio era testar la viabilidad del programa en cuanto a 
adherencia y grado de tolerancia en los pacientes así como el grado de seguridad de la intervención 
en relación a los potenciales efectos adversos encontrados. Como objetivos secundarios se 
encontraban: 1) evaluar la eficacia preliminar del programa en cuanto a aumentar la capacidad 
funcional, la fuerza muscular y la calidad de vida; 2) describir el deterioro funcional y psicológico 
observado tras videocirugía y 3) determinar si tres meses tras la intervención quirúrgica los 
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pacientes habían recuperado sus valores basales en cuanto a capacidad funcional, fuerza muscular 
y calidad de vida. 
Material y método: este estudio fue aprobado por el Comité Autonómico de Ética da Investigación 
de Galicia en el seno de un ensayo clínico aleatorizado y todos los pacientes incluidos firmaron el 
consentimiento informado antes de ser evaluados. Desde Febrero a Junio de 2013 todos los 
pacientes incluidos en lista de espera para resección pulmonar por sospecha clínica o diagnóstico 
confirmado de cáncer de pulmón en el Servicio de Cirugía Torácica del Hospital Clínico 
Universitario de A Coruña (CHUAC) fueron evaluados para su inclusión en el estudio. Los 
pacientes debían de ser mayores de edad, pertenecer al área sanitaria de A Coruña y no haber 
recibido tratamiento neoadyuvante en los seis meses anteriores. Se excluyeron aquellos pacientes 
que presentaban alguna contraindicación médica al ejercicio así como aquellos que presentaban 
algún trastorno del sistema músculo-esquelético que impidiese la realización de los ejercicios.  
El programa de rehabilitación estaba dirigido por una fisioterapeuta especializada en 
rehabilitación pulmonar y constaba de los siguientes elementos: 1) entrenamiento aeróbico en 
ciclo-ergómetro (Monark 818 E, Monark Exercise AB, Sweden) siguiendo un protocolo interválico 
combinando cuatro minutos a baja intensidad (45 – 50 % de la carga máxima tolerada) con un 
minuto de alta intensidad (al 80 – 85% de la carga máxima) durante 30 - 40 minutos; 2) 
entrenamiento de fuerza-resistencia que consistía en la realización de ejercicios para miembros 
superiores e inferiores con bandas elásticas (Thera-Band©, The Hygienic Corporation, Akron, 
Ohio, USA) y ejercicios auto-resistidos con ayuda del peso corporal; 3) ejercicios respiratorios con 
incentivador volumétrico (Coach 2 Espirómetro de incentivo 22-4000 HD, Smith Medicals, USA) 
a realizar en el domicilio en dos sesiones de unos 15 minutos de duración cada una 
aproximadamente. Los pacientes completaron de tres a cinco sesiones semanales de una hora y 
cuatro de duración durante todo el periodo preoperatorio.  
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Las variables de medición seleccionadas para este estudio fueron: 1) adherencia (número 
de pacientes que alcanza al menos un 80% de las sesiones inicialmente planteadas); 2) seguridad 
(número de eventos adversos que precisan atención médica urgente o no urgente; 3) tolerancia al 
esfuerzo (test de 6 minutos marcha); 4) fuerza muscular (Senior Fitness Test) y 5) CVRS (SF – 
36). Los pacientes fueron evaluados al inicio de la intervención (T0), al finalizar la intervención, 
previamente a la cirugía (T1), una semana después del alta hospitalaria (T2) y a los tres meses de 
la cirugía (T3). 
Pese a la distribución normal de las variables y debido al reducido tamaño de la muestra, 
el análisis estadístico se realizó mediante pruebas no paramétricas para muestras relacionadas en 
cada una de las variables de medición. El programa estadístico utilizado fue el SPSS para Windows 
versión 21 (IBM Corporation, Chicago, IL, USA) y un valor de p <.05 fue considerado como 
estadísticamente significativo. 
Resultados: durante el periodo de estudio, 23 pacientes fueron evaluados de los cuales, 12 (52.2%) 
cumplieron los criterios de inclusión establecidos por los investigadores. De los 12 pacientes 
inicialmente incluidos, tres fueron excluidos a posteriori debido a problemas con el transporte al 
centro de rehabilitación (n = 2) o porque fueron sometidos a cirugía con carácter urgente (n = 1). 
Nueve pacientes completaron la intervención y fueron analizados. De media, los pacientes 
completaron un total de 21 sesiones de las 18 inicialmente propuestas (rango 11 – 27). Solo un 
paciente alcanzó menos del 80% de adherencia. Ningún efecto adverso fue registrado durante el 
periodo de entrenamiento. En cuanto a la eficacia preliminar del programa, tras la intervención los 
pacientes aumentaron en 22,5 metros la distancia recorrida con el test de 6 minutos marcha 
(T6MM). Aunque el resultado no alcanzó valores estadísticamente significativos por un margen 
muy estrecho (p = .050), el aumento sí se encuentra dentro del rango identificado como 
clínicamente significativo para pacientes con cáncer de pulmón (Granger et al., 2015). La función 
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muscular medida a través del Senior Fitness Test (SFT) sí experimentó un aumento significativo 
con respecto a los valores basales (Tabla 1). En cambio, los cambios en la calidad de vida según el 
SF-36 fueron mínimos y no alcanzaron valores estadísticamente significativos salvo en el caso de 
la dimensión de salud mental. En el postoperatorio inmediato, el T6MM experimentó una reducción 
significativa con respecto a los valores basales (67,9 ± 65,5 metros), lo que nos indica que incluso 
con el abordaje quirúrgico mínimamente invasivo existe una disminución en la capacidad funcional 
inmediatamente tras la cirugía. La fuerza de los miembros superiores medida con el Test de flexión 
de brazo del SFT también disminuyó significativamente mientras que la de miembros inferiores se 
mantuvo estable (Tabla 1). A los tres meses de la intervención, los pacientes se encontraban por 
encima de los valores basales en el T6MM (105,5 ± 6,8%) mientras que la fuerza de miembros 
superiores e inferiores se mantenían entre el 80 y el 88% de los valores basales respectivamente.  
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Tabla 3: Evolución de las principales variables analizadas a lo largo del estudio 
VARIABLE 
T0 T1 T2 T3 
T6MM (m) 557,6±74,4 580,1±80,7 489,7±98,7** † 529,63±83,2 
Flexión de brazo (nº) 16,9±5,4 20,7±2,6* 20±3,3** 19,2±3,2† † 
Levantarse y 
sentarse de la silla 
(nº) 
 14,6±5,9 15,9±3,9* 16,1±5 13,2±7 
*p <.05 entre T0 y T1; **entre T0 y T2; †entre T1 y T2
† †entre T0 y T3 
Conclusiones: en vista de los resultados preliminares observados en este estudio piloto podemos 
concluir que la rehabilitación pulmonar preoperatoria en pacientes sometidos a videocirugía por 
neoplasia maligna pulmonar es factible, segura y muy probablemente eficaz a la hora de 
incrementar la tolerancia al esfuerzo y la fuerza muscular. Pese al uso de técnicas mínimamente 
invasivas, inmediatamente tras la cirugía existe una pérdida importante de la capacidad funcional 
que aparentemente queda restablecida en los tres primeros meses tras la cirugía. Sin embargo, se 
desconoce si esta recuperación se debe, al menos en parte, al entrenamiento preoperatorio o 
corresponde a la evolución natural de los pacientes, por lo que es necesario un ensayo clínico 
aleatorizado para conocer el impacto de la rehabilitación preoperatoria en la recuperación funcional 
de los pacientes operados por videocirugía.  
ESTUDIO #3: 
Diseño: ensayo clínico aleatorizado controlado a simple ciego para valorar los efectos de un 
programa de rehabilitación pulmonar preoperatorio sobre la tolerancia al esfuerzo, la fuerza 
muscular y la calidad de vida en pacientes con sospecha clínica o diagnóstico confirmado de cáncer 
de pulmón sometidos a videocirugía. 
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Objetivos: los objetivos principales de este estudio fueron: 
1. Analizar la eficacia de un programa de rehabilitación pulmonar preoperatorio para 
incrementar la tolerancia al esfuerzo en pacientes con sospecha clínica o diagnóstico 
confirmado de cáncer de pulmón sometidos a videocirugía. 
2. Conocer si un programa de rehabilitación pulmonar preoperatorio es capaz de prevenir o 
paliar el deterioro funcional observado tras la cirugía en comparación con el tratamiento 
estándar (grupo control). 
Como objetivos secundarios se encontraban: 
1. Examinar los efectos del entrenamiento en la fuerza muscular y la calidad de vida de los 
pacientes. 
2. Comparar la fuerza muscular y la calidad de vida de los pacientes en el grupo de 
rehabilitación y el grupo control durante el postoperatorio inmediato y tardío.  
3. Comparar la estancia hospitalaria y la incidencia de complicaciones postoperatorias en 
ambos grupos con el fin de determinar si la pre-habilitación influye en dichas variables. 
4. Identificar factores de riesgo relacionados con el deterioro de la capacidad funcional en el 
postoperatorio tardío tras videocirugía.  
Material y método: este ensayo clínico fue registrado en la base de datos clinicaltrials.gov con el 
número de identificación NCT01963923. El estudio fue aprobado por el Comité de Ética 
Autonómico de Galicia (número de registro 2011/395) y los pacientes firmaron el consentimiento 
informado antes de someterse a ninguna evaluación. 
 Entre Octubre de 2013 y Abril de 2015, todos los pacientes incluidos en lista de espera para 
resección pulmonar por sospecha clínica o diagnóstico confirmado de cáncer de pulmón y que 
cumplían los criterios establecidos por los investigadores fueron evaluados para su inclusión en el 
estudio. Dichos criterios fueron: 
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 Ser mayor de edad en el momento del iniciar el estudio. 
 Pertenecer al área sanitaria de A Coruña y residir en un radio no superior a 80 km del centro 
hospitalario. 
 Presentar una de las siguientes condiciones: tener una función respiratoria alterada (VEMS 
< 80%, y/o Índice de Masa Corporal (IMC) > 30 kg/m2y/o edad ≥ 75 años o exhibir dos o 
más de las siguientes comorbilidades: enfermedad respiratoria crónica, diabetes, 
hipertensión arterial, enfermedad renal crónica, enfermedad cardiovascular o antecedentes 
personales de cáncer. 
Se excluyeron a aquellos pacientes que habían recibido tratamiento neoadyuvante en los 
seis meses anteriores a ser evaluados así como aquellos con alguna contraindicación al ejercicio o 
con alteraciones cognitivas y/o músculo-esqueléticas graves.  
Aquellos pacientes que cumplieron los criterios de inclusión y aceptaron participar en el 
estudio fueron aleatorizados bien al grupo de intervención o bien al grupo control. Los pacientes 
del grupo control no recibieron atención fisioterápica de ningún tipo mientras que el grupo de 
rehabilitación acudió al centro entre 3 y 5 veces a la semana durante el periodo preoperatorio para 
llevar a cabo el programa de entrenamiento diseñado y que consistía al igual que en el estudio 
anterior de 1) 30 minutos de entrenamiento aeróbico en cicloergómetro (Monark 818 E, Monark 
Exercise AB, Sweden) combinando 4 minutos a baja intensidad (50% potencia máxima tolerada) 
con 1 minuto a intensidad elevada (80% potencia máxima tolerada); 2) entrenamiento de fuerza-
resistencia para miembros superiores e inferiores con bandas elásticas (Thera-Band©, The 
Hygienic Corporation, Akron, Ohio, USA) y ejercicios auto-resistidos con ayuda del peso corporal; 
3) ejercicios respiratorios con incentivador volumétrico (Coach 2 Espirómetro de incentivo 22-
4000 HD, Smith Medicals, USA) a realizar en el domicilio en dos sesiones de unos 15 minutos de 
duración cada una aproximadamente.  
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Las principales variables de medición en este estudio fueron: 1) tolerancia al esfuerzo 
(prueba de carga constante en cicloergómetro al 80% de la potencia máxima tolerada); 2) fuerza 
muscular (SFT); 3) CVRS (SF-36) y 4) estancia hospitalaria y complicaciones postoperatorias.  
Todos los pacientes fueron evaluados al inicio del estudio (T0), a las tres semanas 
aproximadamente de la cirugía (T1) y a los 3 meses (T2). A mayores, los pacientes en el grupo de 
rehabilitación fueron re-evaluados al finalizar el programa de entrenamiento previamente a la 
intervención quirúrgica. 
El análisis estadístico consistió en una prueba t de student para muestras independientes 
en cada una de las principales variables así como una prueba t de muestras relacionadas para evaluar 
los cambios pre-post intervención en el grupo de intervención. La incidencia de complicaciones 
postoperatorias se analizó mediante una prueba de X2. Todas las pruebas fueron realizadas con el 
pack SPSS para Windows versión 22 (IBM Corporation, Chicago, IL, USA) y un valor de p <.05 
fue considerado como estadísticamente significativo para todos los análisis. 
Resultados: 319 pacientes entraron en lista de espera para resección pulmonar por sospecha o 
diagnóstico confirmado de cáncer de pulmón en el departamento de Cirugía Torácica del CHUAC 
durante el periodo de reclutamiento. 68 (21,3%) pacientes fueron inicialmente contactos de los 
cuales finalmente 40 fueron aleatorizados. 22 (55%) pacientes completaron con éxito el estudio y 
fueron analizados.  
 Los pacientes del grupo de rehabilitación registraron un aumento significativo en las tres 
variables principales de medición al finalizar el programa de rehabilitación: tolerancia al esfuerzo 
(test de resistencia submáxima en cicloergómetro), fuerza muscular así como el componente físico 
del test de CVRS (Tabla 2). Tras la intervención quirúrgica, no se encontraron diferencias 
significativas en los dos grupos salvo en la dimensión de dolor corporal del test de calidad de vida 
(Tabla 3). Tampoco se encontraron diferencias significativas ni en la estancia hospitalaria ni en la 
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incidencia de complicaciones postoperatorias. Sin embargo, a los tres meses de la cirugía, los 
pacientes del grupo de rehabilitación mostraron una recuperación completa en todas las variables 
incluso superando los valores basales mientras que el grupo control experimentó un deterioro 
continuo y progresivo tanto a nivel funcional como psicológico. Las diferencias resultaron 
estadísticamente significativas tanto en la tolerancia al esfuerzo (duración mantenida en el test de 
resistencia submáxima en cicloergómetro) como en la fuerza muscular de miembros superiores e 
inferiores y en el componente sumario físico del test de calidad de vida (Tabla 3).  
VARIABLE N BASAL PRE-Cirugía P valor 
Prueba de CCEG (s) 10 322,4±96,2 719±211,2 <.001 
Test de flexión de 
brazos (nª) 
10 13,40±3 16,3±2,9 .002 
Test de levantarse de 
la silla (nª) 
10 11,5±3,7 12,4±4,5 .041 
Función física 10 63,5±20,8 71±14,9 .110 
Rol físico 10 48±30,6 65,9±12,8 .038 
Dolor corporal 10 64,5±26,3 69,2±23,8 .518 
Salud General 10 41,9±20,2 52,2±14,3 .072 
Vitalidad 10 52±16,5 55±15,6 .526 
Función social 10 87,5±22 97,5±5,3 .223 
Rol emocional 10 60,6±19,2 72.7±12,3 .098 
Salud mental 10 63,2±13,6 64,4±19,2 .771 
CSF 10 40,77±8 45,2±6,8 0.08 
CSM 10 45,7±8,3 47,4±7,4 .511 
*CCEG= Carga Constante en Ciclo-ergómetro; CSF=Componente Sumario Físico;  
CSM=Componente Sumario Mental 
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VARIABLE GRUPO Basal Post-Cirugía 
(diferencia 
media) 
p valor 3 meses 
(diferencia 
media) 
p 
valor 
CCEG (s) Rehabilitación 322.4±96.2 +137.7±268.2 
.097 
+226±269.4* 
.005 Control 366.8±205 -25.8±16.71 -137.8±221.7 
T6MM (m) Rehabilitación  420.11±116.3 -15.55±47.731 
.500 
1.88±34.7 
.186 
Control 514.5±100.9 -27.7±33.7* -31.5±64.6 
Flexión de 
brazos (nª) 
Rehabilitación  13.4±3 +1.9±3 
.105 
+1.8±3.3 
.045 
Control 17.3±3.5 -0.25±2.9 -1.8±3.5 
Levantami
ento de la 
silla (n) 
Rehabilitación  11.5±3.7 -0.55±3.5 
.531 
+2±2.2* 
.002 
Control 12.7±2.5 +0.5±3.9 -1.3±1.8* 
*diferencia estadísticamente significativa intra-grupo (p <.05) 
 
Conclusiones: en vista de los resultados obtenidos en este ensayo clínico aleatorizado a simple 
ciego podemos concluir que la rehabilitación pulmonar preoperatoria en pacientes con neoplasias 
malignas no sólo optimiza la condición física basal de los pacientes previo a la cirugía sino que 
además parece contribuir e forma significativa a prevenir el deterioro funcional observado durante 
los primeros meses del postoperatorio. 
CONCLUSIONES 
 En general, los resultados obtenidos con los estudios incluidos en el marco de esta tesis 
doctoral indican que: 
 Existe suficiente evidencia científica para aseverar que los pacientes con cáncer de pulmón 
sometidos a resección pulmonar experimentan un deterioro en su capacidad funcional, 
tolerancia al esfuerzo y calidad de vida durante los primeros meses tras la intervención. 
 La pre-habilitación de pacientes con cáncer de pulmón que van a ser sometidos a cirugía de 
resección pulmonar es útil a la hora de optimizar el estado basal de los pacientes ya que 
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mejora la función pulmonar y muy posiblemente la tolerancia al esfuerzo y la capacidad 
funcional lo que se traduce en una disminución en la estancia hospitalaria y el número de 
complicaciones postoperatorias en aquellos pacientes sometidos a cirugía abierta 
convencional. 
 En pacientes con sospecha clínica o diagnóstico confirmado de cáncer de pulmón operados 
por videocirugía, la rehabilitación pulmonar preoperatoria es viable, segura y fácilmente 
tolerable y puede llevarse a cabo en nuestro medio sin incurrir en un aumento de la demora 
terapéutica. 
 Finalmente, la rehabilitación pulmonar preoperatoria resulta eficaz para aumentar la 
tolerancia al esfuerzo, la fuerza muscular y el componente físico relacionado con la calidad 
de vida; además, en función de las diferencias observadas con respecto al tratamiento 
estándar, la pre-habilitación podría acelerar la recuperación funcional postoperatoria y 
paliar el deterioro tradicionalmente asociado a la cirugía de resección pulmonar. 
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SUPPLEMENTAL FILE no. 9 – SUMMARY OF THE THESIS IN GALICIAN 
INTRODUCCIÓN 
O cancro de pulmón é a primeira causa de morte por cancro no mundo. En España, segundo 
o derradeiro informe publicado polo Instituto Nacional de Estadística, no ano 2013 21,664 persoas 
faleceron a consecuencia deste tumor, o que o sitúa como a terceira causa de morte despois das 
enfermidades cardiovasculares (Instituto Nacional de Estadistica, 2015). De feito, nos vindeiros 
anos, espérase que o cancro de pulmón supere a éstas últimas como a primera causa de morte no 
mundo.  
Aproximadamente, o 85% dos casos de cancro de pulmón corresponden á denominada 
estirpe de células non pequenas (CPCNP) para o cal o tratamiento quirúrxico considérase o máis 
indicado e o que máis posibilidades de supervivencia aporta (Howington et al., 2013). 
Nembargantes, únicamente o 20 – 25% dos pacientes con CPCNP atópanse nun estadio operable 
no momento do diagnóstico, dos cales moitos non poderán someterse a cirurxía de resección do 
tumor por ser considerados pacientes de alto risco quirúrxico debido a súa idade avanzada, á 
presenza de comorbilidades cardíacas e/ou respiratorias graves ou a unha subóptima función física 
e/ou pulmonar, o que leva consigo un peor pronóstico afectando negativamente á supervivencia a 
longo prazo. O concepto de pre-habilitación emerxeu recientemente na literatura en contraposición 
á rehabilitación tradicional como unha maneira de preparar ós pacientes ante una ciruxía maior, 
especialmente a aqueles que teñen maior risco de padecer complicacións postoperatorias e polo 
tanto de experimentar unha recuperación máis longa e tórpida. Así mesmo, a pre-habilitación 
podería incluso reconducir a pacientes con unha moi baixa función pulmonar e/ou tolerancia ó 
esforzo considerados como de alto risco quirúrxico a enfrentarse á cirurxía en óptimas condicións. 
Lamentablemente, existe moi pouca evidencia en relación á eficacia deste tipo de programas 
especialmente no contexto de cirurxía torácica e a maior parte dos estudos levados a cabo foron en 
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pacientes sometidos a unha toracotomía convencional (Jones et al., 2007, Cesario et al., 2007, 
Morano et al., 2013, Sekine et al., 2005). Co actual auxe da cirurxía mínimamente invasiva, 
atopámonos nun momento de apertura dos criterios quirúrxicos provocando que pacientes con peor 
estado basal sexan intervidos o que podería traducirse nun aumento da morbimortalidade 
perioperatoria. Neste novo contexto quirúrxico, descoñécense os efectos que a pre-habilitación 
podría ter sobre a tolerancia ó esforzo dos pacientes así como a nivel postoperatorio sobre a 
incidencia de complicacións postoperatorias e a recuperación física e funcional durante os 
primeiros meses tras a cirurxía.  
OBXECTIVOS 
En vista do rápido incremento no uso da videocirurxía para a resección de neoplasias 
pulmonares así como da falta de estudos sobre o papel da rehabilitación pulmonar e máis 
concretamente da pre-habilitación neste contexto, os principáis obxectivos desta tese de 
doutoramento son: 
5. Identificar, sintetizar e analizar a evidencia científica actual sobre os programas de pre-
habilitación en pacientes con cancro de pulmón sometidos a cirurxía de resección pulmonar. 
6. Examinar a viabilidade, seguridade i eficacia preliminares dun programa de rehabilitación 
pulmonar preoperatorio en pacientes baixo sospeita clínica ou diagnóstico confirmado de 
cancro de pulmón sometidos a resección pulmonar por videocirurxía. 
7. Analizar a eficacia dun programa de rehabilitación pulmonar preoperatorio nesta población 
para incrementar a función física e a calidadee de vida así como para mellorar a 
recuperación postoperatoria. 
8. Proporcionar unha base sólida para futuras investigacións no campo da pre-habilitación en 
cirurxía torácica e outras cirurxías maiores para reducir a morbilidade postoperatoria e 
acelerar a recuperación funcional e psicolóxica. 
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MATERIAL E MÉTODO 
Esta tese de doutoramento encóntrase estructurada en tres estudos, cada un dos cales conta 
con unha metodoloxía propia en función do tipo de investigación e os obxectivos marcados: 1) 
unha revisión sistemática e meta-análise; 2) un estudo piloto de viabilidade e 3) un ensaio 
aleatorizado controlado a simple cego. Os estudos foron levados a cabo no periodo comprendido 
entre Febreiro de 2013 e Novembre de 2015. No seguinte apartado atópase un breve resumo de 
cada un dos estudos incluidos nesta tese en canto a obxectivos individuais, metodoloxía e principais 
resultados. 
RESULTADOS 
ESTUDO #1: 
Deseño: revisión sistemática e meta-análise acerca dos efectos da rehabilitación pulmonar 
preoperatoria en pacientes con cancro de pulmón sometidos a resección pulmonar. 
Obxectivo: o obxectivo principal do estudo foi examinar os efectos da rehabilitación preoperatoria 
en pacientes con cancro de pulmón en canto a incrementar a tolerancia ó esforzo, a capacidade 
funcional, a función pulmonar e a calidade de vida relacionada coa saúde (CVRS). Como 
obxectivos secundarios atopábanse: 1) comparar a incidencia de complicacións postoperatorias e a 
estadia hospitalaria nos pacientes sometidos a pre-habilitación en comparación co tratamiento 
estándar (sen pre-habilitación) e 2) llevar a cabo un meta-análise co fin de cuantificar o tamaño do 
efecto da intervención sobre cada unha das variables de medición seleccionadas. 
Material e método: esta revisión sistemática foi levada a cabo conforme ás recomendacións de 
PRISMA (the Preferred Reporting Items for Systematic Reviews and Meta-analisys). Así mesmo, 
o protocolo foi rexistrado na base de datos de PROSPERO baixo o código de identificación 
CRD42015024283. Seis bases de datos (CINAHL, EMBASE, MEDLINE, PEDro, Pubmed y 
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SCOPUS) foron sistemáticamente revisadas dando lugar a 1.656 referencias. 12 artigos foron 
tamén identificados a través dunha pesquisa manual. A pesquisa inicial foi realizada por unha das 
investigadoras e unha vez eliminados os duplicados e as referencias non relevantes, dúas 
investigadoras analizaron de forma independiente as referencias restantes en base ós criterios de 
inclusión pre-establecidos. Os artigos foron incluidos si: 1) incluían pacientes con cancro de 
pulmón; 2) evaluaban algún tipo de intervención preoperatoria relacionada co exercicio aeróbico 
ou de forza o una combinación de ambos; 3) proporcionaban resultados para algunha das seguintes 
variables: tolerancia ó esforzo, capacidade funcional, función pulmonar, calidade de vida e/ou 
complicacións postoperatorias i estadia hospitalaria. O análise de calidade fue realizado de forma 
independiente por dúas investigadoras utilizando a escala proporcionada por PEDro para ensaios 
clínicos e a Newcastle-Ottawa Scale (NOS) para estudos de cohortes e series de casos. Finalmente, 
naquelas variables nas que se considerou oportuno, ademáis dun análise descriptivo dos resultados, 
realizouse un meta-análise para medir o tamaño do efecto da intervención e xerar os 
correspondentes intervalos de confianza ó 95% (I.C 95%). O programa empregado foi o Review 
Manager© (RevMan) versión 5.3 para Windows©. 
Resultados: tras aplicar os criterios de inclusión e exclusión 21 estudos foron finalmente incluidos 
na revisión sistemática (oito ensaios clínicos, catro estudos de cohortes e nove series de casos) pero 
únicamente 14 entraron no meta-análise. A modalidade de exercicio predominante nos estudos foi 
o adestramento aeróbico seguido dunha combinación entre adestramento aeróbico e de forza. 
Namáis que dous estudos centraron as súas intervencións no adestramento da forza muscular. 
Outros componentes frecuentes nos programas foron os exercicios respiratorios con ou sen 
incentivador, o adestramento da musculatura respiratoria ou as técnicas de relaxación. O análise de 
calidade mostróu un nivel metodolóxico medio (5/10 para os ensaios clínicos segundo a escala 
PEDro e 6/9 para os estudos de cohortes e series de casos segundo a escala NOS).  
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 En canto ás variables analizadas, a maioría dos estudos mostraron un aumento significativo 
pre – post intervención no nivel de tolerancia ó esforzo (consumo de oxígeno máximo) e na 
capacidade funcional (test de 6 minutos marcha). Non obstante, os estudos mostraron unha alta 
heteroxeneidade polo que se considerou inapropiado levar a cabo un meta-análise. Unicamente 
catro estudos analizaron os efectos da intervención sobre a calidade de vida e os resultados foron 
inconsistentes, polo que debido a esto e á a variabilidade encontrada nos instrumentos de medición 
de novo considerouse inapropiado calcular o tamaño do efecto nesta variable. Por outro lado, a 
función pulmonar experimentou un aumento significativo nos dous principais parámetros 
estudados (Capacidade Vital Forzada (CVF) e Volumen Espirado Máximo no primeiro segundo 
(VEMS)). Neste caso, o meta-análise mostrou un aumento significativo pre – post intervención 
(diferencia de medias estandarizada = 0,38; I.C 95%: 0,14 -0,63 e 0,27; I.C 95%: 0,11 – 0,42 
respectivamente). Da mesma maneira, a duración da estadia hospitalaria foi significativamente 
menor nos grupos de pre-habilitación en comparación co tratamiento estándar (diferencia de 
medias = -4,83 días; C.I 95%: -3,76 -5.9) así como a incidencia de complicacións postoperatorias 
(risco relativo (RR) = 0,45; C.I 95%: 0,34 – 0,89). Nembargantes, nesta última variable o nivel de 
heteroxeneidade alcanzou valores substanciales (I2 = 65%) polo que se levou a cabo posteriormente 
un sub-análise para examinar as posibles causas. Deste xeito, encontramos que ó clasificar as 
complicacións postoperatorias segundo a orixe (sólo respiratorio versus respiratorio e/ou outros), 
os estudos que incluíron unicamente complicacións de orixe respiratorio mostraron un tamaño do 
efecto similar (RR = 0,55; I.C 95% 0,34 – 0,89) pero significativamente menos heteroxeneidade 
(I2 = 27%). Tamén o tipo de estudo influiu no nivel de  heteroxeneidade de forma que ó separar os 
ensaios clínicos aleatorizados versus os non aleatorizados y os estudos de cohortes, de nuevo o 
tamaño do efecto mantivose estabe mentras que o nivel de heteroxeneidade se reducía totalmente 
(RR = 0,46; I.C 95: 0,26 – 0,82; I2 = 0%).       
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Conclusións: en conxunto, os resultados obtidos nesta revisión sistemática e meta-análise 
demostran que a pre-habilitación en pacientes con cancro de pulmón sometidos a resección 
pulmonar reduce de forma significativa a morbilidade postoperatoria así como a estadia 
hospitalaria. Así mesmo, a realización dun programa basado no exercicio físico resulta efectiva 
para incrementar a función pulmonar e moi probablemente mellorar a tolerancia ó esforzo e a 
capacidade funcional aínda que nestes casos os resultados non son concluíntes. Finalmente, son 
necesesarios máis estudos para analizar o papel destes programas sobre a calidade de vida dos 
pacientes.   
ESTUDO #2: 
Deseño: estudo piloto para evaluar a viabilidade, tolerancia e eficacia preliminares dun programa 
de rehabilitación pulmonar preoperatorio en pacientes con sospeita clínica ou diagnóstico 
confirmado de cancro de pulmón sometidos a resección pulmonar por videocirurxía. 
Obxectivos: o principal obxectivo deste estudo era probar a viabilidade do programa en canto a 
adherencia e grado de tolerancia dos pacientes así como o grao de seguridade da intervención en 
relación ós potenciais efectos adversos encontrados. Como obxectivos secundarios atopábanse: 1) 
evaluar a eficacia preliminar do programa para aumentar a capacidade funcional, a forza muscular 
e a CVRS; 2) describir o deterioro funcional e psicolóxico observado tras videocirurxía e 3) 
determinar se ós tres meses da intervención quirúrxica os pacientes alcanzaban os seus valores 
basais en canto a capacidade funcional, forza muscular e CVRS. 
Material e método: este estudo foi aprobado polo Comité Autonómico de Ética da Investigación 
(CEIC) de Galicia no seo dun ensaio clínico aleatorizado e todos os pacientes incluidos firmaron o 
consentimento informado antes de seren evaluados. Dende Febreiro a Xuño de 2013 todos os 
pacientes incluidos en lista de espera para resección pulmonar por sospeita clínica ou diagnóstico 
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confirmado de cancro de pulmón no Servizo de Cirurxía Torácica do Hospital Clínico Universitario 
da Coruña (CHUAC) foron evaluados para a súa inclusión no estudo. Os pacientes debían de ser 
maiores de idade, pertencer á área sanitaria da Coruña e non ter recibido tratamento neoadyuvante 
nos seis meses anteriores. Excluíronse aqueles pacientes que presentaban algunha contraindicación 
médica para ó exercicio así como aqueles que presentaban algún trastorno do sistema músculo-
esquelético que lles impedise a realización dos exercicios.  
O programa de rehabilitación estaba dirixido por unha fisioterapeuta especializada en 
rehabilitación pulmonar e constaba dos seguintes elementos: 1) adestramento aeróbico en ciclo-
ergómetro (Monark 818 E, Monark Exercise AB, Sweden) seguindo un protocolo interválico que 
combinaba catro minutos a baixa intensidade (45 – 50 % da carga máxima tolerada) cun minuto de 
alta intensidade (ó 80 – 85% da carga máxima) durante 30 - 40 minutos; 2) adestramento de forza-
resistencia para membros superiores e inferiores que consistía na realización exercicios con bandas 
elásticas (Thera-Band©, The Hygienic Corporation, Akron, Ohio, USA) e exercicios auto-
resistidos con axuda do peso corporal; 3) exercicios respiratorios con incentivador volumétrico 
(Coach 2 Espirómetro de incentivo 22-4000 HD, Smith Medicals, USA) a realizar no domicilio en 
dúas sesións duns 15 minutos de duración cada unha aproximadamente. Os pacientes completaron 
de 3 a 5 sesións semanais de unha hora e cuarto de duración durante o periodo preoperatorio.  
As variables de medición seleccionadas para este estudo foron: 1) adherencia (número de 
pacientes que alcanza canto menos un 80% das sesións inicialmente plantexadas); 2) seguridade 
(número de eventos adversos que precisaron atención médica urxente ou non urxente; 3) tolerancia 
ó esforzo (test de 6 minutos marcha); 4) forza muscular (Senior Fitness Test) e 5) CVRS (SF – 36). 
Os pacientes foron evaluados ó inicio da intervención (T0), ó finalizar a intervención previamente 
á cirurxía (T1), unha semana despois de recibir a alta hospitalaria (T2) y ós tres meses da cirurxía 
(T3). 
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Pese á distribución normal das variables e debido o reducido tamaño da mostra, o análise 
estadístico foi realizado mediante probas non paramétricas para mostras relacionadas en cada unha 
das variables de medición. O programa estadístico empregado foi SPSS para Windows versión 21 
(IBM Corporation, Chicago, IL, USA) e un valor de p <.05 considerouse como estadísticamente 
significativo. 
Resultados: durante o periodo de estudo, 23 pacientes foron evaluados dos cales, 12 (52.2%) 
cumpliron os criterios de inclusión establecidos polos investigadores. Dos 12 pacientes 
inicialmente incluidos, tres foron excluidos posteriormente debido a problemas co transporte ó 
centro de rehabilitación (n = 2) ou porque foron sometidos a cirurxía con carácter urgente (n = 1). 
Nove pacientes completaron con éxito a intervención e foron analizados. De media, os pacientes 
completaron un total de 21 sesións das 18 inicialmente propostas (rango 11 – 27). Solo un paciente 
alcanzou menos do 80% de adherencia. Ningún efecto adverso foi rexistrado durante o periodo de 
adestramento. En cunto á eficacia preliminar do programa, tras a intervención os pacientes 
aumentaron en 22,5 metros a distancia percorrida co test de 6 minutos marcha (T6MM). Aínda que 
o resultado non alcanzou valores estadísticamente significativos por unha marxe moi estreita (p = 
.050), o aumento sí se encontra dentro do rango identificado como clínicamente significativo para 
pacientes con cancro de pulmón (Granger et al., 2015). A función muscular medida co Senior 
Fitness Test (SFT) sí experimentó un aumento significativo con respecto ós valores basais (Tabla 
1). Pola contra, os cambios producidos na CVRS segundo o SF-36 foron mínimos e non alcanzaron 
valores estadísticamente significativos salvo no caso da dimensión de saúde mental. No 
postoperatorio inmediato, a capacidade funcional medida co T6MM experimentou unha reducción 
significativa con respecto ós valores basais (67,9 ± 65,5 metros) o que nos indica que pese á 
utilización dunha abordaxe quirúrxica mínimamente invasiva existe unha disminución na 
capacidade funcional inmediatamente tras cirurxía. A forza dos membros superiores medida co test 
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de flexión de brazo do SFT tamén disminueu significativamente mentras que a dos membros 
inferiores mantívose en valores similares (Tabla 1). Ós tres meses da intervención os pacientes 
atopábanse por riba dos valores basais na distancia percorrida co T6MM (105,5 ± 6,8%) mentras 
que a forza muscular de membros superiores e inferiores se atopaba entre o 80 - 88 % dos valores 
basáis respectivamente.   
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Tabla 4: Evolución de las principales variables analizadas a lo largo del estudo 
VARIABLE 
T0 T1 T2 T3 
T6MM (m) 557,6±74,4 580,1±80,7 489,7±98,7** † 529,63±83,2 
Flexión de brazo (nº) 16,9±5,4 20,7±2,6* 20±3,3** 19,2±3,2† † 
Levantarse y 
sentarse de la silla 
(nº) 
 14,6±5,9 15,9±3,9* 16,1±5 13,2±7 
*p <.05 entre T0 y T1; **entre T0 y T2; †entre T1 y T2
† †entre T0 y T3 
Conclusións: en vista dos resultados preliminares observados neste estudo piloto podemos concluir 
que a rehabilitación pulmonar preoperatoria en pacientes sometidos a videocirurxía por neoplasia 
maligna pulmonar é factible, segura e moi probablemente eficaz á hora de incrementar a tolerancia 
ó esforzo e a forza muscular. Pese á utilización de técnicas mínimamente invasivas, 
inmediatamente tras a cirurxía existe unha pérdida importante da capacidade funcional que 
aparentemente retorna ós niveles basáis nos tres primeiros meses tras a intervención. Non obstante, 
descoñecemos se esta recuperación se debe, a lo menos en parte, ó adestramento preoperatorio ou 
se corresponde á evolución natural dos pacientes, por lo que é preciso un ensaio clínico aleatorizado 
para coñecer o impacto da rehabilitación preoperatoria na recuperación funcional doos pacientes 
operados por videocirurxía.  
ESTUDO #3: 
Deseño: ensaio clínico aleatorizado controlado a simple cego para valorar os efectos dun programa 
de rehabilitación pulmonar preoperatorio sobre a tolerancia ó esforzo, a forza muscular e a calidade 
de vida en pacientes con sospeita clínica ou diagnóstico confirmado de cancro de pulmón sometidos 
a videocirurxía. 
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Obxectivos: os obxectivos principais deste estudo foron: 
1. Analizar a eficacia dun programa de rehabilitación pulmonar preoperatorio para 
incrementar a tolerancia ó esforzo en pacientes con sospeita clínica ou diagnóstico 
confirmado de cancro de pulmón sometidos a videocirurxía. 
2. Coñecer se un programa de rehabilitación pulmonar preoperatorio é capaz de previr ou 
paliar o deterioro funcional observado tras cirurxía en comparación co tratamiento estándar 
(grupo control). 
Como obxectivos secundarios atopábamos: 
1. Examinar os efectos do adestramento sobre a forza muscular e a CVRS dos pacientes. 
2. Comparar a forza muscular e a CVRS dos pacientes no grupo de rehabilitación co grupo 
control durante o postoperatorio inmediato e tardío.  
3. Comparar a estadia hospitalaria e a incidencia de complicacións postoperatorias en ambos 
grupos co fin de determinar se a pre-habilitación inflúe sobre as devanditas variables. 
4. Identificar factores de risco asociados co deterioro da capacidade funcional durante o 
postoperatorio tardío tras videocirurxía.  
Material e método: este ensaio clínico foi rexistrado na base de datos de ensaios clínicos 
(clinicaltrials.gov) co número de identificación NCT01963923. O estudo foi aprobado polo CEIC 
de Galicia (número de rexistro 2011/395) e os pacientes firmaron o consentimento informado antes 
de someterse a ningunha evaluación. 
 Entre Outubro de 2013 e Abril de 2015 todos os pacientes incluidos en lista de espera para 
resección pulmonar por sospeita clínica ou diagnóstico confirmado de cancro de pulmón e que 
cumplían cos criterios establecidos polos investigadores foron evaluados para a súa inclusión no 
estudo. Ditos criterios eran: 
 Ser maior de idade no momento de iniciar o estudo. 
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 Pertencer á área sanitaria da Coruña e residir nun radio non superior a 80 km do centro 
hospitalario. 
 Presentar una de las seguintes condicións: ter unha función respiratoria alterada (VEMS < 
80%, e/ou Índice de Masa Corporal (IMC) > 30 kg/m2 e/ou idade ≥ 75 años ou padecer dúas 
ou máis das seguintes comorbilidades: enfermidade respiratoria crónica, diabetes, 
hipertensión arterial, enfermidade renal crónica, enfermidade cardiovascular ou 
antecedentes personales de cancro. 
Foron excluidos aqueles pacientes que recibiran tratamento neoadyuvante nos seis meses 
previos así como aqueles con algunha contraindicación para realizar exercicio ou que presentaban 
alteraciones cognitivas e/ou músculo-esqueléticas graves.  
Aqueles pacientes que cumpliron cos criterios de inclusión e aceptaron participar no 
estudo foron incluidos de forma aleatoria ben no grupo de intervención ou no grupo control. Os 
pacientes do grupo control non recibiron atención fisioterápica de ningún tipo mentras que o grupo 
de rehabilitación acudeu ó centro entre 3 e 5 veces á semana durante o periodo preoperatorio para 
realizar o programa de adestramento que consistía, ó igual que o estudo anterior, de 1) 30 minutos 
de adestramento aeróbico en cicloergómetro (Monark 818 E, Monark Exercise AB, Sweden) 
combinando 4 minutos a baixa intensidade (50% potencia máxima tolerada) con 1 minuto a 
intensidad elevada (80% potencia máxima tolerada); 2) adestramento de forza-resistencia para 
membros superiores e inferiores con bandas elásticas (Thera-Band©, The Hygienic Corporation, 
Akron, Ohio, USA) e exercicios auto-resistidos con axuda do peso corporal; 3) exercicios 
respiratorios con incentivador volumétrico (Coach 2 Espirómetro de incentivo 22-4000 HD, Smith 
Medicals, USA) a realizar no domicilio en dúas sesións duns 15 minutos de duración cada unha 
aproximadamente.  
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As principáis variables de medición neste estudo foron: 1) tolerancia ó esforzo (proba de 
carga constante en cicloergómetro ó 80% da potencia máxima tolerada); 2) forza muscular (SFT); 
3) CVRS (SF-36) e 4) estancia hospitalaria e complicacións postoperatorias.  
Todos os pacientes foron evaluados ó inicio do estudo (T0), ás tres semanas 
aproximadamente da cirurxía (T1) e ós 3 meses (T2). A maiores, os pacientes no grupo de 
rehabilitación foron re-evaluados ó finalizar o programa de adestramento previamente a la 
intervención quirúrxica. 
O análise estadístico consistiu nunha prueba t de student para mostras independentes para 
cada una das principais variables de medición así como unha prueba t de mostras relacionadas para 
evaluar los cambios pre-post intervención no grupo de intervención. A incidencia de complicacións 
postoperatorias se analizó mediante una prueba de X2. Todas as probas foron realizadas co 
programa estadístico SPSS para Windows versión 22 (IBM Corporation, Chicago, IL, USA) e un 
valor de p <.05 considerouse como estadísticamente significativo para todos os análises. 
Resultados: 319 pacientes entraron en lista de espera para resección pulmonar por sospeita ou 
diagnóstico confirmado de cancro de pulmón no departamento de Cirurxía Torácica do CHUAC 
durante el periodo de reclutamiento. 68 (21.3%) pacientes foron inicialmente contactos dos cales 
finalmente 40 foron aleatorizados. 22 (55%) pacientes completaron con éxito o estudo e foron 
analizados.  
 Os pacientes do grupo de rehabilitación rexistraron un aumento significativo nas tres 
variables principales de medición ó rematar o programa de rehabilitación: tolerancia ó esforzó 
(proba de carga constante en cicloergómetro), forza muscular así como no componente físico da 
CVRS (Tabla 2). Non se atoparon diferencias significativas en ninguna das variables analizadas 
entre os dous grupos ás tres semanas da intervención quirúrxica excepto na dimensión de dor 
corporal do test de calidade de vida (Tabla 3). Tampouco se encontraron diferencias significativas 
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entre os grupos nin na estadia hospitalaria ni en la incidencia de complicacións postoperatorias. 
Nembargantes, ós tres meses da cirurxía, os pacientes do grupo de rehabilitación mostraron unha 
recuperación completa en todas las variables incluso por encima dos valores basáis mentras que os 
pacientes do grupo control experimentaron un deterioro continuo e progresivo a nivel funcional e 
psicolóxico. As diferenzas resultaron estadísticamente significativas tanto na tolerancia al esforzó 
(duración sostida na proba de resistencia submáxima en cicloergómetro) como na forza muscular 
de membros superiores e inferiores e no componente sumario físico do test de calidade de vida 
(Tabla 3).  
VARIABLE N BASAL PRE-Cirurxía P valor 
Proba de CCEG (s) 10 322,4±96,2 719±211,2 <.001 
Test de flexión de 
brazos (nª) 
10 13,40±3 16,3±2,9 .002 
Test de levantarse 
da silla (nª) 
10 11,5±3,7 12,4±4,5 .041 
Función física 10 63,5±20,8 71±14,9 .110 
Rol físico 10 48±30,6 65,9±12,8 .038 
Dor corporal 10 64,5±26,3 69,2±23,8 .518 
Saúde Xeral 10 41,9±20,2 52,2±14,3 .072 
Vitalidade 10 52±16,5 55±15,6 .526 
Función social 10 87,5±22 97,5±5,3 .223 
Rol emocional 10 60,6±19,2 72.7±12,3 .098 
Saúde mental 10 63,2±13,6 64,4±19,2 .771 
CSF 10 40,77±8 45,2±6,8 0.08 
CSM 10 45,7±8,3 47,4±7,4 .511 
*CCEG= Carga Constante en Ciclo-ergómetro; CSF=Componente Sumario Físico;  
CSM=Componente Sumario Mental 
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VARIABLE GRUPO Basal Post-Cirurxía 
(diferencia 
media) 
p valor 3 meses 
(diferencia 
media) 
p 
valor 
CCEG (s) Rehabilitación 322.4±96.2 +137.7±268.2 
.097 
+226±269.4* 
.005 Control 366.8±205 -25.8±16.71 -137.8±221.7 
T6MM (m) Rehabilitación  420.11±116.3 -15.55±47.731 
.500 
1.88±34.7 
.186 
Control 514.5±100.9 -27.7±33.7* -31.5±64.6 
Flexión de 
brazos (nª) 
Rehabilitación  13.4±3 +1.9±3 
.105 
+1.8±3.3 
.045 
Control 17.3±3.5 -0.25±2.9 -1.8±3.5 
Levantame
nto de la 
silla (n) 
Rehabilitación  11.5±3.7 -0.55±3.5 
.531 
+2±2.2* 
.002 
Control 12.7±2.5 +0.5±3.9 -1.3±1.8* 
*diferencia estadísticamente significativa intra-grupo (p <.05) 
 
Conclusións: en vista dos resultados obtidos neste ensaio clínico aleatorizado a simple cego 
podemos concluir que a rehabilitación pulmonar preoperatoria en pacientes con neoplasias 
malignas non só optimiza a condición física basal dos pacientes previo á cirurxía senón que ademáis 
parece contribuir de forma significativa a previr o deterioro funcional observado durante os 
primeros meses do postoperatorio. 
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CONCLUSIÓNS 
 En xeral, os resultados obtidos nos estudos incluidos no marco desta tese de doutoramento 
indican que: 
 Existe suficiente evidencia científica para aseverar que os pacientes con cancro de pulmón 
sometidos a resección pulmonar experimentan un deterioro importante na capacidade 
funcional, tolerancia ó esforzo e CVRS durante os primeiros meses tras a intervención 
quirúrxica. 
 A pre-habilitación de pacientes con cancro de pulmón que van a ser sometidos a cirurxía de 
resección pulmonar resulta útil á hora de optimizar o estado basal dos pacientes dado que 
mellora a función pulmonar preoperatoria e moi posiblemente a tolerancia ó esforzo e a 
capacidade funcional, o que se traduce nunha disminución na duración da estadia 
hospitalaria así como no número de complicacións postoperatorias en aqueles pacientes 
sometidos a cirurxía aberta convencional. 
 En pacientes con sospeita clínica ou diagnóstico confirmado de cancro de pulmón operados 
por videocirurxía a rehabilitación pulmonar preoperatoria resulta viable, segura e 
fácilmente tolerable e pode levarse a cabo no noso medio sen incurrir nun aumento da 
demora terapéutica. 
 Finalmente, a rehabilitación pulmonar preoperatoria resulta eficaz para aumentar a 
tolerancia ó esforzo, a forza muscular e o compoñente físico relacionado coa calidade de 
vida; ademáis, en función das diferencias observadas con respecto ó tratamento estándar, a 
pre-habilitación parece acelerar a recuperación funcional postoperatoria e paliar o deterioro 
asociado á cirurxía de resección pulmonar. 
 
